{"PMC7244415": [["Conflicts of interestsNone.Conflicts of interestsAuthorshipConflicts of interestsThe authors made contributions to all of the following: (1) drafting the article or revising it critically for important intellectual content, (2) final approval of the version to be submitted.Conflicts of interestsFundingConflicts of interestsNone.", [["the version", "TREATMENT", 246, 257]]]], "PMC7204671": [], "a786b0520e24c2477896975e705d6aa0ef5abd66": [["IntroductionThe SNexpression tool has been developed with the aim of providing support to the structural analysis of Symmetric Nets (SN), a High-Level Petri Net (HLPN) formalism, without unfolding the net, allowing one to work at symbolic and parametric 1 level.", [["the structural analysis", "TEST", 90, 113], ["a High-Level Petri Net (HLPN) formalism", "TREATMENT", 138, 177], ["unfolding the net", "PROBLEM", 187, 204], ["Symmetric", "OBSERVATION_MODIFIER", 117, 126], ["Petri Net", "OBSERVATION", 151, 160]]], ["A recently added feature is the possibility of deriving a set of symbolic ordinary differential equations (Symbolic ODE -SODE) from a Stochastic SN (SSN) model, making it possible an efficient computation of the average marking of colored tokens into places.", [["symbolic ordinary differential equations", "PROBLEM", 65, 105], ["a Stochastic SN (SSN) model", "TREATMENT", 132, 159], ["colored tokens", "OBSERVATION", 231, 245]]], ["A first version of SNexpression was presented in [6] , but significant improvements/extensions have been implemented since then.IntroductionThe theoretical work behind the tool has been published in a few papers defining the language for expressing the structural relations in symbolic form and the operators to be applied to the SN arc functions to derive several structural relations [5, 7] or to generate a set of SODE from a model satisfying certain properties [3, 4] .", [["significant improvements/extensions", "PROBLEM", 59, 94], ["significant", "OBSERVATION_MODIFIER", 59, 70], ["improvements", "OBSERVATION", 71, 83]]], ["The basic idea consists of using a syntax similar to the SN arc expressions one, to symbolically represent structural relations useful for checking invariance properties, to deduce model behavioral properties, etc. Each symbolic structural relation is representative of several structural relations defined on the model unfolding: the latter can be derived from the former by instantiating it on specific colors.", [["a syntax", "TREATMENT", 33, 41], ["several", "OBSERVATION_MODIFIER", 270, 277], ["structural", "OBSERVATION_MODIFIER", 278, 288], ["relations", "OBSERVATION", 289, 298]]], ["This approach has advantages: the compact representation, the similarity of the languages used to describe the model and that used to express the structural properties, and to some extent the possibility to apply it to models with parametric color class size, hence providing results that are valid for a family of similar models.Definitions and NotationSNs were introduced (with the name Well-Formed Nets) in [8] .", [["size", "OBSERVATION_MODIFIER", 254, 258]]], ["It is a formalism, similar to Colored Petri Nets, featuring a syntax designed to naturally make symmetries explicit when the modelled system is symmetric (e.g. composed of several similarly behaving entities).", [["a syntax", "TREATMENT", 60, 68], ["Petri Nets", "OBSERVATION", 38, 48], ["symmetric", "OBSERVATION", 144, 153]]], ["A little SN model is depicted in Fig. 1 , it is a small portion of a Distributed Memory fault tolerance mechanism model presented in [2] ; the picture has been drawn with the GreatSPN GUI [1] and then (manually) translated into the textual format accepted by SNexpression (file with .sn extension).", [["SNexpression", "PROTEIN", 259, 271], ["SN model", "OBSERVATION", 9, 17], ["small", "OBSERVATION_MODIFIER", 50, 55], ["portion", "OBSERVATION_MODIFIER", 56, 63], ["Distributed", "OBSERVATION_MODIFIER", 69, 80], ["Memory fault tolerance", "OBSERVATION", 81, 103]]], ["For the sake of space in this section we shall only describe in some detail the color structure of a SN, assuming that the reader is familiar with PN and HLPN formalisms and the definition of places, transitions, input, output and inhibitor arcs, marking.", [["PN", "TREATMENT", 147, 149], ["HLPN formalisms", "TREATMENT", 154, 169], ["output and inhibitor arcs", "TREATMENT", 220, 245]]], ["Transition and place color domains are defined as Cartesian products of classes : D = C ei i , e i \u2265 0, i = 1, . . . , n (class C i appears e i times in the product).", [["class C i", "TEST", 122, 131]]], ["The color domain cd(p) of place p defines the possible colors (tuples of color elements from cd(p)) of the tokens in its marking; the color domain cd(t) of transition t defines its possible firing modes: these are tuples of color elements, and distinct typed variable names (var(t)) are used to refer to such elements in any tuple in cd(t).GreatSPN notationLet us consider the model in Fig. 1 : C = {A, B, C, D}, classes A and D are partitioned into static subclasses; the cd(DM input) = A 2 , B, C, D and a tuple in this place could be dmt1, dmt2, dmv3, val2, rdok ; cd(CheckCM P ) = A, B, C (var(CheckCM P ) = {a, b, c}) and one possible firing mode, also called instance, of this transition is a = dmt1, b = dmv2, c = val1.", [["1 : C = {A, B, C, D}", "CHEMICAL", 391, 411], ["A 2 , B, C, D", "CHEMICAL", 488, 501], ["CheckCM P ) = A, B, C", "CHEMICAL", 571, 592], ["C = {A, B, C, D}, classes A", "SIMPLE_CHEMICAL", 395, 422], ["D", "SIMPLE_CHEMICAL", 427, 428], ["C, D", "SIMPLE_CHEMICAL", 497, 501], ["dmt1", "GENE_OR_GENE_PRODUCT", 537, 541], ["dmt2", "GENE_OR_GENE_PRODUCT", 543, 547], ["dmv3", "GENE_OR_GENE_PRODUCT", 549, 553], ["val2", "GENE_OR_GENE_PRODUCT", 555, 559], ["dmt1", "GENE_OR_GENE_PRODUCT", 701, 705], ["c = val1", "GENE_OR_GENE_PRODUCT", 717, 725], ["color domain cd(p)", "PROTEIN", 4, 22], ["B", "PROTEIN", 494, 495], ["C", "PROTEIN", 497, 498], ["dmt1", "PROTEIN", 537, 541], ["dmt2", "PROTEIN", 543, 547], ["dmv3", "PROTEIN", 549, 553], ["val2", "PROTEIN", 555, 559], ["rdok", "PROTEIN", 561, 565], ["cd", "PROTEIN", 568, 570], ["CheckCM P ) = A", "PROTEIN", 571, 586], ["B", "PROTEIN", 588, 589], ["C", "PROTEIN", 591, 592], ["var", "PROTEIN", 594, 597], ["CheckCM P", "PROTEIN", 598, 607], ["{a", "PROTEIN", 612, 614], ["b", "PROTEIN", 616, 617], ["c}", "PROTEIN", 619, 621], ["dmt1", "PROTEIN", 701, 705], ["dmv2", "PROTEIN", 711, 715], ["c", "PROTEIN", 717, 718], ["val1", "PROTEIN", 721, 725], ["the cd(DM input", "PROBLEM", 469, 484], ["dmv3", "TEST", 549, 553], ["val2", "TEST", 555, 559], ["color elements", "OBSERVATION", 224, 238], ["dmt1", "OBSERVATION", 537, 541]]], ["The enabling conditions of a transition instance and the effect of its firing depend on the functions on its input, inhibitor and output arcs.", [["a transition instance", "TREATMENT", 27, 48], ["inhibitor", "TREATMENT", 116, 125], ["output arcs", "TEST", 130, 141]]], ["Transition CheckCM P has several input and output places and its instances must satisfy predicate a \u2208 A 1 ; the function on the arc from DM input is S A{1}\u2212a, a, b, c, S D{4} , while the functions on the arcs connecting it to place DM master are a, b .", [["P", "DNA", 19, 20], ["several input and output places", "TREATMENT", 25, 56], ["\u2212a", "TEST", 155, 157], ["a", "TEST", 159, 160], ["b", "TEST", 162, 163], ["the arcs", "TREATMENT", 200, 208]]], ["The domain of an arc function linking place p to transition t is cd(t), whereas its codomain is Bag[cd(p)] 3 .", [["Bag[cd(p)] 3", "CHEMICAL", 96, 108], ["Bag[cd(p)] 3", "GENE_OR_GENE_PRODUCT", 96, 108], ["cd(t)", "PROTEIN", 65, 70], ["an arc function", "TREATMENT", 14, 29], ["arc function", "OBSERVATION", 17, 29]]], ["Each class-function f is a linear function defined on a subset of variables of var(t) of the same type.", [["a linear function", "PROBLEM", 25, 42], ["linear", "OBSERVATION_MODIFIER", 27, 33]]], ["Let var Ci (t) be the subset of var(t) of type C i , and C i the set of static subclasses of C i , then f :GreatSPN notationin this context denotes the projection of a transition instance on the k th element of type C i in its color domain; symbol ! denotes the successor operator mapping the value of v k to its successor (the type of v k must be ordered).", [["Let var Ci (t)", "GENE_OR_GENE_PRODUCT", 0, 14], ["type C i", "PROBLEM", 42, 50], ["a transition instance", "PROBLEM", 166, 187], ["v k", "TREATMENT", 336, 339]]], ["Boolean expressions g i (guards) on var(t) may be associated with transitions or individual tuples; their terms are standard predicates checking whether two variables hold the same value, or if a variable \"belongs\" to a given static subclass; if g i is false for a given transition instance, the associated tuple evaluates to the empty-multiset.", [["false", "OBSERVATION", 253, 258]]], ["Scalars in class-functions must be such that no negative coefficients result from the evaluation of any color satisfying the guard possibly associated with the corresponding tuple/transition.GreatSPN notationq are allowed) and on their coefficients which cannot be negative, while the extensions are the use of intersection of basic class functions as tuple elements, and the possibility to use a predicate also as a filter placed as a prefix in front of a tuple (filtering out the elements not satisfying the filter predicate from the tuple evaluation).", [["the evaluation", "TEST", 82, 96], ["any color", "TEST", 100, 109], ["a filter", "TREATMENT", 415, 423], ["a prefix", "TREATMENT", 434, 442], ["the filter", "TREATMENT", 506, 516], ["the tuple evaluation", "TEST", 532, 552], ["filter", "OBSERVATION", 417, 423]]], ["The SNexpression tool implements a calculus on L and provides several off-the-shelf formulas to compute interesting structural properties of SN models.GreatSPN notationTo the best of our knowledge no other tools implement a general calculus for structural analysis of HLPNs.", [["calculus", "DISEASE", 35, 43], ["HLPNs", "DISEASE", 268, 273], ["HLPNs", "CANCER", 268, 273], ["a calculus", "PROBLEM", 33, 43], ["the-shelf formulas", "TREATMENT", 74, 92], ["a general calculus", "PROBLEM", 222, 240], ["structural analysis", "TEST", 245, 264], ["HLPNs", "PROBLEM", 268, 273], ["calculus", "OBSERVATION", 35, 43], ["SN models", "OBSERVATION", 141, 150], ["calculus", "OBSERVATION", 232, 240]]], ["Even very advanced tools, e.g. Snoopy [9] , take advantage of symmetry properties in the color structure to efficiently perform the net unfolding [10] , but do not exploit it for structural analysis.Tool Architecture and FunctionsThe architecture of SNexpression is organized in three layers, depicted in Fig. 2 : the Library for Symbolic Calculus (LSC), the SN management framework (SNF), and the Command Line Interface (CLI).", [["SNexpression", "GENE_OR_GENE_PRODUCT", 250, 262], ["SNexpression", "DNA", 250, 262], ["the net unfolding", "PROBLEM", 128, 145], ["structural analysis", "TEST", 179, 198], ["the Library", "TREATMENT", 314, 325], ["Symbolic Calculus", "PROBLEM", 330, 347], ["the SN management", "TREATMENT", 355, 372], ["architecture", "OBSERVATION_MODIFIER", 234, 246], ["SNexpression", "OBSERVATION", 250, 262], ["three layers", "OBSERVATION_MODIFIER", 279, 291], ["Fig", "OBSERVATION_MODIFIER", 305, 308], ["Calculus", "OBSERVATION", 339, 347], ["LSC", "ANATOMY", 349, 352]]], ["The LSC is a sort of Computer Algebra System that handles base-level SN expressions.", [["LSC", "CELL_TYPE", 4, 7], ["LSC", "ANATOMY", 4, 7], ["base", "OBSERVATION_MODIFIER", 58, 62], ["SN expressions", "OBSERVATION", 69, 83]]], ["The SNF middle layer manages more abstract objects, such as structural relation formulae, directly derived from a SN definition that may be loaded into the system; it also provides the algorithms needed to automatically derive the SODE for a given SSN model, based on a manipulation of SSN annotations.", [["SODE", "DNA", 231, 235], ["a SN definition", "TREATMENT", 112, 127], ["SSN model", "TREATMENT", 248, 257], ["SNF", "OBSERVATION_MODIFIER", 4, 7], ["middle", "OBSERVATION_MODIFIER", 8, 14], ["layer", "OBSERVATION_MODIFIER", 15, 20], ["abstract objects", "OBSERVATION", 34, 50]]], ["The CLI is a shell surrounding both the library and the SN framework, through which the user can operate directly on base-level expressions, using the CLI as a sort of symbolic calculator, or at a higher level, performing structural analysis of (S)SN models previously loaded.Tool Architecture and FunctionsTo help the users operation during a session the CLI provides a multipage textual notebook where it is possible to annotate and save formulae to be submitted, or results, or comments, in other words anything useful to support multi-step complex analysis.", [["CLI", "DISEASE", 4, 7], ["CLI", "DISEASE", 356, 359], ["the CLI", "TREATMENT", 147, 154], ["symbolic calculator", "TEST", 168, 187], ["structural analysis", "TEST", 222, 241], ["multi-step complex analysis", "TEST", 533, 560], ["CLI", "OBSERVATION", 4, 7], ["shell", "OBSERVATION", 13, 18]]], ["Since the format of the LSC output is pretty similar to the syntax of CLI input, copy-and-paste from the notebook to the command window and vice-versa may be conveniently used.Tool Architecture and FunctionsSNexpression is implemented in Java.", [["CLI", "DISEASE", 70, 73], ["the LSC output", "TEST", 20, 34], ["CLI input", "TREATMENT", 70, 79], ["LSC", "ANATOMY", 24, 27], ["output", "OBSERVATION", 28, 34]]], ["The LSC is distributed as a standalone jar file, so that programmers can use it in other projects.", [["LSC", "CELL_TYPE", 4, 7], ["LSC", "ANATOMY", 4, 7], ["distributed", "OBSERVATION_MODIFIER", 11, 22]]], ["Its API is available at URL: www.di.unito.it/ \u223c depierro/SNexpression/libAPI, we plan to make the LSC soon available as open-source project.", [["libAPI", "TREATMENT", 70, 76], ["the LSC", "TREATMENT", 94, 101], ["LSC", "ANATOMY", 98, 101]]], ["At the current release, the CLI and the SNF are built as a unique executable, but we plan to make also the SNF accessible through a public API.", [["CLI", "OBSERVATION", 28, 31]]], ["Since the CLI reads from the standard input, it might be integrated in other tools.", [["CLI reads", "DNA", 10, 19]]], ["The following sections discuss the functions of the three layers of the tool architecture in more detail.The LSC: A Computer Algebra System for SN ExpressionsThe major functionalities and the design of the LSC are summarized here.", [["sections", "ANATOMY", 14, 22], ["LSC", "CELL", 206, 209], ["LSC", "CELL_TYPE", 109, 112], ["LSC", "CELL_TYPE", 206, 209], ["LSC", "ANATOMY", 109, 112], ["major", "OBSERVATION_MODIFIER", 162, 167], ["functionalities", "OBSERVATION", 168, 183], ["LSC", "ANATOMY", 206, 209]]], ["Final expressions manipulated by the LSC match a sort of disjunctive normal form, where only SN functions, guards, filters and sum/intersection operators may occur.The LSC: A Computer Algebra System for SN ExpressionsWith respect to earlier versions, the LSC currently supports both set-and bag-expressions (i.e. espressions returning multisets), with the only exception of composition, which is partially implemented for bag-expressions: its complete definition is work in progress.", [["LSC", "CELL_TYPE", 37, 40], ["bag", "TREATMENT", 291, 294], ["LSC", "ANATOMY", 37, 40], ["LSC", "ANATOMY", 168, 171], ["LSC", "ANATOMY", 255, 258]]], ["The support operator provides a convenient bridge between bag-and set-expressions.The LSC: A Computer Algebra System for SN ExpressionsThanks to its modular layout and intuitive API, the LSC may also be used as a standalone component.", [["LSC", "CELL_TYPE", 86, 89], ["LSC", "CELL_TYPE", 187, 190], ["a convenient bridge between bag", "TREATMENT", 30, 61], ["intuitive API", "TREATMENT", 168, 181], ["the LSC", "TREATMENT", 183, 190], ["a standalone component", "TREATMENT", 211, 233], ["LSC", "ANATOMY", 86, 89], ["LSC", "ANATOMY", 187, 190]]], ["As a direct consequence of its design, it is possible to directly build and manipulate objects (terms) at three different levels: class-functions, guards/filters, and function-tuples.", [["guards/filters", "TREATMENT", 147, 161]]], ["Guards/Filters (standard predicates), class-functions, and single function-tuples have a canonical representative, which coincides with their normal form.", [["Guards/Filters", "TREATMENT", 0, 14], ["Filters", "OBSERVATION", 7, 14]]], ["There is no canonical form for sums (bags) of function-tuples: in general, however, equivalence between expressions may be syntactically checked by using the difference operator.The LSC: A Computer Algebra System for SN ExpressionsLibrary Architecture and API.", [["no", "UNCERTAINTY", 9, 11], ["LSC", "ANATOMY", 182, 185]]], ["Modular testing/debugging: every single element of the language can be managed in a uniform way.", [["Modular testing", "TEST", 0, 15], ["debugging", "PROBLEM", 16, 25]]], ["Efficiency: term normalization complexity is alleviated by a reduced use of recursion (the normalization times for many examples, some of which very complex, vary from msec. to sec.).The LSC: A Computer Algebra System for SN ExpressionsA code snippet illustrating the several steps needed to create and normalize a SN expression (the transpose of a tuple composition) is listed in Fig. 3 .", [["LSC", "CELL_TYPE", 187, 190], ["term normalization complexity", "PROBLEM", 12, 41], ["A code snippet", "TREATMENT", 236, 250], ["a tuple composition", "TREATMENT", 347, 366], ["term normalization", "OBSERVATION", 12, 30], ["reduced", "OBSERVATION_MODIFIER", 61, 68], ["LSC", "ANATOMY", 187, 190]]], ["A (simplified) UML class-diagram describing the top of the LSC type hierarchy, and its connections to the lower levels, can be found in the tool home page, together with a small portion of the library's API concerning simplification methods.The Symmetric Nets Management FrameworkThe SNF implements the method to load a SN description and those to compute some symbolic structural relations on it, listed in Table 1 : some relations are functions on sets, others return multisets.", [["SNF", "PROTEIN", 284, 287], ["A (simplified) UML class-diagram", "TREATMENT", 0, 32], ["LSC", "ANATOMY", 59, 62], ["type hierarchy", "OBSERVATION", 63, 77], ["lower", "ANATOMY_MODIFIER", 106, 111], ["Symmetric", "OBSERVATION_MODIFIER", 245, 254], ["Nets", "OBSERVATION", 255, 259]]], ["For the structural relations computation it exploits the functions implemented in the library (difference, transpose, composition) on one hand, and the information on the loaded SN structure on the other hand: the model structure allows to select transition pairs that might be in import wncalculus . color .", [["wncalculus", "OBSERVATION", 288, 298]]], ["ColorClass ; import wncalculus . classfunction .; import wncalculus . tuple . ) of basic functions: projection, complement, successor, constant (whole class or one static subclass).RB/RBmset(t, p)Operators can be applied to expressions: there are two unary operators, support and transpose, and two binary operators, difference and composition.", [["RB", "PROTEIN", 181, 183], ["RB/RBmset(t, p)Operators", "TREATMENT", 181, 205], ["wncalculus", "OBSERVATION", 20, 30], ["wncalculus", "OBSERVATION", 57, 67]]], ["The support operator can be applied to a multiset-expression to obtain the corresponding expression mapping on sets; the transpose operator is available both for expressions mapping on multisets and for those mapping on sets: the result of its application is an expression of the same type.", [["transpose operator", "DNA", 121, 139], ["The support operator", "TREATMENT", 0, 20], ["expressions mapping", "TEST", 162, 181], ["those mapping", "TEST", 203, 216]]], ["The difference can be applied to any pair of expressions (of the same type) while the composition is completely implemented for expressions mapping on sets and on a significant subset of multiset expressions.", [["expressions mapping", "TEST", 128, 147]]], ["These operators are the basis for the SN structural analysis implemented in the SN Management Framework.", [["the SN structural analysis", "TEST", 34, 60]]], ["For instance the structural conflict between two transitions t 1 and t 2 sharing an input place p is computed as follows: I(t, p) and O(t, p) are respectively the expressions on the input and output arcs connecting p and t.", [["t 1 and t 2", "DNA", 61, 72]]], ["This could be useful to identify the groups of immediate transitions that are potentially in conflict and define how such conflicts should be solved.RB/RBmset(t, p)To support the user in performing experiments with the tool, the CLI embeds a multi-page notebook: it is possible to copy-and-paste commands annotated in the notebook to the command window and then copy-and-paste results from the command window back in the notebook.", [["CLI", "DISEASE", 229, 232], ["RB", "PROTEIN", 149, 151]]], ["When the color classes involved in the expressions processed by the tool have parametric cardinality, the result of a computation is not a single expression but a list of expressions, each with associated a different range of possible values for the classes cardinality: indeed one of the strong points of the tool is its ability to handle expressions without necessarily fixing the color classes sizes, so that the obtained result is valid for a family of models differing only in the size of (some) color classes.Use Cases: Exploiting SNexpressionThe goal of this section is to show on a few practical examples some features of SNexpression.", [["SNexpression", "DNA", 630, 642]]], ["Some symbolic structural properties of interest are the causal connection and structural conflict involving transition Run and the immediate transitions pass, W in and notW in; these properties are useful (among others) for model validation purposes, or to correctly define immediate transition weights.", [["model validation purposes", "TEST", 224, 249], ["symbolic structural", "OBSERVATION", 5, 24], ["properties", "OBSERVATION_MODIFIER", 25, 35]]], ["2) computes the instances c, n , n of pass enabling instance c 1 of W in: the result has a filter and denotes the instances involving the same team c 1, and the last section runner (the predecessor of n ).", [["a filter", "TREATMENT", 89, 97], ["filter", "OBSERVATION", 91, 97]]], ["3) computes the structural auto-conflicts among different instances of W in, while the result of 4) shows that W in and notW in are mutually exclusive: indeed, W inner is input place for notW in and inhibitor place (with arc function S C ) for W in.", [["notW", "PROTEIN", 187, 191]]], ["In SSNs with immediate transitions it is useful to check for confusion, i.e., situations where the model is underspecified (a situation solved by using priorities).", [["confusion", "DISEASE", 61, 70], ["SSNs", "CANCER", 3, 7], ["confusion", "PROBLEM", 61, 70]]], ["There would be confusion if an instance of pass fired while an instance of W in is enabled: this could cause the enabling of another instance of W in in conflict with the former.", [["confusion", "DISEASE", 15, 24], ["confusion", "PROBLEM", 15, 24]]], ["5) shows how to obtain the confusing instances of pass by composing the results of 2) and 3): in this case the SNF is not involved.Use Cases: Exploiting SNexpressionOther structural relations can be computed on the model in Fig. 1 , whose arc functions are a bit more complex as illustrated by relations 6) and 7) in Table 2 .", [["SNF", "PROTEIN", 111, 114]]], ["The resulting expressions have the same domain as the 2 nd parameter of SC, namely A, B, C for 6) and A\u02c62, B, C, D for 7).", [["SC", "PROTEIN", 72, 74], ["B", "PROTEIN", 86, 87], ["B", "PROTEIN", 107, 108]]], ["The technique applies only to models whose underlying stochastic process is density dependent.", [["The technique", "TREATMENT", 0, 13], ["density dependent", "PROBLEM", 76, 93], ["stochastic process", "OBSERVATION", 54, 72], ["density", "OBSERVATION", 76, 83], ["dependent", "OBSERVATION_MODIFIER", 84, 93]]], ["One condition for an SSN to satisfy such property is the coverage of places by P-invariants.", [["P", "DNA", 79, 80]]], ["In [4] an application to a botnet model has been illustrated (this is one of the examples that can be downloaded from the tool's web page).", [["a botnet model", "TREATMENT", 25, 39]]], ["SNexpression can be used to check if a given P-indexed vector of multiset expressions defines a set of colored Pinvariants, and possibly prove the coverage of all place instances.", [["P", "DNA", 45, 46]]], ["The expressions in the P-indexed vector denote functions from the place color domains to the P-invariant's domain.", [["P-indexed vector", "DNA", 23, 39], ["P-invariant's domain", "DNA", 93, 113]]], ["The same result holds for all transitions, thus pinv[] is a P-invariant: it represents |L| invariants, indicating that the number of tokens with second component l \u2208 L is constant, and have the correct label in C. In the tool web page other P-invariants for this model are available.Conclusions and Installation InstructionsSNexpression implements a symbolic calculus useful for studying the structure of a Symmetric Net and deriving information on its behavioral properties.", [["P", "DNA", 241, 242], ["a symbolic calculus", "PROBLEM", 348, 367], ["constant", "OBSERVATION", 171, 179], ["calculus", "OBSERVATION", 359, 367], ["Symmetric", "OBSERVATION_MODIFIER", 407, 416], ["Net", "OBSERVATION", 417, 420]]], ["It has also been used to derive a set of SODE from an SSN model for performance analysis purposes.", [["performance analysis purposes", "TEST", 68, 97]]], ["Several extensions are planned: completing the composition of bag-expressions, further automation of net structural calculus (e.g., checking P-invariants or building Extended Conflict Sets), automatizing the SN partial unfolding procedure which is a preliminary step for the generation of the SODE from a SN model, providing access to the different software layers with suitable APIs.", [["bag-expressions", "TREATMENT", 62, 77], ["net structural calculus", "PROBLEM", 101, 124], ["the SN partial unfolding procedure", "TREATMENT", 204, 238], ["a SN model", "TREATMENT", 303, 313], ["suitable APIs", "TREATMENT", 370, 383], ["net", "OBSERVATION_MODIFIER", 101, 104], ["structural", "OBSERVATION_MODIFIER", 105, 115], ["calculus", "OBSERVATION", 116, 124], ["partial", "OBSERVATION_MODIFIER", 211, 218], ["unfolding", "OBSERVATION", 219, 228], ["suitable APIs", "OBSERVATION", 370, 383]]], ["Finally, we plan to build a bridge between GreatSPN and SNexpression.Conclusions and Installation InstructionsA free version of the tool is available: download the archive SNEx.zip from the project homepage www.di.unito.it/ \u223c depierro/SNexpression, unzip its content into a folder.", [["GreatSPN", "PROTEIN", 43, 51], ["SNexpression", "PROTEIN", 56, 68], ["a bridge between GreatSPN and SNexpression", "TREATMENT", 26, 68], ["SNexpression", "TREATMENT", 235, 247]]], ["The extracted file structure contains the main program SnexCLI.jar and, in the folder lib, the library SNexLib.jar.", [["SnexCLI", "PROTEIN", 55, 62], ["main", "OBSERVATION_MODIFIER", 42, 46]]]], "043aa68f2c784899f71225e8eb233150760a6a54": [["In early April 2009, human cases of infection with 2009 pandemic influenza A (H1N1) virus were first identified in the United States and Mexico (1) .", [["infection", "DISEASE", 36, 45], ["influenza A (H1N1) virus", "DISEASE", 65, 89], ["human", "ORGANISM", 21, 26], ["2009 pandemic influenza A (H1N1) virus", "ORGANISM", 51, 89], ["human", "SPECIES", 21, 26], ["pandemic influenza A (H1N1) virus", "SPECIES", 56, 89], ["human", "SPECIES", 21, 26], ["2009 pandemic influenza A (H1N1) virus", "SPECIES", 51, 89], ["infection", "PROBLEM", 36, 45], ["2009 pandemic influenza A (H1N1) virus", "PROBLEM", 51, 89], ["infection", "OBSERVATION", 36, 45]]], ["The virus then spread rapidly to other regions of the world.", [["The virus", "PROBLEM", 0, 9], ["virus", "OBSERVATION", 4, 9]]], ["As of January 24, 2010, laboratory-confirmed cases of pandemic influenza (H1N1-2009) were being reported in more than 209 countries or regions worldwide, with 14,711 deaths among confirmed cases (2) .", [["influenza", "DISEASE", 63, 72], ["deaths", "DISEASE", 166, 172], ["pandemic influenza", "SPECIES", 54, 72], ["pandemic influenza", "PROBLEM", 54, 72], ["H1N1", "PROBLEM", 74, 78]]], ["Pandemic influenza was introduced to mainland China on May 9, 2009 (3, 4) , and then spread across the whole country.", [["Pandemic influenza", "DISEASE", 0, 18], ["Pandemic influenza", "SPECIES", 0, 18], ["Pandemic influenza", "PROBLEM", 0, 18]]], ["By the end of 2009, more than 120,000 confirmed cases were reported to the Chinese Center for Disease Control and Prevention (CCDC), including 648 deaths (5) .", [["deaths", "DISEASE", 147, 153], ["Disease Control", "TREATMENT", 94, 109]]]], "PMC7437504": [["IntroductionThe novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and subsequent SARS-CoV-2 induced coronavirus disease 2019 (COVID-19) has spread on an unprecedented scale.", [["acute respiratory syndrome coronavirus", "DISEASE", 29, 67], ["SARS", "DISEASE", 99, 103], ["coronavirus disease", "DISEASE", 118, 137], ["COVID-19", "CHEMICAL", 144, 152], ["SARS-CoV-2", "ORGANISM", 71, 81], ["SARS-CoV-2", "ORGANISM", 99, 109], ["coronavirus", "ORGANISM", 118, 129], ["severe acute respiratory syndrome coronavirus", "SPECIES", 22, 67], ["SARS-CoV-2", "SPECIES", 71, 81], ["SARS-CoV-2 induced coronavirus disease 2019 (COVID-19", "SPECIES", 99, 152], ["The novel severe acute respiratory syndrome coronavirus", "PROBLEM", 12, 67], ["SARS", "TEST", 71, 75], ["CoV", "TEST", 76, 79], ["subsequent SARS", "PROBLEM", 88, 103], ["CoV", "TEST", 104, 107], ["coronavirus disease", "PROBLEM", 118, 137], ["COVID", "TEST", 144, 149], ["an unprecedented scale", "TREATMENT", 168, 190], ["severe", "OBSERVATION_MODIFIER", 22, 28], ["acute", "OBSERVATION_MODIFIER", 29, 34], ["respiratory syndrome", "OBSERVATION", 35, 55], ["coronavirus disease", "OBSERVATION", 118, 137]]], ["According to the World Health Organization (WHO), as of the 8th July 2020, there have been 11,669,259 cases and 539,906 COVID-19 related deaths worldwide.", [["deaths", "DISEASE", 137, 143], ["COVID", "TEST", 120, 125]]], ["Evidence from the global outbreak has clearly demonstrated that individuals with pre-existing comorbidities such as hypertension, cardiovascular disease, and diabetes are at a much greater risk of dying from COVID-19 (1, 2).", [["cardiovascular", "ANATOMY", 130, 144], ["hypertension", "DISEASE", 116, 128], ["cardiovascular disease", "DISEASE", 130, 152], ["diabetes", "DISEASE", 158, 166], ["COVID-19", "CHEMICAL", 208, 216], ["the global outbreak", "PROBLEM", 14, 33], ["pre-existing comorbidities", "PROBLEM", 81, 107], ["hypertension", "PROBLEM", 116, 128], ["cardiovascular disease", "PROBLEM", 130, 152], ["diabetes", "PROBLEM", 158, 166], ["COVID", "TEST", 208, 213], ["global", "OBSERVATION_MODIFIER", 18, 24], ["outbreak", "OBSERVATION", 25, 33], ["hypertension", "OBSERVATION", 116, 128], ["cardiovascular disease", "OBSERVATION", 130, 152], ["diabetes", "OBSERVATION", 158, 166]]], ["This is of great concern for individuals living with these conditions, and a major challenge for global healthcare systems and biomedical research.", [["global healthcare systems", "TREATMENT", 97, 122]]], ["Given that comorbidities are associated with high mortality among COVID-19 patients, a better understanding of the biological mechanisms that underpin this risk are needed to enable development of appropriate preventative and therapeutic strategies.IntroductionThe immune system plays a vital role during COVID-19, and the degree of immune dysfunction correlates with disease severity (3, 4).", [["immune system", "ANATOMY", 265, 278], ["immune dysfunction", "DISEASE", 333, 351], ["patients", "ORGANISM", 75, 83], ["patients", "SPECIES", 75, 83], ["comorbidities", "PROBLEM", 11, 24], ["therapeutic strategies", "TREATMENT", 226, 248], ["COVID", "TEST", 305, 310], ["immune dysfunction", "PROBLEM", 333, 351], ["disease severity", "PROBLEM", 368, 384], ["immune dysfunction", "OBSERVATION", 333, 351]]], ["Severe COVID-19 cases are associated with significant lymphopenia and an overactivated innate immune response resulting in hyperinflammation (5).", [["lymphopenia", "DISEASE", 54, 65], ["hyperinflammation", "DISEASE", 123, 140], ["Severe COVID-19 cases", "PROBLEM", 0, 21], ["significant lymphopenia", "PROBLEM", 42, 65], ["an overactivated innate immune response", "PROBLEM", 70, 109], ["hyperinflammation", "PROBLEM", 123, 140], ["significant", "OBSERVATION_MODIFIER", 42, 53], ["lymphopenia", "OBSERVATION", 54, 65], ["immune response", "OBSERVATION", 94, 109]]], ["Many COVID-19 associated comorbidities affect the function of the immune system, which in turn directly impacts the response to COVID-19.", [["immune system", "ANATOMY", 66, 79], ["COVID-19", "CHEMICAL", 128, 136], ["immune system", "ANATOMICAL_SYSTEM", 66, 79], ["associated comorbidities", "PROBLEM", 14, 38], ["COVID", "TEST", 128, 133], ["19 associated", "OBSERVATION_MODIFIER", 11, 24], ["comorbidities", "OBSERVATION", 25, 38]]], ["Furthermore, the myriad of drugs prescribed for these comorbidities will also influence the progression of COVID-19 and limit additional treatment options available for COVID-19.", [["COVID", "DISEASE", 107, 112], ["drugs", "TREATMENT", 27, 32], ["these comorbidities", "PROBLEM", 48, 67], ["COVID", "TEST", 107, 112], ["additional treatment options", "TREATMENT", 126, 154], ["COVID", "TEST", 169, 174]]], ["Here, we review the current SARS-CoV-2 literature and explore how pre-existing comorbidities adversely affect COVID-19 outcome.", [["pre-existing comorbidities", "PROBLEM", 66, 92], ["COVID", "TEST", 110, 115]]], ["Furthermore, we discuss the long-term challenges associated with the use of both novel and repurposed therapies for the treatment of COVID-19 in patients with pre-existing comorbidities.Human CoronavirusesIn December 2019, several cases of an infectious pneumonia with an unknown etiology emerged in Wuhan Province, China.", [["pneumonia", "DISEASE", 254, 263], ["patients", "ORGANISM", 145, 153], ["Human", "ORGANISM", 186, 191], ["patients", "SPECIES", 145, 153], ["Human", "SPECIES", 186, 191], ["Human", "SPECIES", 186, 191], ["the long-term challenges", "TREATMENT", 24, 48], ["repurposed therapies", "TREATMENT", 91, 111], ["the treatment of COVID", "TREATMENT", 116, 138], ["pre-existing comorbidities", "PROBLEM", 159, 185], ["an infectious pneumonia", "PROBLEM", 240, 263], ["infectious", "OBSERVATION_MODIFIER", 243, 253], ["pneumonia", "OBSERVATION", 254, 263]]], ["By January 2020, a novel coronavirus termed SARS-CoV-2 was identified as the cause.", [["coronavirus", "DISEASE", 25, 36], ["SARS", "DISEASE", 44, 48], ["coronavirus", "ORGANISM", 25, 36], ["SARS-CoV-2", "ORGANISM", 44, 54], ["SARS-CoV", "SPECIES", 44, 52], ["a novel coronavirus termed SARS", "PROBLEM", 17, 48]]], ["The virus spread rapidly and was classified as a pandemic by the WHO on the 11th March 2020.", [["The virus spread", "PROBLEM", 0, 16], ["virus", "OBSERVATION", 4, 9]]], ["However, this is not the first pathogenic human coronavirus to emerge in the last decade.", [["human", "ORGANISM", 42, 47], ["human", "SPECIES", 42, 47], ["human coronavirus", "SPECIES", 42, 59]]], ["In 2002, a severe acute respiratory syndrome (SARS) coronavirus (SARS-CoV) with animal to human transmission was reported in Guangdong Province, China (6, 7).", [["acute respiratory syndrome", "DISEASE", 18, 44], ["SARS) coronavirus", "DISEASE", 46, 63], ["SARS-CoV) with animal to human transmission", "DISEASE", 65, 108], ["SARS-CoV", "ORGANISM", 65, 73], ["human", "ORGANISM", 90, 95], ["human", "SPECIES", 90, 95], ["SARS) coronavirus", "SPECIES", 46, 63], ["SARS-CoV", "SPECIES", 65, 73], ["human", "SPECIES", 90, 95], ["a severe acute respiratory syndrome", "PROBLEM", 9, 44], ["SARS) coronavirus", "PROBLEM", 46, 63], ["severe", "OBSERVATION_MODIFIER", 11, 17], ["acute", "OBSERVATION_MODIFIER", 18, 23], ["respiratory syndrome", "OBSERVATION", 24, 44]]], ["Prior to SARS-CoV, four human coronaviruses belonging to the alpha and beta genera of the Coronaviridae family had been identified: HCoV-229E, HCoV-OC43, HCoV-NL63, and HCoV-HKU (8).", [["SARS", "DISEASE", 9, 13], ["SARS-CoV", "ORGANISM", 9, 17], ["human", "ORGANISM", 24, 29], ["alpha", "GENE_OR_GENE_PRODUCT", 61, 66], ["beta", "GENE_OR_GENE_PRODUCT", 71, 75], ["Coronaviridae", "GENE_OR_GENE_PRODUCT", 90, 103], ["HCoV-229E", "CELL", 132, 141], ["HCoV-OC43", "CELL", 143, 152], ["HCoV-NL63", "CELL", 154, 163], ["alpha and beta genera", "PROTEIN", 61, 82], ["Coronaviridae family", "PROTEIN", 90, 110], ["human", "SPECIES", 24, 29], ["SARS-CoV", "SPECIES", 9, 17], ["human coronaviruses", "SPECIES", 24, 43], ["HCoV-229E", "SPECIES", 132, 141], ["SARS", "PROBLEM", 9, 13], ["four human coronaviruses", "PROBLEM", 19, 43], ["HCoV", "TEST", 132, 136], ["HCoV", "TEST", 143, 147], ["OC43", "TEST", 148, 152], ["HCoV", "TEST", 154, 158], ["NL63", "TEST", 159, 163], ["HCoV", "TEST", 169, 173], ["HKU", "TEST", 174, 177]]], ["However, unlike the previously identified coronaviruses, SARS-CoV was phylogenetically distinct (9).", [["SARS", "DISEASE", 57, 61], ["coronaviruses", "ORGANISM", 42, 55], ["SARS-CoV", "ORGANISM", 57, 65], ["SARS-CoV", "SPECIES", 57, 65], ["coronaviruses", "PROBLEM", 42, 55], ["SARS", "PROBLEM", 57, 61], ["coronaviruses", "OBSERVATION", 42, 55]]], ["Furthermore, rather than causing upper respiratory tract infections with mild common cold symptoms, SARS-CoV caused severe lower respiratory tract infections, resulting in viral pneumonia and risk of developing acute respiratory distress syndrome (ARDS).", [["upper respiratory tract", "ANATOMY", 33, 56], ["lower respiratory tract", "ANATOMY", 123, 146], ["respiratory", "ANATOMY", 217, 228], ["respiratory tract infections", "DISEASE", 39, 67], ["SARS-CoV", "DISEASE", 100, 108], ["lower respiratory tract infections", "DISEASE", 123, 157], ["pneumonia", "DISEASE", 178, 187], ["acute respiratory distress syndrome", "DISEASE", 211, 246], ["ARDS", "DISEASE", 248, 252], ["upper", "ORGANISM_SUBDIVISION", 33, 38], ["respiratory tract", "ORGANISM_SUBDIVISION", 39, 56], ["SARS-CoV", "ORGANISM", 100, 108], ["lower", "ORGANISM_SUBDIVISION", 123, 128], ["respiratory tract", "ORGANISM_SUBDIVISION", 129, 146], ["SARS-CoV", "SPECIES", 100, 108], ["upper respiratory tract infections", "PROBLEM", 33, 67], ["mild common cold symptoms", "PROBLEM", 73, 98], ["SARS", "PROBLEM", 100, 104], ["CoV", "PROBLEM", 105, 108], ["severe lower respiratory tract infections", "PROBLEM", 116, 157], ["viral pneumonia", "PROBLEM", 172, 187], ["acute respiratory distress syndrome", "PROBLEM", 211, 246], ["ARDS", "PROBLEM", 248, 252], ["upper", "ANATOMY_MODIFIER", 33, 38], ["respiratory tract", "ANATOMY", 39, 56], ["infections", "OBSERVATION", 57, 67], ["mild", "OBSERVATION_MODIFIER", 73, 77], ["severe", "OBSERVATION_MODIFIER", 116, 122], ["lower", "ANATOMY_MODIFIER", 123, 128], ["respiratory tract", "ANATOMY", 129, 146], ["infections", "OBSERVATION", 147, 157], ["viral", "OBSERVATION_MODIFIER", 172, 177], ["pneumonia", "OBSERVATION", 178, 187], ["acute", "OBSERVATION_MODIFIER", 211, 216], ["respiratory distress syndrome", "OBSERVATION", 217, 246], ["ARDS", "OBSERVATION", 248, 252]]], ["The SARS-CoV outbreak lasted 8 months, and infected 8,098 individuals across 26 different countries, with a mortality rate of ~10% (10).", [["SARS", "DISEASE", 4, 8], ["SARS-CoV", "SPECIES", 4, 12], ["The SARS-CoV outbreak", "PROBLEM", 0, 21], ["a mortality rate", "TEST", 106, 122], ["CoV", "OBSERVATION_MODIFIER", 9, 12]]], ["In 2012, a second novel human coronavirus emerged in Saudi-Arabia and was termed Middle East respiratory syndrome (MERS) coronavirus (MERS-CoV).", [["human coronavirus", "DISEASE", 24, 41], ["Middle East respiratory syndrome (MERS) coronavirus", "DISEASE", 81, 132], ["human", "ORGANISM", 24, 29], ["Middle East respiratory syndrome (MERS) coronavirus", "ORGANISM", 81, 132], ["MERS-CoV", "ORGANISM", 134, 142], ["human", "SPECIES", 24, 29], ["coronavirus", "SPECIES", 30, 41], ["human coronavirus", "SPECIES", 24, 41], ["Middle East respiratory syndrome (MERS) coronavirus", "SPECIES", 81, 132], ["MERS-CoV", "SPECIES", 134, 142], ["a second novel human coronavirus", "TREATMENT", 9, 41], ["Middle East respiratory syndrome", "PROBLEM", 81, 113], ["coronavirus", "PROBLEM", 121, 132], ["Middle", "ANATOMY_MODIFIER", 81, 87], ["respiratory syndrome", "OBSERVATION", 93, 113]]], ["Similar to SARS-CoV, infection with MERS-CoV can cause fatal pneumonia.", [["SARS-CoV", "DISEASE", 11, 19], ["infection", "DISEASE", 21, 30], ["pneumonia", "DISEASE", 61, 70], ["SARS-CoV", "ORGANISM", 11, 19], ["MERS-CoV", "ORGANISM", 36, 44], ["SARS-CoV", "SPECIES", 11, 19], ["MERS-CoV", "SPECIES", 36, 44], ["SARS", "PROBLEM", 11, 15], ["infection", "PROBLEM", 21, 30], ["MERS", "PROBLEM", 36, 40], ["fatal pneumonia", "PROBLEM", 55, 70], ["SARS", "OBSERVATION", 11, 15], ["infection", "OBSERVATION", 21, 30], ["fatal", "OBSERVATION_MODIFIER", 55, 60], ["pneumonia", "OBSERVATION", 61, 70]]], ["To date, the WHO has reported 2,519 MERS-CoV cases, with a mortality rate of ~30% (10).Human CoronavirusesWhile the previous two coronavirus outbreaks were relatively well-contained, the unprecedented spread of the current pandemic has demonstrated increased infectivity of SARS-CoV-2.", [["coronavirus", "DISEASE", 129, 140], ["SARS", "DISEASE", 274, 278], ["Human", "ORGANISM", 87, 92], ["coronavirus", "ORGANISM", 129, 140], ["SARS-CoV-2", "ORGANISM", 274, 284], ["Human", "SPECIES", 87, 92], ["MERS-CoV", "SPECIES", 36, 44], ["Human", "SPECIES", 87, 92], ["SARS-CoV", "SPECIES", 274, 282], ["a mortality rate", "TEST", 57, 73], ["Human Coronaviruses", "PROBLEM", 87, 106], ["the previous two coronavirus outbreaks", "PROBLEM", 112, 150], ["increased infectivity of SARS", "PROBLEM", 249, 278], ["increased", "OBSERVATION_MODIFIER", 249, 258], ["infectivity", "OBSERVATION_MODIFIER", 259, 270]]], ["Early genome sequencing from China revealed that the 30 k base-pair viral genome of SARS-CoV-2 shared 79.6% sequence identity with SARS-CoV, whereas a bat coronavirus previously detected in Rhinolophus affinis shared 96% sequence identity (11, 12).", [["SARS-CoV-2", "ORGANISM", 84, 94], ["SARS-CoV", "ORGANISM", 131, 139], ["bat coronavirus", "ORGANISM", 151, 166], ["Rhinolophus affinis", "ORGANISM", 190, 209], ["30 k base-pair viral genome", "DNA", 53, 80], ["SARS-CoV-2", "DNA", 84, 94], ["bat coronavirus", "SPECIES", 151, 166], ["Rhinolophus affinis", "SPECIES", 190, 209], ["SARS-CoV-2", "SPECIES", 84, 94], ["SARS-CoV", "SPECIES", 131, 139], ["bat coronavirus", "SPECIES", 151, 166], ["Rhinolophus affinis", "SPECIES", 190, 209], ["SARS", "TEST", 84, 88], ["CoV", "TEST", 89, 92], ["sequence identity", "TEST", 108, 125], ["SARS", "TEST", 131, 135], ["CoV", "PROBLEM", 136, 139], ["a bat coronavirus", "PROBLEM", 149, 166], ["bat coronavirus", "ANATOMY", 151, 166]]], ["Whilst MERS-CoV utilizes dipeptidyl peptidase-4 (DDP4) for cell entry, SARS-CoV, and SARS-CoV-2 share the same cell entry receptor; angiotensin converting enzyme II (ACE2) (11, 12).", [["cell", "ANATOMY", 59, 63], ["cell", "ANATOMY", 111, 115], ["angiotensin", "CHEMICAL", 132, 143], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 7, 15], ["dipeptidyl peptidase-4", "GENE_OR_GENE_PRODUCT", 25, 47], ["DDP4", "GENE_OR_GENE_PRODUCT", 49, 53], ["cell", "CELL", 59, 63], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 71, 79], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 85, 95], ["cell", "CELL", 111, 115], ["angiotensin converting enzyme II", "GENE_OR_GENE_PRODUCT", 132, 164], ["ACE2", "GENE_OR_GENE_PRODUCT", 166, 170], ["MERS-CoV", "PROTEIN", 7, 15], ["dipeptidyl peptidase-4", "PROTEIN", 25, 47], ["DDP4", "PROTEIN", 49, 53], ["cell entry receptor", "PROTEIN", 111, 130], ["angiotensin converting enzyme II", "PROTEIN", 132, 164], ["ACE2", "PROTEIN", 166, 170], ["MERS-CoV", "SPECIES", 7, 15], ["SARS-CoV", "SPECIES", 71, 79], ["SARS-CoV", "SPECIES", 85, 93], ["dipeptidyl peptidase", "TREATMENT", 25, 45], ["cell entry", "TEST", 59, 69], ["SARS", "PROBLEM", 71, 75], ["angiotensin converting enzyme II (ACE2)", "TREATMENT", 132, 171]]], ["ACE2 is recognized by the S1- subunit of the spike protein and is ubiquitously expressed in the epithelia of the nasal cavity, airway tract and the alveolar space.", [["epithelia", "ANATOMY", 96, 105], ["nasal cavity", "ANATOMY", 113, 125], ["airway tract", "ANATOMY", 127, 139], ["alveolar space", "ANATOMY", 148, 162], ["ACE2", "GENE_OR_GENE_PRODUCT", 0, 4], ["epithelia", "TISSUE", 96, 105], ["nasal cavity", "MULTI-TISSUE_STRUCTURE", 113, 125], ["airway tract", "MULTI-TISSUE_STRUCTURE", 127, 139], ["alveolar space", "MULTI-TISSUE_STRUCTURE", 148, 162], ["ACE2", "PROTEIN", 0, 4], ["S1- subunit", "PROTEIN", 26, 37], ["spike protein", "PROTEIN", 45, 58], ["ACE2", "TEST", 0, 4], ["the spike protein", "TEST", 41, 58], ["epithelia", "ANATOMY_MODIFIER", 96, 105], ["nasal cavity", "ANATOMY", 113, 125], ["airway tract", "ANATOMY", 127, 139], ["alveolar space", "OBSERVATION", 148, 162]]], ["Notably, reports have shown that the receptor binding domain of SARS-CoV-2 S1 has a higher affinity for ACE2, which may be one contributing factor to the increased viral pathogenesis of SARS-CoV-2 (13, 14).", [["SARS", "DISEASE", 186, 190], ["SARS-CoV-2 S1", "GENE_OR_GENE_PRODUCT", 64, 77], ["ACE2", "GENE_OR_GENE_PRODUCT", 104, 108], ["SARS-CoV-2", "ORGANISM", 186, 196], ["receptor binding domain", "PROTEIN", 37, 60], ["SARS-CoV-2 S1", "PROTEIN", 64, 77], ["ACE2", "PROTEIN", 104, 108], ["SARS-CoV", "SPECIES", 186, 194], ["SARS", "TEST", 64, 68], ["CoV", "TEST", 69, 72], ["ACE2", "PROBLEM", 104, 108], ["the increased viral pathogenesis of SARS", "PROBLEM", 150, 190], ["CoV", "TEST", 191, 194], ["increased", "OBSERVATION_MODIFIER", 154, 163], ["viral", "OBSERVATION", 164, 169]]], ["The scale of the ongoing pandemic demonstrates the need for a more comprehensive understanding of the disease, and of the contributing factors such as pre-existing comorbidities, which are proving detrimental for disease severity and outcome.Immune Dysfunction and Disease Severity ::: Clinical Presentation of COVID-19The immune system plays a vital role during COVID-19, and the degree of immune dysfunction correlates with disease severity (Figure 2) (3, 4).", [["immune system", "ANATOMY", 323, 336], ["Immune Dysfunction", "DISEASE", 242, 260], ["immune dysfunction", "DISEASE", 391, 409], ["COVID-19", "CHEMICAL", 311, 319], ["the disease", "PROBLEM", 98, 109], ["pre-existing comorbidities", "PROBLEM", 151, 177], ["disease severity", "PROBLEM", 213, 229], ["Immune Dysfunction", "PROBLEM", 242, 260], ["Disease Severity", "PROBLEM", 265, 281], ["COVID", "TEST", 311, 316], ["COVID", "TEST", 363, 368], ["immune dysfunction", "PROBLEM", 391, 409], ["disease severity", "PROBLEM", 426, 442], ["disease", "OBSERVATION", 102, 109], ["immune dysfunction", "OBSERVATION", 391, 409]]], ["During SARS-CoV-2 infection the immune system becomes activated, resulting in local inflammation, the recruitment of monocytes, dendritic cells (DCs), natural killer (NK), T and B cells.", [["immune system", "ANATOMY", 32, 45], ["monocytes", "ANATOMY", 117, 126], ["dendritic cells", "ANATOMY", 128, 143], ["DCs", "ANATOMY", 145, 148], ["natural killer (NK)", "ANATOMY", 151, 170], ["T", "ANATOMY", 172, 173], ["B cells", "ANATOMY", 178, 185], ["infection", "DISEASE", 18, 27], ["inflammation", "DISEASE", 84, 96], ["SARS-CoV-2", "ORGANISM", 7, 17], ["monocytes", "CELL", 117, 126], ["dendritic cells", "CELL", 128, 143], ["DCs", "CELL", 145, 148], ["natural killer", "CELL", 151, 165], ["NK", "CELL", 167, 169], ["T", "CELL", 172, 173], ["B cells", "CELL", 178, 185], ["monocytes", "CELL_TYPE", 117, 126], ["dendritic cells", "CELL_TYPE", 128, 143], ["DCs", "CELL_TYPE", 145, 148], ["natural killer (NK), T and B cells", "CELL_TYPE", 151, 185], ["SARS-CoV-2", "SPECIES", 7, 17], ["SARS", "PROBLEM", 7, 11], ["CoV-2 infection the immune system", "PROBLEM", 12, 45], ["local inflammation", "PROBLEM", 78, 96], ["dendritic cells", "PROBLEM", 128, 143], ["infection", "OBSERVATION", 18, 27], ["local", "OBSERVATION_MODIFIER", 78, 83], ["inflammation", "OBSERVATION", 84, 96], ["recruitment", "OBSERVATION_MODIFIER", 102, 113], ["monocytes", "OBSERVATION", 117, 126], ["dendritic cells", "OBSERVATION", 128, 143]]], ["This response may manifest as mild/moderate disease resulting in a fever, cough and fatigue, however this will be followed by resolution of both the infection and inflammation.", [["fever", "DISEASE", 67, 72], ["cough", "DISEASE", 74, 79], ["fatigue", "DISEASE", 84, 91], ["infection", "DISEASE", 149, 158], ["inflammation", "DISEASE", 163, 175], ["mild/moderate disease", "PROBLEM", 30, 51], ["a fever", "PROBLEM", 65, 72], ["cough", "PROBLEM", 74, 79], ["fatigue", "PROBLEM", 84, 91], ["the infection", "PROBLEM", 145, 158], ["inflammation", "PROBLEM", 163, 175], ["mild", "OBSERVATION_MODIFIER", 30, 34], ["moderate", "OBSERVATION_MODIFIER", 35, 43], ["disease", "OBSERVATION", 44, 51], ["fever", "OBSERVATION", 67, 72], ["infection", "OBSERVATION", 149, 158], ["inflammation", "OBSERVATION", 163, 175]]], ["In severe COVID-19 cases, severe lymphopenia and the accumulation of functionally exhausted T and NK cells result in an inability to mount an effective antiviral immune response to clear SARS-CoV-2 (34, 35).", [["T", "ANATOMY", 92, 93], ["NK cells", "ANATOMY", 98, 106], ["COVID", "DISEASE", 10, 15], ["lymphopenia", "DISEASE", 33, 44], ["T", "CELL", 92, 93], ["NK cells", "CELL", 98, 106], ["T and NK cells", "CELL_TYPE", 92, 106], ["SARS-CoV", "SPECIES", 187, 195], ["severe COVID-19 cases", "PROBLEM", 3, 24], ["severe lymphopenia", "PROBLEM", 26, 44], ["functionally exhausted T and NK cells", "PROBLEM", 69, 106], ["an inability", "PROBLEM", 117, 129], ["CoV", "TEST", 192, 195], ["severe", "OBSERVATION_MODIFIER", 3, 9], ["severe", "OBSERVATION_MODIFIER", 26, 32], ["lymphopenia", "OBSERVATION", 33, 44]]], ["Furthermore, interleukin 6 (IL-6) levels remain elevated over time, and are accompanied by high levels of IL-2, IL-7, IL-10, tumor necrosis factor-\u03b1 (TNF-\u03b1), C-X-C motif chemokine 10 (CXCL-10), monocyte chemoattractant protein-1 (MCP-1), and macrophage inflammatory protein-1\u03b1 (MIP-1\u03b1) resulting in systemic cytokine storm (30).", [["necrosis", "DISEASE", 131, 139], ["interleukin 6", "GENE_OR_GENE_PRODUCT", 13, 26], ["IL-6", "GENE_OR_GENE_PRODUCT", 28, 32], ["IL-2", "GENE_OR_GENE_PRODUCT", 106, 110], ["IL-7", "GENE_OR_GENE_PRODUCT", 112, 116], ["IL-10", "GENE_OR_GENE_PRODUCT", 118, 123], ["tumor necrosis factor-\u03b1", "GENE_OR_GENE_PRODUCT", 125, 148], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 150, 155], ["C-X-C motif chemokine 10", "GENE_OR_GENE_PRODUCT", 158, 182], ["CXCL-10", "GENE_OR_GENE_PRODUCT", 184, 191], ["monocyte chemoattractant protein-1", "GENE_OR_GENE_PRODUCT", 194, 228], ["MCP-1", "GENE_OR_GENE_PRODUCT", 230, 235], ["macrophage inflammatory protein-1\u03b1", "GENE_OR_GENE_PRODUCT", 242, 276], ["MIP-1\u03b1", "GENE_OR_GENE_PRODUCT", 278, 284], ["interleukin 6", "PROTEIN", 13, 26], ["TNF", "PROTEIN", 150, 153], ["monocyte chemoattractant protein-1 (MCP-1", "PROTEIN", 194, 235], ["macrophage inflammatory protein-1\u03b1 (MIP-1\u03b1", "PROTEIN", 242, 284], ["cytokine", "PROTEIN", 308, 316], ["interleukin", "TEST", 13, 24], ["IL", "TEST", 28, 30], ["levels", "TEST", 34, 40], ["elevated", "PROBLEM", 48, 56], ["IL", "TEST", 106, 108], ["IL", "TEST", 112, 114], ["IL", "TEST", 118, 120], ["tumor necrosis factor", "TEST", 125, 146], ["TNF", "TEST", 150, 153], ["C", "TEST", 158, 159], ["motif chemokine", "TEST", 164, 179], ["CXCL", "TEST", 184, 188], ["monocyte chemoattractant protein", "TEST", 194, 226], ["MCP", "TEST", 230, 233], ["macrophage inflammatory protein", "TEST", 242, 273], ["MIP", "TEST", 278, 281], ["systemic cytokine storm", "TEST", 299, 322], ["elevated", "OBSERVATION", 48, 56], ["tumor", "ANATOMY", 125, 130], ["necrosis", "OBSERVATION", 131, 139], ["macrophage", "ANATOMY", 242, 252], ["systemic", "ANATOMY", 299, 307], ["cytokine storm", "OBSERVATION", 308, 322]]], ["This uncontrolled systemic hyperinflammation can cause the development of critical and potentially life-threatening complications such as severe pneumonia, ARDS, septic shock and multiple organ failure (17, 30, 33).", [["organ", "ANATOMY", 188, 193], ["hyperinflammation", "DISEASE", 27, 44], ["pneumonia", "DISEASE", 145, 154], ["ARDS", "DISEASE", 156, 160], ["septic shock", "DISEASE", 162, 174], ["multiple organ failure", "DISEASE", 179, 201], ["organ", "ORGAN", 188, 193], ["This uncontrolled systemic hyperinflammation", "PROBLEM", 0, 44], ["potentially life-threatening complications", "PROBLEM", 87, 129], ["severe pneumonia", "PROBLEM", 138, 154], ["ARDS", "PROBLEM", 156, 160], ["septic shock", "PROBLEM", 162, 174], ["multiple organ failure", "PROBLEM", 179, 201], ["systemic hyperinflammation", "OBSERVATION", 18, 44], ["severe", "OBSERVATION_MODIFIER", 138, 144], ["pneumonia", "OBSERVATION", 145, 154], ["ARDS", "OBSERVATION", 156, 160], ["septic shock", "OBSERVATION", 162, 174], ["multiple", "OBSERVATION_MODIFIER", 179, 187], ["organ", "ANATOMY", 188, 193], ["failure", "OBSERVATION", 194, 201]]], ["Both lymphopenia and hyperinflammation are being reported in the majority of COVID-19 cases admitted to hospital and is associated with a poor prognosis (4, 32, 36).Immune Dysfunction and Disease Severity ::: Clinical Presentation of COVID-19More detailed examination has demonstrated negative effects on all lymphocyte subpopulations including CD4+ and CD8+ T cells, B cells, and NK cells (3).", [["lymphocyte", "ANATOMY", 309, 319], ["CD4+ and CD8+ T cells", "ANATOMY", 345, 366], ["B cells", "ANATOMY", 368, 375], ["NK cells", "ANATOMY", 381, 389], ["lymphopenia", "DISEASE", 5, 16], ["hyperinflammation", "DISEASE", 21, 38], ["Immune Dysfunction", "DISEASE", 165, 183], ["lymphocyte", "CELL", 309, 319], ["CD4", "GENE_OR_GENE_PRODUCT", 345, 348], ["CD8", "GENE_OR_GENE_PRODUCT", 354, 357], ["B cells", "CELL", 368, 375], ["NK cells", "CELL", 381, 389], ["lymphocyte subpopulations", "CELL_TYPE", 309, 334], ["CD4+ and CD8+ T cells", "CELL_TYPE", 345, 366], ["B cells", "CELL_TYPE", 368, 375], ["NK cells", "CELL_TYPE", 381, 389], ["Both lymphopenia", "PROBLEM", 0, 16], ["hyperinflammation", "PROBLEM", 21, 38], ["Immune Dysfunction", "PROBLEM", 165, 183], ["COVID", "TEST", 234, 239], ["More detailed examination", "TEST", 242, 267], ["all lymphocyte subpopulations", "TEST", 305, 334], ["CD4", "TEST", 345, 348], ["CD8+ T cells", "PROBLEM", 354, 366], ["B cells", "TEST", 368, 375], ["NK cells", "TEST", 381, 389], ["lymphopenia", "OBSERVATION", 5, 16], ["hyperinflammation", "OBSERVATION", 21, 38], ["negative", "OBSERVATION", 285, 293], ["lymphocyte subpopulations", "OBSERVATION", 309, 334], ["NK cells", "OBSERVATION", 381, 389]]], ["High-dimensional analysis of circulatory immune profiles in mild, moderate and severe COVID-19 patients by mass cytometry revealed that proportions of na\u00efve CD4+ T cells, TGF\u03b2+CD28\u2212 na\u00efve CD4+ T cells, DCs, and macrophages are associated with mild cases, whereas a sharp decline in the proportion of CD8+ T cells and NK cells was observed in severe cases (3).", [["na\u00efve CD4+ T cells", "ANATOMY", 151, 169], ["TGF\u03b2+CD28\u2212 na\u00efve CD4+ T cells", "ANATOMY", 171, 200], ["DCs", "ANATOMY", 202, 205], ["macrophages", "ANATOMY", 211, 222], ["CD8+ T cells", "ANATOMY", 300, 312], ["NK cells", "ANATOMY", 317, 325], ["patients", "ORGANISM", 95, 103], ["CD4", "GENE_OR_GENE_PRODUCT", 157, 160], ["TGF\u03b2", "GENE_OR_GENE_PRODUCT", 171, 175], ["CD28", "GENE_OR_GENE_PRODUCT", 176, 180], ["CD4", "GENE_OR_GENE_PRODUCT", 188, 191], ["DCs", "CELL", 202, 205], ["macrophages", "CELL", 211, 222], ["CD8", "GENE_OR_GENE_PRODUCT", 300, 303], ["NK cells", "CELL", 317, 325], ["na\u00efve CD4+ T cells", "CELL_TYPE", 151, 169], ["TGF\u03b2", "PROTEIN", 171, 175], ["CD28", "PROTEIN", 176, 180], ["na\u00efve CD4+ T cells", "CELL_TYPE", 182, 200], ["DCs", "CELL_TYPE", 202, 205], ["macrophages", "CELL_TYPE", 211, 222], ["CD8+ T cells", "CELL_TYPE", 300, 312], ["NK cells", "CELL_TYPE", 317, 325], ["patients", "SPECIES", 95, 103], ["circulatory immune profiles", "TEST", 29, 56], ["mild, moderate and severe COVID", "PROBLEM", 60, 91], ["mass cytometry", "TEST", 107, 121], ["na\u00efve CD4", "TEST", 151, 160], ["T cells", "TEST", 162, 169], ["TGF", "TEST", 171, 174], ["\u03b2", "TEST", 174, 175], ["CD28", "TEST", 176, 180], ["na\u00efve", "TEST", 182, 187], ["CD4", "TEST", 188, 191], ["T cells", "TEST", 193, 200], ["DCs", "TEST", 202, 205], ["macrophages", "PROBLEM", 211, 222], ["mild cases", "PROBLEM", 243, 253], ["a sharp decline", "PROBLEM", 263, 278], ["T cells", "PROBLEM", 305, 312], ["NK cells", "PROBLEM", 317, 325], ["circulatory immune", "OBSERVATION", 29, 47], ["mild", "OBSERVATION_MODIFIER", 60, 64], ["moderate", "OBSERVATION_MODIFIER", 66, 74], ["severe", "OBSERVATION_MODIFIER", 79, 85], ["macrophages", "ANATOMY", 211, 222], ["mild", "OBSERVATION_MODIFIER", 243, 247], ["cases", "OBSERVATION", 248, 253], ["sharp", "OBSERVATION_MODIFIER", 265, 270], ["T cells", "OBSERVATION", 305, 312], ["NK cells", "OBSERVATION", 317, 325], ["severe", "OBSERVATION_MODIFIER", 342, 348]]], ["Interestingly, single-cell RNA sequencing of PBMCs isolated from hospitalized COVID-19 patients revealed a novel population of developing neutrophils, which appeared to be closely related to plasmablasts, in patients that had developed ARDS (37).", [["PBMCs", "ANATOMY", 45, 50], ["neutrophils", "ANATOMY", 138, 149], ["plasmablasts", "ANATOMY", 191, 203], ["ARDS", "DISEASE", 236, 240], ["PBMCs", "CELL", 45, 50], ["patients", "ORGANISM", 87, 95], ["neutrophils", "CELL", 138, 149], ["plasmablasts", "CELL", 191, 203], ["patients", "ORGANISM", 208, 216], ["PBMCs", "CELL_TYPE", 45, 50], ["developing neutrophils", "CELL_TYPE", 127, 149], ["plasmablasts", "CELL_TYPE", 191, 203], ["patients", "SPECIES", 87, 95], ["patients", "SPECIES", 208, 216], ["PBMCs", "TEST", 45, 50], ["hospitalized COVID", "TEST", 65, 83], ["developing neutrophils", "PROBLEM", 127, 149], ["plasmablasts", "PROBLEM", 191, 203], ["ARDS", "PROBLEM", 236, 240], ["neutrophils", "OBSERVATION", 138, 149], ["ARDS", "OBSERVATION", 236, 240]]], ["As this was a small cohort of patients, further studies are needed to assess whether this novel subset of neutrophils plays a role in the development of ARDS and other COVID-19 complications.", [["neutrophils", "ANATOMY", 106, 117], ["ARDS", "DISEASE", 153, 157], ["patients", "ORGANISM", 30, 38], ["neutrophils", "CELL", 106, 117], ["neutrophils", "CELL_TYPE", 106, 117], ["patients", "SPECIES", 30, 38], ["further studies", "TEST", 40, 55], ["ARDS", "PROBLEM", 153, 157], ["other COVID-19 complications", "PROBLEM", 162, 190], ["small", "OBSERVATION_MODIFIER", 14, 19], ["ARDS", "OBSERVATION", 153, 157]]], ["Functionally, CD8+ T cells and NK cells in severe COVID-19 patients exhibited more signs of exhaustion than mild/moderate patients (34, 35).", [["CD8+ T cells", "ANATOMY", 14, 26], ["NK cells", "ANATOMY", 31, 39], ["CD8", "GENE_OR_GENE_PRODUCT", 14, 17], ["NK cells", "CELL", 31, 39], ["patients", "ORGANISM", 59, 67], ["patients", "ORGANISM", 122, 130], ["CD8+ T cells", "CELL_TYPE", 14, 26], ["NK cells", "CELL_TYPE", 31, 39], ["patients", "SPECIES", 59, 67], ["patients", "SPECIES", 122, 130], ["NK cells", "TEST", 31, 39], ["severe COVID", "TEST", 43, 55], ["exhaustion than mild/moderate patients", "PROBLEM", 92, 130], ["NK cells", "OBSERVATION", 31, 39], ["severe", "OBSERVATION_MODIFIER", 43, 49], ["exhaustion", "OBSERVATION", 92, 102], ["mild", "OBSERVATION_MODIFIER", 108, 112], ["moderate", "OBSERVATION_MODIFIER", 113, 121]]], ["For example, elevated programmed cell death protein-1 (PD-1), cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) and T cell Ig and ITM domain (TIGIT) on CD8+ T cells and increased NKG2A on NK cells (34, 35).", [["cell", "ANATOMY", 33, 37], ["T cell", "ANATOMY", 119, 125], ["CD8+ T cells", "ANATOMY", 155, 167], ["NK cells", "ANATOMY", 191, 199], ["programmed cell death protein-1", "GENE_OR_GENE_PRODUCT", 22, 53], ["PD-1", "GENE_OR_GENE_PRODUCT", 55, 59], ["cytotoxic T-lymphocyte-associated protein-4", "GENE_OR_GENE_PRODUCT", 62, 105], ["CTLA-4", "GENE_OR_GENE_PRODUCT", 107, 113], ["T cell Ig", "GENE_OR_GENE_PRODUCT", 119, 128], ["ITM domain", "GENE_OR_GENE_PRODUCT", 133, 143], ["TIGIT", "GENE_OR_GENE_PRODUCT", 145, 150], ["CD8", "GENE_OR_GENE_PRODUCT", 155, 158], ["NKG2A", "GENE_OR_GENE_PRODUCT", 182, 187], ["NK cells", "CELL", 191, 199], ["programmed cell death protein-1 (PD-1", "PROTEIN", 22, 59], ["cytotoxic T-lymphocyte-associated protein-4 (CTLA-4", "PROTEIN", 62, 113], ["T cell Ig", "PROTEIN", 119, 128], ["ITM domain", "PROTEIN", 133, 143], ["TIGIT", "PROTEIN", 145, 150], ["CD8", "PROTEIN", 155, 158], ["T cells", "CELL_TYPE", 160, 167], ["NKG2A", "PROTEIN", 182, 187], ["NK cells", "CELL_TYPE", 191, 199], ["elevated programmed cell death protein", "PROBLEM", 13, 51], ["PD", "TEST", 55, 57], ["cytotoxic T", "TEST", 62, 73], ["lymphocyte", "TEST", 74, 84], ["protein", "TEST", 96, 103], ["CTLA", "TEST", 107, 111], ["T cell Ig", "TEST", 119, 128], ["ITM domain", "TEST", 133, 143], ["TIGIT", "TEST", 145, 150], ["CD8", "TEST", 155, 158], ["T cells", "PROBLEM", 160, 167], ["NK cells", "TEST", 191, 199], ["elevated", "OBSERVATION_MODIFIER", 13, 21], ["programmed cell", "OBSERVATION", 22, 37], ["increased NKG2A", "OBSERVATION", 172, 187], ["NK cells", "OBSERVATION", 191, 199]]], ["As exhausted T and NK cells are less able to mount an effective antiviral immune response, it is unsurprising that these subsets are unable to eradicate SARS-CoV-2 and correlate with severe COVID-19 cases.Immune Dysfunction and Disease Severity ::: Clinical Presentation of COVID-19In addition to T cell changes, humoral immunity against SARS-CoV-2 is starting to come to light.", [["T", "ANATOMY", 13, 14], ["NK cells", "ANATOMY", 19, 27], ["T cell", "ANATOMY", 297, 303], ["SARS", "DISEASE", 153, 157], ["Immune Dysfunction", "DISEASE", 205, 223], ["SARS", "DISEASE", 338, 342], ["T", "CELL", 13, 14], ["NK cells", "CELL", 19, 27], ["SARS-CoV-2", "ORGANISM", 153, 163], ["COVID-19In", "SIMPLE_CHEMICAL", 274, 284], ["T cell", "CELL", 297, 303], ["SARS-CoV-2", "ORGANISM", 338, 348], ["T and NK cells", "CELL_TYPE", 13, 27], ["COVID", "PROTEIN", 274, 279], ["SARS-CoV", "SPECIES", 153, 161], ["SARS-CoV", "SPECIES", 338, 346], ["SARS", "TEST", 153, 157], ["CoV", "TEST", 158, 161], ["severe COVID", "TEST", 183, 195], ["Immune Dysfunction", "PROBLEM", 205, 223], ["COVID", "TEST", 274, 279], ["T cell changes", "TREATMENT", 297, 311], ["humoral immunity", "TREATMENT", 313, 329], ["SARS", "PROBLEM", 338, 342]]], ["Evidence of SARS-CoV-2 specific antibodies was demonstrated in a study of 173 hospitalized patients.", [["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 12, 22], ["patients", "ORGANISM", 91, 99], ["SARS-CoV-2 specific antibodies", "PROTEIN", 12, 42], ["patients", "SPECIES", 91, 99], ["SARS-CoV", "SPECIES", 12, 20], ["SARS", "PROBLEM", 12, 16], ["CoV", "TEST", 17, 20], ["specific antibodies", "TEST", 23, 42], ["a study", "TEST", 63, 70], ["SARS", "OBSERVATION", 12, 16]]], ["IgG and IgM SARS-CoV2 antibodies were present in 40% of patients within 1 week of onset and 100% by day 15 (38).", [["IgG", "GENE_OR_GENE_PRODUCT", 0, 3], ["IgM", "GENE_OR_GENE_PRODUCT", 8, 11], ["CoV2", "GENE_OR_GENE_PRODUCT", 17, 21], ["patients", "ORGANISM", 56, 64], ["IgG", "PROTEIN", 0, 3], ["IgM SARS-CoV2 antibodies", "PROTEIN", 8, 32], ["patients", "SPECIES", 56, 64], ["IgG", "TEST", 0, 3], ["IgM SARS", "TEST", 8, 16], ["CoV2 antibodies", "TEST", 17, 32]]], ["In another study, most patients developed robust antibody responses between 17 and 23 days, and although delayed, a stronger antibody response was observed in critical patients (39).", [["patients", "ORGANISM", 23, 31], ["patients", "ORGANISM", 168, 176], ["patients", "SPECIES", 23, 31], ["patients", "SPECIES", 168, 176], ["another study", "TEST", 3, 16], ["robust antibody responses", "PROBLEM", 42, 67], ["a stronger antibody response", "PROBLEM", 114, 142]]], ["These findings were also mirrored in a study of 285 COVID-19 patients, who all showed a positive IgG response by day 19, followed by seroconversion to IgM (40).", [["patients", "ORGANISM", 61, 69], ["IgG", "GENE_OR_GENE_PRODUCT", 97, 100], ["IgG", "PROTEIN", 97, 100], ["IgM", "PROTEIN", 151, 154], ["patients", "SPECIES", 61, 69], ["a study", "TEST", 37, 44], ["IgM", "TEST", 151, 154]]], ["Interestingly, antibody titers were found to be higher among severe COVID-19 patients (40), however the authors acknowledge that interpreting an association between antibody response and disease severity is difficult due to the small sample size of severe and critical patients in their study.", [["patients", "ORGANISM", 77, 85], ["patients", "ORGANISM", 269, 277], ["patients", "SPECIES", 77, 85], ["patients", "SPECIES", 269, 277], ["antibody titers", "TEST", 15, 30], ["antibody response", "TEST", 165, 182], ["disease severity", "PROBLEM", 187, 203], ["their study", "TEST", 281, 292], ["small", "OBSERVATION_MODIFIER", 228, 233], ["size", "OBSERVATION_MODIFIER", 241, 245], ["severe", "OBSERVATION_MODIFIER", 249, 255]]], ["A recent study reported low variable plasma antibody titers in convalescent individuals, however they found binding domain specific antibodies with potent anti-viral activity in all individuals (41).Impact of Age, Biological Sex and EthnicityOlder individuals (\u226560 years) are more prone to severe COVID-19 and have a higher mortality rate (15, 18, 36, 42).", [["plasma", "ANATOMY", 37, 43], ["plasma", "ORGANISM_SUBSTANCE", 37, 43], ["plasma antibody", "PROTEIN", 37, 52], ["binding domain specific antibodies", "PROTEIN", 108, 142], ["A recent study", "TEST", 0, 14], ["low variable plasma antibody titers", "PROBLEM", 24, 59], ["binding domain specific antibodies", "PROBLEM", 108, 142], ["severe COVID", "TEST", 290, 302]]], ["Clinically, older patients have more pronounced immune dysfunction compared to younger patients, as lymphocyte counts are lower and pro-inflammatory cytokine levels higher (43).", [["lymphocyte", "ANATOMY", 100, 110], ["immune dysfunction", "DISEASE", 48, 66], ["patients", "ORGANISM", 18, 26], ["patients", "ORGANISM", 87, 95], ["lymphocyte", "CELL", 100, 110], ["pro-inflammatory cytokine", "PROTEIN", 132, 157], ["patients", "SPECIES", 18, 26], ["patients", "SPECIES", 87, 95], ["pronounced immune dysfunction", "PROBLEM", 37, 66], ["lymphocyte counts", "TEST", 100, 117], ["pro-inflammatory cytokine levels", "TEST", 132, 164], ["more pronounced", "OBSERVATION_MODIFIER", 32, 47], ["immune dysfunction", "OBSERVATION", 48, 66], ["lower", "OBSERVATION_MODIFIER", 122, 127]]], ["This is not surprising as aged immune systems are associated with immunosenescence and chronic low-grade inflammation, termed inflammaging (44).", [["inflammation", "DISEASE", 105, 117], ["inflammaging", "DISEASE", 126, 138], ["-grade inflammation", "PATHOLOGICAL_FORMATION", 98, 117], ["immunosenescence", "PROBLEM", 66, 82], ["chronic low-grade inflammation", "PROBLEM", 87, 117], ["not surprising", "UNCERTAINTY", 8, 22], ["chronic", "OBSERVATION_MODIFIER", 87, 94], ["low-grade", "OBSERVATION_MODIFIER", 95, 104], ["inflammation", "OBSERVATION", 105, 117]]], ["Although immunosenescence affects all aspects of the immune system, much of the deterioration in protective viral immunity can be attributed to defective T cell immunity (45).", [["immune system", "ANATOMY", 53, 66], ["T cell", "ANATOMY", 154, 160], ["immune system", "ANATOMICAL_SYSTEM", 53, 66], ["T cell", "CELL", 154, 160], ["the deterioration in protective viral immunity", "PROBLEM", 76, 122], ["defective T cell immunity", "PROBLEM", 144, 169]]], ["The decline of na\u00efve T cell output due to thymic involution (46) and the accumulation of senescent T cells leads to reduced viral host immunity (47).", [["T cell", "ANATOMY", 21, 27], ["thymic", "ANATOMY", 42, 48], ["T cells", "ANATOMY", 99, 106], ["T cell", "CELL", 21, 27], ["thymic", "ORGAN", 42, 48], ["senescent T cells", "CELL", 89, 106], ["senescent T cells", "CELL_TYPE", 89, 106], ["na\u00efve T cell output", "PROBLEM", 15, 34], ["thymic involution", "PROBLEM", 42, 59], ["senescent T cells", "PROBLEM", 89, 106], ["cell output", "OBSERVATION", 23, 34], ["thymic", "ANATOMY", 42, 48], ["involution", "OBSERVATION", 49, 59], ["senescent T cells", "OBSERVATION", 89, 106]]], ["In mice, CD4+ T cells were shown to be crucial against SARS due to their important role in SARS-CoV clearance.", [["CD4+ T cells", "ANATOMY", 9, 21], ["SARS", "DISEASE", 55, 59], ["mice", "ORGANISM", 3, 7], ["CD4", "GENE_OR_GENE_PRODUCT", 9, 12], ["SARS-CoV", "ORGANISM", 91, 99], ["CD4", "PROTEIN", 9, 12], ["T cells", "CELL_TYPE", 14, 21], ["mice", "SPECIES", 3, 7], ["mice", "SPECIES", 3, 7], ["SARS-CoV", "SPECIES", 91, 99], ["T cells", "PROBLEM", 14, 21], ["SARS", "PROBLEM", 55, 59]]], ["This protection was lost in aged mice as senescent CD4+ T cells responded poorly to antigen (48, 49).", [["CD4+ T cells", "ANATOMY", 51, 63], ["mice", "ORGANISM", 33, 37], ["CD4", "GENE_OR_GENE_PRODUCT", 51, 54], ["senescent CD4+ T cells", "CELL_TYPE", 41, 63], ["mice", "SPECIES", 33, 37], ["mice", "SPECIES", 33, 37], ["senescent CD4", "TEST", 41, 54], ["T cells", "PROBLEM", 56, 63], ["antigen", "TEST", 84, 91]]], ["Moreover, in addition to inflammaging, the accumulation of senescent CD8+ T cells and B cells with distinct senescence-associated secretory phenotypes (50, 51) in older individuals results in elevated baseline inflammation, further increasing susceptibility to hyperinflammation and cytokine storm upon SARS-CoV-2 infection.Impact of Age, Biological Sex and EthnicityIn addition to age, biological sex and ethnicity have also been implicated in COVID-19 outcomes.", [["CD8+ T cells", "ANATOMY", 69, 81], ["B cells", "ANATOMY", 86, 93], ["inflammation", "DISEASE", 210, 222], ["hyperinflammation", "DISEASE", 261, 278], ["infection", "DISEASE", 314, 323], ["CD8", "GENE_OR_GENE_PRODUCT", 69, 72], ["B cells", "CELL", 86, 93], ["SARS-CoV-2", "ORGANISM", 303, 313], ["senescent CD8+ T cells", "CELL_TYPE", 59, 81], ["B cells", "CELL_TYPE", 86, 93], ["cytokine", "PROTEIN", 283, 291], ["SARS-CoV", "SPECIES", 303, 311], ["senescent CD8+ T cells", "PROBLEM", 59, 81], ["B cells", "PROBLEM", 86, 93], ["distinct senescence", "PROBLEM", 99, 118], ["secretory phenotypes", "PROBLEM", 130, 150], ["elevated baseline inflammation", "PROBLEM", 192, 222], ["further increasing susceptibility to hyperinflammation", "PROBLEM", 224, 278], ["cytokine storm", "PROBLEM", 283, 297], ["SARS", "PROBLEM", 303, 307], ["CoV", "PROBLEM", 308, 311], ["2 infection", "PROBLEM", 312, 323], ["senescent CD8+ T cells", "OBSERVATION", 59, 81], ["distinct", "OBSERVATION_MODIFIER", 99, 107], ["senescence", "OBSERVATION_MODIFIER", 108, 118], ["secretory phenotypes", "OBSERVATION", 130, 150], ["elevated", "OBSERVATION_MODIFIER", 192, 200], ["baseline", "OBSERVATION_MODIFIER", 201, 209], ["inflammation", "OBSERVATION", 210, 222], ["cytokine storm", "OBSERVATION", 283, 297], ["infection", "OBSERVATION", 314, 323]]], ["Although no major sex differences exist when examining absolute number of COVID-19 cases, disease incidence is higher in males when comparing older individuals (\u226560 years).", [["COVID", "TEST", 74, 79], ["disease incidence", "PROBLEM", 90, 107], ["higher", "OBSERVATION_MODIFIER", 111, 117]]], ["Furthermore, initial reports from China suggested a male bias in mortality (23, 36), which has now been reported in 37 out of 38 countries that have reported sex-disaggregated data, revealing a global male case fatality rate of 7.3% compared to 4.4% in females (52, 53).", [["fatality rate", "TEST", 211, 224]]], ["This finding is consistent with data obtained from the previous SARS and MERS epidemic (54\u201356).", [["SARS", "DISEASE", 64, 68], ["consistent with", "UNCERTAINTY", 16, 31]]], ["The predominant hypothesis to explain these biological sex differences is that estrogen plays a protective role against COVID-19.", [["estrogen", "CHEMICAL", 79, 87], ["estrogen", "CHEMICAL", 79, 87], ["COVID-19", "CHEMICAL", 120, 128], ["estrogen", "SIMPLE_CHEMICAL", 79, 87], ["COVID-19", "GENE_OR_GENE_PRODUCT", 120, 128], ["The predominant hypothesis", "PROBLEM", 0, 26], ["COVID", "TEST", 120, 125]]], ["Following the SARS epidemic, studies in mice demonstrated that ovariectomy or pharmaceutical blocking of estrogen in female mice resulted in elevated immune cell infiltration in the lung and consequently a more severe disease outcome (57).", [["immune cell", "ANATOMY", 150, 161], ["lung", "ANATOMY", 182, 186], ["SARS", "DISEASE", 14, 18], ["estrogen", "CHEMICAL", 105, 113], ["estrogen", "CHEMICAL", 105, 113], ["mice", "ORGANISM", 40, 44], ["ovariectomy", "SIMPLE_CHEMICAL", 63, 74], ["estrogen", "SIMPLE_CHEMICAL", 105, 113], ["female mice", "ORGANISM", 117, 128], ["immune cell", "CELL", 150, 161], ["lung", "ORGAN", 182, 186], ["mice", "SPECIES", 40, 44], ["mice", "SPECIES", 124, 128], ["mice", "SPECIES", 40, 44], ["mice", "SPECIES", 124, 128], ["the SARS epidemic", "PROBLEM", 10, 27], ["studies", "TEST", 29, 36], ["ovariectomy", "TREATMENT", 63, 74], ["pharmaceutical blocking of estrogen", "TREATMENT", 78, 113], ["elevated immune cell infiltration in the lung", "PROBLEM", 141, 186], ["a more severe disease outcome", "PROBLEM", 204, 233], ["ovariectomy", "OBSERVATION", 63, 74], ["elevated", "OBSERVATION_MODIFIER", 141, 149], ["immune cell infiltration", "OBSERVATION", 150, 174], ["lung", "ANATOMY", 182, 186], ["severe", "OBSERVATION_MODIFIER", 211, 217], ["disease", "OBSERVATION", 218, 225]]], ["In support of this, researchers in China reported that lower levels of estrogen were associated with more severe COVID-19 cases in women (58).", [["estrogen", "CHEMICAL", 71, 79], ["COVID", "DISEASE", 113, 118], ["estrogen", "CHEMICAL", 71, 79], ["estrogen", "SIMPLE_CHEMICAL", 71, 79], ["women", "ORGANISM", 131, 136], ["women", "SPECIES", 131, 136], ["lower levels of estrogen", "PROBLEM", 55, 79], ["more severe COVID", "PROBLEM", 101, 118]]], ["Although the exact molecular mechanisms underpinning how estrogen protects against COVID-19 are yet to be confirmed, the influence of estrogen on aging and immunity, ACE2 levels, and sex-related risk factors for comorbidities have all been suggested (52, 53, 59).", [["estrogen", "CHEMICAL", 57, 65], ["estrogen", "CHEMICAL", 134, 142], ["estrogen", "CHEMICAL", 57, 65], ["COVID-19", "CHEMICAL", 83, 91], ["estrogen", "CHEMICAL", 134, 142], ["estrogen", "SIMPLE_CHEMICAL", 57, 65], ["COVID-19", "GENE_OR_GENE_PRODUCT", 83, 91], ["estrogen", "SIMPLE_CHEMICAL", 134, 142], ["ACE2", "GENE_OR_GENE_PRODUCT", 166, 170], ["ACE2", "PROTEIN", 166, 170], ["COVID", "TEST", 83, 88], ["estrogen on aging", "TREATMENT", 134, 151], ["ACE2 levels", "TEST", 166, 177], ["sex-related risk factors", "PROBLEM", 183, 207], ["comorbidities", "PROBLEM", 212, 225]]], ["Due to these benefits, researchers in the UK have commenced investigations into the effects of hormonal therapies such as the contraceptive pill and hormone replacement therapy, however no data has been published yet.", [["hormonal therapies", "TREATMENT", 95, 113], ["the contraceptive pill", "TREATMENT", 122, 144], ["hormone replacement therapy", "TREATMENT", 149, 176]]], ["More recently, data has emerged suggesting that Black, Asian and Minority Ethnic (BAME) individuals are at a greater risk of acquiring SARS-CoV-2 and have worse clinical outcomes (60).", [["SARS", "DISEASE", 135, 139], ["SARS-CoV", "SPECIES", 135, 143], ["Black", "OBSERVATION_MODIFIER", 48, 53]]], ["For instance, in the UK two thirds of COVID-19 fatalities among healthcare workers were BAME individuals (61, 62).", [["fatalities", "DISEASE", 47, 57]]], ["Underlying comorbidities, which are more prevalent in BAME individuals, in addition to cultural, behavioral and socio-economic differences have been proposed as possible causes (60).", [["Underlying comorbidities", "PROBLEM", 0, 24], ["behavioral and socio-economic differences", "PROBLEM", 97, 138], ["comorbidities", "OBSERVATION", 11, 24]]], ["However, more data is needed in order to truly establish whether a relationship between COVID-19 and ethnicity exists.Hypertension and Cardiovascular Disease ::: Impact of Pre-Existing ComorbiditiesHypertension has been repeatedly reported as the highest pre-existing comorbidity in COVID-19 patients (1, 2, 17, 63\u201365).", [["Cardiovascular", "ANATOMY", 135, 149], ["Hypertension", "DISEASE", 118, 130], ["Cardiovascular Disease", "DISEASE", 135, 157], ["Hypertension", "DISEASE", 198, 210], ["patients", "ORGANISM", 292, 300], ["patients", "SPECIES", 292, 300], ["COVID", "TEST", 88, 93], ["Hypertension", "PROBLEM", 118, 130], ["Cardiovascular Disease", "PROBLEM", 135, 157], ["Pre-Existing ComorbiditiesHypertension", "PROBLEM", 172, 210], ["Cardiovascular", "ANATOMY", 135, 149], ["Disease", "OBSERVATION", 150, 157], ["Hypertension", "OBSERVATION", 198, 210]]], ["Retrospective analysis revealed that patients with hypertension have an increased risk for severe infection and mortality (65, 66).", [["hypertension", "DISEASE", 51, 63], ["infection", "DISEASE", 98, 107], ["patients", "ORGANISM", 37, 45], ["patients", "SPECIES", 37, 45], ["Retrospective analysis", "TEST", 0, 22], ["hypertension", "PROBLEM", 51, 63], ["severe infection", "PROBLEM", 91, 107], ["hypertension", "OBSERVATION", 51, 63], ["increased", "OBSERVATION_MODIFIER", 72, 81], ["severe", "OBSERVATION_MODIFIER", 91, 97], ["infection", "OBSERVATION", 98, 107]]], ["However, whether hypertension itself or the use of hypertensive therapies are responsible for these statistics is currently unknown.", [["hypertension", "DISEASE", 17, 29], ["hypertensive", "DISEASE", 51, 63], ["hypertension", "PROBLEM", 17, 29], ["hypertensive therapies", "TREATMENT", 51, 73], ["hypertension", "OBSERVATION", 17, 29]]], ["Hypertensive patients are commonly treated with renin angiotensin system inhibitors, such as ACE inhibitors (ACEI) and angiotensin-receptor blockers (ARB).", [["Hypertensive", "DISEASE", 0, 12], ["angiotensin", "CHEMICAL", 54, 65], ["ACE inhibitors", "CHEMICAL", 93, 107], ["ACEI", "CHEMICAL", 109, 113], ["angiotensin-receptor blockers", "CHEMICAL", 119, 148], ["ARB", "CHEMICAL", 150, 153], ["patients", "ORGANISM", 13, 21], ["renin angiotensin", "GENE_OR_GENE_PRODUCT", 48, 65], ["ACE inhibitors", "SIMPLE_CHEMICAL", 93, 107], ["ACEI", "SIMPLE_CHEMICAL", 109, 113], ["angiotensin-receptor blockers", "SIMPLE_CHEMICAL", 119, 148], ["ARB", "SIMPLE_CHEMICAL", 150, 153], ["patients", "SPECIES", 13, 21], ["Hypertensive", "PROBLEM", 0, 12], ["renin angiotensin system inhibitors", "TREATMENT", 48, 83], ["ACE inhibitors", "TREATMENT", 93, 107], ["ACEI", "TREATMENT", 109, 113], ["angiotensin-receptor blockers", "TREATMENT", 119, 148], ["ARB", "TREATMENT", 150, 153]]], ["As ACEI and ARB can significantly increase ACE2 expression (67), many speculate they are responsible for the increased risk to hypertensive patients (68).", [["ACEI", "CHEMICAL", 3, 7], ["ARB", "CHEMICAL", 12, 15], ["hypertensive", "DISEASE", 127, 139], ["ACEI", "SIMPLE_CHEMICAL", 3, 7], ["ARB", "SIMPLE_CHEMICAL", 12, 15], ["ACE2", "GENE_OR_GENE_PRODUCT", 43, 47], ["patients", "ORGANISM", 140, 148], ["ACE2", "PROTEIN", 43, 47], ["patients", "SPECIES", 140, 148], ["ACEI", "TREATMENT", 3, 7], ["ARB", "TREATMENT", 12, 15], ["ACE2 expression", "TEST", 43, 58], ["the increased risk to hypertensive patients", "PROBLEM", 105, 148]]], ["Conversely, a retrospective review of 417 hospitalized COVID-19 patients, of which 12.23% had underlying hypertensions, indicated that ACEI and ARB may be protective effect against COVID-19, as the percentage of severe cases were lower in patients treated with ACEI/ARB (23.5%) when compared to those treated with other anti-hypertensive treatments such as calcium channel blockers, \u03b2-blockers, and diuretics (48%) (69).", [["hypertensions", "DISEASE", 105, 118], ["ACEI", "CHEMICAL", 135, 139], ["ARB", "CHEMICAL", 144, 147], ["ACEI", "CHEMICAL", 261, 265], ["ARB", "CHEMICAL", 266, 269], ["calcium", "CHEMICAL", 357, 364], ["calcium", "CHEMICAL", 357, 364], ["patients", "ORGANISM", 64, 72], ["ACEI", "SIMPLE_CHEMICAL", 135, 139], ["ARB", "SIMPLE_CHEMICAL", 144, 147], ["patients", "ORGANISM", 239, 247], ["ACEI", "SIMPLE_CHEMICAL", 261, 265], ["ARB", "SIMPLE_CHEMICAL", 266, 269], ["calcium channel blockers", "SIMPLE_CHEMICAL", 357, 381], ["\u03b2-blockers", "SIMPLE_CHEMICAL", 383, 393], ["diuretics", "SIMPLE_CHEMICAL", 399, 408], ["patients", "SPECIES", 64, 72], ["patients", "SPECIES", 239, 247], ["underlying hypertensions", "PROBLEM", 94, 118], ["ACEI", "TREATMENT", 135, 139], ["ARB", "TREATMENT", 144, 147], ["COVID", "TEST", 181, 186], ["severe cases", "PROBLEM", 212, 224], ["ACEI", "TREATMENT", 261, 265], ["ARB", "TREATMENT", 266, 269], ["other anti-hypertensive treatments", "TREATMENT", 314, 348], ["calcium channel blockers", "TREATMENT", 357, 381], ["\u03b2-blockers", "TREATMENT", 383, 393], ["diuretics", "TREATMENT", 399, 408], ["severe", "OBSERVATION_MODIFIER", 212, 218], ["cases", "OBSERVATION", 219, 224]]], ["However, patients treated with non-ACI/ARB were also found to have a higher incidence of additional comorbidities (69), which may have been responsible for the development of severe disease.", [["ARB", "CHEMICAL", 39, 42], ["patients", "ORGANISM", 9, 17], ["patients", "SPECIES", 9, 17], ["non-ACI/ARB", "TREATMENT", 31, 42], ["additional comorbidities", "PROBLEM", 89, 113], ["severe disease", "PROBLEM", 175, 189], ["may have been responsible for", "UNCERTAINTY", 126, 155], ["severe", "OBSERVATION_MODIFIER", 175, 181], ["disease", "OBSERVATION", 182, 189]]], ["Due to the conflicting evidence and opinions among the scientific community, it remains unclear whether treatment with ACEI/ARB has a positive or negative impact on COVID-19 progression, however many are continuing to examine this.Hypertension and Cardiovascular Disease ::: Impact of Pre-Existing ComorbiditiesCardiovascular disease has also been highly reported among COVID-19 patients and is associated with an increased mortality rate (17, 63, 70).", [["Cardiovascular", "ANATOMY", 248, 262], ["Cardiovascular", "ANATOMY", 311, 325], ["ACEI", "CHEMICAL", 119, 123], ["ARB", "CHEMICAL", 124, 127], ["Hypertension", "DISEASE", 231, 243], ["Cardiovascular Disease", "DISEASE", 248, 270], ["Cardiovascular disease", "DISEASE", 311, 333], ["ACEI", "SIMPLE_CHEMICAL", 119, 123], ["ARB", "SIMPLE_CHEMICAL", 124, 127], ["patients", "ORGANISM", 379, 387], ["patients", "SPECIES", 379, 387], ["ACEI", "TREATMENT", 119, 123], ["ARB", "TREATMENT", 124, 127], ["COVID", "TEST", 165, 170], ["Hypertension", "PROBLEM", 231, 243], ["Cardiovascular Disease", "PROBLEM", 248, 270], ["Pre-Existing ComorbiditiesCardiovascular disease", "PROBLEM", 285, 333], ["an increased mortality rate", "PROBLEM", 411, 438], ["Cardiovascular", "ANATOMY", 248, 262], ["Disease", "OBSERVATION", 263, 270], ["Cardiovascular disease", "OBSERVATION", 311, 333], ["increased", "OBSERVATION_MODIFIER", 414, 423]]], ["Furthermore, cardiovascular complications such as thromboembolic events, myocarditis, acute coronary syndrome, arrythmia, cardiogenic shock and heat failure, have been documented in COVID-19 patients without prior cardiovascular disease (71), demonstrating a significant impact of SARS-CoV-2 infection on the heart.", [["cardiovascular", "ANATOMY", 13, 27], ["coronary", "ANATOMY", 92, 100], ["cardiovascular", "ANATOMY", 214, 228], ["heart", "ANATOMY", 309, 314], ["cardiovascular complications", "DISEASE", 13, 41], ["thromboembolic", "DISEASE", 50, 64], ["myocarditis", "DISEASE", 73, 84], ["acute coronary syndrome", "DISEASE", 86, 109], ["arrythmia", "DISEASE", 111, 120], ["cardiogenic shock", "DISEASE", 122, 139], ["heat failure", "DISEASE", 144, 156], ["cardiovascular disease", "DISEASE", 214, 236], ["SARS", "DISEASE", 281, 285], ["infection", "DISEASE", 292, 301], ["cardiovascular", "ANATOMICAL_SYSTEM", 13, 27], ["patients", "ORGANISM", 191, 199], ["cardiovascular", "ANATOMICAL_SYSTEM", 214, 228], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 281, 291], ["heart", "ORGAN", 309, 314], ["patients", "SPECIES", 191, 199], ["cardiovascular complications", "PROBLEM", 13, 41], ["thromboembolic events", "PROBLEM", 50, 71], ["myocarditis", "PROBLEM", 73, 84], ["acute coronary syndrome", "PROBLEM", 86, 109], ["arrythmia", "PROBLEM", 111, 120], ["cardiogenic shock", "PROBLEM", 122, 139], ["heat failure", "PROBLEM", 144, 156], ["prior cardiovascular disease", "PROBLEM", 208, 236], ["SARS", "PROBLEM", 281, 285], ["CoV-2 infection on the heart", "PROBLEM", 286, 314], ["cardiovascular", "ANATOMY", 13, 27], ["complications", "OBSERVATION", 28, 41], ["thromboembolic", "OBSERVATION", 50, 64], ["myocarditis", "OBSERVATION", 73, 84], ["acute", "OBSERVATION_MODIFIER", 86, 91], ["coronary", "ANATOMY", 92, 100], ["syndrome", "OBSERVATION", 101, 109], ["arrythmia", "OBSERVATION", 111, 120], ["cardiogenic shock", "OBSERVATION", 122, 139], ["heat failure", "OBSERVATION", 144, 156], ["cardiovascular", "ANATOMY", 214, 228], ["disease", "OBSERVATION", 229, 236], ["significant", "OBSERVATION_MODIFIER", 259, 270], ["impact", "OBSERVATION_MODIFIER", 271, 277], ["SARS", "OBSERVATION", 281, 285], ["CoV", "OBSERVATION_MODIFIER", 286, 289], ["infection", "OBSERVATION", 292, 301], ["heart", "ANATOMY", 309, 314]]], ["In a case series of 187 COVID-19 patients, those with underlying cardiovascular disease had a mortality rate of 37.5%, which was further increased to 69.44% in a subset of patients who had both underlying cardiovascular disease and elevated troponin T levels, indicative of myocardial injury (70).", [["cardiovascular", "ANATOMY", 65, 79], ["cardiovascular", "ANATOMY", 205, 219], ["myocardial", "ANATOMY", 274, 284], ["cardiovascular disease", "DISEASE", 65, 87], ["cardiovascular disease", "DISEASE", 205, 227], ["myocardial injury", "DISEASE", 274, 291], ["patients", "ORGANISM", 33, 41], ["patients", "ORGANISM", 172, 180], ["cardiovascular", "ANATOMICAL_SYSTEM", 205, 219], ["troponin T", "GENE_OR_GENE_PRODUCT", 241, 251], ["myocardial", "MULTI-TISSUE_STRUCTURE", 274, 284], ["troponin T", "PROTEIN", 241, 251], ["patients", "SPECIES", 33, 41], ["patients", "SPECIES", 172, 180], ["underlying cardiovascular disease", "PROBLEM", 54, 87], ["a mortality rate", "TEST", 92, 108], ["underlying cardiovascular disease", "PROBLEM", 194, 227], ["elevated troponin T levels", "PROBLEM", 232, 258], ["myocardial injury", "PROBLEM", 274, 291], ["cardiovascular", "ANATOMY", 65, 79], ["disease", "OBSERVATION", 80, 87], ["cardiovascular", "ANATOMY", 205, 219], ["disease", "OBSERVATION", 220, 227], ["indicative of", "UNCERTAINTY", 260, 273], ["myocardial", "ANATOMY", 274, 284], ["injury", "OBSERVATION", 285, 291]]], ["Two possible explanations for the increased prevalence and mortality among patients with comorbid cardiovascular disease have been proposed.", [["cardiovascular", "ANATOMY", 98, 112], ["cardiovascular disease", "DISEASE", 98, 120], ["patients", "ORGANISM", 75, 83], ["patients", "SPECIES", 75, 83], ["the increased prevalence", "PROBLEM", 30, 54], ["comorbid cardiovascular disease", "PROBLEM", 89, 120], ["possible explanations for", "UNCERTAINTY", 4, 29]]], ["Firstly, cardiovascular disease is commonly treated with renin angiotensin system inhibitors as described above (72, 73), and secondly, ACE2 is highly expressed in the heart (74).", [["cardiovascular", "ANATOMY", 9, 23], ["heart", "ANATOMY", 168, 173], ["cardiovascular disease", "DISEASE", 9, 31], ["angiotensin", "CHEMICAL", 63, 74], ["cardiovascular", "ANATOMICAL_SYSTEM", 9, 23], ["renin angiotensin", "GENE_OR_GENE_PRODUCT", 57, 74], ["ACE2", "GENE_OR_GENE_PRODUCT", 136, 140], ["heart", "ORGAN", 168, 173], ["renin", "PROTEIN", 57, 62], ["ACE2", "PROTEIN", 136, 140], ["cardiovascular disease", "PROBLEM", 9, 31], ["renin angiotensin system inhibitors", "TREATMENT", 57, 92], ["ACE2", "TEST", 136, 140], ["cardiovascular", "ANATOMY", 9, 23], ["disease", "OBSERVATION", 24, 31], ["heart", "ANATOMY", 168, 173]]], ["A recent study analyzing the cellular distribution of ACE2 in human heart tissue obtained from COVID-19 patients identified that ACE2 was highly expressed in pericytes, cardiomyocytes and fibroblasts (75).", [["cellular", "ANATOMY", 29, 37], ["heart tissue", "ANATOMY", 68, 80], ["pericytes", "ANATOMY", 158, 167], ["cardiomyocytes", "ANATOMY", 169, 183], ["fibroblasts", "ANATOMY", 188, 199], ["cellular", "CELL", 29, 37], ["ACE2", "GENE_OR_GENE_PRODUCT", 54, 58], ["human", "ORGANISM", 62, 67], ["heart tissue", "TISSUE", 68, 80], ["patients", "ORGANISM", 104, 112], ["ACE2", "GENE_OR_GENE_PRODUCT", 129, 133], ["pericytes", "CELL", 158, 167], ["cardiomyocytes", "CELL", 169, 183], ["fibroblasts", "CELL", 188, 199], ["ACE2", "PROTEIN", 54, 58], ["ACE2", "PROTEIN", 129, 133], ["pericytes", "CELL_TYPE", 158, 167], ["cardiomyocytes", "CELL_TYPE", 169, 183], ["fibroblasts", "CELL_TYPE", 188, 199], ["human", "SPECIES", 62, 67], ["patients", "SPECIES", 104, 112], ["human", "SPECIES", 62, 67], ["A recent study", "TEST", 0, 14], ["ACE2 in human heart tissue", "PROBLEM", 54, 80], ["COVID", "TEST", 95, 100], ["ACE2", "TEST", 129, 133], ["human heart", "ANATOMY", 62, 73], ["pericytes", "OBSERVATION", 158, 167], ["cardiomyocytes", "ANATOMY", 169, 183]]], ["Furthermore, CD209, an additional binding receptor for SARS-CoV, was specifically expressed in macrophages (75).", [["macrophages", "ANATOMY", 95, 106], ["CD209", "GENE_OR_GENE_PRODUCT", 13, 18], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 55, 63], ["macrophages", "CELL", 95, 106], ["CD209", "PROTEIN", 13, 18], ["binding receptor", "PROTEIN", 34, 50], ["macrophages", "CELL_TYPE", 95, 106], ["SARS-CoV", "SPECIES", 55, 63], ["CD209", "TEST", 13, 18], ["SARS", "PROBLEM", 55, 59], ["CoV", "PROBLEM", 60, 63], ["macrophages", "ANATOMY", 95, 106]]], ["Due to the increased presence of macrophages in cardiovascular disease, the authors speculate that CD209+ macrophages may enhance viral entry into the human heart.", [["macrophages", "ANATOMY", 33, 44], ["cardiovascular", "ANATOMY", 48, 62], ["CD209+ macrophages", "ANATOMY", 99, 117], ["heart", "ANATOMY", 157, 162], ["cardiovascular disease", "DISEASE", 48, 70], ["macrophages", "CELL", 33, 44], ["cardiovascular", "ANATOMICAL_SYSTEM", 48, 62], ["CD209", "GENE_OR_GENE_PRODUCT", 99, 104], ["human", "ORGANISM", 151, 156], ["heart", "ORGAN", 157, 162], ["macrophages", "CELL_TYPE", 33, 44], ["CD209", "PROTEIN", 99, 104], ["macrophages", "CELL_TYPE", 106, 117], ["human", "SPECIES", 151, 156], ["human", "SPECIES", 151, 156], ["macrophages", "PROBLEM", 33, 44], ["cardiovascular disease", "PROBLEM", 48, 70], ["macrophages", "PROBLEM", 106, 117], ["increased", "OBSERVATION_MODIFIER", 11, 20], ["macrophages", "OBSERVATION", 33, 44], ["cardiovascular disease", "OBSERVATION", 48, 70], ["macrophages", "OBSERVATION", 106, 117], ["human", "ANATOMY_MODIFIER", 151, 156], ["heart", "ANATOMY", 157, 162]]], ["Collectively, this study indicated an intrinsic susceptibility to SARS-CoV-2 infection in the heart, which could explain the high susceptibility to COVID-19 among cardiovascular disease patients and the higher incidence of acute cardiac injury in non-cardiovascular disease patients.Hypertension and Cardiovascular Disease ::: Impact of Pre-Existing ComorbiditiesAccording to numerous reports severe COVID-19 patients are at heightened risk of thromboembolic events, with 20\u201330% of critically ill COVID-19 patients reported to have developed thromboembolic complications (21, 76\u201379).", [["heart", "ANATOMY", 94, 99], ["cardiovascular", "ANATOMY", 163, 177], ["cardiac", "ANATOMY", 229, 236], ["non-cardiovascular", "ANATOMY", 247, 265], ["Cardiovascular", "ANATOMY", 300, 314], ["SARS", "DISEASE", 66, 70], ["infection", "DISEASE", 77, 86], ["COVID-19", "CHEMICAL", 148, 156], ["cardiovascular disease", "DISEASE", 163, 185], ["cardiac injury", "DISEASE", 229, 243], ["non-cardiovascular disease", "DISEASE", 247, 273], ["Hypertension", "DISEASE", 283, 295], ["Cardiovascular Disease", "DISEASE", 300, 322], ["thromboembolic", "DISEASE", 444, 458], ["critically ill", "DISEASE", 482, 496], ["thromboembolic complications", "DISEASE", 542, 570], ["COVID-19", "CHEMICAL", 148, 156], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 66, 76], ["heart", "ORGAN", 94, 99], ["COVID-19", "GENE_OR_GENE_PRODUCT", 148, 156], ["cardiovascular", "ANATOMICAL_SYSTEM", 163, 177], ["patients", "ORGANISM", 186, 194], ["cardiac", "ORGAN", 229, 236], ["patients", "ORGANISM", 274, 282], ["patients", "ORGANISM", 409, 417], ["patients", "ORGANISM", 506, 514], ["patients", "SPECIES", 186, 194], ["patients", "SPECIES", 274, 282], ["patients", "SPECIES", 409, 417], ["patients", "SPECIES", 506, 514], ["SARS-CoV-2", "SPECIES", 66, 76], ["this study", "TEST", 14, 24], ["an intrinsic susceptibility to SARS", "PROBLEM", 35, 70], ["CoV-2 infection in the heart", "PROBLEM", 71, 99], ["COVID", "TEST", 148, 153], ["among cardiovascular disease", "PROBLEM", 157, 185], ["acute cardiac injury", "PROBLEM", 223, 243], ["non-cardiovascular disease patients", "PROBLEM", 247, 282], ["Hypertension", "PROBLEM", 283, 295], ["Cardiovascular Disease", "PROBLEM", 300, 322], ["Pre-Existing Comorbidities", "PROBLEM", 337, 363], ["severe COVID", "PROBLEM", 393, 405], ["thromboembolic events", "PROBLEM", 444, 465], ["critically ill COVID", "TREATMENT", 482, 502], ["thromboembolic complications", "PROBLEM", 542, 570], ["intrinsic", "OBSERVATION_MODIFIER", 38, 47], ["susceptibility", "OBSERVATION", 48, 62], ["SARS", "OBSERVATION", 66, 70], ["infection", "OBSERVATION", 77, 86], ["heart", "ANATOMY", 94, 99], ["high", "OBSERVATION_MODIFIER", 125, 129], ["cardiovascular", "ANATOMY", 163, 177], ["disease", "OBSERVATION", 178, 185], ["higher", "OBSERVATION_MODIFIER", 203, 209], ["incidence", "OBSERVATION_MODIFIER", 210, 219], ["acute", "OBSERVATION_MODIFIER", 223, 228], ["cardiac", "ANATOMY", 229, 236], ["injury", "OBSERVATION", 237, 243], ["non-cardiovascular disease", "OBSERVATION", 247, 273], ["Cardiovascular", "ANATOMY", 300, 314], ["Disease", "OBSERVATION", 315, 322], ["thromboembolic", "OBSERVATION", 444, 458], ["thromboembolic", "OBSERVATION", 542, 556]]], ["Systemic inflammation and subsequent activation of coagulation are both contributing factors to this increased risk (79, 80).", [["inflammation", "DISEASE", 9, 21], ["Systemic inflammation", "PROBLEM", 0, 21], ["subsequent activation of coagulation", "PROBLEM", 26, 62], ["this increased risk", "PROBLEM", 96, 115], ["inflammation", "OBSERVATION", 9, 21]]], ["Coagulation abnormalities have been reported throughout the COVID-19 pandemic and the term COVID-19-associated coagulopathy (CAC) has been used to describe patients displaying coagulation changes (78).", [["Coagulation abnormalities", "DISEASE", 0, 25], ["COVID-19", "CHEMICAL", 91, 99], ["coagulopathy", "DISEASE", 111, 123], ["CAC", "DISEASE", 125, 128], ["patients", "ORGANISM", 156, 164], ["patients", "SPECIES", 156, 164], ["Coagulation abnormalities", "PROBLEM", 0, 25], ["the COVID", "TEST", 56, 65], ["pandemic", "PROBLEM", 69, 77], ["the term COVID", "TEST", 82, 96], ["coagulopathy (CAC", "PROBLEM", 111, 128], ["coagulation changes", "TEST", 176, 195], ["coagulopathy", "OBSERVATION", 111, 123]]], ["Elevated levels of prothrombin, fibrinogen and D-dimer, in addition to elevated inflammatory markers such as C-reactive protein (CRP) and IL-6, are markers of CAC (78).", [["prothrombin", "GENE_OR_GENE_PRODUCT", 19, 30], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 32, 42], ["D-dimer", "GENE_OR_GENE_PRODUCT", 47, 54], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 109, 127], ["CRP", "GENE_OR_GENE_PRODUCT", 129, 132], ["IL-6", "GENE_OR_GENE_PRODUCT", 138, 142], ["prothrombin", "PROTEIN", 19, 30], ["fibrinogen", "PROTEIN", 32, 42], ["D-dimer", "PROTEIN", 47, 54], ["inflammatory markers", "PROTEIN", 80, 100], ["C-reactive protein", "PROTEIN", 109, 127], ["CRP", "PROTEIN", 129, 132], ["IL-6", "PROTEIN", 138, 142], ["Elevated levels", "PROBLEM", 0, 15], ["prothrombin", "TEST", 19, 30], ["fibrinogen", "TEST", 32, 42], ["D-dimer", "PROBLEM", 47, 54], ["elevated inflammatory markers", "PROBLEM", 71, 100], ["C-reactive protein", "PROBLEM", 109, 127], ["CRP", "TEST", 129, 132], ["IL", "TEST", 138, 140], ["CAC", "TEST", 159, 162], ["prothrombin", "OBSERVATION", 19, 30], ["elevated", "OBSERVATION_MODIFIER", 71, 79], ["inflammatory", "OBSERVATION", 80, 92]]], ["In particular, increased D-dimer levels highly correlate with disease severity, as elevated D-dimer presenting at admission or over time are associated with increase mortality in COVID-19 patients (81).", [["D-dimer", "GENE_OR_GENE_PRODUCT", 25, 32], ["D-dimer", "GENE_OR_GENE_PRODUCT", 92, 99], ["patients", "ORGANISM", 188, 196], ["D-dimer", "PROTEIN", 25, 32], ["D-dimer", "PROTEIN", 92, 99], ["patients", "SPECIES", 188, 196], ["increased D-dimer levels", "PROBLEM", 15, 39], ["disease severity", "PROBLEM", 62, 78], ["elevated D-dimer", "PROBLEM", 83, 99], ["increase mortality", "PROBLEM", 157, 175], ["COVID", "TEST", 179, 184], ["increased", "OBSERVATION_MODIFIER", 15, 24], ["D-dimer", "OBSERVATION_MODIFIER", 25, 32], ["elevated", "OBSERVATION_MODIFIER", 83, 91]]], ["Due to the high incidence of thromboembolic events, the use of thromboprophylaxis for patients admitted to hospital with severe COVID-19 has been suggested (76, 78), and CAC should be monitored carefully in all hospitalized COVID-19 patient, particularly those with pre-existing risk of thromboembolic events.Diabetes and Obesity ::: Impact of Pre-Existing ComorbiditiesDiabetes is the third most prevalent underlying comorbidity in COVID-19 patients (2, 17, 63, 82, 83).", [["thromboembolic", "DISEASE", 29, 43], ["COVID-19", "CHEMICAL", 128, 136], ["thromboembolic", "DISEASE", 287, 301], ["Diabetes", "DISEASE", 309, 317], ["Obesity", "DISEASE", 322, 329], ["Diabetes", "DISEASE", 370, 378], ["COVID-19", "CHEMICAL", 128, 136], ["patients", "ORGANISM", 86, 94], ["patient", "ORGANISM", 233, 240], ["patients", "ORGANISM", 442, 450], ["patients", "SPECIES", 86, 94], ["patient", "SPECIES", 233, 240], ["patients", "SPECIES", 442, 450], ["thromboembolic events", "PROBLEM", 29, 50], ["thromboprophylaxis", "TREATMENT", 63, 81], ["severe COVID", "PROBLEM", 121, 133], ["CAC", "TEST", 170, 173], ["thromboembolic events", "PROBLEM", 287, 308], ["Diabetes", "PROBLEM", 309, 317], ["Obesity", "PROBLEM", 322, 329], ["Pre-Existing ComorbiditiesDiabetes", "PROBLEM", 344, 378], ["thromboembolic", "OBSERVATION", 29, 43], ["thromboembolic", "OBSERVATION", 287, 301], ["Obesity", "OBSERVATION", 322, 329], ["ComorbiditiesDiabetes", "OBSERVATION", 357, 378], ["comorbidity", "OBSERVATION", 418, 429]]], ["Type 2 diabetes is a multifactorial disease characterized by chronic inflammation and impaired metabolism and has become an increasing risk to human health.", [["Type 2 diabetes", "DISEASE", 0, 15], ["inflammation", "DISEASE", 69, 81], ["human", "ORGANISM", 143, 148], ["human", "SPECIES", 143, 148], ["human", "SPECIES", 143, 148], ["Type 2 diabetes", "PROBLEM", 0, 15], ["a multifactorial disease", "PROBLEM", 19, 43], ["chronic inflammation", "PROBLEM", 61, 81], ["impaired metabolism", "PROBLEM", 86, 105], ["diabetes", "OBSERVATION", 7, 15], ["multifactorial", "OBSERVATION_MODIFIER", 21, 35], ["disease", "OBSERVATION", 36, 43], ["chronic", "OBSERVATION_MODIFIER", 61, 68], ["inflammation", "OBSERVATION", 69, 81], ["impaired metabolism", "OBSERVATION", 86, 105], ["increasing", "OBSERVATION_MODIFIER", 124, 134]]], ["Diabetic individuals have an increased susceptibility to infection (84), and are at a high risk of developing multiple comorbidities such as cardiovascular disease (83).", [["cardiovascular", "ANATOMY", 141, 155], ["Diabetic", "DISEASE", 0, 8], ["infection", "DISEASE", 57, 66], ["cardiovascular disease", "DISEASE", 141, 163], ["cardiovascular", "ANATOMICAL_SYSTEM", 141, 155], ["Diabetic individuals", "PROBLEM", 0, 20], ["an increased susceptibility to infection", "PROBLEM", 26, 66], ["multiple comorbidities", "PROBLEM", 110, 132], ["cardiovascular disease", "PROBLEM", 141, 163], ["increased", "OBSERVATION_MODIFIER", 29, 38], ["susceptibility", "OBSERVATION_MODIFIER", 39, 53], ["infection", "OBSERVATION", 57, 66], ["multiple", "OBSERVATION_MODIFIER", 110, 118], ["comorbidities", "OBSERVATION", 119, 132], ["cardiovascular disease", "OBSERVATION", 141, 163]]], ["One study on COVID-19 found that diabetic patients were more likely to develop pneumonia and were responsible for 11.7% of severe cases, but only 4% of mild/moderate cases (85).", [["diabetic", "DISEASE", 33, 41], ["pneumonia", "DISEASE", 79, 88], ["patients", "ORGANISM", 42, 50], ["patients", "SPECIES", 42, 50], ["One study", "TEST", 0, 9], ["COVID", "TEST", 13, 18], ["diabetic", "PROBLEM", 33, 41], ["pneumonia", "PROBLEM", 79, 88], ["severe cases", "PROBLEM", 123, 135], ["mild/moderate cases", "PROBLEM", 152, 171], ["diabetic", "OBSERVATION", 33, 41], ["pneumonia", "OBSERVATION", 79, 88], ["mild", "OBSERVATION_MODIFIER", 152, 156], ["moderate", "OBSERVATION_MODIFIER", 157, 165]]], ["There are a number of reasons as to why people with diabetes are more likely to develop severe COVID-19.", [["diabetes", "DISEASE", 52, 60], ["COVID", "DISEASE", 95, 100], ["COVID-19", "CHEMICAL", 95, 103], ["people", "ORGANISM", 40, 46], ["people", "SPECIES", 40, 46], ["diabetes", "PROBLEM", 52, 60], ["severe COVID", "PROBLEM", 88, 100]]], ["Firstly, chronic inflammation in diabetic patients increases their susceptibility to hyperinflammation and the development of cytokine storm.", [["inflammation", "DISEASE", 17, 29], ["diabetic", "DISEASE", 33, 41], ["hyperinflammation", "DISEASE", 85, 102], ["patients", "ORGANISM", 42, 50], ["cytokine", "PROTEIN", 126, 134], ["patients", "SPECIES", 42, 50], ["chronic inflammation in diabetic patients", "PROBLEM", 9, 50], ["their susceptibility to hyperinflammation", "PROBLEM", 61, 102], ["cytokine storm", "PROBLEM", 126, 140], ["chronic", "OBSERVATION_MODIFIER", 9, 16], ["inflammation", "OBSERVATION", 17, 29], ["diabetic", "OBSERVATION_MODIFIER", 33, 41], ["cytokine storm", "OBSERVATION", 126, 140]]], ["This has been already reported in COVID-19 patients, as IL-6 and CRP levels were found to be significantly higher in diabetic patients (83).", [["diabetic", "DISEASE", 117, 125], ["patients", "ORGANISM", 43, 51], ["IL-6", "GENE_OR_GENE_PRODUCT", 56, 60], ["CRP", "GENE_OR_GENE_PRODUCT", 65, 68], ["patients", "ORGANISM", 126, 134], ["IL-6", "PROTEIN", 56, 60], ["CRP", "PROTEIN", 65, 68], ["patients", "SPECIES", 43, 51], ["patients", "SPECIES", 126, 134], ["IL", "TEST", 56, 58], ["CRP levels", "TEST", 65, 75], ["significantly", "OBSERVATION_MODIFIER", 93, 106], ["higher", "OBSERVATION_MODIFIER", 107, 113]]], ["Secondly, it is well-documented that hyperglycaemia can impair the immune response, increase oxidative stress and is associated with the onset of premature senescence (86, 87).", [["hyperglycaemia", "DISEASE", 37, 51], ["premature senescence", "DISEASE", 146, 166], ["hyperglycaemia", "PROBLEM", 37, 51], ["increase oxidative stress", "PROBLEM", 84, 109], ["premature senescence", "PROBLEM", 146, 166]]], ["Consequently, diabetic patients that are unable to control their blood glucose levels may have an even greater vulnerability to severe disease.", [["blood", "ANATOMY", 65, 70], ["diabetic", "DISEASE", 14, 22], ["glucose", "CHEMICAL", 71, 78], ["glucose", "CHEMICAL", 71, 78], ["patients", "ORGANISM", 23, 31], ["blood", "ORGANISM_SUBSTANCE", 65, 70], ["glucose", "SIMPLE_CHEMICAL", 71, 78], ["patients", "SPECIES", 23, 31], ["their blood glucose levels", "TEST", 59, 85], ["severe disease", "PROBLEM", 128, 142], ["diabetic", "OBSERVATION", 14, 22], ["severe", "OBSERVATION_MODIFIER", 128, 134], ["disease", "OBSERVATION", 135, 142]]], ["Finally, in addition to disease etiology, the treatment of diabetes may also impact COVID-19 development.", [["diabetes", "DISEASE", 59, 67], ["diabetes", "PROBLEM", 59, 67], ["COVID", "TEST", 84, 89], ["disease", "OBSERVATION", 24, 31]]], ["As previously discussed for hypertension and cardiovascular disease, the use of renin angiotensin system inhibitors may increase susceptibility to SARS-CoV-2 infection (88, 89).", [["cardiovascular", "ANATOMY", 45, 59], ["hypertension", "DISEASE", 28, 40], ["cardiovascular disease", "DISEASE", 45, 67], ["angiotensin", "CHEMICAL", 86, 97], ["SARS-CoV-2 infection", "DISEASE", 147, 167], ["cardiovascular", "ANATOMICAL_SYSTEM", 45, 59], ["renin angiotensin", "GENE_OR_GENE_PRODUCT", 80, 97], ["SARS-CoV-2", "ORGANISM", 147, 157], ["renin", "PROTEIN", 80, 85], ["SARS-CoV-2", "SPECIES", 147, 157], ["hypertension", "PROBLEM", 28, 40], ["cardiovascular disease", "PROBLEM", 45, 67], ["renin angiotensin system inhibitors", "TREATMENT", 80, 115], ["SARS", "TEST", 147, 151], ["CoV-2 infection", "PROBLEM", 152, 167], ["cardiovascular", "ANATOMY", 45, 59], ["disease", "OBSERVATION", 60, 67]]], ["Furthermore, DPP4 inhibitors commonly used to treat diabetes have an anti-inflammatory effect, resulting in reduced macrophage infiltration, which could impair the innate immune response during COVID-19 (90).Diabetes and Obesity ::: Impact of Pre-Existing ComorbiditiesObesity is associated with most of the common COVID-19 comorbidities such as hypertension, cardiovascular disease and diabetes (91, 92).", [["macrophage", "ANATOMY", 116, 126], ["cardiovascular", "ANATOMY", 360, 374], ["diabetes", "DISEASE", 52, 60], ["Diabetes", "DISEASE", 208, 216], ["Obesity", "DISEASE", 221, 228], ["Obesity", "DISEASE", 269, 276], ["hypertension", "DISEASE", 346, 358], ["cardiovascular disease", "DISEASE", 360, 382], ["diabetes", "DISEASE", 387, 395], ["COVID-19", "CHEMICAL", 194, 202], ["DPP4", "GENE_OR_GENE_PRODUCT", 13, 17], ["macrophage", "CELL", 116, 126], ["DPP4 inhibitors", "TREATMENT", 13, 28], ["diabetes", "PROBLEM", 52, 60], ["an anti-inflammatory effect", "PROBLEM", 66, 93], ["reduced macrophage infiltration", "PROBLEM", 108, 139], ["COVID", "TEST", 194, 199], ["Diabetes", "PROBLEM", 208, 216], ["Obesity", "PROBLEM", 221, 228], ["Pre-Existing ComorbiditiesObesity", "PROBLEM", 243, 276], ["the common COVID-19 comorbidities", "PROBLEM", 304, 337], ["hypertension", "PROBLEM", 346, 358], ["cardiovascular disease", "PROBLEM", 360, 382], ["diabetes", "PROBLEM", 387, 395], ["anti-inflammatory effect", "OBSERVATION", 69, 93], ["reduced", "OBSERVATION_MODIFIER", 108, 115], ["macrophage infiltration", "OBSERVATION", 116, 139], ["Obesity", "OBSERVATION", 221, 228], ["Obesity", "OBSERVATION", 269, 276], ["hypertension", "OBSERVATION", 346, 358], ["cardiovascular disease", "OBSERVATION", 360, 382], ["diabetes", "OBSERVATION", 387, 395]]], ["The global prevalence of obesity varies greatly, for example obesity is more common in the United States and Europe than it is in Asian countries (93).", [["obesity", "DISEASE", 25, 32], ["obesity", "DISEASE", 61, 68], ["obesity", "PROBLEM", 25, 32], ["example obesity", "PROBLEM", 53, 68], ["global", "OBSERVATION_MODIFIER", 4, 10], ["prevalence", "OBSERVATION_MODIFIER", 11, 21], ["obesity", "OBSERVATION", 25, 32], ["obesity", "OBSERVATION", 61, 68]]], ["Consequently, COVID-19 severity and mortality rates may also vary as a result of this.", [["COVID", "TEST", 14, 19], ["mortality rates", "TEST", 36, 51]]], ["One study reported a higher BMI in patients with severe infection, and when comparing survivors vs. non-survivors, it was reported that 88.2% of non-survivors had a BMI above 25 kg/m2, which was a significantly higher proportion than survivors (94).", [["infection", "DISEASE", 56, 65], ["patients", "ORGANISM", 35, 43], ["patients", "SPECIES", 35, 43], ["One study", "TEST", 0, 9], ["a higher BMI", "PROBLEM", 19, 31], ["severe infection", "PROBLEM", 49, 65], ["a BMI", "TEST", 163, 168], ["severe", "OBSERVATION_MODIFIER", 49, 55], ["infection", "OBSERVATION", 56, 65]]], ["However, the cohort for this study was small (n = 30) and further retrospective analysis of existing studies is needed to clarify the impact of obesity on COVID-19.", [["obesity", "DISEASE", 144, 151], ["this study", "TEST", 24, 34], ["further retrospective analysis", "TEST", 58, 88], ["existing studies", "TEST", 92, 108], ["obesity", "PROBLEM", 144, 151], ["COVID", "TEST", 155, 160], ["obesity", "OBSERVATION", 144, 151]]], ["Following the previous H1N1 pandemic, retrospective analyses reported that obesity was associated with increased risk of severe infection and mortality (95), which is in line with the increased risk of infection in obese individuals (96).", [["obesity", "DISEASE", 75, 82], ["infection", "DISEASE", 128, 137], ["infection", "DISEASE", 202, 211], ["retrospective analyses", "TEST", 38, 60], ["obesity", "PROBLEM", 75, 82], ["severe infection", "PROBLEM", 121, 137], ["infection in obese individuals", "PROBLEM", 202, 232], ["obesity", "OBSERVATION", 75, 82], ["severe", "OBSERVATION_MODIFIER", 121, 127], ["infection", "OBSERVATION", 128, 137], ["increased", "OBSERVATION_MODIFIER", 184, 193], ["infection", "OBSERVATION", 202, 211]]], ["In addition to increased risk of comorbidities, obesity is also linked to an impaired immune response (97), with evidence of impaired antibody (98) and T cell (99) responses.", [["T cell", "ANATOMY", 152, 158], ["obesity", "DISEASE", 48, 55], ["T cell", "CELL", 152, 158], ["comorbidities", "PROBLEM", 33, 46], ["obesity", "PROBLEM", 48, 55], ["an impaired immune response", "PROBLEM", 74, 101], ["impaired antibody", "PROBLEM", 125, 142], ["T cell", "TEST", 152, 158], ["increased", "OBSERVATION_MODIFIER", 15, 24], ["comorbidities", "OBSERVATION", 33, 46], ["obesity", "OBSERVATION", 48, 55], ["impaired", "OBSERVATION_MODIFIER", 125, 133], ["antibody", "OBSERVATION", 134, 142]]], ["Furthermore, expression of ACE2 is upregulated in adipocytes of obese individuals and therefore may act as a potential target for SARS-CoV-2 (100).Cancer ::: Impact of Pre-Existing ComorbiditiesThe incidence of cancer as a COVID-19 comorbidity has been low.", [["adipocytes", "ANATOMY", 50, 60], ["Cancer", "ANATOMY", 147, 153], ["cancer", "ANATOMY", 211, 217], ["Cancer", "DISEASE", 147, 153], ["cancer", "DISEASE", 211, 217], ["ACE2", "GENE_OR_GENE_PRODUCT", 27, 31], ["adipocytes", "CELL", 50, 60], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 130, 140], ["Cancer", "CANCER", 147, 153], ["cancer", "CANCER", 211, 217], ["ACE2", "PROTEIN", 27, 31], ["adipocytes", "CELL_TYPE", 50, 60], ["SARS-CoV", "SPECIES", 130, 138], ["ACE2", "PROBLEM", 27, 31], ["obese individuals", "PROBLEM", 64, 81], ["SARS", "TEST", 130, 134], ["CoV", "TEST", 135, 138], ["Pre-Existing Comorbidities", "PROBLEM", 168, 194], ["cancer", "PROBLEM", 211, 217], ["a COVID", "TEST", 221, 228], ["comorbidity", "PROBLEM", 232, 243], ["cancer", "OBSERVATION", 211, 217], ["low", "OBSERVATION_MODIFIER", 253, 256]]], ["In an extensive meta-analysis of 76,993 patients, malignancy accounted for just 0.92% of comorbidities reported (1).", [["malignancy", "DISEASE", 50, 60], ["patients", "ORGANISM", 40, 48], ["patients", "SPECIES", 40, 48], ["an extensive meta-analysis", "TEST", 3, 29], ["malignancy", "PROBLEM", 50, 60], ["comorbidities", "PROBLEM", 89, 102], ["extensive", "OBSERVATION_MODIFIER", 6, 15], ["malignancy", "OBSERVATION", 50, 60]]], ["However, a nationwide analysis in China reported that 1.1% of COVID-19 cases had active cancer, and these patients had a higher proportion of serious events in comparison to individuals without cancer (101).", [["cancer", "ANATOMY", 88, 94], ["cancer", "ANATOMY", 194, 200], ["cancer", "DISEASE", 88, 94], ["cancer", "DISEASE", 194, 200], ["cancer", "CANCER", 88, 94], ["patients", "ORGANISM", 106, 114], ["cancer", "CANCER", 194, 200], ["patients", "SPECIES", 106, 114], ["a nationwide analysis", "TEST", 9, 30], ["COVID", "TEST", 62, 67], ["active cancer", "PROBLEM", 81, 94], ["serious events", "PROBLEM", 142, 156], ["cancer", "PROBLEM", 194, 200], ["active", "OBSERVATION_MODIFIER", 81, 87], ["cancer", "OBSERVATION", 88, 94], ["cancer", "OBSERVATION", 194, 200]]], ["At this current time, it is unclear whether cancer patients are at high risk of COVID-19 due to an immunocompromised state linked to certain cancer therapies.", [["cancer", "ANATOMY", 44, 50], ["cancer", "ANATOMY", 141, 147], ["cancer", "DISEASE", 44, 50], ["cancer", "DISEASE", 141, 147], ["cancer", "CANCER", 44, 50], ["patients", "ORGANISM", 51, 59], ["cancer", "CANCER", 141, 147], ["patients", "SPECIES", 51, 59], ["cancer", "PROBLEM", 44, 50], ["COVID", "TEST", 80, 85], ["an immunocompromised state", "PROBLEM", 96, 122], ["cancer therapies", "TREATMENT", 141, 157], ["unclear whether", "UNCERTAINTY", 28, 43], ["cancer", "OBSERVATION", 44, 50], ["immunocompromised", "OBSERVATION", 99, 116]]], ["In one particular study, patients that underwent recent chemotherapy or surgery had a higher risk of clinically severe events than those who did not.", [["patients", "ORGANISM", 25, 33], ["patients", "SPECIES", 25, 33], ["recent chemotherapy", "TREATMENT", 49, 68], ["surgery", "TREATMENT", 72, 79], ["clinically severe events", "PROBLEM", 101, 125], ["chemotherapy", "OBSERVATION", 56, 68]]], ["However, a limited number of just 19 patients were included in this analysis (102), demonstrating the need for more thorough research.Cancer ::: Impact of Pre-Existing ComorbiditiesFurthermore, not all cancer patients should be considered equally immunocompromised.", [["Cancer", "ANATOMY", 134, 140], ["cancer", "ANATOMY", 202, 208], ["Cancer", "DISEASE", 134, 140], ["cancer", "DISEASE", 202, 208], ["patients", "ORGANISM", 37, 45], ["Cancer", "CANCER", 134, 140], ["cancer", "CANCER", 202, 208], ["patients", "ORGANISM", 209, 217], ["patients", "SPECIES", 37, 45], ["patients", "SPECIES", 209, 217], ["this analysis", "TEST", 63, 76], ["Pre-Existing Comorbidities", "PROBLEM", 155, 181], ["immunocompromised", "PROBLEM", 247, 264], ["cancer", "OBSERVATION", 202, 208], ["immunocompromised", "OBSERVATION", 247, 264]]], ["Cancer patients treated with immuno-oncology therapies such as immune checkpoint inhibitors (ICI) could be more immunocompetent than patients undergoing chemotherapy (103).", [["Cancer", "ANATOMY", 0, 6], ["Cancer", "DISEASE", 0, 6], ["ICI", "CHEMICAL", 93, 96], ["Cancer", "CANCER", 0, 6], ["patients", "ORGANISM", 7, 15], ["patients", "ORGANISM", 133, 141], ["patients", "SPECIES", 7, 15], ["patients", "SPECIES", 133, 141], ["Cancer", "PROBLEM", 0, 6], ["immuno-oncology therapies", "TREATMENT", 29, 54], ["immune checkpoint inhibitors (ICI", "TREATMENT", 63, 96], ["chemotherapy", "TREATMENT", 153, 165]]], ["Nonetheless, there are two major concern associated with the use of immuno-oncology therapies during COVID-19.", [["immuno-oncology therapies", "TREATMENT", 68, 93], ["COVID", "TEST", 101, 106]]], ["Firstly, there is potential overlap between COVID-19 interstitial pneumonia and possible pneumological toxicity from anti-PD-1/PDL-1 agents, which can be fatal.", [["interstitial pneumonia", "DISEASE", 53, 75], ["toxicity", "DISEASE", 103, 111], ["anti-PD-1/PDL-1 agents", "CHEMICAL", 117, 139], ["anti-PD-1", "GENE_OR_GENE_PRODUCT", 117, 126], ["PDL-1", "GENE_OR_GENE_PRODUCT", 127, 132], ["COVID", "TEST", 44, 49], ["interstitial pneumonia", "PROBLEM", 53, 75], ["pneumological toxicity", "PROBLEM", 89, 111], ["anti-PD", "TREATMENT", 117, 124], ["PDL", "TREATMENT", 127, 130], ["interstitial", "ANATOMY_MODIFIER", 53, 65], ["pneumonia", "OBSERVATION", 66, 75], ["possible", "UNCERTAINTY", 80, 88], ["pneumological toxicity", "OBSERVATION", 89, 111]]], ["Although this is a rare immune-related adverse event, it has been reported in 2.5\u20135% of patients treated with anti-PD-1/PDL-1 monotherapy, and 7\u201310% of patients treated with anti-PD-1/anti-CTLA-4 combination therapy (104, 105).", [["anti-PD-1/PDL-1", "CHEMICAL", 110, 125], ["anti-PD-1", "CHEMICAL", 174, 183], ["CTLA-4 combination", "CHEMICAL", 189, 207], ["patients", "ORGANISM", 88, 96], ["anti-PD-1", "GENE_OR_GENE_PRODUCT", 110, 119], ["PDL-1", "GENE_OR_GENE_PRODUCT", 120, 125], ["patients", "ORGANISM", 152, 160], ["anti-PD-1", "GENE_OR_GENE_PRODUCT", 174, 183], ["CTLA-4", "GENE_OR_GENE_PRODUCT", 189, 195], ["patients", "SPECIES", 88, 96], ["patients", "SPECIES", 152, 160], ["anti-PD", "TREATMENT", 110, 117], ["PDL", "TREATMENT", 120, 123], ["monotherapy", "TREATMENT", 126, 137], ["anti-PD", "TREATMENT", 174, 181], ["anti-CTLA", "TREATMENT", 184, 193]]], ["Secondly, there is a risk of cytokine release syndrome associated with T cell-engaging immunotherapy, such as chimeric antigen receptor (CAR) T cells.", [["T cell", "ANATOMY", 71, 77], ["chimeric antigen receptor (CAR) T cells", "ANATOMY", 110, 149], ["T cell", "CELL", 71, 77], ["chimeric antigen receptor", "GENE_OR_GENE_PRODUCT", 110, 135], ["cytokine", "PROTEIN", 29, 37], ["chimeric antigen receptor (CAR) T cells", "CELL_TYPE", 110, 149], ["cytokine release syndrome", "PROBLEM", 29, 54], ["T cell", "PROBLEM", 71, 77], ["engaging immunotherapy", "TREATMENT", 78, 100], ["risk of", "UNCERTAINTY", 21, 28], ["cytokine release syndrome", "OBSERVATION", 29, 54]]], ["Given that cytokine storm has been linked to a negative outcome in COVID-19 due to the development of ARDS and multiple organ failure, ICI and CAR-T cell therapies may exacerbate this hyperinflammatory state and increase mortality in these patients (103).", [["organ", "ANATOMY", 120, 125], ["CAR-T cell", "ANATOMY", 143, 153], ["ARDS", "DISEASE", 102, 106], ["multiple organ failure", "DISEASE", 111, 133], ["ICI", "CHEMICAL", 135, 138], ["ICI", "CHEMICAL", 135, 138], ["organ", "ORGAN", 120, 125], ["ICI", "SIMPLE_CHEMICAL", 135, 138], ["CAR-T cell", "CELL", 143, 153], ["patients", "ORGANISM", 240, 248], ["cytokine", "PROTEIN", 11, 19], ["patients", "SPECIES", 240, 248], ["COVID", "TEST", 67, 72], ["ARDS", "PROBLEM", 102, 106], ["multiple organ failure", "PROBLEM", 111, 133], ["ICI", "TREATMENT", 135, 138], ["CAR-T cell therapies", "TREATMENT", 143, 163], ["this hyperinflammatory state", "PROBLEM", 179, 207], ["ARDS", "OBSERVATION", 102, 106], ["multiple", "OBSERVATION_MODIFIER", 111, 119], ["organ", "ANATOMY", 120, 125], ["failure", "OBSERVATION", 126, 133], ["increase", "OBSERVATION_MODIFIER", 212, 220], ["mortality", "OBSERVATION_MODIFIER", 221, 230]]], ["Overall, despite the lower incidence of cancer among COVID-19 patients, those being treated with immunocompromising therapies such as chemotherapy, and those susceptible to immune-related adverse events in response to immuno-oncology therapies should be monitored carefully.Respiratory Diseases ::: Impact of Pre-Existing ComorbiditiesAs infection with SARS-CoV-2 results in an acute respiratory disease that can progress to ARDS, respiratory failure and potentially even death, it is reasonable to speculate that patients with pre-existing respiratory disease would be at increased risk of severe COVID-19.", [["cancer", "ANATOMY", 40, 46], ["respiratory", "ANATOMY", 384, 395], ["respiratory", "ANATOMY", 431, 442], ["respiratory", "ANATOMY", 541, 552], ["cancer", "DISEASE", 40, 46], ["Respiratory Diseases", "DISEASE", 274, 294], ["ComorbiditiesAs infection", "DISEASE", 322, 347], ["SARS", "DISEASE", 353, 357], ["respiratory disease", "DISEASE", 384, 403], ["ARDS", "DISEASE", 425, 429], ["respiratory failure", "DISEASE", 431, 450], ["death", "DISEASE", 472, 477], ["respiratory disease", "DISEASE", 541, 560], ["COVID", "DISEASE", 598, 603], ["COVID-19", "CHEMICAL", 598, 606], ["cancer", "CANCER", 40, 46], ["patients", "ORGANISM", 62, 70], ["patients", "ORGANISM", 514, 522], ["patients", "SPECIES", 62, 70], ["patients", "SPECIES", 514, 522], ["SARS-CoV", "SPECIES", 353, 361], ["cancer", "PROBLEM", 40, 46], ["immunocompromising therapies", "TREATMENT", 97, 125], ["chemotherapy", "TREATMENT", 134, 146], ["adverse events", "PROBLEM", 188, 202], ["immuno-oncology therapies", "TREATMENT", 218, 243], ["Respiratory Diseases", "PROBLEM", 274, 294], ["Pre-Existing ComorbiditiesAs infection", "PROBLEM", 309, 347], ["SARS", "PROBLEM", 353, 357], ["CoV", "TEST", 358, 361], ["an acute respiratory disease", "PROBLEM", 375, 403], ["ARDS", "PROBLEM", 425, 429], ["respiratory failure", "PROBLEM", 431, 450], ["pre-existing respiratory disease", "PROBLEM", 528, 560], ["severe COVID", "PROBLEM", 591, 603], ["cancer", "OBSERVATION", 40, 46], ["Diseases", "OBSERVATION", 286, 294], ["infection", "OBSERVATION", 338, 347], ["acute", "OBSERVATION_MODIFIER", 378, 383], ["respiratory disease", "OBSERVATION", 384, 403], ["ARDS", "OBSERVATION", 425, 429], ["respiratory failure", "OBSERVATION", 431, 450], ["respiratory disease", "OBSERVATION", 541, 560], ["severe", "OBSERVATION_MODIFIER", 591, 597]]], ["Surprisingly, this risk is not as striking as one might anticipate, as the prevalence of asthma was just 0.90% in a study of 548 COVID-19 patients in China (106).", [["asthma", "DISEASE", 89, 95], ["patients", "ORGANISM", 138, 146], ["patients", "SPECIES", 138, 146], ["asthma", "PROBLEM", 89, 95], ["a study", "TEST", 114, 121], ["COVID", "TEST", 129, 134], ["asthma", "OBSERVATION", 89, 95]]], ["Furthermore, the incidence of chronic obstructive pulmonary disease (COPD) among hospitalized COVID-19 patients was reported to be just 0.95% in a meta-analysis of 76,993 patients (1).", [["pulmonary", "ANATOMY", 50, 59], ["chronic obstructive pulmonary disease", "DISEASE", 30, 67], ["COPD", "DISEASE", 69, 73], ["COVID", "DISEASE", 94, 99], ["pulmonary", "ORGAN", 50, 59], ["patients", "ORGANISM", 103, 111], ["patients", "ORGANISM", 171, 179], ["patients", "SPECIES", 103, 111], ["patients", "SPECIES", 171, 179], ["chronic obstructive pulmonary disease", "PROBLEM", 30, 67], ["COPD)", "PROBLEM", 69, 74], ["a meta-analysis", "TEST", 145, 160], ["chronic", "OBSERVATION_MODIFIER", 30, 37], ["obstructive", "OBSERVATION_MODIFIER", 38, 49], ["pulmonary", "ANATOMY", 50, 59], ["disease", "OBSERVATION", 60, 67], ["COPD", "OBSERVATION", 69, 73]]], ["Conversely, the Center For Disease Control and Prevention (CDC) recently released data of US hospitalizations indicating that COPD is present in 9.2% of patients (107).", [["COPD", "DISEASE", 126, 130], ["patients", "ORGANISM", 153, 161], ["patients", "SPECIES", 153, 161], ["Disease Control", "TREATMENT", 27, 42], ["COPD", "PROBLEM", 126, 130], ["COPD", "OBSERVATION", 126, 130]]], ["A possible explanation for this global variation could be due to differences in therapeutics agents and disease management.", [["this global variation", "PROBLEM", 27, 48], ["therapeutics agents", "TREATMENT", 80, 99], ["disease management", "TREATMENT", 104, 122], ["possible explanation for", "UNCERTAINTY", 2, 26]]], ["For instance, a global survey assessing the severity and control of 7,786 asthmatic adults worldwide published that individuals in Japan and Asia-Pacific regions reported less severe disease than those in Europe and the United States (108).Liver and Kidney Disease ::: Impact of Pre-Existing ComorbiditiesThe prevalence of chronic liver disease in COVID-19 patients is estimated to be 3% (19, 109).", [["Liver", "ANATOMY", 240, 245], ["Kidney", "ANATOMY", 250, 256], ["liver", "ANATOMY", 331, 336], ["Liver and Kidney Disease", "DISEASE", 240, 264], ["chronic liver disease", "DISEASE", 323, 344], ["Liver", "ORGAN", 240, 245], ["Kidney", "ORGAN", 250, 256], ["liver", "ORGAN", 331, 336], ["patients", "ORGANISM", 357, 365], ["patients", "SPECIES", 357, 365], ["a global survey", "TEST", 14, 29], ["less severe disease", "PROBLEM", 171, 190], ["Pre-Existing Comorbidities", "PROBLEM", 279, 305], ["chronic liver disease", "PROBLEM", 323, 344], ["less", "OBSERVATION_MODIFIER", 171, 175], ["severe", "OBSERVATION_MODIFIER", 176, 182], ["disease", "OBSERVATION", 183, 190], ["Kidney", "ANATOMY", 250, 256], ["Disease", "OBSERVATION", 257, 264], ["chronic", "OBSERVATION_MODIFIER", 323, 330], ["liver", "ANATOMY", 331, 336], ["disease", "OBSERVATION", 337, 344]]], ["However, liver damage has been repeatedly reported as a common complication in response to COVID-19 (30, 36, 109).", [["liver", "ANATOMY", 9, 14], ["liver damage", "DISEASE", 9, 21], ["COVID-19", "CHEMICAL", 91, 99], ["COVID-19", "CHEMICAL", 91, 99], ["liver", "ORGAN", 9, 14], ["liver damage", "PROBLEM", 9, 21], ["a common complication", "PROBLEM", 54, 75], ["COVID", "TEST", 91, 96], ["liver", "ANATOMY", 9, 14], ["damage", "OBSERVATION", 15, 21]]], ["In a study of 1,100 patients in China, elevated levels of the liver enzyme aspartate aminotransferase (AST) were reported in 18% of mild/moderate COVID-19 patients, and 56% of severe COVID-19 patients (36).", [["liver", "ANATOMY", 62, 67], ["aspartate", "CHEMICAL", 75, 84], ["COVID", "DISEASE", 146, 151], ["COVID", "DISEASE", 183, 188], ["aspartate", "CHEMICAL", 75, 84], ["patients", "ORGANISM", 20, 28], ["liver", "ORGAN", 62, 67], ["aspartate aminotransferase", "GENE_OR_GENE_PRODUCT", 75, 101], ["AST", "SIMPLE_CHEMICAL", 103, 106], ["patients", "ORGANISM", 155, 163], ["patients", "ORGANISM", 192, 200], ["liver enzyme", "PROTEIN", 62, 74], ["aspartate aminotransferase", "PROTEIN", 75, 101], ["AST", "PROTEIN", 103, 106], ["patients", "SPECIES", 20, 28], ["patients", "SPECIES", 155, 163], ["patients", "SPECIES", 192, 200], ["a study", "TEST", 3, 10], ["elevated levels", "PROBLEM", 39, 54], ["the liver enzyme aspartate aminotransferase", "TEST", 58, 101], ["AST", "TEST", 103, 106], ["mild/moderate COVID", "PROBLEM", 132, 151], ["severe COVID", "TEST", 176, 188], ["elevated", "OBSERVATION", 39, 47], ["liver", "ANATOMY", 62, 67], ["moderate", "OBSERVATION_MODIFIER", 137, 145]]], ["The same study also reported elevated levels of alanine aminotransferase (ALT) in 20% of mild/moderate COVID-19 patients and 28% of severe COVID-19 patients (36).", [["alanine", "CHEMICAL", 48, 55], ["COVID", "DISEASE", 103, 108], ["COVID", "DISEASE", 139, 144], ["alanine", "CHEMICAL", 48, 55], ["alanine", "AMINO_ACID", 48, 55], ["aminotransferase", "GENE_OR_GENE_PRODUCT", 56, 72], ["ALT", "SIMPLE_CHEMICAL", 74, 77], ["patients", "ORGANISM", 112, 120], ["patients", "ORGANISM", 148, 156], ["alanine aminotransferase", "PROTEIN", 48, 72], ["ALT", "PROTEIN", 74, 77], ["patients", "SPECIES", 112, 120], ["patients", "SPECIES", 148, 156], ["The same study", "TEST", 0, 14], ["elevated levels", "PROBLEM", 29, 44], ["alanine aminotransferase", "TEST", 48, 72], ["ALT", "TEST", 74, 77], ["mild/moderate COVID", "PROBLEM", 89, 108], ["severe COVID", "TEST", 132, 144], ["elevated", "OBSERVATION", 29, 37], ["mild", "OBSERVATION_MODIFIER", 89, 93], ["moderate", "OBSERVATION_MODIFIER", 94, 102]]], ["Consequently, it has been proposed that liver damage associated with severe COVID-19 patients is due to dysregulated innate immunity against SARS-CoV-2, or hepatoxicity in response to treatments, rather than pre-existing liver disease.Liver and Kidney Disease ::: Impact of Pre-Existing ComorbiditiesChronic kidney disease is associated with an increased risk of pneumonia, and elevated mortality from infectious diseases has been reported in patients with end stage renal disease (110).", [["liver", "ANATOMY", 40, 45], ["liver", "ANATOMY", 221, 226], ["Liver", "ANATOMY", 235, 240], ["Kidney", "ANATOMY", 245, 251], ["kidney", "ANATOMY", 308, 314], ["renal", "ANATOMY", 467, 472], ["liver damage", "DISEASE", 40, 52], ["COVID", "DISEASE", 76, 81], ["SARS", "DISEASE", 141, 145], ["hepatoxicity", "DISEASE", 156, 168], ["liver disease", "DISEASE", 221, 234], ["Liver and Kidney Disease", "DISEASE", 235, 259], ["Chronic kidney disease", "DISEASE", 300, 322], ["pneumonia", "DISEASE", 363, 372], ["infectious diseases", "DISEASE", 402, 421], ["end stage renal disease", "DISEASE", 457, 480], ["liver", "ORGAN", 40, 45], ["patients", "ORGANISM", 85, 93], ["SARS-CoV-2", "ORGANISM", 141, 151], ["liver", "ORGAN", 221, 226], ["Liver", "ORGAN", 235, 240], ["Kidney", "ORGAN", 245, 251], ["kidney", "ORGAN", 308, 314], ["patients", "ORGANISM", 443, 451], ["renal", "ORGAN", 467, 472], ["patients", "SPECIES", 85, 93], ["patients", "SPECIES", 443, 451], ["SARS-CoV", "SPECIES", 141, 149], ["liver damage", "PROBLEM", 40, 52], ["severe COVID", "PROBLEM", 69, 81], ["dysregulated innate immunity", "PROBLEM", 104, 132], ["SARS", "PROBLEM", 141, 145], ["CoV", "TEST", 146, 149], ["hepatoxicity", "PROBLEM", 156, 168], ["treatments", "TREATMENT", 184, 194], ["pre-existing liver disease", "PROBLEM", 208, 234], ["Pre-Existing ComorbiditiesChronic kidney disease", "PROBLEM", 274, 322], ["pneumonia", "PROBLEM", 363, 372], ["elevated mortality", "PROBLEM", 378, 396], ["infectious diseases", "PROBLEM", 402, 421], ["end stage renal disease", "PROBLEM", 457, 480], ["liver", "ANATOMY", 40, 45], ["damage", "OBSERVATION", 46, 52], ["severe", "OBSERVATION_MODIFIER", 69, 75], ["liver", "ANATOMY", 221, 226], ["disease", "OBSERVATION", 227, 234], ["Kidney", "ANATOMY", 245, 251], ["Disease", "OBSERVATION", 252, 259], ["Comorbidities", "OBSERVATION_MODIFIER", 287, 300], ["Chronic", "OBSERVATION_MODIFIER", 300, 307], ["kidney", "ANATOMY", 308, 314], ["disease", "OBSERVATION", 315, 322], ["increased", "OBSERVATION_MODIFIER", 345, 354], ["pneumonia", "OBSERVATION", 363, 372], ["elevated", "OBSERVATION_MODIFIER", 378, 386], ["mortality", "OBSERVATION_MODIFIER", 387, 396], ["infectious", "OBSERVATION_MODIFIER", 402, 412], ["end stage", "OBSERVATION_MODIFIER", 457, 466], ["renal", "ANATOMY", 467, 472], ["disease", "OBSERVATION", 473, 480]]], ["In an extensive meta-analysis, chronic kidney disease accounted for 0.83% of comorbidities in COVID-19 patients (1).", [["kidney", "ANATOMY", 39, 45], ["chronic kidney disease", "DISEASE", 31, 53], ["kidney", "ORGAN", 39, 45], ["patients", "ORGANISM", 103, 111], ["patients", "SPECIES", 103, 111], ["chronic kidney disease", "PROBLEM", 31, 53], ["comorbidities", "PROBLEM", 77, 90], ["COVID", "TEST", 94, 99], ["extensive", "OBSERVATION_MODIFIER", 6, 15], ["meta-analysis", "OBSERVATION", 16, 29], ["chronic", "OBSERVATION_MODIFIER", 31, 38], ["kidney", "ANATOMY", 39, 45], ["disease", "OBSERVATION", 46, 53]]], ["While the prevalence of chronic kidney disease among COVID-19 patients is low, those with pre-existing kidney disease have been associated with severe disease and increased mortalities (111).", [["kidney", "ANATOMY", 32, 38], ["kidney", "ANATOMY", 103, 109], ["chronic kidney disease", "DISEASE", 24, 46], ["kidney disease", "DISEASE", 103, 117], ["kidney", "ORGAN", 32, 38], ["patients", "ORGANISM", 62, 70], ["kidney", "ORGAN", 103, 109], ["patients", "SPECIES", 62, 70], ["chronic kidney disease", "PROBLEM", 24, 46], ["COVID", "TEST", 53, 58], ["pre-existing kidney disease", "PROBLEM", 90, 117], ["severe disease", "PROBLEM", 144, 158], ["increased mortalities", "PROBLEM", 163, 184], ["chronic", "OBSERVATION_MODIFIER", 24, 31], ["kidney", "ANATOMY", 32, 38], ["disease", "OBSERVATION", 39, 46], ["low", "OBSERVATION_MODIFIER", 74, 77], ["kidney", "ANATOMY", 103, 109], ["disease", "OBSERVATION", 110, 117], ["associated with", "UNCERTAINTY", 128, 143], ["severe", "OBSERVATION_MODIFIER", 144, 150], ["disease", "OBSERVATION", 151, 158], ["increased", "OBSERVATION_MODIFIER", 163, 172], ["mortalities", "OBSERVATION_MODIFIER", 173, 184]]], ["ACE2 expression in the kidney is elevated in chronic kidney disease (112).", [["kidney", "ANATOMY", 23, 29], ["kidney", "ANATOMY", 53, 59], ["chronic kidney disease", "DISEASE", 45, 67], ["ACE2", "GENE_OR_GENE_PRODUCT", 0, 4], ["kidney", "ORGAN", 23, 29], ["kidney", "ORGAN", 53, 59], ["ACE2", "PROTEIN", 0, 4], ["ACE2 expression in the kidney", "PROBLEM", 0, 29], ["chronic kidney disease", "PROBLEM", 45, 67], ["expression", "OBSERVATION", 5, 15], ["kidney", "ANATOMY", 23, 29], ["elevated", "OBSERVATION", 33, 41], ["chronic", "OBSERVATION_MODIFIER", 45, 52], ["kidney", "ANATOMY", 53, 59], ["disease", "OBSERVATION", 60, 67]]], ["However, elevated ACE2 expression in the kidney does not appear to correlate with increased susceptibility to SARS-CoV-2 in the same way as it does in the heart.", [["kidney", "ANATOMY", 41, 47], ["heart", "ANATOMY", 155, 160], ["SARS", "DISEASE", 110, 114], ["ACE2", "GENE_OR_GENE_PRODUCT", 18, 22], ["kidney", "ORGAN", 41, 47], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 110, 120], ["heart", "ORGAN", 155, 160], ["ACE2", "PROTEIN", 18, 22], ["SARS-CoV", "SPECIES", 110, 118], ["elevated ACE2 expression in the kidney", "PROBLEM", 9, 47], ["increased susceptibility to SARS", "PROBLEM", 82, 114], ["CoV", "TEST", 115, 118], ["elevated", "OBSERVATION_MODIFIER", 9, 17], ["ACE2 expression", "OBSERVATION", 18, 33], ["kidney", "ANATOMY", 41, 47], ["increased", "OBSERVATION_MODIFIER", 82, 91], ["susceptibility", "OBSERVATION", 92, 106], ["heart", "ANATOMY", 155, 160]]], ["Nonetheless, chronic kidney disease is associated with persistent, low-grade inflammation which could exacerbate COVID-19 symptoms.", [["kidney", "ANATOMY", 21, 27], ["chronic kidney disease", "DISEASE", 13, 35], ["inflammation", "DISEASE", 77, 89], ["kidney", "ORGAN", 21, 27], ["chronic kidney disease", "PROBLEM", 13, 35], ["low-grade inflammation", "PROBLEM", 67, 89], ["COVID", "TEST", 113, 118], ["19 symptoms", "PROBLEM", 119, 130], ["chronic", "OBSERVATION_MODIFIER", 13, 20], ["kidney", "ANATOMY", 21, 27], ["disease", "OBSERVATION", 28, 35], ["associated with", "UNCERTAINTY", 39, 54], ["persistent", "OBSERVATION_MODIFIER", 55, 65], ["low-grade", "OBSERVATION_MODIFIER", 67, 76], ["inflammation", "OBSERVATION", 77, 89]]], ["Several factors contribute to this inflammation such as elevated cytokines including IL-6 and CRP, oxidative stress and impaired metabolism (113).", [["inflammation", "DISEASE", 35, 47], ["IL-6", "GENE_OR_GENE_PRODUCT", 85, 89], ["CRP", "GENE_OR_GENE_PRODUCT", 94, 97], ["cytokines", "PROTEIN", 65, 74], ["IL-6", "PROTEIN", 85, 89], ["CRP", "PROTEIN", 94, 97], ["Several factors", "PROBLEM", 0, 15], ["this inflammation", "PROBLEM", 30, 47], ["elevated cytokines", "PROBLEM", 56, 74], ["IL", "TEST", 85, 87], ["CRP", "TEST", 94, 97], ["oxidative stress", "PROBLEM", 99, 115], ["impaired metabolism", "PROBLEM", 120, 139], ["inflammation", "OBSERVATION", 35, 47], ["elevated", "OBSERVATION_MODIFIER", 56, 64], ["cytokines", "OBSERVATION", 65, 74], ["oxidative stress", "OBSERVATION", 99, 115], ["impaired", "OBSERVATION_MODIFIER", 120, 128], ["metabolism", "OBSERVATION_MODIFIER", 129, 139]]], ["Therefore, the underlying pathogenesis of chronic kidney disease may increase vulnerability to hyperinflammation and cytokine storm upon SARS-CoV-2 infection, resulting in severe COVID-19.Autoimmune Diseases ::: Impact of Pre-Existing ComorbiditiesAutoimmune diseases are conditions characterized by inappropriate immune activation and destruction of healthy cells.", [["kidney", "ANATOMY", 50, 56], ["cells", "ANATOMY", 359, 364], ["chronic kidney disease", "DISEASE", 42, 64], ["hyperinflammation", "DISEASE", 95, 112], ["infection", "DISEASE", 148, 157], ["Autoimmune Diseases", "DISEASE", 188, 207], ["Autoimmune diseases", "DISEASE", 248, 267], ["kidney", "ORGAN", 50, 56], ["SARS-CoV-2", "ORGANISM", 137, 147], ["cells", "CELL", 359, 364], ["cytokine", "PROTEIN", 117, 125], ["healthy cells", "CELL_TYPE", 351, 364], ["SARS-CoV", "SPECIES", 137, 145], ["chronic kidney disease", "PROBLEM", 42, 64], ["hyperinflammation", "PROBLEM", 95, 112], ["cytokine storm", "PROBLEM", 117, 131], ["SARS", "PROBLEM", 137, 141], ["CoV-2 infection", "PROBLEM", 142, 157], ["severe COVID", "PROBLEM", 172, 184], ["Autoimmune Diseases", "PROBLEM", 188, 207], ["Pre-Existing ComorbiditiesAutoimmune diseases", "PROBLEM", 222, 267], ["inappropriate immune activation", "PROBLEM", 300, 331], ["destruction of healthy cells", "PROBLEM", 336, 364], ["chronic", "OBSERVATION_MODIFIER", 42, 49], ["kidney", "ANATOMY", 50, 56], ["disease", "OBSERVATION", 57, 64], ["cytokine storm", "OBSERVATION", 117, 131], ["infection", "OBSERVATION", 148, 157], ["severe", "OBSERVATION_MODIFIER", 172, 178], ["Autoimmune diseases", "OBSERVATION", 248, 267], ["immune activation", "OBSERVATION", 314, 331], ["healthy cells", "OBSERVATION", 351, 364]]], ["Lymphopenia is common among autoimmune diseases such as type 1 diabetes, rheumatoid arthritis and systemic erythematosus lupus (114), and since lymphopenia is regarded as a major risk factor for developing severe COVID-19, individuals living with an autoimmune condition may be perceived as high risk.", [["Lymphopenia", "DISEASE", 0, 11], ["autoimmune diseases", "DISEASE", 28, 47], ["type 1 diabetes", "DISEASE", 56, 71], ["rheumatoid arthritis", "DISEASE", 73, 93], ["systemic erythematosus lupus", "DISEASE", 98, 126], ["lymphopenia", "DISEASE", 144, 155], ["autoimmune condition", "DISEASE", 250, 270], ["individuals", "ORGANISM", 223, 234], ["Lymphopenia", "PROBLEM", 0, 11], ["autoimmune diseases", "PROBLEM", 28, 47], ["type 1 diabetes", "PROBLEM", 56, 71], ["rheumatoid arthritis", "PROBLEM", 73, 93], ["systemic erythematosus lupus", "PROBLEM", 98, 126], ["lymphopenia", "PROBLEM", 144, 155], ["developing severe COVID", "PROBLEM", 195, 218], ["an autoimmune condition", "PROBLEM", 247, 270], ["diabetes", "OBSERVATION", 63, 71], ["rheumatoid", "OBSERVATION_MODIFIER", 73, 83], ["arthritis", "OBSERVATION", 84, 93], ["systemic", "OBSERVATION_MODIFIER", 98, 106], ["erythematosus lupus", "OBSERVATION", 107, 126], ["severe", "OBSERVATION_MODIFIER", 206, 212]]], ["However, unlike other comorbidities mentioned above, autoimmune diseases have not been reported as a risk factor in the current meta-analyses.", [["autoimmune diseases", "DISEASE", 53, 72], ["unlike other comorbidities", "PROBLEM", 9, 35], ["autoimmune diseases", "PROBLEM", 53, 72], ["comorbidities", "OBSERVATION", 22, 35]]], ["One possible explanation could be that autoimmune diseases are often treated with drugs designed to restrict immune activation, many of which are now being repurposed for COVID-19 and will be discussed below.", [["autoimmune diseases", "DISEASE", 39, 58], ["autoimmune diseases", "PROBLEM", 39, 58], ["drugs", "TREATMENT", 82, 87], ["COVID", "TEST", 171, 176], ["possible explanation could be", "UNCERTAINTY", 4, 33], ["autoimmune", "OBSERVATION", 39, 49]]], ["Furthermore, potential alterations in patient behaviors in order to shield themselves from infection could influence reporting of autoimmunity as a risk factor.Vaccines ::: Considerations for COVID-19 TherapiesThe SARS-CoV-2 genome and spike protein structure was discovered very rapidly (115), enabling focussed development of both RNA- and protein-based vaccines.", [["infection", "DISEASE", 91, 100], ["autoimmunity", "DISEASE", 130, 142], ["patient", "ORGANISM", 38, 45], ["SARS-CoV-2", "ORGANISM", 214, 224], ["SARS-CoV-2 genome", "DNA", 214, 231], ["patient", "SPECIES", 38, 45], ["SARS-CoV", "SPECIES", 214, 222], ["potential alterations in patient behaviors", "PROBLEM", 13, 55], ["infection", "PROBLEM", 91, 100], ["autoimmunity", "PROBLEM", 130, 142], ["a risk factor", "PROBLEM", 146, 159], ["COVID", "TEST", 192, 197], ["Therapies", "TREATMENT", 201, 210], ["The SARS", "TEST", 210, 218], ["CoV", "TEST", 219, 222], ["spike protein structure", "PROBLEM", 236, 259], ["both RNA", "TEST", 328, 336], ["protein-based vaccines", "TREATMENT", 342, 364], ["infection", "OBSERVATION", 91, 100]]], ["However, vaccine development is a challenging and time-consuming process.", [["vaccine", "TREATMENT", 9, 16]]], ["Following the SARS-CoV epidemic, several vaccines were developed and assessed using animal models.", [["SARS", "DISEASE", 14, 18], ["SARS-CoV", "SPECIES", 14, 22], ["the SARS-CoV epidemic", "PROBLEM", 10, 31], ["several vaccines", "TREATMENT", 33, 49]]], ["Vaccination with live virus was shown to cause complications in mice such as lung damage (116, 117), and although recombinant spike protein based vaccines were able to protect animals from SARS-CoV challenge, they were ineffective at inducing sterilizing immunity (118).", [["lung", "ANATOMY", 77, 81], ["lung damage", "DISEASE", 77, 88], ["SARS", "DISEASE", 189, 193], ["mice", "ORGANISM", 64, 68], ["lung", "ORGAN", 77, 81], ["SARS-CoV", "ORGANISM", 189, 197], ["recombinant spike protein", "PROTEIN", 114, 139], ["mice", "SPECIES", 64, 68], ["mice", "SPECIES", 64, 68], ["SARS-CoV", "SPECIES", 189, 197], ["Vaccination", "TREATMENT", 0, 11], ["live virus", "PROBLEM", 17, 27], ["complications in mice", "PROBLEM", 47, 68], ["lung damage", "PROBLEM", 77, 88], ["recombinant spike protein based vaccines", "TREATMENT", 114, 154], ["SARS", "PROBLEM", 189, 193], ["CoV challenge", "TREATMENT", 194, 207], ["lung", "ANATOMY", 77, 81], ["damage", "OBSERVATION", 82, 88]]], ["Other vaccines with inactivated SARS-CoV and MERS-CoV have demonstrated reduced viral titers, reduced morbidity and greater survival in animal models (119, 120).", [["SARS-CoV", "ORGANISM", 32, 40], ["MERS-CoV", "ORGANISM", 45, 53], ["SARS-CoV", "SPECIES", 32, 40], ["MERS-CoV", "SPECIES", 45, 53], ["Other vaccines", "TREATMENT", 0, 14], ["inactivated SARS", "PROBLEM", 20, 36], ["MERS-CoV", "TEST", 45, 53], ["reduced viral titers", "PROBLEM", 72, 92], ["reduced morbidity", "PROBLEM", 94, 111], ["reduced", "OBSERVATION_MODIFIER", 72, 79], ["viral titers", "OBSERVATION", 80, 92], ["reduced", "OBSERVATION_MODIFIER", 94, 101], ["morbidity", "OBSERVATION_MODIFIER", 102, 111], ["greater", "OBSERVATION_MODIFIER", 116, 123]]], ["However, the rapid eradication of SARS-CoV reduced demand for development.", [["SARS", "DISEASE", 34, 38], ["SARS-CoV", "ORGANISM", 34, 42], ["SARS-CoV", "SPECIES", 34, 42], ["SARS", "PROBLEM", 34, 38], ["CoV reduced demand", "TREATMENT", 39, 57], ["rapid", "OBSERVATION_MODIFIER", 13, 18], ["eradication", "OBSERVATION", 19, 30]]], ["Some MERS-CoV vaccines are currently in pre-clinical and clinical development (121), however as MERS-CoV is less closely related, it is unlikely that these will cross-protect against SARS-CoV-2.", [["SARS", "DISEASE", 183, 187], ["MERS-CoV", "ORGANISM", 5, 13], ["MERS-CoV", "ORGANISM", 96, 104], ["SARS-CoV-2", "ORGANISM", 183, 193], ["MERS-CoV", "SPECIES", 5, 13], ["MERS-CoV", "SPECIES", 96, 104], ["SARS-CoV", "SPECIES", 183, 191], ["Some MERS", "PROBLEM", 0, 9], ["CoV vaccines", "TREATMENT", 10, 22], ["SARS", "PROBLEM", 183, 187], ["CoV", "TEST", 188, 191], ["MERS", "OBSERVATION", 5, 9], ["less closely", "OBSERVATION_MODIFIER", 108, 120]]], ["Learnings from previous coronavirus outbreaks indicate that antibody responses are not particularly long-lived, with SARS-CoV antibodies lasting on average just 2 years (122).", [["coronavirus", "DISEASE", 24, 35], ["coronavirus", "ORGANISM", 24, 35], ["SARS-CoV antibodies", "PROTEIN", 117, 136], ["SARS-CoV", "SPECIES", 117, 125], ["previous coronavirus outbreaks", "PROBLEM", 15, 45], ["antibody responses", "TEST", 60, 78], ["SARS", "PROBLEM", 117, 121], ["CoV antibodies", "PROBLEM", 122, 136], ["coronavirus", "OBSERVATION", 24, 35]]], ["This apparent lack of long-term protection exacerbates the need for an effective vaccine or vaccine programme to protect against potential recurrent seasonal SARS-CoV-2 infections.Vaccines ::: Considerations for COVID-19 TherapiesOn the 6th July 2020, the WHO reported 160 candidate SARS-CoV-2 vaccines under development worldwide (123).", [["SARS-CoV-2 infections", "DISEASE", 158, 179], ["SARS", "DISEASE", 283, 287], ["SARS-CoV-2", "ORGANISM", 158, 168], ["SARS-CoV-2", "SPECIES", 158, 168], ["long-term protection", "TREATMENT", 22, 42], ["an effective vaccine", "TREATMENT", 68, 88], ["vaccine programme", "TREATMENT", 92, 109], ["potential recurrent seasonal SARS", "PROBLEM", 129, 162], ["CoV-2 infections", "PROBLEM", 163, 179], ["COVID", "TEST", 212, 217], ["CoV-2 vaccines", "TREATMENT", 288, 302], ["long-term protection", "OBSERVATION_MODIFIER", 22, 42], ["SARS", "OBSERVATION", 158, 162]]], ["Some of the most promising include an mRNA vaccine; mRNA-1273 (124), a DNA plasmid vaccine (125), and an adenovirus vaccine; ChAdOx1 nCoV-19 (126).", [["mRNA-1273", "CHEMICAL", 52, 61], ["mRNA-1273 (124)", "GENE_OR_GENE_PRODUCT", 52, 67], ["DNA", "CELLULAR_COMPONENT", 71, 74], ["adenovirus", "ORGANISM", 105, 115], ["an mRNA vaccine", "TEST", 35, 50], ["mRNA", "TEST", 52, 56], ["a DNA plasmid vaccine", "TREATMENT", 69, 90], ["an adenovirus vaccine", "TREATMENT", 102, 123], ["ChAdOx1 nCoV", "TEST", 125, 137]]], ["Although clinical evaluation is underway, outcomes are not available yet.", [["clinical evaluation", "TEST", 9, 28]]], ["Furthermore, vaccine efficacy depends upon an individual's ability to mount a strong immune response against it.", [["vaccine efficacy", "TREATMENT", 13, 29]]], ["Consequently, vaccine regimens that grant protection in healthy individuals may not be adequate for older individuals and those with comorbid conditions who have increased immunosenescence (127).", [["vaccine regimens", "TREATMENT", 14, 30], ["comorbid conditions", "PROBLEM", 133, 152]]], ["For influenza, the use of adjuvant (128) and high dose vaccines (129, 130) have been developed and implemented to increase vaccine immunogenicity for older and high-risk comorbid adults.", [["influenza", "DISEASE", 4, 13], ["adults", "ORGANISM", 179, 185], ["influenza", "PROBLEM", 4, 13], ["adjuvant", "TREATMENT", 26, 34], ["high dose vaccines", "TREATMENT", 45, 63]]], ["Therefore, similar measures are likely to be needed to fine tune a SARS-CoV-2 vaccine once it becomes available.", [["SARS", "DISEASE", 67, 71], ["CoV-2", "ORGANISM", 72, 77], ["a SARS-CoV-2 vaccine", "TREATMENT", 65, 85]]], ["In the interim, rolling out a SARS-CoV-2 vaccine with proven efficacy in healthy individuals could result in herd immunity, preventing transmission to those more vulnerable and offer indirect protection.Convalescent Plasma Therapy ::: Considerations for COVID-19 TherapiesAnother therapeutic approach intended to prevent COVID-19 is convalescent plasma therapy.", [["plasma", "ANATOMY", 346, 352], ["SARS", "DISEASE", 30, 34], ["COVID-19", "CHEMICAL", 321, 329], ["COVID-19", "CHEMICAL", 254, 262], ["COVID-19", "CHEMICAL", 321, 329], ["herd", "ORGANISM_SUBDIVISION", 109, 113], ["Plasma", "ORGANISM_SUBSTANCE", 216, 222], ["convalescent", "ORGANISM", 333, 345], ["plasma", "ORGANISM_SUBSTANCE", 346, 352], ["a SARS-CoV-2 vaccine", "TREATMENT", 28, 48], ["indirect protection", "TREATMENT", 183, 202], ["COVID", "TEST", 254, 259], ["Therapies", "TREATMENT", 263, 272], ["Another therapeutic approach", "TREATMENT", 272, 300], ["COVID", "TEST", 321, 326], ["convalescent plasma therapy", "TREATMENT", 333, 360]]], ["Previous use during the SARS (131) and MERS (132) epidemics, and H1N1 pandemic (133), demonstrated reasonable efficacy and safety.", [["SARS", "DISEASE", 24, 28], ["pandemic", "DISEASE", 70, 78], ["the SARS", "TEST", 20, 28], ["epidemics", "PROBLEM", 50, 59], ["H1N1", "PROBLEM", 65, 69]]], ["Evidence from those outbreaks revealed that convalescent plasma contained neutralizing antibodies (134), and a meta-analysis from 32 SARS-CoV and influenza studies, reported a significant reduction in mortality following convalescent plasma therapy (135).", [["plasma", "ANATOMY", 57, 63], ["plasma", "ANATOMY", 234, 240], ["plasma", "ORGANISM_SUBSTANCE", 57, 63], ["plasma", "ORGANISM_SUBSTANCE", 234, 240], ["neutralizing antibodies", "PROTEIN", 74, 97], ["SARS-CoV", "SPECIES", 133, 141], ["convalescent plasma", "TEST", 44, 63], ["neutralizing antibodies", "TEST", 74, 97], ["a meta-analysis", "TEST", 109, 124], ["SARS", "TEST", 133, 137], ["influenza studies", "TEST", 146, 163], ["a significant reduction in mortality", "PROBLEM", 174, 210], ["convalescent plasma therapy", "TREATMENT", 221, 248], ["significant", "OBSERVATION_MODIFIER", 176, 187], ["reduction", "OBSERVATION_MODIFIER", 188, 197]]], ["Several convalescent plasma studies for SARS-CoV-2 have been reported.", [["plasma", "ANATOMY", 21, 27], ["plasma", "ORGANISM_SUBSTANCE", 21, 27], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 40, 50], ["SARS-CoV", "SPECIES", 40, 48], ["Several convalescent plasma studies", "TEST", 0, 35], ["SARS", "PROBLEM", 40, 44], ["CoV", "TEST", 45, 48]]], ["In China, a small pilot study was conducted to test convalescent plasma collected from 40 recently recovered patients on 10 severe COVID-19 patients, four of which had underlying conditions including hypertension and cardiovascular disease (136).", [["plasma", "ANATOMY", 65, 71], ["cardiovascular", "ANATOMY", 217, 231], ["hypertension", "DISEASE", 200, 212], ["cardiovascular disease", "DISEASE", 217, 239], ["plasma", "ORGANISM_SUBSTANCE", 65, 71], ["patients", "ORGANISM", 109, 117], ["patients", "ORGANISM", 140, 148], ["cardiovascular", "ANATOMICAL_SYSTEM", 217, 231], ["patients", "SPECIES", 109, 117], ["patients", "SPECIES", 140, 148], ["a small pilot study", "TEST", 10, 29], ["test convalescent plasma", "TEST", 47, 71], ["underlying conditions", "PROBLEM", 168, 189], ["hypertension", "PROBLEM", 200, 212], ["cardiovascular disease", "PROBLEM", 217, 239], ["small", "OBSERVATION_MODIFIER", 12, 17], ["hypertension", "OBSERVATION", 200, 212], ["cardiovascular disease", "OBSERVATION", 217, 239]]], ["From the 40 patients, 39 had high neutralizing antibody titers of \u22651:640.", [["patients", "ORGANISM", 12, 20], ["patients", "SPECIES", 12, 20], ["high neutralizing antibody titers", "PROBLEM", 29, 62]]], ["No serious adverse events were reported following transfusion, and all patients experienced improved symptoms within 1 to 3 days post-transfusion.", [["patients", "ORGANISM", 71, 79], ["patients", "SPECIES", 71, 79], ["serious adverse events", "PROBLEM", 3, 25], ["transfusion", "TREATMENT", 50, 61], ["improved symptoms", "PROBLEM", 92, 109], ["serious", "OBSERVATION_MODIFIER", 3, 10]]], ["However, there are many caveats to this study, the very small sample size and the use of concomitant treatments mean it is not possible to ascertain if clinical improvements were due to convalescent plasma.", [["plasma", "ANATOMY", 199, 205], ["plasma", "ORGANISM_SUBSTANCE", 199, 205], ["this study", "TEST", 35, 45], ["the very small sample size", "PROBLEM", 47, 73], ["concomitant treatments", "TREATMENT", 89, 111], ["convalescent plasma", "TEST", 186, 205], ["many", "OBSERVATION_MODIFIER", 19, 23], ["caveats", "OBSERVATION", 24, 31], ["very", "OBSERVATION_MODIFIER", 51, 55], ["small", "OBSERVATION_MODIFIER", 56, 61], ["sample", "OBSERVATION_MODIFIER", 62, 68], ["size", "OBSERVATION_MODIFIER", 69, 73], ["not possible", "UNCERTAINTY", 123, 135]]], ["Consequently, additional large scale, controlled, randomized trials are needed and are currently underway.Convalescent Plasma Therapy ::: Considerations for COVID-19 TherapiesDespite no adverse events being reported in the small sample sizes currently being tested for COVID-19, plasma transfusions are not without risk.", [["plasma", "ANATOMY", 279, 285], ["COVID-19", "CHEMICAL", 269, 277], ["Plasma", "ORGANISM_SUBSTANCE", 119, 125], ["COVID-19", "SIMPLE_CHEMICAL", 269, 277], ["plasma", "ORGANISM_SUBSTANCE", 279, 285], ["additional large scale", "TREATMENT", 14, 36], ["randomized trials", "TREATMENT", 50, 67], ["Convalescent Plasma Therapy", "TREATMENT", 106, 133], ["COVID-19 Therapies", "TREATMENT", 157, 175], ["adverse events", "PROBLEM", 186, 200], ["COVID", "TEST", 269, 274], ["plasma transfusions", "TREATMENT", 279, 298], ["large", "OBSERVATION_MODIFIER", 25, 30], ["scale", "OBSERVATION_MODIFIER", 31, 36], ["Plasma Therapy", "OBSERVATION", 119, 133], ["not without", "UNCERTAINTY", 303, 314]]], ["As with any transfusion, there is a risk of transfusion transmitted infections, albeit small (137).", [["transfusion transmitted infections", "DISEASE", 44, 78], ["any transfusion", "TREATMENT", 8, 23], ["transfusion transmitted infections", "PROBLEM", 44, 78], ["infections", "OBSERVATION", 68, 78], ["small", "OBSERVATION_MODIFIER", 87, 92]]], ["Perhaps of more concern are the non-infectious risks such as allergic reactions, transfusion related acute lung injury characterized by acute hypoxemia and pulmonary oedema, and transfusion associated circulatory overload, characterized by hypertension, tachycardia, tachypnoea and dyspnea (138).", [["lung", "ANATOMY", 107, 111], ["pulmonary", "ANATOMY", 156, 165], ["circulatory", "ANATOMY", 201, 212], ["allergic reactions", "DISEASE", 61, 79], ["acute lung injury", "DISEASE", 101, 118], ["hypoxemia", "DISEASE", 142, 151], ["pulmonary oedema", "DISEASE", 156, 172], ["circulatory overload", "DISEASE", 201, 221], ["hypertension", "DISEASE", 240, 252], ["tachycardia", "DISEASE", 254, 265], ["tachypnoea", "DISEASE", 267, 277], ["dyspnea", "DISEASE", 282, 289], ["lung", "ORGAN", 107, 111], ["pulmonary", "ORGAN", 156, 165], ["the non-infectious risks", "PROBLEM", 28, 52], ["allergic reactions", "PROBLEM", 61, 79], ["acute lung injury", "PROBLEM", 101, 118], ["acute hypoxemia", "PROBLEM", 136, 151], ["pulmonary oedema", "PROBLEM", 156, 172], ["transfusion associated circulatory overload", "PROBLEM", 178, 221], ["hypertension", "PROBLEM", 240, 252], ["tachycardia", "PROBLEM", 254, 265], ["tachypnoea", "PROBLEM", 267, 277], ["dyspnea", "PROBLEM", 282, 289], ["non-infectious", "OBSERVATION", 32, 46], ["acute", "OBSERVATION_MODIFIER", 101, 106], ["lung", "ANATOMY", 107, 111], ["injury", "OBSERVATION", 112, 118], ["acute", "OBSERVATION_MODIFIER", 136, 141], ["hypoxemia", "OBSERVATION", 142, 151], ["pulmonary", "ANATOMY", 156, 165], ["oedema", "OBSERVATION", 166, 172], ["circulatory overload", "OBSERVATION", 201, 221], ["hypertension", "OBSERVATION", 240, 252], ["tachycardia", "OBSERVATION", 254, 265], ["tachypnoea", "OBSERVATION_MODIFIER", 267, 277]]], ["These are of particular concern for severe COVID-19 patients with extensive lung damage, and for those with pre-existing hypertension, cardiovascular disease or renal failure (138, 139).", [["lung", "ANATOMY", 76, 80], ["cardiovascular", "ANATOMY", 135, 149], ["renal", "ANATOMY", 161, 166], ["COVID", "DISEASE", 43, 48], ["lung damage", "DISEASE", 76, 87], ["hypertension", "DISEASE", 121, 133], ["cardiovascular disease", "DISEASE", 135, 157], ["renal failure", "DISEASE", 161, 174], ["patients", "ORGANISM", 52, 60], ["lung", "ORGAN", 76, 80], ["renal", "ORGAN", 161, 166], ["patients", "SPECIES", 52, 60], ["severe COVID", "PROBLEM", 36, 48], ["extensive lung damage", "PROBLEM", 66, 87], ["pre-existing hypertension", "PROBLEM", 108, 133], ["cardiovascular disease", "PROBLEM", 135, 157], ["renal failure", "PROBLEM", 161, 174], ["severe", "OBSERVATION_MODIFIER", 36, 42], ["extensive", "OBSERVATION_MODIFIER", 66, 75], ["lung", "ANATOMY", 76, 80], ["damage", "OBSERVATION", 81, 87], ["hypertension", "OBSERVATION", 121, 133], ["cardiovascular", "ANATOMY", 135, 149], ["disease", "OBSERVATION", 150, 157], ["renal", "ANATOMY", 161, 166], ["failure", "OBSERVATION", 167, 174]]], ["Due to the increased prevalence of comorbidities among COVID-19 patients, those predisposed to transfusion-related adverse events will need to be carefully evaluated.", [["patients", "ORGANISM", 64, 72], ["patients", "SPECIES", 64, 72], ["comorbidities", "PROBLEM", 35, 48], ["transfusion", "TREATMENT", 95, 106], ["adverse events", "PROBLEM", 115, 129]]], ["As transfusion volume and rate have both been identified as risk factors for transfusion associated circulatory overload (140), COVID-19 trials should examine these parameters to ensure safety in comorbid patients.Chloroquine and Hydroxychloroquine ::: Challenges to Overcome With Repurposed DrugsAt present, the most contested repurposed drug is chloroquine and its analog hydroxychloroquine.", [["circulatory overload", "DISEASE", 100, 120], ["Chloroquine", "CHEMICAL", 214, 225], ["Hydroxychloroquine", "CHEMICAL", 230, 248], ["chloroquine", "CHEMICAL", 347, 358], ["hydroxychloroquine", "CHEMICAL", 374, 392], ["Chloroquine", "CHEMICAL", 214, 225], ["Hydroxychloroquine", "CHEMICAL", 230, 248], ["chloroquine", "CHEMICAL", 347, 358], ["hydroxychloroquine", "CHEMICAL", 374, 392], ["patients", "ORGANISM", 205, 213], ["Chloroquine", "SIMPLE_CHEMICAL", 214, 225], ["Hydroxychloroquine", "SIMPLE_CHEMICAL", 230, 248], ["chloroquine", "SIMPLE_CHEMICAL", 347, 358], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 374, 392], ["patients", "SPECIES", 205, 213], ["transfusion volume", "TREATMENT", 3, 21], ["transfusion associated circulatory overload", "PROBLEM", 77, 120], ["COVID", "TEST", 128, 133], ["these parameters", "TEST", 159, 175], ["Chloroquine", "TREATMENT", 214, 225], ["Hydroxychloroquine", "TREATMENT", 230, 248], ["Repurposed DrugsAt", "TREATMENT", 281, 299], ["chloroquine", "TREATMENT", 347, 358], ["its analog hydroxychloroquine", "TREATMENT", 363, 392], ["circulatory overload", "OBSERVATION", 100, 120]]], ["Following the 2002 SARS-CoV epidemic, researchers found that in vitro treatment of chloroquine could increase endosomal pH and impair terminal glycosylation of ACE2 receptors on the cell surface, therefore inhibiting SARS-CoV-ACE2 interactions and preventing virus entry (141, 142).", [["endosomal", "ANATOMY", 110, 119], ["cell surface", "ANATOMY", 182, 194], ["SARS", "DISEASE", 19, 23], ["chloroquine", "CHEMICAL", 83, 94], ["chloroquine", "CHEMICAL", 83, 94], ["chloroquine", "SIMPLE_CHEMICAL", 83, 94], ["endosomal", "CELLULAR_COMPONENT", 110, 119], ["ACE2 receptors", "GENE_OR_GENE_PRODUCT", 160, 174], ["cell surface", "CELLULAR_COMPONENT", 182, 194], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 217, 225], ["ACE2", "GENE_OR_GENE_PRODUCT", 226, 230], ["ACE2 receptors", "PROTEIN", 160, 174], ["ACE2", "PROTEIN", 226, 230], ["SARS-CoV", "SPECIES", 19, 27], ["chloroquine", "TREATMENT", 83, 94], ["endosomal pH", "PROBLEM", 110, 122], ["ACE2 receptors", "TREATMENT", 160, 174], ["SARS", "PROBLEM", 217, 221], ["CoV-ACE2 interactions", "TREATMENT", 222, 243], ["virus entry", "TEST", 259, 270], ["endosomal pH", "OBSERVATION", 110, 122]]], ["Similarly, after the 2012 MERS-CoV epidemic, researchers demonstrated that chloroquine could inhibit in vitro replication of MERS-CoV in well-established cell lines (143) and primary mature antigen presenting cells (144).", [["cell lines", "ANATOMY", 154, 164], ["cells", "ANATOMY", 209, 214], ["chloroquine", "CHEMICAL", 75, 86], ["chloroquine", "CHEMICAL", 75, 86], ["chloroquine", "SIMPLE_CHEMICAL", 75, 86], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 125, 133], ["cell lines", "CELL", 154, 164], ["antigen", "GENE_OR_GENE_PRODUCT", 190, 197], ["cells", "CELL", 209, 214], ["cell lines", "CELL_LINE", 154, 164], ["143", "CELL_LINE", 166, 169], ["primary mature antigen presenting cells", "CELL_TYPE", 175, 214], ["MERS-CoV", "SPECIES", 125, 133], ["chloroquine", "TREATMENT", 75, 86], ["cell lines", "OBSERVATION", 154, 164]]], ["However, as SARS-CoV and MERS-CoV resolved relatively quickly, continued assessment of chloroquine remained limited.", [["chloroquine", "CHEMICAL", 87, 98], ["chloroquine", "CHEMICAL", 87, 98], ["SARS-CoV", "ORGANISM", 12, 20], ["MERS-CoV", "ORGANISM", 25, 33], ["chloroquine", "SIMPLE_CHEMICAL", 87, 98], ["SARS-CoV", "SPECIES", 12, 20], ["MERS-CoV", "SPECIES", 25, 33], ["SARS", "PROBLEM", 12, 16], ["MERS", "PROBLEM", 25, 29], ["CoV", "PROBLEM", 30, 33], ["chloroquine", "TREATMENT", 87, 98]]], ["Furthermore, although in vitro treatment can inhibit SARS-CoV-2 (145), the use of chloroquine and hydroxychloroquine for COVID-19 in the clinic is highly controversial.", [["chloroquine", "CHEMICAL", 82, 93], ["hydroxychloroquine", "CHEMICAL", 98, 116], ["COVID-19", "CHEMICAL", 121, 129], ["chloroquine", "CHEMICAL", 82, 93], ["hydroxychloroquine", "CHEMICAL", 98, 116], ["COVID-19", "CHEMICAL", 121, 129], ["SARS-CoV-2", "ORGANISM", 53, 63], ["chloroquine", "SIMPLE_CHEMICAL", 82, 93], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 98, 116], ["SARS-CoV", "SPECIES", 53, 61], ["vitro treatment", "TREATMENT", 25, 40], ["SARS", "PROBLEM", 53, 57], ["CoV", "TEST", 58, 61], ["chloroquine", "TREATMENT", 82, 93], ["hydroxychloroquine", "TREATMENT", 98, 116], ["COVID", "TREATMENT", 121, 126]]], ["A series of early clinical trials conducted in China reported apparent efficacy of chloroquine phosphate in treating COVID-19 (146).", [["chloroquine phosphate", "CHEMICAL", 83, 104], ["COVID-19", "CHEMICAL", 117, 125], ["chloroquine phosphate", "CHEMICAL", 83, 104], ["COVID-19", "CHEMICAL", 117, 125], ["chloroquine", "SIMPLE_CHEMICAL", 83, 94], ["early clinical trials", "TREATMENT", 12, 33], ["chloroquine phosphate", "TREATMENT", 83, 104], ["COVID", "TEST", 117, 122]]], ["This was followed by a small, non-randomized study of just 36 patients from France, which demonstrated a clinical benefit from the use of hydroxychloroquine, but lacked an appropriate control group and a long-term follow-up (147).", [["hydroxychloroquine", "CHEMICAL", 138, 156], ["hydroxychloroquine", "CHEMICAL", 138, 156], ["patients", "ORGANISM", 62, 70], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 138, 156], ["patients", "SPECIES", 62, 70], ["non-randomized study", "TEST", 30, 50], ["hydroxychloroquine", "TREATMENT", 138, 156], ["small", "OBSERVATION_MODIFIER", 23, 28]]], ["However, an observational study of 1,376 patients treated with hydroxychloroquine report no sign of efficacy for COVID-19 (148).", [["hydroxychloroquine", "CHEMICAL", 63, 81], ["COVID-19", "CHEMICAL", 113, 121], ["hydroxychloroquine", "CHEMICAL", 63, 81], ["COVID-19", "CHEMICAL", 113, 121], ["patients", "ORGANISM", 41, 49], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 63, 81], ["patients", "SPECIES", 41, 49], ["an observational study", "TEST", 9, 31], ["hydroxychloroquine", "TREATMENT", 63, 81], ["COVID", "TEST", 113, 118]]], ["This was further confirmed by results from the large Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial that examined 1,542 hospitalized COVID-19 patients treated with hydroxychloroquine and reported no significant difference in mortality when compared to 3,132 standard of care patients (149, 150).Lopinavir/Ritonavir ::: Broad-Spectrum Antiviral Agents ::: Challenges to Overcome With Repurposed DrugsLopinavir is a protease inhibitor often formulated with low-dose ritonavir and traditionally used to treat HIV patients (151).", [["hydroxychloroquine", "CHEMICAL", 176, 194], ["Lopinavir", "CHEMICAL", 307, 316], ["Ritonavir", "CHEMICAL", 317, 326], ["DrugsLopinavir", "CHEMICAL", 406, 420], ["ritonavir", "CHEMICAL", 476, 485], ["HIV", "DISEASE", 518, 521], ["COVID-19", "CHEMICAL", 78, 86], ["hydroxychloroquine", "CHEMICAL", 176, 194], ["Lopinavir", "CHEMICAL", 307, 316], ["Ritonavir", "CHEMICAL", 317, 326], ["DrugsLopinavir", "CHEMICAL", 406, 420], ["ritonavir", "CHEMICAL", 476, 485], ["patients", "ORGANISM", 154, 162], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 176, 194], ["patients", "ORGANISM", 287, 295], ["Lopinavir", "SIMPLE_CHEMICAL", 307, 316], ["Ritonavir", "SIMPLE_CHEMICAL", 317, 326], ["DrugsLopinavir", "SIMPLE_CHEMICAL", 406, 420], ["ritonavir", "SIMPLE_CHEMICAL", 476, 485], ["HIV", "ORGANISM", 518, 521], ["patients", "ORGANISM", 522, 530], ["patients", "SPECIES", 154, 162], ["patients", "SPECIES", 287, 295], ["HIV", "SPECIES", 518, 521], ["patients", "SPECIES", 522, 530], ["HIV", "SPECIES", 518, 521], ["COVID", "TEST", 78, 83], ["hydroxychloroquine", "TREATMENT", 176, 194], ["significant difference in mortality", "PROBLEM", 211, 246], ["Lopinavir", "TREATMENT", 307, 316], ["Repurposed DrugsLopinavir", "TREATMENT", 395, 420], ["a protease inhibitor", "TREATMENT", 424, 444], ["low-dose ritonavir", "TREATMENT", 467, 485], ["no", "UNCERTAINTY", 208, 210], ["significant", "OBSERVATION_MODIFIER", 211, 222], ["difference", "OBSERVATION_MODIFIER", 223, 233], ["Antiviral Agents", "OBSERVATION", 346, 362]]], ["Lopinavir/ritonavir was previously assessed in a small, non-randomized study conducted in Hong Kong during the SARS-CoV epidemic.", [["Lopinavir/ritonavir", "CHEMICAL", 0, 19], ["SARS-CoV epidemic", "DISEASE", 111, 128], ["Lopinavir", "CHEMICAL", 0, 9], ["ritonavir", "CHEMICAL", 10, 19], ["Lopinavir", "SIMPLE_CHEMICAL", 0, 9], ["ritonavir", "SIMPLE_CHEMICAL", 10, 19], ["SARS-CoV", "SPECIES", 111, 119], ["Lopinavir", "TREATMENT", 0, 9], ["ritonavir", "TREATMENT", 10, 19], ["non-randomized study", "TEST", 56, 76], ["CoV epidemic", "PROBLEM", 116, 128]]], ["This study demonstrated that lopinavir/ritonavir treatment resulted in reduced viral load and milder disease, with less recurrence of fever, diarrhea, and improved chest radiographs when compared with those treated with ribavirin, an alternative antiviral (152).", [["chest", "ANATOMY", 164, 169], ["lopinavir/ritonavir", "CHEMICAL", 29, 48], ["fever", "DISEASE", 134, 139], ["diarrhea", "DISEASE", 141, 149], ["ribavirin", "CHEMICAL", 220, 229], ["lopinavir", "CHEMICAL", 29, 38], ["ritonavir", "CHEMICAL", 39, 48], ["ribavirin", "CHEMICAL", 220, 229], ["lopinavir", "SIMPLE_CHEMICAL", 29, 38], ["ritonavir", "SIMPLE_CHEMICAL", 39, 48], ["ribavirin", "SIMPLE_CHEMICAL", 220, 229], ["This study", "TEST", 0, 10], ["lopinavir/ritonavir treatment", "TREATMENT", 29, 58], ["reduced viral load", "PROBLEM", 71, 89], ["milder disease", "PROBLEM", 94, 108], ["fever", "PROBLEM", 134, 139], ["diarrhea", "PROBLEM", 141, 149], ["improved chest radiographs", "TEST", 155, 181], ["ribavirin", "TREATMENT", 220, 229], ["an alternative antiviral", "TREATMENT", 231, 255], ["reduced", "OBSERVATION_MODIFIER", 71, 78], ["viral load", "OBSERVATION", 79, 89], ["milder disease", "OBSERVATION", 94, 108], ["less", "OBSERVATION_MODIFIER", 115, 119], ["recurrence", "OBSERVATION_MODIFIER", 120, 130], ["fever", "OBSERVATION", 134, 139], ["chest", "ANATOMY", 164, 169]]], ["During the current outbreak, two independent case studies of COVID-19 patients hospitalized in South Korea, reported a reduction in viral load and subsequent recovery of patients following the administration of lopinavir/ritonavir (153, 154).", [["lopinavir/ritonavir", "CHEMICAL", 211, 230], ["lopinavir", "CHEMICAL", 211, 220], ["ritonavir", "CHEMICAL", 221, 230], ["patients", "ORGANISM", 70, 78], ["patients", "ORGANISM", 170, 178], ["lopinavir", "SIMPLE_CHEMICAL", 211, 220], ["ritonavir", "SIMPLE_CHEMICAL", 221, 230], ["patients", "SPECIES", 70, 78], ["patients", "SPECIES", 170, 178], ["COVID", "TEST", 61, 66], ["a reduction in viral load", "PROBLEM", 117, 142], ["lopinavir", "TREATMENT", 211, 220], ["ritonavir", "TREATMENT", 221, 230], ["viral load", "OBSERVATION", 132, 142]]], ["However, a randomized control study in China of 199 severe COVID-19 patients demonstrated no difference in mortality, or in the amount of viral RNA detected (155).", [["COVID", "DISEASE", 59, 64], ["patients", "ORGANISM", 68, 76], ["viral RNA", "RNA", 138, 147], ["patients", "SPECIES", 68, 76], ["a randomized control study", "TEST", 9, 35], ["severe COVID", "TEST", 52, 64], ["difference in mortality", "PROBLEM", 93, 116], ["viral RNA", "PROBLEM", 138, 147], ["no", "UNCERTAINTY", 90, 92], ["difference", "OBSERVATION_MODIFIER", 93, 103], ["amount", "OBSERVATION_MODIFIER", 128, 134], ["viral RNA", "OBSERVATION", 138, 147]]], ["Furthermore, recent findings from the RECOVERY trial comparing 1,596 patients randomized to lopinavir/ritonavir to 3,376 standard of care patients concluded no clinical benefit from the use of lopinavir/ritonavir (149, 156).", [["lopinavir/ritonavir", "CHEMICAL", 92, 111], ["lopinavir/ritonavir", "CHEMICAL", 193, 212], ["lopinavir", "CHEMICAL", 92, 101], ["ritonavir", "CHEMICAL", 102, 111], ["lopinavir", "CHEMICAL", 193, 202], ["ritonavir", "CHEMICAL", 203, 212], ["patients", "ORGANISM", 69, 77], ["lopinavir", "SIMPLE_CHEMICAL", 92, 101], ["ritonavir", "SIMPLE_CHEMICAL", 102, 111], ["patients", "ORGANISM", 138, 146], ["lopinavir", "SIMPLE_CHEMICAL", 193, 202], ["ritonavir", "SIMPLE_CHEMICAL", 203, 212], ["patients", "SPECIES", 69, 77], ["patients", "SPECIES", 138, 146], ["lopinavir", "TREATMENT", 92, 101], ["ritonavir", "TREATMENT", 102, 111], ["lopinavir", "TREATMENT", 193, 202], ["ritonavir", "TREATMENT", 203, 212]]], ["Moreover, protease inhibitors such as lopinavir/ritonavir have been associated with hepatotoxicity during HIV treatment (157, 158), and drug-to-drug interaction (DDI) with certain statins, for example rosuvastatin, can increase the risk of myopathy (159, 160).", [["lopinavir/ritonavir", "CHEMICAL", 38, 57], ["hepatotoxicity", "DISEASE", 84, 98], ["statins", "CHEMICAL", 180, 187], ["rosuvastatin", "CHEMICAL", 201, 213], ["myopathy", "DISEASE", 240, 248], ["lopinavir", "CHEMICAL", 38, 47], ["ritonavir", "CHEMICAL", 48, 57], ["statins", "CHEMICAL", 180, 187], ["rosuvastatin", "CHEMICAL", 201, 213], ["lopinavir", "SIMPLE_CHEMICAL", 38, 47], ["ritonavir", "SIMPLE_CHEMICAL", 48, 57], ["statins", "SIMPLE_CHEMICAL", 180, 187], ["rosuvastatin", "SIMPLE_CHEMICAL", 201, 213], ["HIV", "SPECIES", 106, 109], ["protease inhibitors", "TREATMENT", 10, 29], ["lopinavir", "TREATMENT", 38, 47], ["ritonavir", "TREATMENT", 48, 57], ["hepatotoxicity", "PROBLEM", 84, 98], ["HIV treatment", "TREATMENT", 106, 119], ["certain statins", "TREATMENT", 172, 187], ["rosuvastatin", "TREATMENT", 201, 213], ["myopathy", "PROBLEM", 240, 248], ["myopathy", "OBSERVATION", 240, 248]]], ["Therefore, administration to COVID-19 patients with pre-existing liver disease and those being treated with statins could prove detrimental.", [["liver", "ANATOMY", 65, 70], ["liver disease", "DISEASE", 65, 78], ["statins", "CHEMICAL", 108, 115], ["statins", "CHEMICAL", 108, 115], ["patients", "ORGANISM", 38, 46], ["liver", "ORGAN", 65, 70], ["patients", "SPECIES", 38, 46], ["COVID", "TEST", 29, 34], ["pre-existing liver disease", "PROBLEM", 52, 78], ["statins", "TREATMENT", 108, 115], ["liver", "ANATOMY", 65, 70], ["disease", "OBSERVATION", 71, 78]]], ["Like other members of the protease inhibitor class, lopinavir/ritonavir has also been associated with metabolic changes that can result in hyperglycaemia (161), hyperlipidaemia (162), and insulin resistance (163).", [["lopinavir/ritonavir", "CHEMICAL", 52, 71], ["hyperglycaemia", "DISEASE", 139, 153], ["hyperlipidaemia", "DISEASE", 161, 176], ["lopinavir", "CHEMICAL", 52, 61], ["ritonavir", "CHEMICAL", 62, 71], ["lopinavir", "SIMPLE_CHEMICAL", 52, 61], ["ritonavir", "SIMPLE_CHEMICAL", 62, 71], ["insulin", "GENE_OR_GENE_PRODUCT", 188, 195], ["the protease inhibitor class", "TREATMENT", 22, 50], ["lopinavir", "TREATMENT", 52, 61], ["ritonavir", "TREATMENT", 62, 71], ["metabolic changes", "PROBLEM", 102, 119], ["hyperglycaemia", "PROBLEM", 139, 153], ["hyperlipidaemia", "PROBLEM", 161, 176], ["insulin resistance", "TEST", 188, 206], ["insulin resistance", "OBSERVATION", 188, 206]]], ["Due to the lack of efficacy and increased risk of toxicity to certain COVID-19 patients lopinavir/ritonavir could be prove more harmful to patients and should therefore be avoided.Oseltamivir and Favipiravir ::: Broad-Spectrum Antiviral Agents ::: Challenges to Overcome With Repurposed DrugsOseltamivir and favipiravir, two antiviral treatments traditionally used to treat influenza, have also been examined for use in COVID-19.", [["toxicity", "DISEASE", 50, 58], ["lopinavir/ritonavir", "CHEMICAL", 88, 107], ["Oseltamivir", "CHEMICAL", 180, 191], ["Favipiravir", "CHEMICAL", 196, 207], ["DrugsOseltamivir", "CHEMICAL", 287, 303], ["favipiravir", "CHEMICAL", 308, 319], ["influenza", "DISEASE", 374, 383], ["lopinavir", "CHEMICAL", 88, 97], ["ritonavir", "CHEMICAL", 98, 107], ["Oseltamivir", "CHEMICAL", 180, 191], ["Favipiravir", "CHEMICAL", 196, 207], ["DrugsOseltamivir", "CHEMICAL", 287, 303], ["favipiravir", "CHEMICAL", 308, 319], ["patients", "ORGANISM", 79, 87], ["lopinavir", "SIMPLE_CHEMICAL", 88, 97], ["ritonavir", "SIMPLE_CHEMICAL", 98, 107], ["patients", "ORGANISM", 139, 147], ["Oseltamivir", "SIMPLE_CHEMICAL", 180, 191], ["Favipiravir", "SIMPLE_CHEMICAL", 196, 207], ["DrugsOseltamivir", "SIMPLE_CHEMICAL", 287, 303], ["favipiravir", "SIMPLE_CHEMICAL", 308, 319], ["patients", "SPECIES", 79, 87], ["patients", "SPECIES", 139, 147], ["increased risk of toxicity", "PROBLEM", 32, 58], ["COVID", "TEST", 70, 75], ["lopinavir", "TREATMENT", 88, 97], ["ritonavir", "TREATMENT", 98, 107], ["Oseltamivir", "TREATMENT", 180, 191], ["Repurposed DrugsOseltamivir", "TREATMENT", 276, 303], ["favipiravir", "TREATMENT", 308, 319], ["two antiviral treatments", "TREATMENT", 321, 345], ["influenza", "PROBLEM", 374, 383], ["Antiviral Agents", "OBSERVATION", 227, 243]]], ["Oseltamivir is a neuraminidase inhibitor, which has been extensively used as a prophylactic against influenza.", [["Oseltamivir", "CHEMICAL", 0, 11], ["influenza", "DISEASE", 100, 109], ["Oseltamivir", "CHEMICAL", 0, 11], ["Oseltamivir", "SIMPLE_CHEMICAL", 0, 11], ["neuraminidase", "GENE_OR_GENE_PRODUCT", 17, 30], ["Oseltamivir", "TREATMENT", 0, 11], ["a neuraminidase inhibitor", "TREATMENT", 15, 40], ["influenza", "PROBLEM", 100, 109]]], ["In a small, single-center study of 138 patients with SARS-CoV-2 pneumonia in China, 89.9% of patients received oseltamivir alongside anti-bacterial drugs such as moxifloxacin, ceftriaxone, azithromycin, and glucocorticoid therapy (18).", [["SARS-CoV-2 pneumonia", "DISEASE", 53, 73], ["oseltamivir", "CHEMICAL", 111, 122], ["moxifloxacin", "CHEMICAL", 162, 174], ["ceftriaxone", "CHEMICAL", 176, 187], ["azithromycin", "CHEMICAL", 189, 201], ["oseltamivir", "CHEMICAL", 111, 122], ["moxifloxacin", "CHEMICAL", 162, 174], ["ceftriaxone", "CHEMICAL", 176, 187], ["azithromycin", "CHEMICAL", 189, 201], ["patients", "ORGANISM", 39, 47], ["patients", "ORGANISM", 93, 101], ["oseltamivir", "SIMPLE_CHEMICAL", 111, 122], ["moxifloxacin", "SIMPLE_CHEMICAL", 162, 174], ["ceftriaxone", "SIMPLE_CHEMICAL", 176, 187], ["azithromycin", "SIMPLE_CHEMICAL", 189, 201], ["glucocorticoid", "SIMPLE_CHEMICAL", 207, 221], ["patients", "SPECIES", 39, 47], ["patients", "SPECIES", 93, 101], ["center study", "TEST", 19, 31], ["SARS", "PROBLEM", 53, 57], ["CoV", "TEST", 58, 61], ["pneumonia", "PROBLEM", 64, 73], ["oseltamivir", "TREATMENT", 111, 122], ["anti-bacterial drugs", "TREATMENT", 133, 153], ["moxifloxacin", "TREATMENT", 162, 174], ["ceftriaxone", "TREATMENT", 176, 187], ["azithromycin", "TREATMENT", 189, 201], ["glucocorticoid therapy", "TREATMENT", 207, 229], ["small", "OBSERVATION_MODIFIER", 5, 10], ["pneumonia", "OBSERVATION", 64, 73]]], ["The study concluded no effective outcomes based on oseltamivir (18).", [["oseltamivir", "CHEMICAL", 51, 62], ["oseltamivir", "CHEMICAL", 51, 62], ["oseltamivir", "SIMPLE_CHEMICAL", 51, 62], ["The study", "TEST", 0, 9], ["effective outcomes", "PROBLEM", 23, 41], ["oseltamivir", "TREATMENT", 51, 62], ["no", "UNCERTAINTY", 20, 22], ["effective", "OBSERVATION_MODIFIER", 23, 32]]], ["However, the small study size, lack of appropriate control and the fact that many patients remained hospitalized at the time of publications limits full interpretations.", [["patients", "ORGANISM", 82, 90], ["patients", "SPECIES", 82, 90], ["the small study size", "PROBLEM", 9, 29], ["small", "OBSERVATION_MODIFIER", 13, 18], ["size", "OBSERVATION_MODIFIER", 25, 29]]], ["Favipiravir is an antiviral with potent inhibitory activity against viral RNA-dependent RNA polymerase.", [["Favipiravir", "CHEMICAL", 0, 11], ["Favipiravir", "CHEMICAL", 0, 11], ["Favipiravir", "SIMPLE_CHEMICAL", 0, 11], ["viral RNA", "RNA", 68, 77], ["RNA polymerase", "PROTEIN", 88, 102], ["Favipiravir", "TREATMENT", 0, 11], ["an antiviral", "TREATMENT", 15, 27], ["potent inhibitory activity", "TREATMENT", 33, 59], ["viral RNA-dependent RNA polymerase", "PROBLEM", 68, 102]]], ["Experimentally, favipiravir demonstrated effective SARS-CoV-2 inhibition in Vero E6 cells (145).", [["Vero E6 cells", "ANATOMY", 76, 89], ["favipiravir", "CHEMICAL", 16, 27], ["favipiravir", "CHEMICAL", 16, 27], ["favipiravir", "SIMPLE_CHEMICAL", 16, 27], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 51, 61], ["Vero E6 cells", "CELL", 76, 89], ["Vero E6 cells", "CELL_LINE", 76, 89], ["Vero E6", "SPECIES", 76, 83], ["favipiravir", "TEST", 16, 27], ["effective SARS", "PROBLEM", 41, 55], ["CoV", "TEST", 56, 59]]], ["Furthermore, a small, open-label, non-randomized comparative study of 80 patients in China, compared clinical outcomes of patients treated with favipiravir and lopinavir/ritonavir (164).", [["favipiravir", "CHEMICAL", 144, 155], ["lopinavir/ritonavir", "CHEMICAL", 160, 179], ["favipiravir", "CHEMICAL", 144, 155], ["lopinavir", "CHEMICAL", 160, 169], ["ritonavir", "CHEMICAL", 170, 179], ["patients", "ORGANISM", 73, 81], ["patients", "ORGANISM", 122, 130], ["favipiravir", "SIMPLE_CHEMICAL", 144, 155], ["lopinavir", "SIMPLE_CHEMICAL", 160, 169], ["ritonavir", "SIMPLE_CHEMICAL", 170, 179], ["patients", "SPECIES", 73, 81], ["patients", "SPECIES", 122, 130], ["non-randomized comparative study", "TEST", 34, 66], ["favipiravir", "TREATMENT", 144, 155], ["lopinavir", "TREATMENT", 160, 169], ["ritonavir", "TREATMENT", 170, 179], ["small", "OBSERVATION_MODIFIER", 15, 20]]], ["The median time until viral clearance was 4 days with favipiravir compared to 11 days with lopinavir/ritonavir.", [["favipiravir", "CHEMICAL", 54, 65], ["lopinavir/ritonavir", "CHEMICAL", 91, 110], ["favipiravir", "CHEMICAL", 54, 65], ["lopinavir", "CHEMICAL", 91, 100], ["ritonavir", "CHEMICAL", 101, 110], ["favipiravir", "SIMPLE_CHEMICAL", 54, 65], ["lopinavir", "SIMPLE_CHEMICAL", 91, 100], ["ritonavir", "SIMPLE_CHEMICAL", 101, 110], ["favipiravir", "TREATMENT", 54, 65], ["lopinavir", "TREATMENT", 91, 100], ["ritonavir", "TREATMENT", 101, 110]]], ["At day 14, CT scans of the chest from patients treated with favipiravir demonstrated significant improvements.", [["chest", "ANATOMY", 27, 32], ["favipiravir", "CHEMICAL", 60, 71], ["favipiravir", "CHEMICAL", 60, 71], ["chest", "ORGANISM_SUBDIVISION", 27, 32], ["patients", "ORGANISM", 38, 46], ["favipiravir", "SIMPLE_CHEMICAL", 60, 71], ["patients", "SPECIES", 38, 46], ["CT scans of the chest", "TEST", 11, 32], ["favipiravir", "TREATMENT", 60, 71], ["chest", "ANATOMY", 27, 32], ["significant", "OBSERVATION_MODIFIER", 85, 96], ["improvements", "OBSERVATION", 97, 109]]], ["Adverse events occurred in 11% of favipiravir treated patients compared to 55% of lopinavir/ritonavir treated patients (164).", [["favipiravir", "CHEMICAL", 34, 45], ["lopinavir/ritonavir", "CHEMICAL", 82, 101], ["favipiravir", "CHEMICAL", 34, 45], ["lopinavir", "CHEMICAL", 82, 91], ["ritonavir", "CHEMICAL", 92, 101], ["favipiravir", "SIMPLE_CHEMICAL", 34, 45], ["patients", "ORGANISM", 54, 62], ["lopinavir", "SIMPLE_CHEMICAL", 82, 91], ["ritonavir", "SIMPLE_CHEMICAL", 92, 101], ["patients", "ORGANISM", 110, 118], ["patients", "SPECIES", 54, 62], ["patients", "SPECIES", 110, 118], ["Adverse events", "PROBLEM", 0, 14], ["favipiravir", "TREATMENT", 34, 45], ["lopinavir", "TREATMENT", 82, 91], ["ritonavir", "TREATMENT", 92, 101]]], ["However, despite initial promise more robust clinical data is needed in order to establish the efficacy and safety of favipiravir as a treatment of COVID-19.Remdesivir ::: Broad-Spectrum Antiviral Agents ::: Challenges to Overcome With Repurposed DrugsAnother antiviral agent being examined for use in COVID-19 is remdesivir.", [["favipiravir", "CHEMICAL", 118, 129], ["COVID-19", "CHEMICAL", 302, 310], ["remdesivir", "CHEMICAL", 314, 324], ["favipiravir", "CHEMICAL", 118, 129], ["COVID-19", "CHEMICAL", 148, 156], ["COVID-19", "CHEMICAL", 302, 310], ["favipiravir", "SIMPLE_CHEMICAL", 118, 129], ["COVID-19", "SIMPLE_CHEMICAL", 302, 310], ["remdesivir", "SIMPLE_CHEMICAL", 314, 324], ["favipiravir", "TREATMENT", 118, 129], ["COVID", "TEST", 148, 153], ["Repurposed DrugsAnother antiviral agent", "TREATMENT", 236, 275], ["remdesivir", "TREATMENT", 314, 324], ["Antiviral Agents", "OBSERVATION", 187, 203]]], ["When metabolized into its active form, remdesivir inhibits viral RNA polymerases, causing a decrease in viral RNA production.", [["remdesivir", "CHEMICAL", 39, 49], ["remdesivir", "CHEMICAL", 39, 49], ["remdesivir", "SIMPLE_CHEMICAL", 39, 49], ["viral RNA polymerases", "PROTEIN", 59, 80], ["viral RNA", "RNA", 104, 113], ["remdesivir", "TREATMENT", 39, 49], ["viral RNA polymerases", "PROBLEM", 59, 80], ["a decrease in viral RNA production", "PROBLEM", 90, 124], ["active", "OBSERVATION_MODIFIER", 26, 32], ["viral RNA polymerases", "OBSERVATION", 59, 80], ["decrease", "OBSERVATION_MODIFIER", 92, 100], ["viral RNA production", "OBSERVATION", 104, 124]]], ["Remdesivir has been shown to inhibit SARS-CoV and MERS-CoV in human airway epithelial in vitro models (165, 166), and in combination with interferon beta, remdesivir has been shown to be superior to lopinavir/ritonavir in a MERS-CoV mouse model (167).", [["airway epithelial", "ANATOMY", 68, 85], ["Remdesivir", "CHEMICAL", 0, 10], ["remdesivir", "CHEMICAL", 155, 165], ["lopinavir/ritonavir", "CHEMICAL", 199, 218], ["Remdesivir", "CHEMICAL", 0, 10], ["lopinavir", "CHEMICAL", 199, 208], ["ritonavir", "CHEMICAL", 209, 218], ["Remdesivir", "SIMPLE_CHEMICAL", 0, 10], ["SARS-CoV", "ORGANISM", 37, 45], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 50, 58], ["human", "ORGANISM", 62, 67], ["airway epithelial", "CELL", 68, 85], ["interferon beta", "GENE_OR_GENE_PRODUCT", 138, 153], ["remdesivir", "SIMPLE_CHEMICAL", 155, 165], ["lopinavir", "SIMPLE_CHEMICAL", 199, 208], ["ritonavir", "SIMPLE_CHEMICAL", 209, 218], ["MERS-CoV mouse", "ORGANISM", 224, 238], ["interferon beta", "PROTEIN", 138, 153], ["human", "SPECIES", 62, 67], ["mouse", "SPECIES", 233, 238], ["SARS-CoV", "SPECIES", 37, 45], ["MERS-CoV", "SPECIES", 50, 58], ["human", "SPECIES", 62, 67], ["MERS-CoV mouse", "SPECIES", 224, 238], ["Remdesivir", "TREATMENT", 0, 10], ["SARS", "PROBLEM", 37, 41], ["CoV", "TEST", 42, 45], ["MERS", "TEST", 50, 54], ["CoV in human airway epithelial in vitro models", "TEST", 55, 101], ["interferon beta", "TREATMENT", 138, 153], ["remdesivir", "TREATMENT", 155, 165], ["lopinavir", "TREATMENT", 199, 208], ["ritonavir", "TREATMENT", 209, 218], ["airway", "ANATOMY", 68, 74], ["epithelial", "ANATOMY_MODIFIER", 75, 85]]], ["For instance, preliminary results from the National Institute of Allergy and Infectious Diseases Adaptive COVID-19 Treatment Trial involving 1,063 patients, demonstrated that remdesivir accelerated recovered by 31% compared to placebo (169).", [["Infectious Diseases", "DISEASE", 77, 96], ["remdesivir", "CHEMICAL", 175, 185], ["remdesivir", "CHEMICAL", 175, 185], ["patients", "ORGANISM", 147, 155], ["remdesivir", "SIMPLE_CHEMICAL", 175, 185], ["patients", "SPECIES", 147, 155], ["Adaptive COVID", "TREATMENT", 97, 111]]], ["Furthermore, recent results from the Phase 3 SIMPLE trial investigating the use of remdesivir in patients with moderate COVID-19 showed that patients receiving remdesivir treatment were 65% more likely to have improved clinically by day 11 than standard of care patients (170, 171).", [["remdesivir", "CHEMICAL", 83, 93], ["remdesivir", "CHEMICAL", 160, 170], ["remdesivir", "CHEMICAL", 83, 93], ["remdesivir", "CHEMICAL", 160, 170], ["remdesivir", "SIMPLE_CHEMICAL", 83, 93], ["patients", "ORGANISM", 97, 105], ["patients", "ORGANISM", 141, 149], ["patients", "ORGANISM", 262, 270], ["patients", "SPECIES", 97, 105], ["patients", "SPECIES", 141, 149], ["patients", "SPECIES", 262, 270], ["remdesivir", "TREATMENT", 83, 93], ["moderate COVID", "TEST", 111, 125], ["remdesivir treatment", "TREATMENT", 160, 180]]], ["Due to the success of these two trials, the use of remdesivir has been approved by the FDA, EMA, UK, and Japan as a treatment for COVID-19.", [["remdesivir", "CHEMICAL", 51, 61], ["remdesivir", "CHEMICAL", 51, 61], ["remdesivir", "SIMPLE_CHEMICAL", 51, 61], ["remdesivir", "TREATMENT", 51, 61], ["COVID", "TEST", 130, 135]]], ["Despite proven efficacy, adverse events in response to remdesivir have been reported in 60% of patients of which 12% were severe (168).", [["remdesivir", "CHEMICAL", 55, 65], ["remdesivir", "CHEMICAL", 55, 65], ["remdesivir", "SIMPLE_CHEMICAL", 55, 65], ["patients", "ORGANISM", 95, 103], ["patients", "SPECIES", 95, 103], ["adverse events", "PROBLEM", 25, 39], ["remdesivir", "TREATMENT", 55, 65]]], ["These included septic shock, multiple organ dysfunction syndrome, acute kidney injury and hypotension.", [["organ", "ANATOMY", 38, 43], ["kidney", "ANATOMY", 72, 78], ["septic shock", "DISEASE", 15, 27], ["multiple organ dysfunction syndrome", "DISEASE", 29, 64], ["acute kidney injury", "DISEASE", 66, 85], ["hypotension", "DISEASE", 90, 101], ["organ", "ORGAN", 38, 43], ["kidney", "ORGAN", 72, 78], ["septic shock", "PROBLEM", 15, 27], ["multiple organ dysfunction syndrome", "PROBLEM", 29, 64], ["acute kidney injury", "PROBLEM", 66, 85], ["hypotension", "PROBLEM", 90, 101], ["septic shock", "OBSERVATION", 15, 27], ["multiple", "OBSERVATION_MODIFIER", 29, 37], ["organ dysfunction syndrome", "OBSERVATION", 38, 64], ["acute", "OBSERVATION_MODIFIER", 66, 71], ["kidney", "ANATOMY", 72, 78], ["injury", "OBSERVATION", 79, 85], ["hypotension", "OBSERVATION", 90, 101]]], ["Therefore, the use of remdesivir in comorbid patients with increased susceptible to these adverse events requires further evaluation.Mesenchymal Stem Cell (MSC) Therapy ::: Anti-inflammatory Treatments ::: Challenges to Overcome With Repurposed DrugsDue to their immunomodulatory properties, MSCs are being clinically assessed to treat inflammatory conditions such as systemic lupus erythematosus (172) and graft vs. host disease following allogeneic haemopoietic stem-cell transplantation (173).", [["Mesenchymal Stem Cell", "ANATOMY", 133, 154], ["MSC", "ANATOMY", 156, 159], ["MSCs", "ANATOMY", 292, 296], ["graft", "ANATOMY", 407, 412], ["haemopoietic stem-cell", "ANATOMY", 451, 473], ["remdesivir", "CHEMICAL", 22, 32], ["systemic lupus erythematosus", "DISEASE", 368, 396], ["host disease", "DISEASE", 417, 429], ["remdesivir", "CHEMICAL", 22, 32], ["remdesivir", "SIMPLE_CHEMICAL", 22, 32], ["patients", "ORGANISM", 45, 53], ["Mesenchymal Stem Cell", "CELL", 133, 154], ["MSC", "CELL", 156, 159], ["MSCs", "CELL", 292, 296], ["graft", "TISSUE", 407, 412], ["haemopoietic stem-cell", "CELL", 451, 473], ["MSCs", "CELL_TYPE", 292, 296], ["patients", "SPECIES", 45, 53], ["remdesivir", "TREATMENT", 22, 32], ["these adverse events", "PROBLEM", 84, 104], ["further evaluation", "TEST", 114, 132], ["Mesenchymal Stem Cell (MSC) Therapy", "TREATMENT", 133, 168], ["Repurposed DrugsDue", "TREATMENT", 234, 253], ["their immunomodulatory properties", "TREATMENT", 257, 290], ["MSCs", "TREATMENT", 292, 296], ["inflammatory conditions", "PROBLEM", 336, 359], ["systemic lupus erythematosus", "PROBLEM", 368, 396], ["graft vs", "TEST", 407, 415], ["host disease", "PROBLEM", 417, 429], ["allogeneic haemopoietic stem-cell transplantation", "TREATMENT", 440, 489], ["Stem Cell", "OBSERVATION", 145, 154], ["systemic", "OBSERVATION_MODIFIER", 368, 376], ["lupus erythematosus", "OBSERVATION", 377, 396], ["graft", "OBSERVATION", 407, 412], ["allogeneic haemopoietic stem", "OBSERVATION", 440, 468], ["cell transplantation", "OBSERVATION", 469, 489]]], ["Consequently, a pilot study was initiated to investigate the potential therapeutic benefit of MSCs for COVID-19 infected patients in China.", [["MSCs", "ANATOMY", 94, 98], ["COVID-19 infected", "DISEASE", 103, 120], ["MSCs", "CELL", 94, 98], ["COVID-19", "CELL", 103, 111], ["patients", "ORGANISM", 121, 129], ["MSCs", "CELL_TYPE", 94, 98], ["patients", "SPECIES", 121, 129], ["a pilot study", "TEST", 14, 27], ["MSCs", "TREATMENT", 94, 98], ["COVID", "TEST", 103, 108]]], ["The study involved just 10 COVID-19 patients who were monitored for 14 days post-MSC injection (174).", [["MSC", "ANATOMY", 81, 84], ["patients", "ORGANISM", 36, 44], ["MSC", "CELL", 81, 84], ["patients", "SPECIES", 36, 44], ["The study", "TEST", 0, 9]]], ["MSC treatment was well-tolerated and no adverse events occurred during treatment.", [["MSC", "ANATOMY", 0, 3], ["MSC", "CELL", 0, 3], ["MSC treatment", "TREATMENT", 0, 13], ["adverse events", "PROBLEM", 40, 54], ["treatment", "TREATMENT", 71, 80]]], ["Furthermore, virtually all clinical symptoms subsided, with 3 patients being discharged 10 days post-MSC injection (174).", [["MSC", "ANATOMY", 101, 104], ["patients", "ORGANISM", 62, 70], ["MSC", "CELL", 101, 104], ["patients", "SPECIES", 62, 70], ["all clinical symptoms", "PROBLEM", 23, 44]]], ["Mass cytometry of PBMCs revealed that peripheral lymphocytes, regulatory CD14+CD11c+CD11bmid DCs and IL-10 increased.", [["PBMCs", "ANATOMY", 18, 23], ["peripheral lymphocytes", "ANATOMY", 38, 60], ["regulatory CD14+CD11c+CD11bmid DCs", "ANATOMY", 62, 96], ["PBMCs", "CELL", 18, 23], ["peripheral lymphocytes", "CELL", 38, 60], ["CD14", "GENE_OR_GENE_PRODUCT", 73, 77], ["CD11c", "GENE_OR_GENE_PRODUCT", 78, 83], ["IL-10", "GENE_OR_GENE_PRODUCT", 101, 106], ["PBMCs", "CELL_TYPE", 18, 23], ["peripheral lymphocytes", "CELL_TYPE", 38, 60], ["CD14", "PROTEIN", 73, 77], ["CD11c", "PROTEIN", 78, 83], ["CD11", "PROTEIN", 84, 88], ["DCs", "CELL_TYPE", 93, 96], ["IL", "PROTEIN", 101, 103], ["Mass cytometry", "TEST", 0, 14], ["PBMCs", "TEST", 18, 23], ["peripheral lymphocytes", "TEST", 38, 60], ["regulatory CD14", "TEST", 62, 77], ["CD11c", "TEST", 78, 83], ["CD11", "TEST", 84, 88], ["DCs", "TEST", 93, 96], ["IL", "TEST", 101, 103], ["peripheral", "ANATOMY_MODIFIER", 38, 48], ["lymphocytes", "ANATOMY", 49, 60]]], ["Whereas, CRP, TNF-\u03b1 and overactivated CXCR3+ CD4+/CD8+/NK cells decreased 3 to 6 days following injection compared to placebo group.", [["overactivated CXCR3+ CD4+/CD8+/NK cells", "ANATOMY", 24, 63], ["CRP", "GENE_OR_GENE_PRODUCT", 9, 12], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 14, 19], ["CXCR3", "GENE_OR_GENE_PRODUCT", 38, 43], ["CD4", "GENE_OR_GENE_PRODUCT", 45, 48], ["CD8", "GENE_OR_GENE_PRODUCT", 50, 53], ["CRP", "PROTEIN", 9, 12], ["TNF", "PROTEIN", 14, 17], ["CXCR3", "PROTEIN", 38, 43], ["CD4", "PROTEIN", 45, 48], ["CD8", "PROTEIN", 50, 53], ["NK cells", "CELL_TYPE", 55, 63], ["CRP", "TEST", 9, 12], ["TNF", "TEST", 14, 17], ["overactivated", "TEST", 24, 37], ["CXCR3", "TEST", 38, 43], ["CD4", "TEST", 45, 48], ["CD8", "TEST", 50, 53], ["NK cells", "PROBLEM", 55, 63], ["injection", "TREATMENT", 96, 105], ["NK", "ANATOMY", 55, 57]]], ["MSCs were shown to be ACE2 negative, meaning they were immune to SARS-CoV-2 infection (174).", [["MSCs", "ANATOMY", 0, 4], ["SARS-CoV-2 infection", "DISEASE", 65, 85], ["MSCs", "CELL", 0, 4], ["ACE2", "GENE_OR_GENE_PRODUCT", 22, 26], ["SARS-CoV-2", "ORGANISM", 65, 75], ["MSCs", "CELL_TYPE", 0, 4], ["ACE2", "PROTEIN", 22, 26], ["SARS-CoV-2", "SPECIES", 65, 75], ["MSCs", "PROBLEM", 0, 4], ["ACE2", "TEST", 22, 26], ["SARS", "PROBLEM", 65, 69], ["CoV", "TEST", 70, 73], ["2 infection", "PROBLEM", 74, 85]]], ["Although this pilot study shows promise, more robust clinical data is required to validate therapeutic benefit and safety.", [["this pilot study", "TEST", 9, 25]]], ["Moreover, the use of MSCs would require clinical grade MSC production and may not be a plausible solution for many healthcare systems.Anti-IL-6 ::: Anti-inflammatory Treatments ::: Challenges to Overcome With Repurposed DrugsIL-6 is considered the key cytokine responsible for the induction of cytokine storm during SARS-CoV, MERS-CoV and SARS-Cov-2 infections (30, 175, 176).", [["MSCs", "ANATOMY", 21, 25], ["MSC", "ANATOMY", 55, 58], ["infections", "DISEASE", 350, 360], ["DrugsIL-6", "CHEMICAL", 220, 229], ["MSCs", "CELL", 21, 25], ["MSC", "CELL", 55, 58], ["Anti-IL-6", "SIMPLE_CHEMICAL", 134, 143], ["DrugsIL-6", "GENE_OR_GENE_PRODUCT", 220, 229], ["SARS-CoV", "ORGANISM", 316, 324], ["MERS-CoV", "ORGANISM", 326, 334], ["SARS-Cov-2", "ORGANISM", 339, 349], ["MSCs", "CELL_TYPE", 21, 25], ["cytokine", "PROTEIN", 252, 260], ["cytokine", "PROTEIN", 294, 302], ["SARS-CoV", "SPECIES", 316, 324], ["MERS-CoV", "SPECIES", 326, 334], ["MSCs", "TREATMENT", 21, 25], ["clinical grade MSC production", "PROBLEM", 40, 69], ["Repurposed DrugsIL", "TREATMENT", 209, 227], ["cytokine storm", "PROBLEM", 294, 308], ["SARS", "PROBLEM", 316, 320], ["CoV", "TEST", 321, 324], ["MERS", "TEST", 326, 330], ["CoV", "PROBLEM", 331, 334], ["SARS", "PROBLEM", 339, 343], ["Cov", "TEST", 344, 347], ["Anti-inflammatory Treatments", "OBSERVATION", 148, 176]]], ["Consequently, the recombinant humanized anti-human IL-6 receptor monoclonal antibody tocilizumab, currently used to treat rheumatoid arthritis (RA), has been examined for use during COVID-19.", [["tocilizumab", "CHEMICAL", 85, 96], ["rheumatoid arthritis", "DISEASE", 122, 142], ["RA", "DISEASE", 144, 146], ["IL-6 receptor", "GENE_OR_GENE_PRODUCT", 51, 64], ["recombinant humanized anti-human IL-6 receptor monoclonal antibody", "PROTEIN", 18, 84], ["the recombinant humanized anti-human IL", "TREATMENT", 14, 53], ["receptor monoclonal antibody tocilizumab", "TREATMENT", 56, 96], ["rheumatoid arthritis", "PROBLEM", 122, 142], ["COVID", "TEST", 182, 187], ["rheumatoid arthritis", "OBSERVATION", 122, 142]]], ["Tocilizumab first demonstrated effectiveness in a small retrospective study of 20 patients with severe COVID-19 pneumonia in China (177).", [["Tocilizumab", "CHEMICAL", 0, 11], ["COVID", "DISEASE", 103, 108], ["pneumonia", "DISEASE", 112, 121], ["Tocilizumab", "CHEMICAL", 0, 11], ["Tocilizumab", "SIMPLE_CHEMICAL", 0, 11], ["patients", "ORGANISM", 82, 90], ["patients", "SPECIES", 82, 90], ["Tocilizumab", "TREATMENT", 0, 11], ["a small retrospective study", "TEST", 48, 75], ["severe COVID", "PROBLEM", 96, 108], ["pneumonia", "PROBLEM", 112, 121], ["severe", "OBSERVATION_MODIFIER", 96, 102], ["pneumonia", "OBSERVATION", 112, 121]]], ["Oxygen intake was reduced, and improved symptoms occurred in 75% of patients.", [["Oxygen", "CHEMICAL", 0, 6], ["Oxygen", "CHEMICAL", 0, 6], ["Oxygen", "SIMPLE_CHEMICAL", 0, 6], ["patients", "ORGANISM", 68, 76], ["patients", "SPECIES", 68, 76], ["Oxygen intake", "TEST", 0, 13], ["improved symptoms", "PROBLEM", 31, 48]]], ["Lymphocyte levels returned to normal in 56% of patients and CRP levels reduced significantly in 84.2% of patients (177).", [["Lymphocyte", "ANATOMY", 0, 10], ["Lymphocyte", "CELL", 0, 10], ["patients", "ORGANISM", 47, 55], ["CRP", "GENE_OR_GENE_PRODUCT", 60, 63], ["patients", "ORGANISM", 105, 113], ["CRP", "PROTEIN", 60, 63], ["patients", "SPECIES", 47, 55], ["patients", "SPECIES", 105, 113], ["Lymphocyte levels", "TEST", 0, 17], ["CRP levels", "TEST", 60, 70], ["normal", "OBSERVATION_MODIFIER", 30, 36]]], ["Several case studies have also demonstrated rapid clinical improvements following tocilizumab (178\u2013180).", [["tocilizumab", "CHEMICAL", 82, 93], ["tocilizumab", "SIMPLE_CHEMICAL", 82, 93], ["Several case studies", "TEST", 0, 20], ["tocilizumab", "TREATMENT", 82, 93]]], ["Although these initial studies are promising, the full clinical trial data is still unavailable.", [["these initial studies", "TEST", 9, 30], ["the full clinical trial data", "TEST", 46, 74]]], ["Furthermore, although safety profiles for tocilizumab are well-established for intermittent use in RA, the safety of tocilizumab when used in combination with antiviral agents and other comorbid therapies has not been established.Kinase Inhibitors ::: Anti-inflammatory Treatments ::: Challenges to Overcome With Repurposed DrugsOther anti-inflammatory treatments now being tested clinically for their use against COVID-19 are Janus kinase (JAK) and Bruton's tyrosine kinase (BTK) inhibitors.", [["tocilizumab", "CHEMICAL", 42, 53], ["RA", "DISEASE", 99, 101], ["tocilizumab", "CHEMICAL", 117, 128], ["tyrosine", "CHEMICAL", 459, 467], ["tyrosine", "CHEMICAL", 459, 467], ["tocilizumab", "SIMPLE_CHEMICAL", 42, 53], ["tocilizumab", "SIMPLE_CHEMICAL", 117, 128], ["Kinase", "GENE_OR_GENE_PRODUCT", 230, 236], ["COVID-19", "SIMPLE_CHEMICAL", 414, 422], ["Janus kinase", "GENE_OR_GENE_PRODUCT", 427, 439], ["JAK", "GENE_OR_GENE_PRODUCT", 441, 444], ["Bruton's tyrosine kinase", "GENE_OR_GENE_PRODUCT", 450, 474], ["BTK", "GENE_OR_GENE_PRODUCT", 476, 479], ["Janus kinase", "PROTEIN", 427, 439], ["JAK", "PROTEIN", 441, 444], ["Bruton's tyrosine kinase", "PROTEIN", 450, 474], ["BTK", "PROTEIN", 476, 479], ["tocilizumab", "TREATMENT", 42, 53], ["intermittent use in RA", "TREATMENT", 79, 101], ["tocilizumab", "TREATMENT", 117, 128], ["antiviral agents", "TREATMENT", 159, 175], ["other comorbid therapies", "TREATMENT", 180, 204], ["Repurposed DrugsOther anti-inflammatory treatments", "TREATMENT", 313, 363], ["COVID", "TEST", 414, 419], ["Janus kinase (JAK)", "TREATMENT", 427, 445], ["Bruton's tyrosine kinase (BTK) inhibitors", "TREATMENT", 450, 491], ["RA", "ANATOMY", 99, 101]]], ["The JAK-signal transducer and activator of transcription (JAK/STAT) pathway mediates the signal transduction of numerous cytokines in a number of immune cells such as T cell, NK cells, and DCs (181).", [["immune cells", "ANATOMY", 146, 158], ["T cell", "ANATOMY", 167, 173], ["NK cells", "ANATOMY", 175, 183], ["DCs", "ANATOMY", 189, 192], ["JAK-signal transducer and activator of transcription", "GENE_OR_GENE_PRODUCT", 4, 56], ["JAK", "GENE_OR_GENE_PRODUCT", 58, 61], ["STAT", "GENE_OR_GENE_PRODUCT", 62, 66], ["immune cells", "CELL", 146, 158], ["T cell", "CELL", 167, 173], ["NK cells", "CELL", 175, 183], ["DCs", "CELL", 189, 192], ["JAK", "PROTEIN", 4, 7], ["JAK", "PROTEIN", 58, 61], ["STAT", "PROTEIN", 62, 66], ["cytokines", "PROTEIN", 121, 130], ["immune cells", "CELL_TYPE", 146, 158], ["T cell", "CELL_TYPE", 167, 173], ["NK cells", "CELL_TYPE", 175, 183], ["DCs", "CELL_TYPE", 189, 192], ["transcription (JAK/STAT) pathway", "TREATMENT", 43, 75], ["numerous cytokines", "PROBLEM", 112, 130], ["immune cells", "PROBLEM", 146, 158], ["T cell", "TEST", 167, 173], ["NK cells", "TEST", 175, 183], ["DCs", "TEST", 189, 192], ["numerous", "OBSERVATION_MODIFIER", 112, 120], ["cytokines", "OBSERVATION", 121, 130], ["immune cells", "OBSERVATION", 146, 158], ["NK cells", "OBSERVATION", 175, 183]]], ["Consequently, JAK inhibitors have emerged as effective treatments for many autoimmune and immune-mediated disease.", [["autoimmune and immune-mediated disease", "DISEASE", 75, 113], ["JAK", "GENE_OR_GENE_PRODUCT", 14, 17], ["JAK", "PROTEIN", 14, 17], ["JAK inhibitors", "TREATMENT", 14, 28], ["effective treatments", "TREATMENT", 45, 65], ["many autoimmune and immune-mediated disease", "PROBLEM", 70, 113], ["autoimmune", "OBSERVATION", 75, 85], ["disease", "OBSERVATION", 106, 113]]], ["At present, a number of JAK inhibitors such as ruxolitinib (182), baricitinib (183), and fedratinib (184), are being assessed as a potential treatment for COVID-19.", [["ruxolitinib", "CHEMICAL", 47, 58], ["baricitinib", "CHEMICAL", 66, 77], ["fedratinib", "CHEMICAL", 89, 99], ["ruxolitinib", "CHEMICAL", 47, 58], ["baricitinib", "CHEMICAL", 66, 77], ["fedratinib", "CHEMICAL", 89, 99], ["JAK", "GENE_OR_GENE_PRODUCT", 24, 27], ["ruxolitinib", "SIMPLE_CHEMICAL", 47, 58], ["baricitinib", "SIMPLE_CHEMICAL", 66, 77], ["fedratinib", "SIMPLE_CHEMICAL", 89, 99], ["JAK", "PROTEIN", 24, 27], ["JAK inhibitors", "TREATMENT", 24, 38], ["ruxolitinib", "TEST", 47, 58], ["baricitinib", "TEST", 66, 77], ["COVID", "TEST", 155, 160]]], ["Preliminary results from a pilot study evaluating 88 hospitalized patients, 20 of which were treated with baricitinib, demonstrated significant reductions in serum IL-6, IL-1\u03b2, and TNF-\u03b1, as well as a rapid recovery of circulatory T and B cell frequencies following baricitinib treatment (185).", [["serum", "ANATOMY", 158, 163], ["circulatory T", "ANATOMY", 219, 232], ["B cell", "ANATOMY", 237, 243], ["baricitinib", "CHEMICAL", 106, 117], ["baricitinib", "CHEMICAL", 266, 277], ["baricitinib", "CHEMICAL", 106, 117], ["baricitinib", "CHEMICAL", 266, 277], ["patients", "ORGANISM", 66, 74], ["baricitinib", "SIMPLE_CHEMICAL", 106, 117], ["serum", "ORGANISM_SUBSTANCE", 158, 163], ["IL-6", "GENE_OR_GENE_PRODUCT", 164, 168], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 170, 175], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 181, 186], ["circulatory T", "CELL", 219, 232], ["B cell", "CELL", 237, 243], ["baricitinib", "SIMPLE_CHEMICAL", 266, 277], ["serum IL-6", "PROTEIN", 158, 168], ["IL-1\u03b2", "PROTEIN", 170, 175], ["TNF", "PROTEIN", 181, 184], ["patients", "SPECIES", 66, 74], ["a pilot study", "TEST", 25, 38], ["baricitinib", "TREATMENT", 106, 117], ["significant reductions", "PROBLEM", 132, 154], ["serum IL", "TEST", 158, 166], ["IL", "TEST", 170, 172], ["TNF", "TEST", 181, 184], ["circulatory T and B cell frequencies", "TREATMENT", 219, 255], ["baricitinib treatment", "TREATMENT", 266, 287], ["significant", "OBSERVATION_MODIFIER", 132, 143], ["reductions", "OBSERVATION_MODIFIER", 144, 154], ["circulatory", "ANATOMY", 219, 230]]], ["Consequently, a Phase 3 Adaptive COVID-19 Treatment Trial (ATTC-2) has now been established in order to evaluation the use of baricitinib in combination with remdesivir compared to remdesivir alone (186).", [["baricitinib", "CHEMICAL", 126, 137], ["remdesivir", "CHEMICAL", 158, 168], ["remdesivir", "CHEMICAL", 181, 191], ["baricitinib", "CHEMICAL", 126, 137], ["remdesivir", "CHEMICAL", 158, 168], ["remdesivir", "CHEMICAL", 181, 191], ["baricitinib", "SIMPLE_CHEMICAL", 126, 137], ["remdesivir", "SIMPLE_CHEMICAL", 158, 168], ["remdesivir", "SIMPLE_CHEMICAL", 181, 191], ["a Phase 3 Adaptive COVID", "TREATMENT", 14, 38], ["Treatment Trial (ATTC-2", "TREATMENT", 42, 65], ["baricitinib", "TREATMENT", 126, 137], ["remdesivir", "TREATMENT", 158, 168]]], ["However, despite promising initial findings, as JAK inhibitors block a wide range of cytokines including IFN-\u03b1, which is crucial during early innate immunity in response to viral infections, the impact of this on viral clearance needs to be evaluated.", [["viral infections", "DISEASE", 173, 189], ["JAK", "GENE_OR_GENE_PRODUCT", 48, 51], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 105, 110], ["JAK", "PROTEIN", 48, 51], ["cytokines", "PROTEIN", 85, 94], ["IFN-\u03b1", "PROTEIN", 105, 110], ["JAK inhibitors block", "PROBLEM", 48, 68], ["cytokines", "PROBLEM", 85, 94], ["IFN", "TEST", 105, 108], ["viral infections", "PROBLEM", 173, 189], ["viral clearance", "TREATMENT", 213, 228], ["viral infections", "OBSERVATION", 173, 189]]], ["Furthermore, ruxolitinib and baricitinib have both been associated with increased weight gain, cholesterol and albumin levels (187, 188).", [["ruxolitinib", "CHEMICAL", 13, 24], ["baricitinib", "CHEMICAL", 29, 40], ["weight gain", "DISEASE", 82, 93], ["cholesterol", "CHEMICAL", 95, 106], ["ruxolitinib", "CHEMICAL", 13, 24], ["baricitinib", "CHEMICAL", 29, 40], ["cholesterol", "CHEMICAL", 95, 106], ["ruxolitinib", "SIMPLE_CHEMICAL", 13, 24], ["baricitinib", "SIMPLE_CHEMICAL", 29, 40], ["cholesterol", "SIMPLE_CHEMICAL", 95, 106], ["albumin", "GENE_OR_GENE_PRODUCT", 111, 118], ["ruxolitinib", "TREATMENT", 13, 24], ["baricitinib", "TREATMENT", 29, 40], ["increased weight gain", "PROBLEM", 72, 93], ["cholesterol", "TEST", 95, 106], ["albumin levels", "TEST", 111, 125], ["ruxolitinib", "OBSERVATION", 13, 24], ["increased", "OBSERVATION_MODIFIER", 72, 81], ["weight gain", "OBSERVATION", 82, 93], ["albumin levels", "OBSERVATION_MODIFIER", 111, 125]]], ["Although no causal association has been reported yet, the issue should not be dismissed and COVID-19 patients with metabolic and cardiovascular comorbidities should be carefully considered before use.Kinase Inhibitors ::: Anti-inflammatory Treatments ::: Challenges to Overcome With Repurposed DrugsBruton's tyrosine kinase (BTK) is a key regulator of cell surface receptors expressed primarily in B cells, but also in monocytes/macrophages and neutrophils (189).", [["cardiovascular", "ANATOMY", 129, 143], ["cell surface", "ANATOMY", 352, 364], ["B cells", "ANATOMY", 398, 405], ["monocytes", "ANATOMY", 419, 428], ["macrophages", "ANATOMY", 429, 440], ["neutrophils", "ANATOMY", 445, 456], ["metabolic and cardiovascular comorbidities", "DISEASE", 115, 157], ["tyrosine", "CHEMICAL", 308, 316], ["tyrosine", "CHEMICAL", 308, 316], ["patients", "ORGANISM", 101, 109], ["cardiovascular", "ANATOMICAL_SYSTEM", 129, 143], ["Kinase", "GENE_OR_GENE_PRODUCT", 200, 206], ["DrugsBruton's tyrosine kinase", "GENE_OR_GENE_PRODUCT", 294, 323], ["BTK", "GENE_OR_GENE_PRODUCT", 325, 328], ["cell", "CELL", 352, 356], ["B cells", "CELL", 398, 405], ["monocytes", "CELL", 419, 428], ["macrophages", "CELL", 429, 440], ["neutrophils", "CELL", 445, 456], ["Repurposed DrugsBruton's tyrosine kinase", "PROTEIN", 283, 323], ["BTK", "PROTEIN", 325, 328], ["cell surface receptors", "PROTEIN", 352, 374], ["B cells", "CELL_TYPE", 398, 405], ["monocytes", "CELL_TYPE", 419, 428], ["macrophages", "CELL_TYPE", 429, 440], ["neutrophils", "CELL_TYPE", 445, 456], ["patients", "SPECIES", 101, 109], ["metabolic and cardiovascular comorbidities", "PROBLEM", 115, 157], ["Repurposed DrugsBruton's tyrosine kinase", "TREATMENT", 283, 323], ["cell surface receptors", "TEST", 352, 374], ["monocytes/macrophages", "TEST", 419, 440], ["neutrophils", "TEST", 445, 456], ["no", "UNCERTAINTY", 9, 11], ["monocytes", "ANATOMY", 419, 428], ["macrophages", "ANATOMY", 429, 440]]], ["Currently, BTK inhibitors are used to treat various B cell malignancies and chronic graft vs. host diseases (190).", [["B cell malignancies", "ANATOMY", 52, 71], ["graft", "ANATOMY", 84, 89], ["B cell malignancies", "DISEASE", 52, 71], ["host diseases", "DISEASE", 94, 107], ["BTK", "GENE_OR_GENE_PRODUCT", 11, 14], ["B cell malignancies", "CELL", 52, 71], ["graft", "TISSUE", 84, 89], ["BTK", "PROTEIN", 11, 14], ["BTK inhibitors", "TREATMENT", 11, 25], ["various B cell malignancies", "PROBLEM", 44, 71], ["chronic graft vs", "PROBLEM", 76, 92], ["host diseases", "PROBLEM", 94, 107], ["cell malignancies", "OBSERVATION", 54, 71], ["chronic", "OBSERVATION_MODIFIER", 76, 83], ["graft", "OBSERVATION", 84, 89]]], ["As BTK can regulate IL-6, TNF-\u03b1, and MCP-1, BTK inhibitors are being tested in combination with CAR-T cells (191), to alleviate cytokine release syndrome.", [["CAR-T cells", "ANATOMY", 96, 107], ["BTK", "GENE_OR_GENE_PRODUCT", 3, 6], ["IL-6", "GENE_OR_GENE_PRODUCT", 20, 24], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 26, 31], ["MCP-1", "GENE_OR_GENE_PRODUCT", 37, 42], ["BTK", "GENE_OR_GENE_PRODUCT", 44, 47], ["CAR-T cells", "CELL", 96, 107], ["BTK", "PROTEIN", 3, 6], ["IL-6", "PROTEIN", 20, 24], ["TNF", "PROTEIN", 26, 29], ["MCP", "PROTEIN", 37, 40], ["BTK", "PROTEIN", 44, 47], ["CAR", "PROTEIN", 96, 99], ["T cells", "CELL_TYPE", 100, 107], ["cytokine", "PROTEIN", 128, 136], ["IL", "TEST", 20, 22], ["TNF", "TEST", 26, 29], ["MCP", "TEST", 37, 40], ["BTK inhibitors", "TREATMENT", 44, 58], ["cytokine release syndrome", "PROBLEM", 128, 153]]], ["Furthermore, in chronic lymphocytic leukemia, BTK inhibitors have been shown to increase CD4+ and CD8+ T cell, and significantly downregulate PD-1 and CTLA-4 (192), highlighting a potential reversal of T cell exhaustion, which could be beneficial in COVID-19.", [["chronic lymphocytic leukemia", "ANATOMY", 16, 44], ["CD4+ and CD8+ T cell", "ANATOMY", 89, 109], ["T cell", "ANATOMY", 202, 208], ["chronic lymphocytic leukemia", "DISEASE", 16, 44], ["chronic lymphocytic leukemia", "CANCER", 16, 44], ["BTK", "GENE_OR_GENE_PRODUCT", 46, 49], ["CD4", "GENE_OR_GENE_PRODUCT", 89, 92], ["CD8", "GENE_OR_GENE_PRODUCT", 98, 101], ["PD-1", "GENE_OR_GENE_PRODUCT", 142, 146], ["CTLA-4", "GENE_OR_GENE_PRODUCT", 151, 157], ["T cell", "CELL", 202, 208], ["COVID-19", "CELL", 250, 258], ["BTK", "PROTEIN", 46, 49], ["CD4", "PROTEIN", 89, 92], ["CD8", "PROTEIN", 98, 101], ["chronic lymphocytic leukemia", "PROBLEM", 16, 44], ["BTK inhibitors", "TREATMENT", 46, 60], ["CD4", "TEST", 89, 92], ["CD8+ T cell", "PROBLEM", 98, 109], ["PD", "TEST", 142, 144], ["CTLA", "TEST", 151, 155], ["T cell exhaustion", "PROBLEM", 202, 219], ["COVID", "TEST", 250, 255], ["chronic", "OBSERVATION_MODIFIER", 16, 23], ["lymphocytic leukemia", "OBSERVATION", 24, 44], ["increase", "OBSERVATION_MODIFIER", 80, 88], ["CD4", "OBSERVATION", 89, 92], ["T cell", "OBSERVATION", 103, 109], ["T cell exhaustion", "OBSERVATION", 202, 219]]], ["Consequently, clinical trials to assess the use of BTK inhibitors against COVID-19 are underway.Corticosteroids ::: Anti-inflammatory Treatments ::: Challenges to Overcome With Repurposed DrugsThe use of corticosteroids to treat COVID-19 remained largely uncertain until recently.", [["COVID-19", "CHEMICAL", 74, 82], ["COVID-19", "CHEMICAL", 229, 237], ["COVID-19", "CHEMICAL", 74, 82], ["corticosteroids", "CHEMICAL", 204, 219], ["COVID-19", "CHEMICAL", 229, 237], ["BTK", "GENE_OR_GENE_PRODUCT", 51, 54], ["BTK", "PROTEIN", 51, 54], ["BTK inhibitors", "TREATMENT", 51, 65], ["COVID", "TEST", 74, 79], ["Corticosteroids", "TREATMENT", 96, 111], ["Repurposed Drugs", "TREATMENT", 177, 193], ["corticosteroids", "TREATMENT", 204, 219], ["COVID", "TEST", 229, 234]]], ["Although individuals being treated with long term corticosteroid were instructed to continue with their medication, the use of corticosteroids specifically to treat COVID-19 was not recommended (193).", [["COVID-19", "CHEMICAL", 165, 173], ["corticosteroids", "CHEMICAL", 127, 142], ["COVID-19", "CHEMICAL", 165, 173], ["individuals", "ORGANISM", 9, 20], ["long term corticosteroid", "TREATMENT", 40, 64], ["their medication", "TREATMENT", 98, 114], ["corticosteroids", "TREATMENT", 127, 142], ["COVID", "TEST", 165, 170]]], ["This was largely due to the unknown impact of immune suppression on viral clearance and potential adverse outcomes.", [["immune suppression", "PROBLEM", 46, 64], ["viral clearance", "TREATMENT", 68, 83], ["potential adverse outcomes", "PROBLEM", 88, 114], ["immune suppression", "OBSERVATION", 46, 64]]], ["However, preliminary data from the RECOVERY trial evaluating 2,104 patients randomly allocated to receive dexamethasone has proven significant clinical improvements (194).", [["dexamethasone", "CHEMICAL", 106, 119], ["dexamethasone", "CHEMICAL", 106, 119], ["patients", "ORGANISM", 67, 75], ["dexamethasone", "SIMPLE_CHEMICAL", 106, 119], ["patients", "SPECIES", 67, 75], ["dexamethasone", "TREATMENT", 106, 119]]], ["Dexamethasone is a steroid used to reduce inflammation in a myriad of inflammatory conditions and now reported to reduce COVID-19 related deaths among patients receiving respiratory support by one-third (194).", [["respiratory", "ANATOMY", 170, 181], ["Dexamethasone", "CHEMICAL", 0, 13], ["steroid", "CHEMICAL", 19, 26], ["inflammation", "DISEASE", 42, 54], ["deaths", "DISEASE", 138, 144], ["Dexamethasone", "CHEMICAL", 0, 13], ["steroid", "CHEMICAL", 19, 26], ["Dexamethasone", "SIMPLE_CHEMICAL", 0, 13], ["steroid", "SIMPLE_CHEMICAL", 19, 26], ["patients", "ORGANISM", 151, 159], ["patients", "SPECIES", 151, 159], ["Dexamethasone", "TREATMENT", 0, 13], ["a steroid", "TREATMENT", 17, 26], ["inflammation", "PROBLEM", 42, 54], ["inflammatory conditions", "PROBLEM", 70, 93], ["respiratory support", "TREATMENT", 170, 189], ["inflammation", "OBSERVATION", 42, 54], ["inflammatory", "OBSERVATION", 70, 82]]], ["In response to these findings the demand for dexamethasone to treat the most critical COVID-19 patients has surged globally (195).", [["dexamethasone", "CHEMICAL", 45, 58], ["dexamethasone", "CHEMICAL", 45, 58], ["dexamethasone", "SIMPLE_CHEMICAL", 45, 58], ["patients", "ORGANISM", 95, 103], ["patients", "SPECIES", 95, 103], ["dexamethasone", "TREATMENT", 45, 58]]], ["Whilst these findings are exciting, safety data detailing potential adverse events and the impact of co-medications, such as non-steroidal anti-inflammatory drugs, has not yet been reported and thus dexamethasone should still be considered carefully prior to administration.SummaryPatients with pre-existing comorbidities are at a greater risk of dying from COVID-19.", [["non-steroidal", "ANATOMY", 125, 138], ["dexamethasone", "CHEMICAL", 199, 212], ["dexamethasone", "CHEMICAL", 199, 212], ["dexamethasone", "SIMPLE_CHEMICAL", 199, 212], ["potential adverse events", "PROBLEM", 58, 82], ["co-medications", "TREATMENT", 101, 115], ["non-steroidal anti-inflammatory drugs", "TREATMENT", 125, 162], ["dexamethasone", "TREATMENT", 199, 212], ["pre-existing comorbidities", "PROBLEM", 295, 321], ["COVID", "TEST", 358, 363], ["comorbidities", "OBSERVATION", 308, 321]]], ["However, not all comorbidities confer the same risk.", [["all comorbidities", "PROBLEM", 13, 30]]], ["By exploring the underlying disease etiologies and common therapies used to treat these conditions, we have discussed their impact on COVID-19.", [["the underlying disease etiologies", "PROBLEM", 13, 46], ["common therapies", "TREATMENT", 51, 67], ["these conditions", "PROBLEM", 82, 98], ["COVID", "TEST", 134, 139], ["disease", "OBSERVATION", 28, 35]]], ["Comorbidities closely associated with age, chronic inflammation and dysregulated metabolism such as hypertension, cardiovascular disease, and diabetes are the most prevalent comorbidities.", [["cardiovascular", "ANATOMY", 114, 128], ["inflammation", "DISEASE", 51, 63], ["hypertension", "DISEASE", 100, 112], ["cardiovascular disease", "DISEASE", 114, 136], ["diabetes", "DISEASE", 142, 150], ["Comorbidities", "PROBLEM", 0, 13], ["chronic inflammation", "PROBLEM", 43, 63], ["dysregulated metabolism", "PROBLEM", 68, 91], ["hypertension", "PROBLEM", 100, 112], ["cardiovascular disease", "PROBLEM", 114, 136], ["diabetes", "PROBLEM", 142, 150], ["chronic", "OBSERVATION_MODIFIER", 43, 50], ["inflammation", "OBSERVATION", 51, 63], ["dysregulated metabolism", "OBSERVATION", 68, 91], ["hypertension", "OBSERVATION", 100, 112], ["cardiovascular disease", "OBSERVATION", 114, 136], ["diabetes", "OBSERVATION", 142, 150]]], ["However, many of these comorbidities are strongly associated with each other.", [["these comorbidities", "PROBLEM", 17, 36], ["comorbidities", "OBSERVATION", 23, 36]]], ["Consequently, many patients will have multiple comorbidities and therefore while we have discussed these individually, the reality is that a combination of factors will be at play.", [["patients", "ORGANISM", 19, 27], ["patients", "SPECIES", 19, 27], ["multiple comorbidities", "PROBLEM", 38, 60]]], ["Furthermore, as multiple drug use is inevitable for patients with pre-existing comorbidities, the impact of overlaying drugs on an already compromised state and the possibility of DDI leading to adverse events needs to be carefully considered.", [["patients", "ORGANISM", 52, 60], ["patients", "SPECIES", 52, 60], ["pre-existing comorbidities", "PROBLEM", 66, 92], ["overlaying drugs", "TREATMENT", 108, 124], ["DDI", "PROBLEM", 180, 183], ["adverse events", "PROBLEM", 195, 209]]], ["As the scale of this pandemic continues to accelerate globally, we hope this review provides healthcare professionals and biomedical researchers with a more comprehensive understanding of the impact of pre-existing comorbidities on COVID-19 development and treatment.Author's NoteThe authors LC and MC are fellows of the AstraZeneca postdoc programme.", [["pre-existing comorbidities", "PROBLEM", 202, 228], ["COVID", "TREATMENT", 232, 237], ["treatment", "TREATMENT", 257, 266]]], ["All authors contributed extensively to the discussion of the content and researched data for the article.Conflict of InterestAll authors are employees of AstraZeneca.", [["AstraZeneca", "CHEMICAL", 154, 165], ["AstraZeneca", "SIMPLE_CHEMICAL", 154, 165], ["AstraZeneca", "TREATMENT", 154, 165]]]], "fe1a7499648f283fd038af8422a103083b892216": [["INTRODUCTIONEnterotoxigenic Escherichia coli (ETEC) are involved in the post-weaning diarrhoea syndrome in pigs.", [["diarrhoea syndrome", "DISEASE", 85, 103], ["INTRODUCTIONEnterotoxigenic Escherichia coli", "GENE_OR_GENE_PRODUCT", 0, 44], ["ETEC", "ORGANISM", 46, 50], ["pigs", "ORGANISM", 107, 111], ["Escherichia coli", "SPECIES", 28, 44], ["pigs", "SPECIES", 107, 111], ["Escherichia coli", "SPECIES", 28, 44], ["ETEC", "SPECIES", 46, 50], ["pigs", "SPECIES", 107, 111], ["INTRODUCTIONEnterotoxigenic Escherichia coli", "PROBLEM", 0, 44], ["weaning diarrhoea syndrome", "PROBLEM", 77, 103], ["Escherichia coli", "OBSERVATION", 28, 44], ["diarrhoea syndrome", "OBSERVATION", 85, 103]]], ["However, experiments performed in our laboratory to induce hypersecretion diarrhoea by inoculation of newly-weaned piglets with ETEC, possessing fimbrial adhesins and producing heat-labile (LT) and heat-stable (STa and STb) enterotoxins, were not always successful (Cox et al., 1986a) .", [["hypersecretion diarrhoea", "DISEASE", 59, 83], ["ETEC", "CHEMICAL", 128, 132], ["piglets", "ORGANISM", 115, 122], ["fimbrial adhesins", "GENE_OR_GENE_PRODUCT", 145, 162], ["STa", "GENE_OR_GENE_PRODUCT", 211, 214], ["fimbrial adhesins", "PROTEIN", 145, 162], ["LT", "PROTEIN", 190, 192], ["STa and STb) enterotoxins", "PROTEIN", 211, 236], ["piglets", "SPECIES", 115, 122], ["ETEC", "SPECIES", 128, 132], ["hypersecretion diarrhoea", "PROBLEM", 59, 83], ["ETEC", "TREATMENT", 128, 132], ["heat", "TEST", 198, 202], ["enterotoxins", "PROBLEM", 224, 236], ["stable", "OBSERVATION", 203, 209]]], ["Post-weaning diarrhoea has a multifactorial etiology.", [["diarrhoea", "DISEASE", 13, 22], ["weaning diarrhoea", "PROBLEM", 5, 22], ["multifactorial", "OBSERVATION_MODIFIER", 29, 43]]], ["The genetic susceptibility of the host to adhesion of ETEC as well as nutritional, environmental and immunological factors and the presence of a rotavirus infection can probably seriously influence the occurrence and the severity of the diarrhoea (Tzipori etal., 1980; Lecce et al., 1982; Lecce, 1983; Sellwood, 1983; Bijlsma et al., 1985) .INTRODUCTIONWhen the experimental ETEC infection was preceded by oral chloramphenicol treatment we observed an enhanced occurrence, severity and duration of diarrhoea (Cox et uf., 1986a) .", [["oral", "ANATOMY", 406, 410], ["rotavirus infection", "DISEASE", 145, 164], ["diarrhoea", "DISEASE", 237, 246], ["ETEC infection", "DISEASE", 375, 389], ["chloramphenicol", "CHEMICAL", 411, 426], ["diarrhoea", "DISEASE", 498, 507], ["chloramphenicol", "CHEMICAL", 411, 426], ["ETEC", "GENE_OR_GENE_PRODUCT", 54, 58], ["rotavirus", "ORGANISM", 145, 154], ["ETEC", "ORGANISM", 375, 379], ["oral", "ORGANISM_SUBDIVISION", 406, 410], ["chloramphenicol", "SIMPLE_CHEMICAL", 411, 426], ["rotavirus", "SPECIES", 145, 154], ["ETEC", "SPECIES", 375, 379], ["ETEC", "PROBLEM", 54, 58], ["a rotavirus infection", "PROBLEM", 143, 164], ["the diarrhoea", "PROBLEM", 233, 246], ["the experimental ETEC infection", "PROBLEM", 358, 389], ["oral chloramphenicol treatment", "TREATMENT", 406, 436], ["diarrhoea", "PROBLEM", 498, 507], ["infection", "OBSERVATION", 155, 164], ["infection", "OBSERVATION", 380, 389]]], ["This 'colonization-resistance-suppressing' antibiotic probably makes the gut more susceptible to ETEC (Kaufman, 1984) .", [["gut", "ANATOMY", 73, 76], ["ETEC", "DISEASE", 97, 101], ["gut", "ORGANISM_SUBDIVISION", 73, 76], ["This 'colonization", "PROBLEM", 0, 18], ["suppressing' antibiotic", "TREATMENT", 30, 53]]], ["The induced diarrhoea, however, was still insufficiently pronounced to result in significant hypovolaemia and shock.INTRODUCTIONWe therefore introduced a combined viral-bacterial infection into our piglet diarrhoea 0165-7380/88/$03.50 0 1988 Geo Abstracts Ltd model.", [["diarrhoea", "DISEASE", 12, 21], ["hypovolaemia", "DISEASE", 93, 105], ["shock", "DISEASE", 110, 115], ["viral-bacterial infection", "DISEASE", 163, 188], ["diarrhoea", "DISEASE", 205, 214], ["piglet", "ORGANISM", 198, 204], ["piglet", "SPECIES", 198, 204], ["The induced diarrhoea", "PROBLEM", 0, 21], ["significant hypovolaemia", "PROBLEM", 81, 105], ["shock", "PROBLEM", 110, 115], ["a combined viral-bacterial infection", "PROBLEM", 152, 188], ["our piglet diarrhoea", "PROBLEM", 194, 214], ["diarrhoea", "OBSERVATION", 12, 21], ["significant", "OBSERVATION_MODIFIER", 81, 92], ["hypovolaemia", "OBSERVATION", 93, 105], ["shock", "OBSERVATION", 110, 115], ["bacterial infection", "OBSERVATION", 169, 188]]], ["Since rotavirus is enzootic in Belgian piggeries and most pigs are infected before the age of 6 to 7 weeks (Debouck, 1984) , we inoculated piglets with transmissible gastroenteritis (TGE) virus, a coronavirus, prior to ETEC infection.", [["rotavirus", "DISEASE", 6, 15], ["transmissible gastroenteritis", "DISEASE", 152, 181], ["TGE", "DISEASE", 183, 186], ["coronavirus", "DISEASE", 197, 208], ["ETEC infection", "DISEASE", 219, 233], ["rotavirus", "ORGANISM", 6, 15], ["pigs", "ORGANISM", 58, 62], ["piglets", "ORGANISM", 139, 146], ["ETEC", "ORGANISM", 219, 223], ["pigs", "SPECIES", 58, 62], ["piglets", "SPECIES", 139, 146], ["rotavirus", "SPECIES", 6, 15], ["pigs", "SPECIES", 58, 62], ["transmissible gastroenteritis (TGE) virus", "SPECIES", 152, 193], ["ETEC", "SPECIES", 219, 223], ["rotavirus", "PROBLEM", 6, 15], ["transmissible gastroenteritis (TGE) virus", "PROBLEM", 152, 193], ["a coronavirus", "PROBLEM", 195, 208], ["ETEC infection", "PROBLEM", 219, 233], ["enzootic", "OBSERVATION_MODIFIER", 19, 27], ["infected", "OBSERVATION", 67, 75], ["gastroenteritis", "OBSERVATION", 166, 181], ["infection", "OBSERVATION", 224, 233]]], ["This combined infection resulted in pronounced diarrhoea and hypovolaemia and in 100% mortality within 5 days of TGE virus inoculation (Cox et al., 1986b) .", [["infection", "DISEASE", 14, 23], ["diarrhoea", "DISEASE", 47, 56], ["hypovolaemia", "DISEASE", 61, 73], ["TGE", "CHEMICAL", 113, 116], ["This combined infection", "PROBLEM", 0, 23], ["pronounced diarrhoea", "PROBLEM", 36, 56], ["hypovolaemia", "PROBLEM", 61, 73], ["TGE virus inoculation", "PROBLEM", 113, 134], ["infection", "OBSERVATION", 14, 23], ["pronounced", "OBSERVATION_MODIFIER", 36, 46], ["diarrhoea", "OBSERVATION", 47, 56], ["hypovolaemia", "OBSERVATION", 61, 73]]], ["We recently reported the effect of the antisecretory drugs chlorpromazine, verapamil, clonidine and propranolol on diarrhoea and survival in our piglet diarrhoea model Cools et al., 1987) .", [["chlorpromazine", "CHEMICAL", 59, 73], ["verapamil", "CHEMICAL", 75, 84], ["clonidine", "CHEMICAL", 86, 95], ["propranolol", "CHEMICAL", 100, 111], ["diarrhoea", "DISEASE", 115, 124], ["diarrhoea", "DISEASE", 152, 161], ["chlorpromazine", "CHEMICAL", 59, 73], ["verapamil", "CHEMICAL", 75, 84], ["clonidine", "CHEMICAL", 86, 95], ["propranolol", "CHEMICAL", 100, 111], ["chlorpromazine", "SIMPLE_CHEMICAL", 59, 73], ["verapamil", "SIMPLE_CHEMICAL", 75, 84], ["clonidine", "SIMPLE_CHEMICAL", 86, 95], ["propranolol", "SIMPLE_CHEMICAL", 100, 111], ["piglet", "ORGANISM", 145, 151], ["the antisecretory drugs", "TREATMENT", 35, 58], ["chlorpromazine", "TREATMENT", 59, 73], ["verapamil", "TREATMENT", 75, 84], ["clonidine", "TREATMENT", 86, 95], ["propranolol", "TREATMENT", 100, 111], ["diarrhoea", "PROBLEM", 115, 124], ["survival", "TREATMENT", 129, 137]]], ["Several studies suggest the involvement of prostaglandins as important messengers in the secretory response of the enterocytes to bacterial enterotoxins (Bennett, 1971; Wise et al., 1983; Powell, 1986) .", [["enterocytes", "ANATOMY", 115, 126], ["prostaglandins", "CHEMICAL", 43, 57], ["prostaglandins", "CHEMICAL", 43, 57], ["prostaglandins", "SIMPLE_CHEMICAL", 43, 57], ["enterocytes", "MULTI-TISSUE_STRUCTURE", 115, 126], ["Several studies", "TEST", 0, 15], ["prostaglandins", "TREATMENT", 43, 57], ["enterocytes", "ANATOMY", 115, 126]]], ["Non-steroidal anti-inflammatory drugs (NSAID's), which inhibit prostaglandin synthesis by blocking the cyclooxygenase pathway, have been shown to reduce cholera or ETEC-induced hypersecretion in several species (Willard, 1985; Greenough & Rabbani, 1986) .", [["prostaglandin", "CHEMICAL", 63, 76], ["cholera", "DISEASE", 153, 160], ["ETEC", "CHEMICAL", 164, 168], ["hypersecretion", "DISEASE", 177, 191], ["prostaglandin", "CHEMICAL", 63, 76], ["Non-steroidal anti-inflammatory drugs", "SIMPLE_CHEMICAL", 0, 37], ["NSAID", "SIMPLE_CHEMICAL", 39, 44], ["prostaglandin", "SIMPLE_CHEMICAL", 63, 76], ["cyclooxygenase", "GENE_OR_GENE_PRODUCT", 103, 117], ["ETEC", "GENE_OR_GENE_PRODUCT", 164, 168], ["cyclooxygenase", "PROTEIN", 103, 117], ["Non-steroidal anti-inflammatory drugs", "TREATMENT", 0, 37], ["NSAID's", "TREATMENT", 39, 46], ["prostaglandin synthesis", "TREATMENT", 63, 86], ["the cyclooxygenase pathway", "TREATMENT", 99, 125], ["cholera", "PROBLEM", 153, 160], ["ETEC", "PROBLEM", 164, 168], ["hypersecretion", "PROBLEM", 177, 191], ["anti-inflammatory drugs", "OBSERVATION", 14, 37], ["hypersecretion", "OBSERVATION", 177, 191]]], ["However, in clinical trials in man, aspirin and indomethacin were ineffective in the treatment of cholera-induced hypersecretion diarrhoea (Greenough & Rabbani, 1986) .INTRODUCTIONThe purpose of the present study was to evaluate the pathological changes induced by the combined TGE virus and ETEC inoculation in newly-weaned piglets and to examine the possible effects of flurbiprofen, a potent NSAID of the arylacetic acid class, on this diarrhoea model.MATERIALSAND METHODS The experiments were performed on 29 newly-weaned, 3-4 week old female piglets, weighing 3.2 to 7.2 kg, from primiparous sows purchased from the same commercial farm.", [["aspirin", "CHEMICAL", 36, 43], ["indomethacin", "CHEMICAL", 48, 60], ["cholera", "DISEASE", 98, 105], ["hypersecretion diarrhoea", "DISEASE", 114, 138], ["TGE", "CHEMICAL", 278, 281], ["ETEC", "CHEMICAL", 292, 296], ["flurbiprofen", "CHEMICAL", 372, 384], ["arylacetic acid", "CHEMICAL", 408, 423], ["diarrhoea", "DISEASE", 439, 448], ["aspirin", "CHEMICAL", 36, 43], ["indomethacin", "CHEMICAL", 48, 60], ["flurbiprofen", "CHEMICAL", 372, 384], ["arylacetic acid", "CHEMICAL", 408, 423], ["man", "ORGANISM", 31, 34], ["aspirin", "SIMPLE_CHEMICAL", 36, 43], ["indomethacin", "SIMPLE_CHEMICAL", 48, 60], ["TGE virus", "ORGANISM", 278, 287], ["ETEC", "ORGANISM", 292, 296], ["piglets", "ORGANISM", 325, 332], ["flurbiprofen", "SIMPLE_CHEMICAL", 372, 384], ["NSAID", "SIMPLE_CHEMICAL", 395, 400], ["arylacetic acid", "SIMPLE_CHEMICAL", 408, 423], ["piglets", "ORGANISM", 547, 554], ["sows", "ORGANISM", 597, 601], ["man", "SPECIES", 31, 34], ["piglets", "SPECIES", 325, 332], ["piglets", "SPECIES", 547, 554], ["sows", "SPECIES", 597, 601], ["TGE virus", "SPECIES", 278, 287], ["ETEC", "SPECIES", 292, 296], ["aspirin", "TREATMENT", 36, 43], ["indomethacin", "TREATMENT", 48, 60], ["cholera-induced hypersecretion diarrhoea", "PROBLEM", 98, 138], ["the present study", "TEST", 195, 212], ["the pathological changes", "PROBLEM", 229, 253], ["the combined TGE virus", "PROBLEM", 265, 287], ["ETEC inoculation", "PROBLEM", 292, 308], ["flurbiprofen", "TREATMENT", 372, 384], ["a potent NSAID", "TREATMENT", 386, 400], ["the arylacetic acid class", "TREATMENT", 404, 429], ["this diarrhoea model", "PROBLEM", 434, 454]]], ["The piglets were of mixed breeding (Pietrain x Belgian Landrace).", [["piglets", "ORGANISM", 4, 11], ["piglets", "SPECIES", 4, 11], ["mixed breeding", "OBSERVATION", 20, 34]]], ["They were individually housed at 27\u00b0C and allowed to drink UHT sterilized whole cow's milk ad libitum.", [["UHT", "CHEMICAL", 59, 62], ["C", "SIMPLE_CHEMICAL", 36, 37], ["cow", "ORGANISM", 80, 83], ["milk", "ORGANISM_SUBSTANCE", 86, 90], ["cow", "SPECIES", 80, 83], ["milk", "SPECIES", 86, 90], ["cow", "SPECIES", 80, 83]]], ["On day 1 of the experiment the piglets were anaesthetized with 15 mg/kg methomidate (Hypnodil@, Janssen) and 2 mg/kg azaperone (Stressnil@, Janssen) and a Silastic catheter (Dow Corning) was implanted in the left carotid artery for daily blood sampling and pressure recording.", [["left carotid artery", "ANATOMY", 208, 227], ["blood", "ANATOMY", 238, 243], ["methomidate", "CHEMICAL", 72, 83], ["Hypnodil@", "CHEMICAL", 85, 94], ["azaperone", "CHEMICAL", 117, 126], ["methomidate", "CHEMICAL", 72, 83], ["azaperone", "CHEMICAL", 117, 126], ["piglets", "ORGANISM", 31, 38], ["methomidate", "SIMPLE_CHEMICAL", 72, 83], ["Hypnodil@", "SIMPLE_CHEMICAL", 85, 94], ["azaperone", "SIMPLE_CHEMICAL", 117, 126], ["Stressnil@", "SIMPLE_CHEMICAL", 128, 138], ["left carotid artery", "MULTI-TISSUE_STRUCTURE", 208, 227], ["blood", "ORGANISM_SUBSTANCE", 238, 243], ["piglets", "SPECIES", 31, 38], ["methomidate", "TREATMENT", 72, 83], ["Hypnodil@", "TREATMENT", 85, 94], ["azaperone", "TREATMENT", 117, 126], ["a Silastic catheter (Dow Corning)", "TREATMENT", 153, 186], ["daily blood sampling", "TEST", 232, 252], ["pressure recording", "TEST", 257, 275], ["left carotid artery", "ANATOMY", 208, 227]]], ["To enhance ETEC colonization of the small intestine, the piglets were pretreated on days 1, 2 and 3 with chloramphenicol (Chloromycetin@, Parke-Davis; 1,875 mg/l milk).", [["small intestine", "ANATOMY", 36, 51], ["chloramphenicol", "CHEMICAL", 105, 120], ["Chloromycetin@", "CHEMICAL", 122, 136], ["chloramphenicol", "CHEMICAL", 105, 120], ["Chloromycetin@", "CHEMICAL", 122, 136], ["ETEC", "CELL", 11, 15], ["small intestine", "ORGAN", 36, 51], ["piglets", "ORGANISM", 57, 64], ["chloramphenicol", "SIMPLE_CHEMICAL", 105, 120], ["Chloromycetin@", "SIMPLE_CHEMICAL", 122, 136], ["milk", "ORGANISM_SUBSTANCE", 162, 166], ["piglets", "SPECIES", 57, 64], ["ETEC colonization of the small intestine", "PROBLEM", 11, 51], ["chloramphenicol (Chloromycetin@", "TREATMENT", 105, 136], ["ETEC", "OBSERVATION_MODIFIER", 11, 15], ["colonization", "OBSERVATION", 16, 28], ["small intestine", "ANATOMY", 36, 51]]], ["After a starvation period during the first three hours of day 4, the piglets were orally inoculated with TGE virus (1.66 x 106 pig infective dose/ animal).", [["TGE", "CHEMICAL", 105, 108], ["piglets", "ORGANISM", 69, 76], ["TGE virus", "ORGANISM", 105, 114], ["pig", "ORGANISM", 127, 130], ["piglets", "SPECIES", 69, 76], ["TGE virus", "SPECIES", 105, 114], ["pig", "SPECIES", 127, 130], ["the piglets", "TREATMENT", 65, 76], ["TGE virus", "PROBLEM", 105, 114]]], ["Twenty-four hours later (day 5) the piglets were again starved for 3 hours, after which 62 ml of a 1.4% NaHCO, solution was given intragastrically to prevent ,ETEC destruction.", [["NaHCO", "CHEMICAL", 104, 109], ["NaHCO", "CHEMICAL", 104, 109], ["piglets", "ORGANISM", 36, 43], ["NaHCO", "SIMPLE_CHEMICAL", 104, 109], ["piglets", "SPECIES", 36, 43], ["a 1.4% NaHCO, solution", "TREATMENT", 97, 119], ["ETEC destruction", "PROBLEM", 159, 175], ["destruction", "OBSERVATION", 164, 175]]], ["Fifteen minutes later they were each intragastrically inoculated with 10 ml of a suspension of two ETEC strains.", [["strains", "ANATOMY", 104, 111], ["a suspension of two ETEC strains", "TREATMENT", 79, 111]]], ["Both strains, O,,:K,,:Kxxac, LT, STa and STb enterotoxin positive, were grown on brain heart infusion agar,(.Oxoid) at 37\u00b0C for 24 hours.", [["brain heart", "ANATOMY", 81, 92], [":K", "SIMPLE_CHEMICAL", 17, 19], ["Kxxac", "SIMPLE_CHEMICAL", 22, 27], ["LT", "GENE_OR_GENE_PRODUCT", 29, 31], ["STa", "GENE_OR_GENE_PRODUCT", 33, 36], ["STb enterotoxin", "GENE_OR_GENE_PRODUCT", 41, 56], ["brain", "ORGAN", 81, 86], ["heart", "ORGAN", 87, 92], ["LT", "PROTEIN", 29, 31], ["STa", "PROTEIN", 33, 36], ["K", "TEST", 18, 19], ["Kxxac", "TEST", 22, 27], ["LT", "TEST", 29, 31], ["STb enterotoxin positive", "PROBLEM", 41, 65], ["strains", "OBSERVATION", 5, 12], ["LT", "ANATOMY", 29, 31], ["STa", "ANATOMY", 33, 36], ["heart", "ANATOMY", 87, 92]]], ["The bacteria, w.ere suspended and dil,uted in sterile physiological saline to an \"&?o of.0.4, approximately 1.2 .X IQ: bacteria/ml, as.de.termined by via.b!e'count., Flurbiprofen treatment was started 5 hours after:>the ,ETEC inoculation and was performed 3 consecutive ,days., Eight piglets (Aurbiprsfefi 'group) were intramuscufarly.i~njected with Qurbiprofen (B0ots)at.a dose of 1 mg/kg/l2 b.", [["Flurbiprofen", "CHEMICAL", 166, 178], ["Qurbiprofen", "CHEMICAL", 350, 361], ["Flurbiprofen", "CHEMICAL", 166, 178], ["Qurbiprofen", "CHEMICAL", 350, 361], ["Flurbiprofen", "SIMPLE_CHEMICAL", 166, 178], ["piglets", "ORGANISM", 284, 291], ["Qurbiprofen", "SIMPLE_CHEMICAL", 350, 361], ["B0ots", "SIMPLE_CHEMICAL", 363, 368], ["piglets", "SPECIES", 284, 291], ["The bacteria", "PROBLEM", 0, 12], ["dil", "TREATMENT", 34, 37], ["sterile physiological saline", "TREATMENT", 46, 74], ["bacteria", "PROBLEM", 119, 127], ["Flurbiprofen treatment", "TREATMENT", 166, 188], ["ETEC inoculation", "TREATMENT", 221, 237], ["Eight piglets (Aurbiprsfefi 'group)", "TREATMENT", 278, 313], ["Qurbiprofen (B0ots)", "TREATMENT", 350, 369], ["bacteria", "OBSERVATION", 4, 12]]], ["Flurbiprofen w.as dissolved in 0.1 M NaOH (10 mg/ml) and the solution was neutralized to pH 7.4with 0.1 M HCl.", [["Flurbiprofen", "CHEMICAL", 0, 12], ["NaOH", "CHEMICAL", 37, 41], ["HCl", "CHEMICAL", 106, 109], ["Flurbiprofen", "CHEMICAL", 0, 12], ["NaOH", "CHEMICAL", 37, 41], ["HCl", "CHEMICAL", 106, 109], ["Flurbiprofen", "SIMPLE_CHEMICAL", 0, 12], ["Flurbiprofen", "TREATMENT", 0, 12], ["the solution", "TREATMENT", 57, 69], ["pH", "TEST", 89, 91]]], ["Xylocaine (2 mg) was added ta reduce the pain induced by the intramuscular injection of flurbiprofen.MATERIALS,.", [["intramuscular", "ANATOMY", 61, 74], ["Xylocaine", "CHEMICAL", 0, 9], ["pain", "DISEASE", 41, 45], ["flurbiprofen", "CHEMICAL", 88, 100], ["Xylocaine", "CHEMICAL", 0, 9], ["flurbiprofen", "CHEMICAL", 88, 100], ["Xylocaine", "SIMPLE_CHEMICAL", 0, 9], ["intramuscular", "IMMATERIAL_ANATOMICAL_ENTITY", 61, 74], ["flurbiprofen", "SIMPLE_CHEMICAL", 88, 100], ["Xylocaine", "TREATMENT", 0, 9], ["the pain", "PROBLEM", 37, 45], ["the intramuscular injection of flurbiprofen", "TREATMENT", 57, 100]]], ["The other piglets (n = 21):were kept as untreated controls (control group).", [["piglets", "ORGANISM", 10, 17], ["piglets", "SPECIES", 10, 17]]], ["Weight change, milk intake, body temperature, appearance and severity of diarrhoea, and clinical symptoms were registered daily; From day 3 onwards the following parameters were also evaluated.: survival rate; frequency of respiration; arterial blood pres-sure (Pa); heart rate (HR); haematocrit (Hct); plasma protein (Merck kit), glucose {Merck kit) and lactic acid (Boehringer kit) concentrations; arterial pH, pOf and pC0, (Astrup, Radiometer); base excess (BE) and bicarbonate (porcine acid-base alignment nomogram for arterial blood; Hannon, 1984) ; leucocyte count; serum concentrations of sodium, potassium (flame photometry), chloride (chloridometer) and calcium (atomic absorption); sodium and potassium concentrations and osmolality (cryoscopy) of faecal water, obtained as the supernatant after centrifugation of freshly collected faeces at 6,000 g for 5 min; faecal ETEC excretion; and the faecal shedding of TGE virus, rotalike-and rotavirus (enzyme-linked immunosorbent assay).MATERIALSThe severity of diarrhoea was evaluated by arbitrarily scoring the consistency of the faeces (0 = normal; 1 = pasty; 2 = semiliquid; 3 = watery).", [["milk", "ANATOMY", 15, 19], ["body", "ANATOMY", 28, 32], ["arterial", "ANATOMY", 236, 244], ["blood", "ANATOMY", 245, 250], ["heart", "ANATOMY", 267, 272], ["plasma", "ANATOMY", 303, 309], ["arterial", "ANATOMY", 400, 408], ["arterial blood", "ANATOMY", 523, 537], ["leucocyte", "ANATOMY", 555, 564], ["serum", "ANATOMY", 572, 577], ["faecal", "ANATOMY", 758, 764], ["supernatant", "ANATOMY", 788, 799], ["faeces", "ANATOMY", 842, 848], ["faecal", "ANATOMY", 902, 908], ["faeces", "ANATOMY", 1086, 1092], ["diarrhoea", "DISEASE", 73, 82], ["glucose", "CHEMICAL", 331, 338], ["lactic acid", "CHEMICAL", 355, 366], ["BE", "CHEMICAL", 461, 463], ["bicarbonate", "CHEMICAL", 469, 480], ["sodium", "CHEMICAL", 596, 602], ["potassium", "CHEMICAL", 604, 613], ["chloride", "CHEMICAL", 634, 642], ["chloridometer", "CHEMICAL", 644, 657], ["calcium", "CHEMICAL", 663, 670], ["sodium", "CHEMICAL", 692, 698], ["potassium", "CHEMICAL", 703, 712], ["ETEC", "CHEMICAL", 878, 882], ["diarrhoea", "DISEASE", 1016, 1025], ["watery", "DISEASE", 1137, 1143], ["glucose", "CHEMICAL", 331, 338], ["lactic acid", "CHEMICAL", 355, 366], ["bicarbonate", "CHEMICAL", 469, 480], ["sodium", "CHEMICAL", 596, 602], ["potassium", "CHEMICAL", 604, 613], ["chloride", "CHEMICAL", 634, 642], ["chloridometer", "CHEMICAL", 644, 657], ["calcium", "CHEMICAL", 663, 670], ["sodium", "CHEMICAL", 692, 698], ["potassium", "CHEMICAL", 703, 712], ["milk", "ORGANISM_SUBSTANCE", 15, 19], ["body", "ORGANISM_SUBDIVISION", 28, 32], ["blood", "ORGANISM_SUBSTANCE", 245, 250], ["heart", "ORGAN", 267, 272], ["plasma", "ORGANISM_SUBSTANCE", 303, 309], ["glucose", "SIMPLE_CHEMICAL", 331, 338], ["lactic acid", "SIMPLE_CHEMICAL", 355, 366], ["arterial", "MULTI-TISSUE_STRUCTURE", 400, 408], ["pOf", "SIMPLE_CHEMICAL", 413, 416], ["bicarbonate", "SIMPLE_CHEMICAL", 469, 480], ["blood", "ORGANISM_SUBSTANCE", 532, 537], ["leucocyte", "CELL", 555, 564], ["serum", "ORGANISM_SUBSTANCE", 572, 577], ["sodium", "SIMPLE_CHEMICAL", 596, 602], ["potassium", "SIMPLE_CHEMICAL", 604, 613], ["chloride", "SIMPLE_CHEMICAL", 634, 642], ["chloridometer", "SIMPLE_CHEMICAL", 644, 657], ["calcium", "SIMPLE_CHEMICAL", 663, 670], ["sodium", "SIMPLE_CHEMICAL", 692, 698], ["potassium", "SIMPLE_CHEMICAL", 703, 712], ["faeces", "ORGANISM_SUBDIVISION", 842, 848], ["faecal", "ORGANISM_SUBSTANCE", 902, 908], ["TGE virus", "ORGANISM", 921, 930], ["rotavirus", "ORGANISM", 945, 954], ["faeces", "ORGANISM_SUBDIVISION", 1086, 1092], ["watery", "ORGANISM_SUBDIVISION", 1137, 1143], ["plasma protein", "PROTEIN", 303, 317], ["TGE virus", "SPECIES", 921, 930], ["rotavirus", "SPECIES", 945, 954], ["Weight change", "PROBLEM", 0, 13], ["body temperature", "TEST", 28, 44], ["diarrhoea", "PROBLEM", 73, 82], ["clinical symptoms", "PROBLEM", 88, 105], ["survival rate", "TEST", 195, 208], ["respiration", "TEST", 223, 234], ["arterial blood pres", "TEST", 236, 255], ["heart rate", "TEST", 267, 277], ["HR", "TEST", 279, 281], ["haematocrit", "TEST", 284, 295], ["Hct", "TEST", 297, 300], ["plasma protein (Merck kit", "TEST", 303, 328], ["glucose", "TEST", 331, 338], ["Merck kit", "TEST", 340, 349], ["lactic acid", "TEST", 355, 366], ["Boehringer kit", "TEST", 368, 382], ["concentrations", "TEST", 384, 398], ["arterial pH", "TEST", 400, 411], ["pOf", "TEST", 413, 416], ["pC0", "TEST", 421, 424], ["Astrup", "TEST", 427, 433], ["base excess", "TEST", 448, 459], ["bicarbonate (porcine acid-base alignment nomogram", "TEST", 469, 518], ["arterial blood", "TEST", 523, 537], ["Hannon", "TEST", 539, 545], ["leucocyte count", "TEST", 555, 570], ["serum concentrations", "TEST", 572, 592], ["sodium", "TEST", 596, 602], ["potassium", "TEST", 604, 613], ["flame photometry", "TEST", 615, 631], ["chloride (chloridometer)", "TREATMENT", 634, 658], ["calcium (atomic absorption", "TEST", 663, 689], ["sodium", "TEST", 692, 698], ["potassium concentrations", "TEST", 703, 727], ["osmolality", "TEST", 732, 742], ["faecal water", "TREATMENT", 758, 770], ["faecal ETEC excretion", "TEST", 871, 892], ["the faecal shedding of TGE virus", "PROBLEM", 898, 930], ["rotalike", "TEST", 932, 940], ["rotavirus", "PROBLEM", 945, 954], ["enzyme", "TEST", 956, 962], ["immunosorbent assay", "TEST", 970, 989], ["diarrhoea", "PROBLEM", 1016, 1025], ["diarrhoea", "OBSERVATION", 73, 82], ["heart", "ANATOMY", 267, 272], ["arterial", "ANATOMY", 400, 408], ["diarrhoea", "OBSERVATION", 1016, 1025]]], ["Scoring was always performed by the same person.", [["person", "SPECIES", 41, 47]]], ["The osmotic gap was calculated from the faecal water values as the difference between the measured osmolality and the estimated osmolality, based on twice the sum of the sodium and potassium concentrations (Shiau et al., 1985) .", [["sodium", "CHEMICAL", 170, 176], ["potassium", "CHEMICAL", 181, 190], ["sodium", "CHEMICAL", 170, 176], ["potassium", "CHEMICAL", 181, 190], ["sodium", "SIMPLE_CHEMICAL", 170, 176], ["potassium", "SIMPLE_CHEMICAL", 181, 190], ["The osmotic gap", "TEST", 0, 15], ["the faecal water values", "TEST", 36, 59], ["the measured osmolality", "TEST", 86, 109], ["the estimated osmolality", "TEST", 114, 138], ["the sodium and potassium concentrations", "TREATMENT", 166, 205], ["osmotic gap", "OBSERVATION", 4, 15]]], ["Secretory diarrhoea is commonly associated with a negative osmotic gap, whereas osmotic diarrhoea is associated with a positive osmotic gap of greater than 160 mosmol/l, at least in man (Shiau et al., 1985) .", [["Secretory diarrhoea", "DISEASE", 0, 19], ["diarrhoea", "DISEASE", 88, 97], ["man", "ORGANISM", 182, 185], ["man", "SPECIES", 182, 185], ["Secretory diarrhoea", "PROBLEM", 0, 19], ["a negative osmotic gap", "PROBLEM", 48, 70], ["osmotic diarrhoea", "PROBLEM", 80, 97], ["a positive osmotic gap", "PROBLEM", 117, 139], ["diarrhoea", "OBSERVATION", 10, 19], ["negative osmotic gap", "OBSERVATION_MODIFIER", 50, 70]]], ["Faecal ETEC excretion was evaluated as the approximate percentage of haemolytic E. coli among the total number of aerobic bacteria in rectal swabs inoculated onto blood agar plates at 37\u00b0C for 24 hours and was also arbitrarily scored (0 = 0%; 1 = &25%; 2 = 25-50%; 3 = 50-75%; 4 = 75-100%).MATERIALSThe carotid arterial pressure was registered with a saline-filled polyethylene catheter connected to a miniature pressure transducer (Gaeltec).", [["Faecal", "ANATOMY", 0, 6], ["rectal swabs", "ANATOMY", 134, 146], ["blood", "ANATOMY", 163, 168], ["carotid arterial", "ANATOMY", 303, 319], ["ETEC", "CHEMICAL", 7, 11], ["polyethylene", "CHEMICAL", 365, 377], ["Faecal", "ORGANISM_SUBSTANCE", 0, 6], ["E. coli", "ORGANISM", 80, 87], ["rectal swabs", "ORGANISM_SUBSTANCE", 134, 146], ["blood", "ORGANISM_SUBSTANCE", 163, 168], ["carotid arterial", "MULTI-TISSUE_STRUCTURE", 303, 319], ["E. coli", "SPECIES", 80, 87], ["E. coli", "SPECIES", 80, 87], ["Faecal ETEC excretion", "TEST", 0, 21], ["haemolytic E. coli", "PROBLEM", 69, 87], ["aerobic bacteria", "PROBLEM", 114, 130], ["rectal swabs", "TEST", 134, 146], ["blood agar plates", "TEST", 163, 180], ["a saline-filled polyethylene catheter", "TREATMENT", 349, 386], ["a miniature pressure transducer", "TREATMENT", 400, 431], ["haemolytic", "OBSERVATION_MODIFIER", 69, 79], ["E. coli", "OBSERVATION", 80, 87], ["total", "OBSERVATION_MODIFIER", 98, 103], ["aerobic bacteria", "OBSERVATION", 114, 130], ["rectal swabs", "ANATOMY", 134, 146], ["carotid arterial", "ANATOMY", 303, 319], ["pressure", "OBSERVATION_MODIFIER", 320, 328], ["polyethylene catheter", "OBSERVATION", 365, 386]]], ["The electrocardiogram (ECG), which was used to measure HR. was monitored with five ECG electrodes fixed with rubber bands cranial to the left and right shoulder joint, above the seventh vertebral spine and on the abdomen cranial to the left and right stifle joint.", [["cranial", "ANATOMY", 122, 129], ["left", "ANATOMY", 137, 141], ["right shoulder joint", "ANATOMY", 146, 166], ["vertebral spine", "ANATOMY", 186, 201], ["abdomen cranial", "ANATOMY", 213, 228], ["left", "ANATOMY", 236, 240], ["right stifle joint", "ANATOMY", 245, 263], ["shoulder joint", "MULTI-TISSUE_STRUCTURE", 152, 166], ["vertebral spine", "MULTI-TISSUE_STRUCTURE", 186, 201], ["abdomen cranial", "MULTI-TISSUE_STRUCTURE", 213, 228], ["stifle joint", "MULTI-TISSUE_STRUCTURE", 251, 263], ["The electrocardiogram", "TEST", 0, 21], ["ECG", "TEST", 23, 26], ["five ECG electrodes", "TREATMENT", 78, 97], ["rubber bands", "TEST", 109, 121], ["rubber bands", "OBSERVATION", 109, 121], ["cranial", "ANATOMY_MODIFIER", 122, 129], ["left", "ANATOMY_MODIFIER", 137, 141], ["right", "ANATOMY_MODIFIER", 146, 151], ["shoulder joint", "ANATOMY", 152, 166], ["above", "ANATOMY_MODIFIER", 168, 173], ["seventh vertebral spine", "ANATOMY", 178, 201], ["abdomen", "ANATOMY", 213, 220], ["cranial", "ANATOMY_MODIFIER", 221, 228], ["left", "ANATOMY_MODIFIER", 236, 240], ["right", "ANATOMY_MODIFIER", 245, 250], ["stifle joint", "ANATOMY", 251, 263]]], ["Pa and ECG were recordedon a Beckman multichannel recorder.MATERIALSShocked piglets died spontaneously or were killed with an overdose of methomidate.", [["overdose", "DISEASE", 126, 134], ["methomidate", "CHEMICAL", 138, 149], ["methomidate", "CHEMICAL", 138, 149], ["piglets", "ORGANISM", 76, 83], ["methomidate", "SIMPLE_CHEMICAL", 138, 149], ["piglets", "SPECIES", 76, 83], ["Pa", "TEST", 0, 2], ["ECG", "TEST", 7, 10], ["a Beckman multichannel recorder", "TEST", 27, 58], ["methomidate", "TREATMENT", 138, 149]]], ["The other piglets were euthanatized with methomidate 10 days after the start of the experiment.", [["methomidate", "CHEMICAL", 41, 52], ["methomidate", "CHEMICAL", 41, 52], ["piglets", "ORGANISM", 10, 17], ["piglets", "SPECIES", 10, 17], ["methomidate", "TREATMENT", 41, 52]]], ["All piglets were examined post mortem.MATERIALSThe genetic susceptibility of the piglets to K,,,,-ETEC adhesion to their small intestinal villi was determined by the in vitro technique described by Girardeau (1980) .", [["small intestinal villi", "ANATOMY", 121, 143], ["K", "CHEMICAL", 92, 93], ["piglets", "ORGANISM", 4, 11], ["piglets", "ORGANISM", 81, 88], ["intestinal villi", "MULTI-TISSUE_STRUCTURE", 127, 143], ["piglets", "SPECIES", 4, 11], ["piglets", "SPECIES", 81, 88], ["K", "TEST", 92, 93], ["small", "OBSERVATION_MODIFIER", 121, 126], ["intestinal villi", "ANATOMY", 127, 143]]], ["The daily diarrhoea score and faecal ETEC score are expressed as medians and ranges or individual values and were statistically analysed using the Mann-Whitney U or Wilcoxon tests.", [["diarrhoea", "DISEASE", 10, 19], ["The daily diarrhoea score", "PROBLEM", 0, 25], ["faecal ETEC score", "TEST", 30, 47], ["Wilcoxon tests", "TEST", 165, 179]]], ["A one-way analysis of variance and simple contrasts were used to assess the statistical significance between the values of the different parameters registered after the experimental infection and the values measured before infection on day 3.", [["infection", "DISEASE", 182, 191], ["infection", "DISEASE", 223, 232], ["simple contrasts", "PROBLEM", 35, 51], ["the experimental infection", "PROBLEM", 165, 191], ["the values", "TEST", 196, 206], ["infection", "PROBLEM", 223, 232], ["experimental", "OBSERVATION_MODIFIER", 169, 181], ["infection", "OBSERVATION", 182, 191]]], ["The Mann-Whitney U test was used to demonstrate significant differences for time-matched values of the flurbiprofen group and the control group.", [["flurbiprofen", "CHEMICAL", 103, 115], ["flurbiprofen", "CHEMICAL", 103, 115], ["flurbiprofen", "SIMPLE_CHEMICAL", 103, 115], ["U test", "TEST", 17, 23], ["the flurbiprofen group", "TREATMENT", 99, 121], ["significant", "OBSERVATION_MODIFIER", 48, 59]]], ["The percentage of survival in both groups was statistically evaluated using the Mantel modification of the Gehan generalised Wilcoxon test.RESULTSThe post mortem in vitro adhesion assay revealed that the villi of all piglets from the control and the flurbiprofen group were susceptible to adhesion by K,,,,-ETEC to their enterocytes.Control groupExperimental infection with TGE virus and ETEC resulted in a pronounced mortality (71% of the animals), starting from day 5 and reaching maximal values on days 5 to 6 ( Figure 1 ).", [["villi", "ANATOMY", 204, 209], ["enterocytes", "ANATOMY", 321, 332], ["flurbiprofen", "CHEMICAL", 250, 262], ["K", "CHEMICAL", 301, 302], ["infection", "DISEASE", 359, 368], ["ETEC", "CHEMICAL", 388, 392], ["flurbiprofen", "CHEMICAL", 250, 262], ["villi", "MULTI-TISSUE_STRUCTURE", 204, 209], ["piglets", "ORGANISM", 217, 224], ["flurbiprofen", "SIMPLE_CHEMICAL", 250, 262], ["K", "SIMPLE_CHEMICAL", 301, 302], ["enterocytes", "CELL", 321, 332], ["TGE virus", "ORGANISM", 374, 383], ["ETEC", "ORGANISM", 388, 392], ["enterocytes", "CELL_TYPE", 321, 332], ["piglets", "SPECIES", 217, 224], ["TGE virus", "SPECIES", 374, 383], ["ETEC", "SPECIES", 388, 392], ["the Gehan generalised Wilcoxon test", "TEST", 103, 138], ["mortem in vitro adhesion assay", "TEST", 155, 185], ["the flurbiprofen group", "TREATMENT", 246, 268], ["K", "TEST", 301, 302], ["Control groupExperimental infection", "PROBLEM", 333, 368], ["TGE virus", "PROBLEM", 374, 383], ["ETEC", "PROBLEM", 388, 392], ["a pronounced mortality", "PROBLEM", 405, 427], ["percentage", "OBSERVATION_MODIFIER", 4, 14], ["survival", "OBSERVATION_MODIFIER", 18, 26], ["villi", "ANATOMY", 204, 209], ["enterocytes", "ANATOMY", 321, 332], ["groupExperimental", "OBSERVATION_MODIFIER", 341, 358], ["infection", "OBSERVATION", 359, 368], ["pronounced", "OBSERVATION_MODIFIER", 407, 417]]], ["Mortality was provoked by the pronounced watery diarrhoea, resulting in a hypovolaemic shock ( Figure 2 ).", [["diarrhoea", "DISEASE", 48, 57], ["shock", "DISEASE", 87, 92], ["the pronounced watery diarrhoea", "PROBLEM", 26, 57], ["a hypovolaemic shock", "PROBLEM", 72, 92], ["pronounced", "OBSERVATION_MODIFIER", 30, 40], ["watery", "OBSERVATION_MODIFIER", 41, 47], ["diarrhoea", "OBSERVATION", 48, 57], ["hypovolaemic shock", "OBSERVATION", 74, 92]]], ["Vomiting was observed in 65% of the animals.", [["Vomiting", "DISEASE", 0, 8], ["Vomiting", "PROBLEM", 0, 8]]], ["Hypovolaemic piglets had a poor appetite, severe depression and cyanosis of the extremities.", [["extremities", "ANATOMY", 80, 91], ["depression", "DISEASE", 49, 59], ["cyanosis of the extremities", "DISEASE", 64, 91], ["piglets", "ORGANISM", 13, 20], ["extremities", "ORGANISM_SUBDIVISION", 80, 91], ["piglets", "SPECIES", 13, 20], ["Hypovolaemic piglets", "PROBLEM", 0, 20], ["a poor appetite", "PROBLEM", 25, 40], ["severe depression", "PROBLEM", 42, 59], ["cyanosis of the extremities", "PROBLEM", 64, 91], ["poor appetite", "OBSERVATION_MODIFIER", 27, 40], ["severe", "OBSERVATION_MODIFIER", 42, 48], ["depression", "OBSERVATION", 49, 59], ["cyanosis", "OBSERVATION", 64, 72], ["extremities", "ANATOMY", 80, 91]]], ["In the terminal stage some pigs lay in lateral decubitus with the eyes retracted in the orbits, the flanks sunken and a prominent pelvis as a result of the severe dehydration.", [["lateral decubitus", "ANATOMY", 39, 56], ["eyes", "ANATOMY", 66, 70], ["flanks", "ANATOMY", 100, 106], ["pelvis", "ANATOMY", 130, 136], ["dehydration", "DISEASE", 163, 174], ["pigs", "ORGANISM", 27, 31], ["lateral decubitus", "MULTI-TISSUE_STRUCTURE", 39, 56], ["eyes", "ORGAN", 66, 70], ["flanks", "ORGANISM_SUBDIVISION", 100, 106], ["pelvis", "ORGAN", 130, 136], ["pigs", "SPECIES", 27, 31], ["the flanks sunken", "PROBLEM", 96, 113], ["a prominent pelvis", "PROBLEM", 118, 136], ["the severe dehydration", "PROBLEM", 152, 174], ["terminal", "OBSERVATION_MODIFIER", 7, 15], ["stage", "OBSERVATION_MODIFIER", 16, 21], ["some", "OBSERVATION_MODIFIER", 22, 26], ["pigs lay", "OBSERVATION", 27, 35], ["lateral", "ANATOMY_MODIFIER", 39, 46], ["decubitus", "ANATOMY_MODIFIER", 47, 56], ["eyes", "OBSERVATION", 66, 70], ["orbits", "ANATOMY", 88, 94], ["flanks", "ANATOMY", 100, 106], ["sunken", "OBSERVATION", 107, 113], ["prominent", "OBSERVATION_MODIFIER", 120, 129], ["pelvis", "ANATOMY", 130, 136], ["severe", "OBSERVATION_MODIFIER", 156, 162], ["dehydration", "OBSERVATION", 163, 174]]], ["The piglets developed diarrhoeic faeces during the chloramphenicol pretreafnient ( Figure 2 ; day 3).", [["diarrhoeic faeces", "ANATOMY", 22, 39], ["chloramphenicol", "CHEMICAL", 51, 66], ["chloramphenicol", "CHEMICAL", 51, 66], ["piglets", "ORGANISM", 4, 11], ["faeces", "ORGANISM_SUBSTANCE", 33, 39], ["chloramphenicol", "SIMPLE_CHEMICAL", 51, 66], ["piglets", "SPECIES", 4, 11], ["diarrhoeic faeces", "PROBLEM", 22, 39], ["the chloramphenicol pretreafnient", "TREATMENT", 47, 80], ["diarrhoeic faeces", "OBSERVATION", 22, 39]]], ["Diarrhoea, however, seriously worsened following inoculation with TGE virus and ETEC (PcO.01).", [["Diarrhoea", "DISEASE", 0, 9], ["TGE virus", "ORGANISM", 66, 75], ["TGE virus", "SPECIES", 66, 75], ["Diarrhoea", "PROBLEM", 0, 9], ["inoculation", "PROBLEM", 49, 60], ["TGE virus", "TREATMENT", 66, 75], ["ETEC", "PROBLEM", 80, 84], ["worsened", "OBSERVATION_MODIFIER", 30, 38]]], ["The faecal osmotic gap significantly increased from -14k11.6 mosmol/l on day 3 to 53.6-Cl5.8 mosmol/l on day 5 (P<O.Ol) and 95.6k27.5 mosmol/l on day 7 (P<O.OOl).Control groupFrom about 20 hours following ETEC-infection a substantial number of haemolytic E. coli were shed in the faeces (Figure 3) .", [["faecal", "ANATOMY", 4, 10], ["faeces", "ANATOMY", 280, 286], ["ETEC", "CHEMICAL", 205, 209], ["infection", "DISEASE", 210, 219], ["faecal", "ORGANISM_SUBSTANCE", 4, 10], ["E. coli", "ORGANISM", 255, 262], ["faeces", "ORGANISM_SUBDIVISION", 280, 286], ["E. coli", "SPECIES", 255, 262], ["E. coli", "SPECIES", 255, 262], ["The faecal osmotic gap", "TEST", 0, 22], ["mosmol", "TEST", 93, 99], ["P", "TEST", 112, 113], ["k", "TEST", 128, 129], ["mosmol", "TEST", 134, 140], ["ETEC", "PROBLEM", 205, 209], ["infection", "PROBLEM", 210, 219], ["haemolytic E. coli", "PROBLEM", 244, 262], ["faecal", "ANATOMY", 4, 10], ["osmotic gap", "OBSERVATION", 11, 22], ["significantly", "OBSERVATION_MODIFIER", 23, 36], ["increased", "OBSERVATION_MODIFIER", 37, 46], ["infection", "OBSERVATION", 210, 219], ["substantial", "OBSERVATION_MODIFIER", 222, 233], ["number", "OBSERVATION_MODIFIER", 234, 240], ["haemolytic", "OBSERVATION_MODIFIER", 244, 254], ["E. coli", "OBSERVATION", 255, 262]]], ["TGE virus were demonstrated in the faeces of all the piglets.", [["faeces", "ANATOMY", 35, 41], ["TGE virus", "ORGANISM", 0, 9], ["faeces", "ORGANISM_SUBDIVISION", 35, 41], ["piglets", "ORGANISM", 53, 60], ["piglets", "SPECIES", 53, 60], ["TGE virus", "SPECIES", 0, 9], ["TGE virus", "PROBLEM", 0, 9], ["virus", "OBSERVATION", 4, 9], ["faeces", "OBSERVATION", 35, 41], ["piglets", "OBSERVATION", 53, 60]]], ["Rota-and rotalikevirus, were each only detected in the faeces of one pig.Control groupDaily milk intake revealed a non-significant decrease (control value on day 3: 0.944rtO.106 l), followed by an increase to 1.447f0.3511 on day 10.", [["faeces", "ANATOMY", 55, 61], ["milk", "ANATOMY", 92, 96], ["rotalikevirus", "GENE_OR_GENE_PRODUCT", 9, 22], ["faeces", "ORGANISM_SUBDIVISION", 55, 61], ["pig", "ORGANISM", 69, 72], ["milk", "ORGANISM_SUBSTANCE", 92, 96], ["pig", "SPECIES", 69, 72], ["pig", "SPECIES", 69, 72], ["Rota", "TEST", 0, 4], ["a non-significant decrease (control value", "PROBLEM", 113, 154], ["non-significant", "OBSERVATION_MODIFIER", 115, 130], ["decrease", "OBSERVATION_MODIFIER", 131, 139]]], ["The pronounced and sustained diarrhoea, vomiting and loss of appetite resulted in a significant decrease in body weight (Figure 4) .Control groupHct initially increased and then gradually decreased ( Figure 5 ).", [["body", "ANATOMY", 108, 112], ["diarrhoea", "DISEASE", 29, 38], ["vomiting", "DISEASE", 40, 48], ["loss of appetite", "DISEASE", 53, 69], ["body", "ORGANISM_SUBDIVISION", 108, 112], ["The pronounced and sustained diarrhoea", "PROBLEM", 0, 38], ["vomiting", "PROBLEM", 40, 48], ["loss of appetite", "PROBLEM", 53, 69], ["a significant decrease in body weight", "PROBLEM", 82, 119], ["pronounced", "OBSERVATION_MODIFIER", 4, 14], ["sustained", "OBSERVATION_MODIFIER", 19, 28], ["diarrhoea", "OBSERVATION", 29, 38], ["significant", "OBSERVATION_MODIFIER", 84, 95], ["decrease", "OBSERVATION_MODIFIER", 96, 104], ["increased", "OBSERVATION_MODIFIER", 159, 168], ["gradually", "OBSERVATION_MODIFIER", 178, 187], ["decreased", "OBSERVATION_MODIFIER", 188, 197]]], ["In shocked and expiring piglets, however, a significant increase in Hct was observed, from 38.1+0.8% on day 3 to 43.9+0.9% just before death (KO.05).", [["death", "DISEASE", 135, 140], ["piglets", "ORGANISM", 24, 31], ["Hct", "GENE_OR_GENE_PRODUCT", 68, 71], ["piglets", "SPECIES", 24, 31], ["a significant increase", "PROBLEM", 42, 64], ["Hct", "TEST", 68, 71], ["shocked", "OBSERVATION", 3, 10], ["significant", "OBSERVATION_MODIFIER", 44, 55], ["increase", "OBSERVATION_MODIFIER", 56, 64]]], ["Dehydration and hypovolaemia also resulted in a significant increase in the total plasma protein concentration from 4.6kO.2 g/d1 on day 3 to 5.7f0.2 g/d1 on day 6 (P<O.OOl) and also in HR, from 151f6 beats/min on day 3 to 184+9 beats/min on day 5 (P<O.Ol), and in a significant decrease in Pa ( Figure 6) .Control groupArterial pH revealed a significant decrease from 7.48f0.03 on day 3 to 7.32kO.14 on day 7 (Pt0.05) and the lactic acid concentration also significantly decreased, from 21.7k2.2 mg/dl on day 3 to 12.9k1.6 mg/dl on day 5 (KO.01).", [["plasma", "ANATOMY", 82, 88], ["Dehydration", "DISEASE", 0, 11], ["hypovolaemia", "DISEASE", 16, 28], ["lactic acid", "CHEMICAL", 426, 437], ["lactic acid", "CHEMICAL", 426, 437], ["plasma", "ORGANISM_SUBSTANCE", 82, 88], ["lactic acid", "SIMPLE_CHEMICAL", 426, 437], ["Dehydration", "PROBLEM", 0, 11], ["hypovolaemia", "PROBLEM", 16, 28], ["a significant increase", "PROBLEM", 46, 68], ["the total plasma protein concentration", "TEST", 72, 110], ["HR", "TEST", 185, 187], ["Control groupArterial pH", "TEST", 306, 330], ["a significant decrease", "PROBLEM", 340, 362], ["the lactic acid concentration", "TEST", 422, 451], ["k", "TEST", 491, 492], ["k", "TEST", 518, 519], ["hypovolaemia", "OBSERVATION", 16, 28], ["significant", "OBSERVATION_MODIFIER", 48, 59], ["increase", "OBSERVATION_MODIFIER", 60, 68], ["significant", "OBSERVATION_MODIFIER", 266, 277], ["decrease", "OBSERVATION_MODIFIER", 278, 286], ["significant", "OBSERVATION_MODIFIER", 342, 353], ["decrease", "OBSERVATION_MODIFIER", 354, 362]]], ["After an initial nonsignificant increase on day 6, the plasma glucose concentration decreased from 94.lk6.1 mg/dl on day 3 to 76.754.0 mgldl on day 10 (PcO.05).", [["plasma", "ANATOMY", 55, 61], ["glucose", "CHEMICAL", 62, 69], ["glucose", "CHEMICAL", 62, 69], ["plasma", "ORGANISM_SUBSTANCE", 55, 61], ["glucose", "SIMPLE_CHEMICAL", 62, 69], ["the plasma glucose concentration", "TEST", 51, 83], ["lk", "TEST", 102, 104], ["nonsignificant", "OBSERVATION_MODIFIER", 17, 31], ["increase", "OBSERVATION_MODIFIER", 32, 40]]], ["The values for pOz (control value on day 3: 9O.Ok3.4 mm Hg), pC02 (control value: 29.651 mm Hg) and the frequency of respiration (control value: 26.3+2.8/min) did not change significantly.Control groupIn shocked and expiring piglets BE decreased from -6.8k2.4 mEq/l on day 3 to -24.6f3.70 mEq/l on day5 (P<O.OOl) and bicarbonate decreased from 23.3k1.9 mEq/l on day 3 to 8.6+ 1.9 mEq/l on day 5 (P<O.OOl).", [["BE", "CHEMICAL", 233, 235], ["bicarbonate", "CHEMICAL", 317, 328], ["Hg", "CHEMICAL", 56, 58], ["pC02", "CHEMICAL", 61, 65], ["Hg", "CHEMICAL", 92, 94], ["bicarbonate", "CHEMICAL", 317, 328], ["piglets", "ORGANISM", 225, 232], ["bicarbonate", "SIMPLE_CHEMICAL", 317, 328], ["piglets", "SPECIES", 225, 232], ["The values", "TEST", 0, 10], ["pOz", "TEST", 15, 18], ["k", "TEST", 48, 49], ["Hg", "TEST", 56, 58], ["pC02", "TEST", 61, 65], ["mm Hg", "TEST", 89, 94], ["respiration (control value", "TEST", 117, 143], ["bicarbonate", "TEST", 317, 328]]], ["The corresponding value for pH on day 5 was 7.28f0.05 (P<O.Ol).Control groupDespite the pronounced dehydration there were no significant changes in the serum concentrations of potassium (control value on day 3: 4.1kO.l mEq/l), chloride (control value: 97.1+1.8 mEq/l) or calcium (5.1kO.2 mEq/l).", [["serum", "ANATOMY", 152, 157], ["dehydration", "DISEASE", 99, 110], ["potassium", "CHEMICAL", 176, 185], ["chloride", "CHEMICAL", 227, 235], ["calcium", "CHEMICAL", 271, 278], ["potassium", "CHEMICAL", 176, 185], ["chloride", "CHEMICAL", 227, 235], ["calcium", "CHEMICAL", 271, 278], ["serum", "ORGANISM_SUBSTANCE", 152, 157], ["potassium", "SIMPLE_CHEMICAL", 176, 185], ["chloride", "SIMPLE_CHEMICAL", 227, 235], ["calcium", "SIMPLE_CHEMICAL", 271, 278], ["pH", "TEST", 28, 30], ["the pronounced dehydration", "PROBLEM", 84, 110], ["significant changes", "PROBLEM", 125, 144], ["the serum concentrations", "TEST", 148, 172], ["potassium", "TEST", 176, 185], ["chloride", "TEST", 227, 235], ["calcium", "TEST", 271, 278], ["pronounced", "OBSERVATION_MODIFIER", 88, 98], ["dehydration", "OBSERVATION", 99, 110], ["no", "UNCERTAINTY", 122, 124], ["significant", "OBSERVATION_MODIFIER", 125, 136], ["changes", "OBSERVATION", 137, 144]]], ["Sodium concentration revealed a significant increase from 13Ok2.5 mEq/l on day 3 to 137k1.5 mEq/l on day 6 (WO.01). followed by a return to near the control value on day 10 in surviving piglets.Control groupFollowing the TGE virus and ETEC inoculation, the leucocyte count significantly decreased (Figure 7) .", [["leucocyte", "ANATOMY", 257, 266], ["Sodium", "CHEMICAL", 0, 6], ["ETEC", "CHEMICAL", 235, 239], ["Sodium", "CHEMICAL", 0, 6], ["Sodium", "SIMPLE_CHEMICAL", 0, 6], ["piglets", "ORGANISM", 186, 193], ["TGE virus", "ORGANISM", 221, 230], ["ETEC", "ORGANISM", 235, 239], ["leucocyte", "CELL", 257, 266], ["piglets", "SPECIES", 186, 193], ["TGE virus", "SPECIES", 221, 230], ["ETEC", "SPECIES", 235, 239], ["Sodium concentration", "TEST", 0, 20], ["a significant increase", "PROBLEM", 30, 52], ["the TGE virus", "PROBLEM", 217, 230], ["ETEC inoculation", "TEST", 235, 251], ["the leucocyte count", "TEST", 253, 272], ["significant", "OBSERVATION_MODIFIER", 32, 43], ["increase", "OBSERVATION_MODIFIER", 44, 52]]], ["In surviving piglets this parameter increased to give a significant leucocytosis on day 10 (Figure 7) .", [["leucocytosis", "DISEASE", 68, 80], ["piglets", "ORGANISM", 13, 20], ["piglets", "SPECIES", 13, 20], ["a significant leucocytosis", "PROBLEM", 54, 80], ["significant", "OBSERVATION_MODIFIER", 56, 67], ["leucocytosis", "OBSERVATION", 68, 80]]], ["After an initial, non-significant decrease the body temperature returned to near the control value and was significantly increased on day 10 in surviving animals (Figure 8 ).Control groupNecropsy revealed erosions and congestion of the mucosa of the fundic region of the stomach, a congested, thin-walled small intestine, especially the ileum, with a watery content, and sometimes also congestion of the colon wall.Flurbiprofen groupFlurbiprofen treatment was without beneficial effects on the mortality induced by the combined TGE virus and ETEC inoculation (Figure 1 ; P>O.O5).", [["body", "ANATOMY", 47, 51], ["mucosa", "ANATOMY", 236, 242], ["fundic region", "ANATOMY", 250, 263], ["stomach", "ANATOMY", 271, 278], ["intestine", "ANATOMY", 311, 320], ["ileum", "ANATOMY", 337, 342], ["colon wall", "ANATOMY", 404, 414], ["erosions", "DISEASE", 205, 213], ["watery", "DISEASE", 351, 357], ["Flurbiprofen", "CHEMICAL", 415, 427], ["groupFlurbiprofen", "CHEMICAL", 428, 445], ["TGE", "CHEMICAL", 528, 531], ["ETEC", "CHEMICAL", 542, 546], ["Flurbiprofen", "CHEMICAL", 415, 427], ["body", "ORGANISM_SUBDIVISION", 47, 51], ["mucosa", "MULTI-TISSUE_STRUCTURE", 236, 242], ["fundic", "ORGANISM_SUBDIVISION", 250, 256], ["stomach", "ORGAN", 271, 278], ["small intestine", "ORGAN", 305, 320], ["ileum", "ORGAN", 337, 342], ["watery", "ORGANISM_SUBDIVISION", 351, 357], ["colon wall", "MULTI-TISSUE_STRUCTURE", 404, 414], ["Flurbiprofen", "SIMPLE_CHEMICAL", 415, 427], ["groupFlurbiprofen", "SIMPLE_CHEMICAL", 428, 445], ["ETEC", "SIMPLE_CHEMICAL", 542, 546], ["TGE virus", "SPECIES", 528, 537], ["non-significant decrease the body temperature", "PROBLEM", 18, 63], ["erosions", "PROBLEM", 205, 213], ["congestion of the mucosa of the fundic region of the stomach", "PROBLEM", 218, 278], ["a congested, thin-walled small intestine", "PROBLEM", 280, 320], ["a watery content", "PROBLEM", 349, 365], ["congestion of the colon wall", "PROBLEM", 386, 414], ["Flurbiprofen groupFlurbiprofen treatment", "TREATMENT", 415, 455], ["beneficial effects", "PROBLEM", 468, 486], ["the combined TGE virus", "PROBLEM", 515, 537], ["ETEC inoculation", "PROBLEM", 542, 558], ["non-significant", "OBSERVATION_MODIFIER", 18, 33], ["decrease", "OBSERVATION_MODIFIER", 34, 42], ["increased", "OBSERVATION_MODIFIER", 121, 130], ["erosions", "OBSERVATION", 205, 213], ["congestion", "OBSERVATION", 218, 228], ["mucosa", "ANATOMY_MODIFIER", 236, 242], ["fundic", "ANATOMY_MODIFIER", 250, 256], ["region", "ANATOMY_MODIFIER", 257, 263], ["stomach", "ANATOMY", 271, 278], ["congested", "OBSERVATION", 282, 291], ["thin", "OBSERVATION_MODIFIER", 293, 297], ["walled", "ANATOMY_MODIFIER", 298, 304], ["small intestine", "ANATOMY", 305, 320], ["ileum", "ANATOMY", 337, 342], ["watery content", "OBSERVATION", 351, 365], ["congestion", "OBSERVATION", 386, 396], ["colon", "ANATOMY", 404, 409], ["wall", "ANATOMY_MODIFIER", 410, 414]]], ["As in the control group, the pigs developed severe diarrhoea during the chloramphenicol pretreatment period haemolytic E. coli (Figure 3 ). a significantly more pronounced decrease in leucocyte count ( Figure 7) and a temporary normalization of body temperature (Figure 8 ).", [["leucocyte", "ANATOMY", 184, 193], ["body", "ANATOMY", 245, 249], ["diarrhoea", "DISEASE", 51, 60], ["chloramphenicol", "CHEMICAL", 72, 87], ["haemolytic E. coli", "DISEASE", 108, 126], ["chloramphenicol", "CHEMICAL", 72, 87], ["pigs", "ORGANISM", 29, 33], ["chloramphenicol", "SIMPLE_CHEMICAL", 72, 87], ["E. coli", "ORGANISM", 119, 126], ["leucocyte", "CELL", 184, 193], ["body", "ORGANISM_SUBDIVISION", 245, 249], ["pigs", "SPECIES", 29, 33], ["E. coli", "SPECIES", 119, 126], ["pigs", "SPECIES", 29, 33], ["E. coli", "SPECIES", 119, 126], ["severe diarrhoea", "PROBLEM", 44, 60], ["the chloramphenicol pretreatment", "TREATMENT", 68, 100], ["haemolytic E. coli", "PROBLEM", 108, 126], ["a significantly more pronounced decrease", "PROBLEM", 140, 180], ["leucocyte count", "TEST", 184, 199], ["body temperature", "PROBLEM", 245, 261], ["severe", "OBSERVATION_MODIFIER", 44, 50], ["diarrhoea", "OBSERVATION", 51, 60], ["haemolytic", "OBSERVATION_MODIFIER", 108, 118], ["E. coli", "OBSERVATION", 119, 126], ["significantly more", "OBSERVATION_MODIFIER", 142, 160], ["pronounced", "OBSERVATION_MODIFIER", 161, 171], ["decrease", "OBSERVATION_MODIFIER", 172, 180], ["leucocyte count", "OBSERVATION", 184, 199]]], ["After the later administrations, however, the evolution of all the parameters studied was comparable to that of the control group (Figures 3-8DISCUSSIONSince the turn of the century E. coli has been implicated in the aetiology of porcine weaning diarrhoea (colibacillosis).", [["diarrhoea", "DISEASE", 246, 255], ["colibacillosis", "DISEASE", 257, 271], ["E. coli", "ORGANISM", 182, 189], ["porcine", "ORGANISM", 230, 237], ["E. coli", "SPECIES", 182, 189], ["porcine", "SPECIES", 230, 237], ["E. coli", "SPECIES", 182, 189], ["the century E. coli", "PROBLEM", 170, 189], ["porcine weaning diarrhoea (colibacillosis)", "PROBLEM", 230, 272]]], ["The causal strains are usually haemolytic, possess fimbriae which mediate specific adherence of the E. co/i to receptors on villous enterocytes and produce enterotoxins (Lecce, 1983) .", [["villous enterocytes", "ANATOMY", 124, 143], ["haemolytic", "DISEASE", 31, 41], ["fimbriae", "GENE_OR_GENE_PRODUCT", 51, 59], ["villous enterocytes", "MULTI-TISSUE_STRUCTURE", 124, 143], ["E. co/i to receptors", "PROTEIN", 100, 120], ["villous enterocytes", "CELL_TYPE", 124, 143], ["enterotoxins", "PROTEIN", 156, 168], ["The causal strains", "PROBLEM", 0, 18], ["haemolytic", "PROBLEM", 31, 41], ["fimbriae", "PROBLEM", 51, 59], ["villous enterocytes", "PROBLEM", 124, 143], ["enterotoxins", "PROBLEM", 156, 168], ["villous enterocytes", "ANATOMY", 124, 143]]], ["The enterotoxins LT and STa induce fluid secretion by the crypt cells, mediated by cyclic AMP and cyclic GMP respectively, whereas LT also inhibits absorption by villous cells.", [["fluid", "ANATOMY", 35, 40], ["crypt cells", "ANATOMY", 58, 69], ["villous cells", "ANATOMY", 162, 175], ["STa", "CHEMICAL", 24, 27], ["AMP", "CHEMICAL", 90, 93], ["GMP", "CHEMICAL", 105, 108], ["cyclic AMP", "CHEMICAL", 83, 93], ["cyclic GMP", "CHEMICAL", 98, 108], ["enterotoxins LT", "GENE_OR_GENE_PRODUCT", 4, 19], ["STa", "SIMPLE_CHEMICAL", 24, 27], ["fluid", "ORGANISM_SUBSTANCE", 35, 40], ["crypt cells", "CELL", 58, 69], ["AMP", "SIMPLE_CHEMICAL", 90, 93], ["cyclic GMP", "SIMPLE_CHEMICAL", 98, 108], ["LT", "SIMPLE_CHEMICAL", 131, 133], ["villous cells", "CELL", 162, 175], ["LT", "PROTEIN", 17, 19], ["crypt cells", "CELL_TYPE", 58, 69], ["LT", "PROTEIN", 131, 133], ["villous cells", "CELL_TYPE", 162, 175], ["The enterotoxins LT and STa induce fluid secretion", "TEST", 0, 50], ["the crypt cells", "PROBLEM", 54, 69], ["cyclic AMP and cyclic GMP", "TREATMENT", 83, 108], ["villous cells", "PROBLEM", 162, 175], ["LT", "ANATOMY", 17, 19], ["fluid secretion", "OBSERVATION", 35, 50], ["crypt cells", "OBSERVATION", 58, 69], ["villous cells", "OBSERVATION", 162, 175]]], ["Although STb can induce villous atrophy, the exact mechanism through which it increases intestinal fluid loss is still unclear (Whipp et al., 1987) .DISCUSSIONIn the past five years there has been steady progress in research on potentially useful drugs which can reduce fluid loss in secretory diarrhoeas.", [["villous", "ANATOMY", 24, 31], ["intestinal fluid", "ANATOMY", 88, 104], ["fluid", "ANATOMY", 270, 275], ["secretory diarrhoeas", "ANATOMY", 284, 304], ["STb", "CHEMICAL", 9, 12], ["villous atrophy", "DISEASE", 24, 39], ["intestinal fluid loss", "DISEASE", 88, 109], ["fluid loss", "DISEASE", 270, 280], ["diarrhoeas", "DISEASE", 294, 304], ["STb", "GENE_OR_GENE_PRODUCT", 9, 12], ["villous", "TISSUE", 24, 31], ["intestinal", "ORGAN", 88, 98], ["fluid", "ORGANISM_SUBSTANCE", 270, 275], ["STb", "PROTEIN", 9, 12], ["STb", "PROBLEM", 9, 12], ["villous atrophy", "PROBLEM", 24, 39], ["intestinal fluid loss", "PROBLEM", 88, 109], ["useful drugs", "TREATMENT", 240, 252], ["fluid loss in secretory diarrhoeas", "PROBLEM", 270, 304], ["villous", "OBSERVATION_MODIFIER", 24, 31], ["atrophy", "OBSERVATION", 32, 39], ["intestinal", "ANATOMY", 88, 98], ["fluid loss", "OBSERVATION", 99, 109], ["fluid loss", "OBSERVATION", 270, 280], ["secretory diarrhoeas", "OBSERVATION", 284, 304]]], ["In spite of promising activity in animal models, the recently tested antisecretory drugs have only reduced secretory diarrhoea in humans by 50%, chlorpromazine and nicotine having the most effect (Powell, 1986; Greenough & Rabbani, 1986) .DISCUSSIONRecently rotavirus has been shown to be causally associated with weaning diarrhoea of pigs.", [["diarrhoea", "DISEASE", 117, 126], ["chlorpromazine", "CHEMICAL", 145, 159], ["nicotine", "CHEMICAL", 164, 172], ["diarrhoea", "DISEASE", 322, 331], ["chlorpromazine", "CHEMICAL", 145, 159], ["nicotine", "CHEMICAL", 164, 172], ["humans", "ORGANISM", 130, 136], ["chlorpromazine", "SIMPLE_CHEMICAL", 145, 159], ["nicotine", "SIMPLE_CHEMICAL", 164, 172], ["rotavirus", "ORGANISM", 258, 267], ["pigs", "ORGANISM", 335, 339], ["humans", "SPECIES", 130, 136], ["pigs", "SPECIES", 335, 339], ["humans", "SPECIES", 130, 136], ["rotavirus", "SPECIES", 258, 267], ["pigs", "SPECIES", 335, 339], ["promising activity in animal models", "PROBLEM", 12, 47], ["antisecretory drugs", "TREATMENT", 69, 88], ["reduced secretory diarrhoea", "PROBLEM", 99, 126], ["chlorpromazine", "TREATMENT", 145, 159], ["nicotine", "TREATMENT", 164, 172], ["rotavirus", "PROBLEM", 258, 267], ["weaning diarrhoea of pigs", "PROBLEM", 314, 339], ["promising", "OBSERVATION_MODIFIER", 12, 21], ["activity", "OBSERVATION", 22, 30], ["secretory diarrhoea", "OBSERVATION", 107, 126]]], ["This virus multiplies in and destroys the absorptive cells of the villi of the small intestine, leading to malabsorption, dehydration and death in very young piglets (Lecce, 1983 ).", [["absorptive cells", "ANATOMY", 42, 58], ["villi", "ANATOMY", 66, 71], ["small intestine", "ANATOMY", 79, 94], ["malabsorption", "DISEASE", 107, 120], ["dehydration", "DISEASE", 122, 133], ["death", "DISEASE", 138, 143], ["absorptive cells", "CELL", 42, 58], ["villi", "MULTI-TISSUE_STRUCTURE", 66, 71], ["small intestine", "ORGAN", 79, 94], ["piglets", "ORGANISM", 158, 165], ["absorptive cells", "CELL_TYPE", 42, 58], ["piglets", "SPECIES", 158, 165], ["This virus multiplies", "PROBLEM", 0, 21], ["malabsorption", "PROBLEM", 107, 120], ["dehydration", "PROBLEM", 122, 133], ["death", "PROBLEM", 138, 143], ["absorptive cells", "OBSERVATION", 42, 58], ["villi", "ANATOMY_MODIFIER", 66, 71], ["small intestine", "ANATOMY", 79, 94], ["leading to", "UNCERTAINTY", 96, 106], ["malabsorption", "OBSERVATION", 107, 120], ["dehydration", "OBSERVATION_MODIFIER", 122, 133]]], ["In our model TGE virus, another enteropathogenic virus, was selected since rotavirus is enzootic in Belgian piggeries (Debouck, 1984) , since the effects of this coronavirus in swine are well characterized and since, like rotavirus, it infects only mature epithelial cells and does not infect the undifferentiated crypt cells.", [["epithelial cells", "ANATOMY", 256, 272], ["crypt cells", "ANATOMY", 314, 325], ["coronavirus", "DISEASE", 162, 173], ["TGE virus", "ORGANISM", 13, 22], ["rotavirus", "ORGANISM", 75, 84], ["coronavirus", "ORGANISM", 162, 173], ["swine", "ORGANISM", 177, 182], ["rotavirus", "ORGANISM", 222, 231], ["epithelial cells", "CELL", 256, 272], ["crypt cells", "CELL", 314, 325], ["mature epithelial cells", "CELL_TYPE", 249, 272], ["undifferentiated crypt cells", "CELL_TYPE", 297, 325], ["coronavirus", "SPECIES", 162, 173], ["swine", "SPECIES", 177, 182], ["TGE virus", "SPECIES", 13, 22], ["rotavirus", "SPECIES", 75, 84], ["swine", "SPECIES", 177, 182], ["rotavirus", "SPECIES", 222, 231], ["another enteropathogenic virus", "PROBLEM", 24, 54], ["rotavirus", "PROBLEM", 75, 84], ["this coronavirus", "PROBLEM", 157, 173], ["rotavirus", "PROBLEM", 222, 231], ["the undifferentiated crypt cells", "PROBLEM", 293, 325], ["enteropathogenic virus", "OBSERVATION", 32, 54], ["enzootic", "OBSERVATION_MODIFIER", 88, 96], ["coronavirus", "OBSERVATION", 162, 173], ["epithelial cells", "OBSERVATION", 256, 272], ["undifferentiated crypt cells", "OBSERVATION", 297, 325]]], ["TGE virus consistently induces villous atrophy and crypt hyperplasia.", [["villous", "ANATOMY", 31, 38], ["crypt hyperplasia", "ANATOMY", 51, 68], ["villous atrophy", "DISEASE", 31, 46], ["hyperplasia", "DISEASE", 57, 68], ["TGE virus", "ORGANISM", 0, 9], ["villous atrophy", "PATHOLOGICAL_FORMATION", 31, 46], ["crypt hyperplasia", "PATHOLOGICAL_FORMATION", 51, 68], ["TGE virus", "SPECIES", 0, 9], ["TGE virus", "PROBLEM", 0, 9], ["villous atrophy", "PROBLEM", 31, 46], ["crypt hyperplasia", "PROBLEM", 51, 68], ["virus", "OBSERVATION", 4, 9], ["villous atrophy", "OBSERVATION", 31, 46], ["crypt hyperplasia", "OBSERVATION", 51, 68]]], ["The disease is most acute and almost invariably fatal in the very young piglet, in which vomiting and profuse diarrhoea can lead rapidly to dehydration and death.", [["piglet", "ANATOMY", 72, 78], ["vomiting", "DISEASE", 89, 97], ["diarrhoea", "DISEASE", 110, 119], ["dehydration", "DISEASE", 140, 151], ["death", "DISEASE", 156, 161], ["piglet", "ORGANISM", 72, 78], ["piglet", "SPECIES", 72, 78], ["The disease", "PROBLEM", 0, 11], ["vomiting", "PROBLEM", 89, 97], ["profuse diarrhoea", "PROBLEM", 102, 119], ["dehydration", "PROBLEM", 140, 151], ["death", "PROBLEM", 156, 161], ["disease", "OBSERVATION", 4, 11], ["most", "OBSERVATION_MODIFIER", 15, 19], ["acute", "OBSERVATION_MODIFIER", 20, 25], ["almost", "OBSERVATION_MODIFIER", 30, 36], ["invariably", "OBSERVATION_MODIFIER", 37, 47], ["fatal", "OBSERVATION", 48, 53], ["very", "OBSERVATION_MODIFIER", 61, 65], ["young piglet", "OBSERVATION_MODIFIER", 66, 78]]], ["Young pigs over 3 weeks old, as in our study, experience a debilitating diarrhoea of 10 to 14 days duration but usually survive (Aitken, 1983; Whipp et al., 1985) .", [["diarrhoea", "DISEASE", 72, 81], ["pigs", "ORGANISM", 6, 10], ["pigs", "SPECIES", 6, 10], ["pigs", "SPECIES", 6, 10], ["our study", "TEST", 35, 44], ["a debilitating diarrhoea", "PROBLEM", 57, 81], ["debilitating", "OBSERVATION_MODIFIER", 59, 71], ["diarrhoea", "OBSERVATION", 72, 81]]], ["We recently demonstrated the adhesion of the two ETEC-strains used in our present study to the atrophic villi following TGE virus inoculation in newlyweaned pigs (Cox et al., in press ).DISCUSSIONIn our model, dually-infected piglets experience profuse diarrhoea, vomiting, dehydration, weight loss and hypovolaemic shock, causing the death of 71% of the animals.", [["atrophic villi", "ANATOMY", 95, 109], ["TGE", "CHEMICAL", 120, 123], ["diarrhoea", "DISEASE", 253, 262], ["vomiting", "DISEASE", 264, 272], ["dehydration", "DISEASE", 274, 285], ["weight loss", "DISEASE", 287, 298], ["hypovolaemic shock", "DISEASE", 303, 321], ["death", "DISEASE", 335, 340], ["villi", "MULTI-TISSUE_STRUCTURE", 104, 109], ["TGE virus", "ORGANISM", 120, 129], ["pigs", "ORGANISM", 157, 161], ["piglets", "ORGANISM", 226, 233], ["pigs", "SPECIES", 157, 161], ["piglets", "SPECIES", 226, 233], ["pigs", "SPECIES", 157, 161], ["strains", "PROBLEM", 54, 61], ["the atrophic villi", "PROBLEM", 91, 109], ["TGE virus inoculation", "TREATMENT", 120, 141], ["profuse diarrhoea", "PROBLEM", 245, 262], ["vomiting", "PROBLEM", 264, 272], ["dehydration", "PROBLEM", 274, 285], ["weight loss", "PROBLEM", 287, 298], ["hypovolaemic shock", "PROBLEM", 303, 321], ["the death", "PROBLEM", 331, 340], ["adhesion", "OBSERVATION_MODIFIER", 29, 37], ["atrophic", "OBSERVATION", 95, 103], ["villi", "ANATOMY", 104, 109], ["hypovolaemic shock", "OBSERVATION", 303, 321]]], ["The induced diarrhoea is probably a combination of malabsorption (TGE virus) and hypersecretion (ETEC).", [["diarrhoea", "DISEASE", 12, 21], ["malabsorption", "DISEASE", 51, 64], ["ETEC", "DISEASE", 97, 101], ["The induced diarrhoea", "PROBLEM", 0, 21], ["malabsorption (TGE virus)", "PROBLEM", 51, 76], ["hypersecretion (ETEC", "PROBLEM", 81, 101], ["diarrhoea", "OBSERVATION", 12, 21], ["probably a combination of", "UNCERTAINTY", 25, 50], ["malabsorption", "OBSERVATION", 51, 64], ["hypersecretion", "OBSERVATION", 81, 95]]], ["As a consequence of malabsorption the accumulation of non-absorbable nutrients, such as lactose, promotes a rise in luminal osmotic pressure, encouraging fluid movement from blood to lumen.", [["luminal", "ANATOMY", 116, 123], ["fluid", "ANATOMY", 154, 159], ["blood", "ANATOMY", 174, 179], ["lumen", "ANATOMY", 183, 188], ["malabsorption", "DISEASE", 20, 33], ["lactose", "CHEMICAL", 88, 95], ["luminal", "CHEMICAL", 116, 123], ["lactose", "CHEMICAL", 88, 95], ["lactose", "SIMPLE_CHEMICAL", 88, 95], ["luminal", "IMMATERIAL_ANATOMICAL_ENTITY", 116, 123], ["blood", "ORGANISM_SUBSTANCE", 174, 179], ["lumen", "IMMATERIAL_ANATOMICAL_ENTITY", 183, 188], ["malabsorption", "PROBLEM", 20, 33], ["non-absorbable nutrients", "TREATMENT", 54, 78], ["lactose", "TREATMENT", 88, 95], ["luminal osmotic pressure", "TREATMENT", 116, 140], ["malabsorption", "OBSERVATION", 20, 33], ["accumulation", "OBSERVATION_MODIFIER", 38, 50], ["non-absorbable nutrients", "OBSERVATION", 54, 78], ["luminal", "ANATOMY", 116, 123], ["osmotic pressure", "OBSERVATION", 124, 140], ["fluid movement", "OBSERVATION", 154, 168]]], ["At present the osmotic effect is considered to be the major component of TGE virus diarrhoea (Aitken, 1983) .", [["diarrhoea", "DISEASE", 83, 92], ["TGE virus diarrhoea", "ORGANISM", 73, 92], ["TGE virus diarrhoea", "SPECIES", 73, 92], ["the osmotic effect", "PROBLEM", 11, 29], ["TGE virus diarrhoea", "PROBLEM", 73, 92], ["osmotic effect", "OBSERVATION", 15, 29], ["TGE virus", "OBSERVATION", 73, 82]]], ["The evolution of the osmotic gap of the faecal water from secretory diarrhoea (day 3) to near osmotic diarrhoea (day 7) in our study is an interesting observation in this context.DISCUSSIONThe clinical signs in dying piglets in our study agree with the observations on E. coli infection in gnotobiotic pigs (Kenworthy & de G. Mitchell, 1976) .DISCUSSIONThe diarrhoea occurring during the chloramphenicol pretreatment (days 1 to 3) in both groups studied can be explained by the change in the diet from sow's to cow's milk, by the loss of maternal immunity, by environmental changes (Tzipori et al., 1980; Lecce, 1983) , and probably by suppression of the gut flora by the antibiotic resulting in an increased susceptibility to infection by potentially pathogenic microorganisms (Kaufman, 1984) .", [["milk", "ANATOMY", 517, 521], ["gut flora", "ANATOMY", 655, 664], ["diarrhoea", "DISEASE", 68, 77], ["diarrhoea", "DISEASE", 102, 111], ["E. coli infection", "DISEASE", 269, 286], ["diarrhoea", "DISEASE", 357, 366], ["chloramphenicol", "CHEMICAL", 388, 403], ["infection", "DISEASE", 727, 736], ["chloramphenicol", "CHEMICAL", 388, 403], ["piglets", "ORGANISM", 217, 224], ["E. coli", "ORGANISM", 269, 276], ["gnotobiotic pigs", "ORGANISM", 290, 306], ["chloramphenicol", "SIMPLE_CHEMICAL", 388, 403], ["sow", "ORGANISM_SUBDIVISION", 502, 505], ["cow", "ORGANISM", 511, 514], ["milk", "ORGANISM_SUBSTANCE", 517, 521], ["gut flora", "ORGANISM_SUBDIVISION", 655, 664], ["piglets", "SPECIES", 217, 224], ["E. coli", "SPECIES", 269, 276], ["gnotobiotic pigs", "SPECIES", 290, 306], ["cow", "SPECIES", 511, 514], ["E. coli", "SPECIES", 269, 276], ["pigs", "SPECIES", 302, 306], ["cow", "SPECIES", 511, 514], ["the osmotic gap", "TEST", 17, 32], ["secretory diarrhoea", "PROBLEM", 58, 77], ["near osmotic diarrhoea", "PROBLEM", 89, 111], ["our study", "TEST", 123, 132], ["our study", "TEST", 228, 237], ["E. coli infection", "PROBLEM", 269, 286], ["The diarrhoea", "PROBLEM", 353, 366], ["the chloramphenicol pretreatment", "TREATMENT", 384, 416], ["cow's milk", "TREATMENT", 511, 521], ["the gut flora", "PROBLEM", 651, 664], ["the antibiotic", "TREATMENT", 668, 682], ["an increased susceptibility to infection", "PROBLEM", 696, 736], ["pathogenic microorganisms", "PROBLEM", 752, 777], ["osmotic gap", "OBSERVATION", 21, 32], ["faecal", "ANATOMY", 40, 46], ["secretory diarrhoea", "OBSERVATION", 58, 77], ["osmotic diarrhoea", "OBSERVATION", 94, 111], ["coli infection", "OBSERVATION", 272, 286], ["diarrhoea", "OBSERVATION", 357, 366], ["increased", "OBSERVATION_MODIFIER", 699, 708], ["infection", "OBSERVATION", 727, 736]]], ["In healthy, nondiarrhoeal, colostrum fed neonatal calves, oral administration of chlo-ramphenicol induces diarrhoea by partial decrease of villous height and crypt depth (Rollin ef al., 1986) .DISCUSSIONThe high control values for arterial pH (day 3) in piglets of both groups in the present study agree with the observation on conscious immature pigs of 2 to 3 months old.", [["oral", "ANATOMY", 58, 62], ["villous", "ANATOMY", 139, 146], ["crypt", "ANATOMY", 158, 163], ["arterial", "ANATOMY", 231, 239], ["chlo-ramphenicol", "CHEMICAL", 81, 97], ["diarrhoea", "DISEASE", 106, 115], ["chlo-ramphenicol", "CHEMICAL", 81, 97], ["colostrum", "ORGANISM", 27, 36], ["calves", "ORGANISM", 50, 56], ["oral", "ORGANISM_SUBDIVISION", 58, 62], ["chlo-ramphenicol", "SIMPLE_CHEMICAL", 81, 97], ["villous", "TISSUE", 139, 146], ["crypt", "TISSUE", 158, 163], ["arterial", "MULTI-TISSUE_STRUCTURE", 231, 239], ["piglets", "ORGANISM", 254, 261], ["pigs", "ORGANISM", 347, 351], ["calves", "SPECIES", 50, 56], ["piglets", "SPECIES", 254, 261], ["pigs", "SPECIES", 347, 351], ["oral administration", "TREATMENT", 58, 77], ["chlo-ramphenicol", "TREATMENT", 81, 97], ["diarrhoea", "PROBLEM", 106, 115], ["partial decrease of villous height", "PROBLEM", 119, 153], ["crypt depth", "PROBLEM", 158, 169], ["arterial pH", "TEST", 231, 242], ["the present study", "TEST", 280, 297], ["the observation", "TEST", 309, 324], ["conscious immature pigs", "TREATMENT", 328, 351], ["partial", "OBSERVATION_MODIFIER", 119, 126], ["decrease", "OBSERVATION_MODIFIER", 127, 135], ["villous height", "OBSERVATION", 139, 153], ["crypt depth", "OBSERVATION_MODIFIER", 158, 169]]], ["Pigs of this age, however, reveal a higher pC0, value, a higher HC03-concentration, a lower p02 value and a lower Hct (Hannon, 1983) .", [["Pigs", "ORGANISM", 0, 4], ["HC03", "SIMPLE_CHEMICAL", 64, 68], ["HC03", "PROTEIN", 64, 68], ["p02", "PROTEIN", 92, 95], ["Pigs", "SPECIES", 0, 4], ["a higher pC0", "PROBLEM", 34, 46], ["a lower p02 value", "PROBLEM", 84, 101], ["a lower Hct", "TEST", 106, 117]]], ["Differences in our results can probably partly be attributed to the diarrhoea occurring on day 3.", [["diarrhoea", "DISEASE", 68, 77], ["the diarrhoea", "PROBLEM", 64, 77], ["diarrhoea", "OBSERVATION", 68, 77]]], ["The decrease in Hct, following the initial increase, in surviving pigs of our study can probably be explained by a haemodilution effect, resulting from the daily extraction of blood.DISCUSSIONWhen piglets developed hypovolaemia and shock some characteristic changes occurred within a few hours: an abrupt rise in Hct, a pronounced decrease in BE and a concomitant decrease in bicarbonate resulting in an acidosis.", [["blood", "ANATOMY", 176, 181], ["haemodilution", "DISEASE", 115, 128], ["hypovolaemia", "DISEASE", 215, 227], ["shock", "DISEASE", 232, 237], ["BE", "CHEMICAL", 343, 345], ["bicarbonate", "CHEMICAL", 376, 387], ["acidosis", "DISEASE", 404, 412], ["bicarbonate", "CHEMICAL", 376, 387], ["Hct", "SIMPLE_CHEMICAL", 16, 19], ["pigs", "ORGANISM", 66, 70], ["blood", "ORGANISM_SUBSTANCE", 176, 181], ["piglets", "ORGANISM", 197, 204], ["Hct", "SIMPLE_CHEMICAL", 313, 316], ["bicarbonate", "SIMPLE_CHEMICAL", 376, 387], ["Hct", "PROTEIN", 16, 19], ["piglets", "SPECIES", 197, 204], ["The decrease in Hct", "PROBLEM", 0, 19], ["our study", "TEST", 74, 83], ["a haemodilution effect", "PROBLEM", 113, 135], ["the daily extraction of blood", "TREATMENT", 152, 181], ["hypovolaemia", "PROBLEM", 215, 227], ["shock", "PROBLEM", 232, 237], ["an abrupt rise in Hct", "PROBLEM", 295, 316], ["a pronounced decrease", "PROBLEM", 318, 339], ["a concomitant decrease in bicarbonate", "TREATMENT", 350, 387], ["an acidosis", "PROBLEM", 401, 412], ["decrease", "OBSERVATION_MODIFIER", 4, 12], ["Hct", "OBSERVATION_MODIFIER", 16, 19], ["increase", "OBSERVATION_MODIFIER", 43, 51], ["probably be explained", "UNCERTAINTY", 88, 109], ["haemodilution effect", "OBSERVATION", 115, 135], ["hypovolaemia", "OBSERVATION", 215, 227], ["shock", "OBSERVATION", 232, 237], ["abrupt", "OBSERVATION_MODIFIER", 298, 304], ["rise", "OBSERVATION_MODIFIER", 305, 309], ["pronounced", "OBSERVATION_MODIFIER", 320, 330], ["decrease", "OBSERVATION_MODIFIER", 331, 339], ["decrease", "OBSERVATION_MODIFIER", 364, 372], ["acidosis", "OBSERVATION", 404, 412]]], ["Since lactic acid did not increase but significantly decreased, other acid metabolites must be responsible for this metabolic acidosis.", [["lactic acid", "CHEMICAL", 6, 17], ["acidosis", "DISEASE", 126, 134], ["lactic acid", "CHEMICAL", 6, 17], ["lactic acid", "SIMPLE_CHEMICAL", 6, 17], ["lactic acid", "TEST", 6, 17], ["other acid metabolites", "PROBLEM", 64, 86], ["this metabolic acidosis", "PROBLEM", 111, 134], ["increase", "OBSERVATION_MODIFIER", 26, 34], ["significantly", "OBSERVATION_MODIFIER", 39, 52], ["decreased", "OBSERVATION_MODIFIER", 53, 62], ["metabolic acidosis", "OBSERVATION", 116, 134]]], ["In experiments on ETEC-induced and spontaneous diarrhoea in neonatal piglets a metabolic acidosis with low pH and an abrupt decrease in BE and an increase in Hct was also reported in dying animals (Andren & Persson, 1983) .", [["ETEC", "CHEMICAL", 18, 22], ["diarrhoea", "DISEASE", 47, 56], ["acidosis", "DISEASE", 89, 97], ["BE", "CHEMICAL", 136, 138], ["piglets", "ORGANISM", 69, 76], ["Hct", "GENE_OR_GENE_PRODUCT", 158, 161], ["Hct", "PROTEIN", 158, 161], ["piglets", "SPECIES", 69, 76], ["ETEC", "PROBLEM", 18, 22], ["spontaneous diarrhoea", "PROBLEM", 35, 56], ["neonatal piglets", "PROBLEM", 60, 76], ["a metabolic acidosis", "PROBLEM", 77, 97], ["low pH", "PROBLEM", 103, 109], ["an abrupt decrease", "PROBLEM", 114, 132], ["an increase in Hct", "PROBLEM", 143, 161], ["spontaneous", "OBSERVATION_MODIFIER", 35, 46], ["diarrhoea", "OBSERVATION", 47, 56], ["metabolic acidosis", "OBSERVATION", 79, 97], ["low pH", "OBSERVATION_MODIFIER", 103, 109], ["abrupt", "OBSERVATION_MODIFIER", 117, 123], ["decrease", "OBSERVATION_MODIFIER", 124, 132], ["increase", "OBSERVATION_MODIFIER", 146, 154]]], ["Kutas and Szabo (1971) likewise reported low pH and BE values in diarrhoeic piglets, resulting from experimental E. coli infection.", [["BE", "CHEMICAL", 52, 54], ["E. coli infection", "DISEASE", 113, 130], ["BE", "SIMPLE_CHEMICAL", 52, 54], ["piglets", "ORGANISM", 76, 83], ["E. coli", "ORGANISM", 113, 120], ["piglets", "SPECIES", 76, 83], ["E. coli", "SPECIES", 113, 120], ["E. coli", "SPECIES", 113, 120], ["low pH", "PROBLEM", 41, 47], ["diarrhoeic piglets", "PROBLEM", 65, 83], ["experimental E. coli infection", "PROBLEM", 100, 130], ["low pH", "OBSERVATION_MODIFIER", 41, 47], ["diarrhoeic piglets", "OBSERVATION", 65, 83], ["E. coli infection", "OBSERVATION", 113, 130]]], ["In shocked animals in our study, the BE values were lower than -10 mEq/l, a critical limit below which the prognosis should be considered poor, at least in neonatal piglets (Andren & Persson, 1983) .DISCUSSIONIn experiments on gnotobiotic pigs, 27 to 34 days old when infected with ETEC-strains, animals developed a severe diarrhoea resulting in dehydration and death between 16 and 36 hours after infection.", [["BE", "CHEMICAL", 37, 39], ["diarrhoea", "DISEASE", 323, 332], ["dehydration", "DISEASE", 346, 357], ["death", "DISEASE", 362, 367], ["infection", "DISEASE", 398, 407], ["piglets", "ORGANISM", 165, 172], ["gnotobiotic pigs", "ORGANISM", 227, 243], ["ETEC", "ORGANISM", 282, 286], ["animals", "ORGANISM", 296, 303], ["piglets", "SPECIES", 165, 172], ["pigs", "SPECIES", 239, 243], ["pigs", "SPECIES", 239, 243], ["our study", "TEST", 22, 31], ["gnotobiotic pigs", "TREATMENT", 227, 243], ["ETEC", "PROBLEM", 282, 286], ["strains", "PROBLEM", 287, 294], ["a severe diarrhoea", "PROBLEM", 314, 332], ["dehydration", "PROBLEM", 346, 357], ["death", "PROBLEM", 362, 367], ["infection", "PROBLEM", 398, 407], ["severe", "OBSERVATION_MODIFIER", 316, 322], ["diarrhoea", "OBSERVATION", 323, 332], ["dehydration", "OBSERVATION", 346, 357], ["infection", "OBSERVATION", 398, 407]]], ["As in the piglets in our control group, no elevation of body temperature was recorded during this period.", [["body", "ANATOMY", 56, 60], ["piglets", "ORGANISM", 10, 17], ["body", "ORGANISM_SUBDIVISION", 56, 60], ["elevation of body temperature", "PROBLEM", 43, 72], ["no", "UNCERTAINTY", 40, 42], ["elevation", "OBSERVATION_MODIFIER", 43, 52]]], ["Pigs also revealed a neutropenia soon after infection and an abrupt increase in Hct (Kenworthy & de G. Mitchell, 1976) .", [["neutropenia", "DISEASE", 21, 32], ["infection", "DISEASE", 44, 53], ["Pigs", "ORGANISM", 0, 4], ["Pigs", "SPECIES", 0, 4], ["Pigs", "TREATMENT", 0, 4], ["a neutropenia", "PROBLEM", 19, 32], ["infection", "PROBLEM", 44, 53], ["an abrupt increase in Hct", "PROBLEM", 58, 83], ["neutropenia", "OBSERVATION", 21, 32], ["abrupt", "OBSERVATION_MODIFIER", 61, 67], ["increase", "OBSERVATION_MODIFIER", 68, 76]]], ["Polymorphonuclear cell infiltration in the intestinal mucosa was observed in pigs following infection with TGE virus or with STb producing ETEC strains (Pensaert et al., 1970; Rose & Moon, 1985) .", [["Polymorphonuclear cell", "ANATOMY", 0, 22], ["intestinal mucosa", "ANATOMY", 43, 60], ["infection", "DISEASE", 92, 101], ["STb", "CHEMICAL", 125, 128], ["Polymorphonuclear cell", "CELL", 0, 22], ["intestinal mucosa", "MULTI-TISSUE_STRUCTURE", 43, 60], ["pigs", "ORGANISM", 77, 81], ["TGE virus", "ORGANISM", 107, 116], ["STb", "GENE_OR_GENE_PRODUCT", 125, 128], ["ETEC", "ORGANISM", 139, 143], ["pigs", "SPECIES", 77, 81], ["pigs", "SPECIES", 77, 81], ["TGE virus", "SPECIES", 107, 116], ["Polymorphonuclear cell infiltration", "PROBLEM", 0, 35], ["the intestinal mucosa", "PROBLEM", 39, 60], ["infection", "PROBLEM", 92, 101], ["TGE virus", "PROBLEM", 107, 116], ["STb producing ETEC strains", "PROBLEM", 125, 151], ["cell infiltration", "OBSERVATION", 18, 35], ["intestinal mucosa", "ANATOMY", 43, 60], ["infection", "OBSERVATION", 92, 101]]], ["This observation can probably partly explain the severe neutropenia observed in our study.DISCUSSIONThe post mortem findings in the piglets in the present study correspond to those observed in piglets which have died from post weaning diarrhoea.DISCUSSIONSeveral studies suggest the involvement of prostaglandins in the LT and ST enterotoxin-induced hypersecretion (Berridge, 1984; Petzinger, 1984; Donowitz et al., 1986) .", [["neutropenia", "DISEASE", 56, 67], ["diarrhoea", "DISEASE", 235, 244], ["prostaglandins", "CHEMICAL", 298, 312], ["enterotoxin", "CHEMICAL", 330, 341], ["hypersecretion", "DISEASE", 350, 364], ["prostaglandins", "CHEMICAL", 298, 312], ["piglets", "ORGANISM", 132, 139], ["piglets", "ORGANISM", 193, 200], ["prostaglandins", "SIMPLE_CHEMICAL", 298, 312], ["ST enterotoxin", "GENE_OR_GENE_PRODUCT", 327, 341], ["piglets", "SPECIES", 132, 139], ["piglets", "SPECIES", 193, 200], ["the severe neutropenia", "PROBLEM", 45, 67], ["our study", "TEST", 80, 89], ["the present study", "TEST", 143, 160], ["post weaning diarrhoea", "PROBLEM", 222, 244], ["DISCUSSIONSeveral studies", "TEST", 245, 270], ["prostaglandins in the LT and ST enterotoxin", "PROBLEM", 298, 341], ["hypersecretion", "PROBLEM", 350, 364], ["probably partly explain", "UNCERTAINTY", 21, 44], ["severe", "OBSERVATION_MODIFIER", 49, 55], ["neutropenia", "OBSERVATION", 56, 67], ["LT", "ANATOMY", 320, 322], ["hypersecretion", "OBSERVATION", 350, 364]]], ["Results of studies on the effects of aspirin, indomethacin and other NSAID's are, however, somewhat inconsistent.", [["aspirin", "CHEMICAL", 37, 44], ["indomethacin", "CHEMICAL", 46, 58], ["aspirin", "CHEMICAL", 37, 44], ["indomethacin", "CHEMICAL", 46, 58], ["aspirin", "SIMPLE_CHEMICAL", 37, 44], ["indomethacin", "SIMPLE_CHEMICAL", 46, 58], ["NSAID", "SIMPLE_CHEMICAL", 69, 74], ["studies", "TEST", 11, 18], ["aspirin", "TREATMENT", 37, 44], ["indomethacin", "TREATMENT", 46, 58], ["other NSAID's", "TREATMENT", 63, 76]]], ["In vivo, indomethacin inhibits secretion caused by Vibrio cholerae, cholera toxin and ST enterotoxin of E. coli.", [["indomethacin", "CHEMICAL", 9, 21], ["cholera toxin", "CHEMICAL", 68, 81], ["indomethacin", "CHEMICAL", 9, 21], ["indomethacin", "SIMPLE_CHEMICAL", 9, 21], ["Vibrio cholerae", "ORGANISM", 51, 66], ["cholera toxin", "SIMPLE_CHEMICAL", 68, 81], ["ST enterotoxin", "GENE_OR_GENE_PRODUCT", 86, 100], ["E. coli", "ORGANISM", 104, 111], ["Vibrio cholerae", "SPECIES", 51, 66], ["E. coli", "SPECIES", 104, 111], ["Vibrio cholerae", "SPECIES", 51, 66], ["E. coli", "SPECIES", 104, 111], ["indomethacin", "TREATMENT", 9, 21], ["secretion", "PROBLEM", 31, 40], ["Vibrio cholerae", "PROBLEM", 51, 66], ["cholera toxin", "TREATMENT", 68, 81], ["ST enterotoxin", "TREATMENT", 86, 100], ["E. coli", "PROBLEM", 104, 111], ["E. coli", "OBSERVATION", 104, 111]]], ["In vitro, this agent decreases the effects of CAMP and of drugs that stimulate the adenylate cyclase-CAMP system.", [["adenylate", "CHEMICAL", 83, 92], ["CAMP", "GENE_OR_GENE_PRODUCT", 46, 50], ["adenylate cyclase-CAMP", "GENE_OR_GENE_PRODUCT", 83, 105], ["adenylate cyclase", "PROTEIN", 83, 100], ["CAMP", "PROTEIN", 101, 105], ["CAMP and of drugs", "TREATMENT", 46, 63], ["the adenylate cyclase", "TREATMENT", 79, 100], ["CAMP system", "TREATMENT", 101, 112]]], ["In vivo, aspirin inhibits small intestinal secretion provoked by cholera toxin and E. coli LT enterotoxin but not E. coli ST enterotoxin (Donowitz et al., 1986) .", [["intestinal", "ANATOMY", 32, 42], ["aspirin", "CHEMICAL", 9, 16], ["cholera toxin", "CHEMICAL", 65, 78], ["aspirin", "CHEMICAL", 9, 16], ["aspirin", "SIMPLE_CHEMICAL", 9, 16], ["intestinal", "ORGAN", 32, 42], ["cholera toxin", "SIMPLE_CHEMICAL", 65, 78], ["E. coli", "ORGANISM", 83, 90], ["LT enterotoxin", "ORGANISM", 91, 105], ["E. coli", "ORGANISM", 114, 121], ["ST enterotoxin", "ORGANISM", 122, 136], ["cholera toxin", "PROTEIN", 65, 78], ["E. coli", "SPECIES", 83, 90], ["E. coli", "SPECIES", 114, 121], ["E. coli", "SPECIES", 83, 90], ["E. coli", "SPECIES", 114, 121], ["aspirin", "TREATMENT", 9, 16], ["small intestinal secretion", "PROBLEM", 26, 52], ["cholera toxin", "PROBLEM", 65, 78], ["E. coli LT enterotoxin", "PROBLEM", 83, 105], ["E. coli ST enterotoxin", "PROBLEM", 114, 136], ["small", "OBSERVATION_MODIFIER", 26, 31], ["intestinal", "ANATOMY", 32, 42]]], ["In ligated calf's jejunal loops, salicylates reduced E. coli ST induced hypersecretion (Wise et al., 1983) .", [["jejunal loops", "ANATOMY", 18, 31], ["salicylates", "CHEMICAL", 33, 44], ["calf", "ORGANISM_SUBDIVISION", 11, 15], ["jejunal loops", "MULTI-TISSUE_STRUCTURE", 18, 31], ["salicylates", "SIMPLE_CHEMICAL", 33, 44], ["E. coli", "ORGANISM", 53, 60], ["calf", "SPECIES", 11, 15], ["E. coli", "SPECIES", 53, 60], ["E. coli", "SPECIES", 53, 60], ["salicylates", "TREATMENT", 33, 44], ["E. coli ST induced hypersecretion", "PROBLEM", 53, 86], ["ligated", "ANATOMY_MODIFIER", 3, 10], ["calf", "ANATOMY", 11, 15], ["'s", "ANATOMY_MODIFIER", 15, 17], ["jejunal loops", "ANATOMY", 18, 31], ["salicylates", "OBSERVATION_MODIFIER", 33, 44], ["reduced", "OBSERVATION_MODIFIER", 45, 52], ["coli", "OBSERVATION_MODIFIER", 56, 60], ["hypersecretion", "OBSERVATION", 72, 86]]], ["In the porcine jejunal loop, however, this NSAID was ineffective in reducing E. coli ST induced hypersecretion (Ahrens & Zhu, 1982) .", [["jejunal loop", "ANATOMY", 15, 27], ["porcine", "ORGANISM", 7, 14], ["jejunal loop", "MULTI-TISSUE_STRUCTURE", 15, 27], ["NSAID", "SIMPLE_CHEMICAL", 43, 48], ["E. coli", "ORGANISM", 77, 84], ["ST", "ORGANISM", 85, 87], ["E. coli", "SPECIES", 77, 84], ["E. coli", "SPECIES", 77, 84], ["the porcine jejunal loop", "TREATMENT", 3, 27], ["this NSAID", "TREATMENT", 38, 48], ["E. coli ST induced hypersecretion", "PROBLEM", 77, 110], ["porcine", "ANATOMY_MODIFIER", 7, 14], ["jejunal loop", "ANATOMY", 15, 27], ["hypersecretion", "OBSERVATION", 96, 110]]], ["The inhibitory effect of the NSAID's appears to be due to increased absorption, although it is associated with some inhibition of activation of the cyclic AMP-system by LT enterotoxin of Vibrio cholerue and E. coli.", [["NSAID", "CHEMICAL", 29, 34], ["AMP", "CHEMICAL", 155, 158], ["cyclic AMP", "CHEMICAL", 148, 158], ["NSAID", "SIMPLE_CHEMICAL", 29, 34], ["AMP", "SIMPLE_CHEMICAL", 155, 158], ["LT enterotoxin", "GENE_OR_GENE_PRODUCT", 169, 183], ["Vibrio cholerue", "ORGANISM", 187, 202], ["E. coli", "ORGANISM", 207, 214], ["LT enterotoxin", "PROTEIN", 169, 183], ["Vibrio cholerue", "SPECIES", 187, 202], ["E. coli", "SPECIES", 207, 214], ["Vibrio cholerue", "SPECIES", 187, 202], ["E. coli", "SPECIES", 207, 214], ["the NSAID's", "TREATMENT", 25, 36], ["increased absorption", "PROBLEM", 58, 78], ["the cyclic AMP", "TREATMENT", 144, 158], ["Vibrio cholerue", "PROBLEM", 187, 202], ["E. coli", "PROBLEM", 207, 214], ["increased", "OBSERVATION_MODIFIER", 58, 67], ["absorption", "OBSERVATION", 68, 78], ["E. coli", "OBSERVATION", 207, 214]]], ["(Donowitz et al., 1986) .DISCUSSIONIn the present experiments we studied the effect of flurbiprofen, a potent NSAID, on diarrhoea induced by combined TGE virus and ETEC infection in newly-weaned piglets.", [["flurbiprofen", "CHEMICAL", 87, 99], ["NSAID", "CHEMICAL", 110, 115], ["diarrhoea", "DISEASE", 120, 129], ["TGE", "CHEMICAL", 150, 153], ["ETEC", "CHEMICAL", 164, 168], ["infection", "DISEASE", 169, 178], ["flurbiprofen", "CHEMICAL", 87, 99], ["flurbiprofen", "SIMPLE_CHEMICAL", 87, 99], ["NSAID", "SIMPLE_CHEMICAL", 110, 115], ["TGE virus", "ORGANISM", 150, 159], ["ETEC", "ORGANISM", 164, 168], ["piglets", "ORGANISM", 195, 202], ["piglets", "SPECIES", 195, 202], ["TGE virus", "SPECIES", 150, 159], ["ETEC", "SPECIES", 164, 168], ["flurbiprofen", "TREATMENT", 87, 99], ["a potent NSAID", "TREATMENT", 101, 115], ["diarrhoea", "PROBLEM", 120, 129], ["combined TGE virus", "PROBLEM", 141, 159], ["ETEC infection", "PROBLEM", 164, 178], ["infection", "OBSERVATION", 169, 178]]], ["The dosage, 1 mg/kg/l2 h, was derived from the oral dose in humans and from the plasma mean half-life value of approximately 7 hours after oral dosage in man (Szpunar et al., 1987) .", [["oral", "ANATOMY", 47, 51], ["plasma", "ANATOMY", 80, 86], ["oral", "ANATOMY", 139, 143], ["oral", "ORGANISM_SUBDIVISION", 47, 51], ["humans", "ORGANISM", 60, 66], ["plasma", "ORGANISM_SUBSTANCE", 80, 86], ["oral", "ORGANISM_SUBDIVISION", 139, 143], ["man", "ORGANISM", 154, 157], ["humans", "SPECIES", 60, 66], ["man", "SPECIES", 154, 157], ["humans", "SPECIES", 60, 66], ["The dosage", "TREATMENT", 0, 10]]], ["In our model flurbiprofen was without significant beneficial effect on diarrhoea score or lethality suggesting that prostaglandins are rather unimportant in the pathophysiology of the malabsorption and hypersecretion diarrhoea.", [["flurbiprofen", "CHEMICAL", 13, 25], ["diarrhoea", "DISEASE", 71, 80], ["prostaglandins", "CHEMICAL", 116, 130], ["malabsorption", "DISEASE", 184, 197], ["hypersecretion diarrhoea", "DISEASE", 202, 226], ["flurbiprofen", "CHEMICAL", 13, 25], ["prostaglandins", "CHEMICAL", 116, 130], ["flurbiprofen", "SIMPLE_CHEMICAL", 13, 25], ["prostaglandins", "SIMPLE_CHEMICAL", 116, 130], ["our model flurbiprofen", "TREATMENT", 3, 25], ["diarrhoea score", "PROBLEM", 71, 86], ["lethality", "PROBLEM", 90, 99], ["the malabsorption", "PROBLEM", 180, 197], ["hypersecretion diarrhoea", "PROBLEM", 202, 226], ["prostaglandins", "OBSERVATION", 116, 130], ["malabsorption", "OBSERVATION", 184, 197], ["hypersecretion diarrhoea", "OBSERVATION", 202, 226]]], ["Only the first administration of this NSAID resulted in a temporary amelioration of some parameters studied.", [["NSAID", "SIMPLE_CHEMICAL", 38, 43], ["this NSAID", "TREATMENT", 33, 43], ["a temporary amelioration", "TREATMENT", 56, 80], ["temporary amelioration", "OBSERVATION", 58, 80]]], ["The treatment, however, induced a decreased activity.DISCUSSIONThe effects of various NSAID's on cholera toxin-induced intestinal secretion in a number of animal species have generally shown them to be effective when given before but not after toxin administration (Wise et al., 1983) .", [["intestinal", "ANATOMY", 119, 129], ["cholera toxin", "CHEMICAL", 97, 110], ["NSAID", "SIMPLE_CHEMICAL", 86, 91], ["cholera toxin", "SIMPLE_CHEMICAL", 97, 110], ["intestinal", "ORGAN", 119, 129], ["The treatment", "TREATMENT", 0, 13], ["a decreased activity", "PROBLEM", 32, 52], ["various NSAID's", "TREATMENT", 78, 93], ["cholera toxin", "TREATMENT", 97, 110], ["intestinal secretion", "PROBLEM", 119, 139], ["animal species", "PROBLEM", 155, 169], ["decreased activity", "OBSERVATION", 34, 52], ["intestinal", "ANATOMY", 119, 129], ["secretion", "OBSERVATION", 130, 139]]], ["In our experiments flurbiprofen was administered following the combined viral-bacterial inoculation.", [["flurbiprofen", "CHEMICAL", 19, 31], ["flurbiprofen", "CHEMICAL", 19, 31], ["flurbiprofen", "SIMPLE_CHEMICAL", 19, 31], ["flurbiprofen", "TREATMENT", 19, 31], ["the combined viral-bacterial inoculation", "PROBLEM", 59, 99], ["bacterial inoculation", "OBSERVATION", 78, 99]]], ["It recently appears that arachidonic acid metabolites may play an important role in invasive, inflammatory diarrhoea, but not in secretory diarrhoea (Powell, 1986; Turnberg, 1986 ).", [["arachidonic acid", "CHEMICAL", 25, 41], ["diarrhoea", "DISEASE", 107, 116], ["secretory diarrhoea", "DISEASE", 129, 148], ["arachidonic acid", "CHEMICAL", 25, 41], ["arachidonic acid", "SIMPLE_CHEMICAL", 25, 41], ["arachidonic acid metabolites", "PROBLEM", 25, 53], ["inflammatory diarrhoea", "PROBLEM", 94, 116], ["secretory diarrhoea", "PROBLEM", 129, 148], ["arachidonic acid", "OBSERVATION", 25, 41], ["invasive", "OBSERVATION_MODIFIER", 84, 92], ["inflammatory", "OBSERVATION_MODIFIER", 94, 106]]], ["In our model the dual infection induced inflammatory intestinal changes (unpublished observation), as consistently occur following TGE virus and STb enterotoxin exposure (Pensaert et al., 1970; Rose & Moon, 1985) .", [["intestinal", "ANATOMY", 53, 63], ["infection", "DISEASE", 22, 31], ["intestinal", "ORGAN", 53, 63], ["TGE virus", "ORGANISM", 131, 140], ["STb enterotoxin", "GENE_OR_GENE_PRODUCT", 145, 160], ["TGE virus", "SPECIES", 131, 140], ["the dual infection induced inflammatory intestinal changes", "PROBLEM", 13, 71], ["TGE virus", "PROBLEM", 131, 140], ["STb enterotoxin exposure", "PROBLEM", 145, 169], ["dual", "OBSERVATION_MODIFIER", 17, 21], ["infection", "OBSERVATION", 22, 31], ["inflammatory", "OBSERVATION_MODIFIER", 40, 52], ["intestinal", "ANATOMY", 53, 63]]], ["No beneficial effect of the NSAID studied, however, was observed.", [["NSAID", "SIMPLE_CHEMICAL", 28, 33], ["the NSAID", "TREATMENT", 24, 33], ["beneficial", "OBSERVATION_MODIFIER", 3, 13], ["effect", "OBSERVATION_MODIFIER", 14, 20]]], ["Perhaps treatment with NSAID's would be more appropriate in diarrhoeic conditions caused by enteroinvasive bacterial strains (Petzinger, 1984) .", [["NSAID", "SIMPLE_CHEMICAL", 23, 28], ["NSAID's", "TREATMENT", 23, 30], ["diarrhoeic conditions", "PROBLEM", 60, 81], ["enteroinvasive bacterial strains", "PROBLEM", 92, 124]]]], "PMC7528676": [["Weight-of-evidence strategiesAn alternative to falsely balanced discussions, which potentially can alter the environment in favour of evidence-based perspectives, is weight-of-evidence reporting (Dunwoody, 2005; Kohl et al., 2016).", [["Weight", "TEST", 0, 6], ["weight", "TEST", 166, 172]]], ["A weight-of-evidence strategy \u2018calls on journalists not to determine what\u2019s true, but instead to find out where the bulk of evidence and expert thought lies on the truth continuum and then communicate that to the audiences\u2019 (Dunwoody, 2005, p.", [["A weight", "TEST", 0, 8]]], ["Thus, weight-of-evidence strategies neither overestimate positions that are backed up with little evidence, nor do they neglect the existence of contrasting positions (Kohl et al., 2016).", [["weight", "TEST", 6, 12]]], ["Instead, weight-of-evidence strategies provide each position in a public discussion with a weight corresponding to the amount of evidence that supports the position.", [["weight", "TEST", 9, 15]]], ["Previous research shows that weight-of-evidence strategies in newspaper articles can mitigate damage to the audience\u2019s attitudinal beliefs from misleading reports (Clarke, Dixon, Holton & McKeever, 2015; Clarke, McKeever, et al., 2015; Kohl et al., 2016).", [["Previous research", "TEST", 0, 17], ["weight", "TEST", 29, 35]]], ["Given these promising findings, it is now necessary to explore how weight-of-evidence strategies can be best applied in public discussions about science.Outnumbering as a weight-of-evidence strategyA variety of cues can be used as weights of evidence in public discussions.", [["weight", "TEST", 67, 73], ["a weight", "TEST", 169, 177]]], ["In line with research on scientific consensus (Lewandowsky, Gignac & Vaughan, 2012; van der Linden, Clarke, & Maibach, 2015), using majorities as informational evidence seems especially reasonable when the majority comprises experts in the field under discussion.Outnumbering as a weight-of-evidence strategySecond, the number of discussants who are invited to represent each position can cause a multiple-source effect.", [["a weight", "TEST", 279, 287], ["multiple", "OBSERVATION_MODIFIER", 397, 405]]], ["Several studies have shown that arguments are more persuasive when presented by multiple sources rather than a single source (Harkins & Petty, 1987; Petty, Harkins & Williams, 1980).", [["Several studies", "TEST", 0, 15]]], ["Multiple sources are perceived as independent pools of knowledge that are likely to represent a wide variety of perspectives, while a single source\u2019s perspective is likely to be known after the first argument (Harkins & Petty, 1987).", [["likely to represent", "UNCERTAINTY", 74, 93]]], ["267).Outnumbering as a weight-of-evidence strategyDue to the consistent theoretical and empirical persuasive advantage of having multiple discussants, we expect that the relative number of guests representing a certain position can serve as a weight-of-evidence strategy in a public discussion.", [["a weight", "TEST", 21, 29], ["a weight", "TEST", 241, 249]]], ["This mitigation will be achieved either due to the fact that the relative number of advocates serves as a social cue (Experiments 1\u20133), or due to an additional multiple-source effect (Experiment 3).Forewarning as a weight-of-evidence strategyAnother weight-of-evidence strategy is to warn the audience prior to the discussion.", [["a weight", "TEST", 213, 221], ["Another weight", "TEST", 242, 256]]], ["A common psychological intervention that uses prior information to apply weight to subsequent information is forewarning (McGuire & Papageorgis, 1962; Quinn & Wood, 2003).", [["A common psychological intervention", "TREATMENT", 0, 35]]], ["Due to falsely balanced public discussions\u2019 biased nature, we expect that forewarning about the false-balance effect can serve as a weight-of-evidence strategy in favour of the scientific position.", [["a weight", "TEST", 130, 138]]], ["Thus, the forewarning hypothesis expects that when individuals read a general explanation of the false-balance effect, denial messages\u2019 damage will be mitigated compared with a control group.Issue involvement and rebuttal as moderatorsSome extant findings challenge the idea that weight-of-evidence strategies are a universal approach to counter science denialism in public discussions.", [["weight", "TEST", 280, 286]]], ["Moreover, outnumbering can be classified as a peripheral cue.", [["a peripheral cue", "TEST", 44, 60]]], ["Dual process models suggest that peripheral cues should be more effective with less-involved audiences because peripheral cues do not require as much motivation as a central message feature to be persuasive (Petty & Cacioppo, 1986).", [["peripheral cues", "TREATMENT", 33, 48]]], ["Given the mixed assumptions, the involvement-as-moderator research question explores whether and how the audience\u2019s issue involvement will moderate weight-of-evidence strategies\u2019 efficacy.Issue involvement and rebuttal as moderatorsSecond, the two outlined weight-of-evidence strategies\u2019 efficacy may depend on whether an advocate responds to the denier\u2019s claim with a counter message, that is, whether or not a rebuttal is present.", [["weight", "TEST", 148, 154], ["weight", "TEST", 257, 263]]], ["If science deniers present misinformation, and advocates respond with rebuttal messages (Schmid & Betsch, 2019), then weight-of-evidence strategies can decrease the misinformation\u2019s persuasiveness and/or increase the rebuttal\u2019s persuasiveness.", [["weight", "TEST", 118, 124]]], ["In the absence of a rebuttal, weight-of-evidence strategies only can decrease the persuasiveness of deniers\u2019 misinformation.", [["weight", "TEST", 30, 36]]], ["Thus, given the lack of previous research on the topic, the rebuttal-as-moderator research question explores whether and how weight-of-evidence strategies\u2019 efficacy will depend on rebuttal messages\u2019 presence.", [["weight", "TEST", 125, 131]]], ["We refer to the failure to deliver a rebuttal as advocate silent.OverviewIn three preregistered laboratory experiments, we tested the efficacy of outnumbering (Experiments 1\u20133) and forewarning (Experiments 2 and 3) to counter the damage from science denialism in public discussions (Figure 1).", [["the damage", "PROBLEM", 226, 236]]], ["We further explored whether these strategies\u2019 efficacy depends on the audience\u2019s issue involvement and on advocates\u2019 successful delivery of rebuttals.", [["successful delivery of rebuttals", "TREATMENT", 117, 149]]], ["All experiments focussed on public discussions about vaccination as a content domain.", [["vaccination", "TREATMENT", 53, 64]]], ["Vaccination is a behaviour favoured by science that has been addressed repeatedly through science denialism and falsely balanced discussions (Dixon & Clarke, 2013).", [["Vaccination", "TREATMENT", 0, 11]]], ["Thus, vaccination is an appropriate testing ground for interventions to counter misinformation.", [["vaccination", "TREATMENT", 6, 17], ["an appropriate testing", "TEST", 21, 43], ["interventions", "TREATMENT", 55, 68]]], ["All tested interventions aim to mitigate damage from science deniers to the public\u2019s acceptance of science.", [["All tested interventions", "TREATMENT", 0, 24], ["damage", "PROBLEM", 41, 47]]], ["Thus, samples were not drawn from the population of science deniers as they have a low willingness to change their mind compared to the general public, and an investigation of the effectiveness of weight-of-evidence strategies in this population would likely fail (WHO, 2016).", [["samples", "ANATOMY", 6, 13], ["samples", "TEST", 6, 13], ["weight", "TEST", 197, 203]]], ["All studies used Schmid and Betsch\u2019s (2019) research scenario, in which participants read information about the fictitious disease dysomeria and learned that vaccination against the disease was available and recommended.", [["dysomeria", "DISEASE", 131, 140], ["participants", "ORGANISM", 72, 84], ["participants", "SPECIES", 72, 84], ["All studies", "TEST", 0, 11], ["the fictitious disease dysomeria", "PROBLEM", 108, 140], ["vaccination", "TREATMENT", 158, 169], ["the disease", "PROBLEM", 178, 189]]], ["Subsequently, participants watched a mock TV discussion between vaccine deniers and advocates for science, in which relevant independent variables were manipulated.", [["participants", "SPECIES", 14, 26], ["vaccine", "TREATMENT", 64, 71]]], ["Participants indicated their attitudes towards vaccination and the intention to get vaccinated against the fictitious disease before and after the discussion.", [["Participants", "SPECIES", 0, 12], ["vaccination", "TREATMENT", 47, 58]]], ["As described under the rebuttal as the moderator\u2019s research question, weight-of-evidence strategies could be effective because they decrease the persuasiveness of deniers\u2019 messages and/or increase the persuasiveness of the rebuttal message by providing each message with a weight equivalent to the amount of evidence that supports the position.", [["weight", "TEST", 70, 76]]], ["Following this rationale, failure to detect any weight-of-evidence strategies\u2019 effects may be due to mere inefficacy of either the deniers\u2019 message or the advocates\u2019 rebuttal message in producing any persuasive effect.", [["failure", "PROBLEM", 26, 33], ["weight", "TEST", 48, 54]]], ["Thus, replicating the damaging effect from denial messages and the mitigating effect from rebuttal messages from Schmid and Betsch (2019) indicated successful manipulation in all subsequent experiments.Participants and design ::: Method ::: Experiment 1A-priori power analyses using GPower (Faul et al., 2009) revealed a minimum sample size of N = 368 to detect an interaction effect (minimum effect size of interest of d = 0.20) with a power of .80 in a mixed within-between ANOVA (eight groups, two measurements, \u03b1 = .05).", [["Participants", "SPECIES", 202, 214], ["denial messages", "TREATMENT", 43, 58], ["an interaction effect", "PROBLEM", 362, 383]]], ["The effect size of the power analysis was chosen to detect conventionally small effect sizes (J. Cohen, 1977).", [["the power analysis", "TEST", 19, 37], ["effect", "OBSERVATION_MODIFIER", 4, 10], ["size", "OBSERVATION_MODIFIER", 11, 15], ["small", "OBSERVATION_MODIFIER", 74, 79], ["effect", "OBSERVATION_MODIFIER", 80, 86], ["sizes", "OBSERVATION_MODIFIER", 87, 92]]], ["Subjects volunteered to participate during their university welcome week and did not receive any incentives.", [["Subjects", "ORGANISM", 0, 8]]], ["In contrast to Experiment 1, we did not preregister any exclusion criteria, but planned to stratify results based on individuals\u2019 attention.Materials and procedure ::: Method ::: Experiment 2The forewarning was implemented within the scenario.", [["procedure", "TREATMENT", 154, 163]]], ["The participants imagined to be users of an online media centre that broadcasted the TV discussion.", [["participants", "SPECIES", 4, 16]]], ["The control group read a neutral text about data protection for online users who access a media centre (Supplementary Method) while the experimental group read an explanatory text about false balance in media reports (Figure 1).Measures ::: Method ::: Experiment 2In addition to the measures in Experiment 1 (Table 1, Supplementary Table 1), participants indicated their confidence in the fictitious vaccination before and after the TV discussion.", [["participants", "SPECIES", 342, 354], ["a media centre (Supplementary Method", "TREATMENT", 88, 124]]], ["Confidence assesses one\u2019s beliefs in vaccination\u2019s safety and efficacy, as well as perceived trustworthiness of the institutions that deliver them (Betsch et al., 2018).", [["Confidence assesses", "TEST", 0, 19]]], ["As an additional attention check, we asked participants in an open format about the number of advocates and deniers who were present during the discussion (Supplementary Table 1).Results ::: Experiment 2Seventy-seven percent of the full sample was female, with a mean age of 19.96 (SDage = 2.26) for all participants.", [["participants", "SPECIES", 43, 55], ["participants", "SPECIES", 304, 316], ["an additional attention check", "TEST", 3, 32], ["SDage", "TEST", 282, 287]]], ["Thus, we repeated the primary analyses with a sample containing only those participants who recalled the correct information, with differences in the full sample reported below.", [["participants", "SPECIES", 75, 87]]], ["No evidence of differences existed between conditions in prior attitudes, intention to get vaccinated or confidence (all ps \u2265 .084 in 2 \u00d7 2 \u00d7 2 ANOVAs).Results ::: Experiment 2Tables 2, 3, 4 and Figure 3 present the results of the 2 \u00d7 2 \u00d7 2 \u00d7 2 repeated-measures ANOVA models for individuals\u2019 attitudes, confidence and intention.", [["all ps", "TEST", 117, 123], ["evidence of", "UNCERTAINTY", 3, 14], ["differences", "OBSERVATION", 15, 26]]], ["Replicating the results from Experiment 1, watching the public debate significantly damaged individuals\u2019 attitudes towards vaccination, including intention to get vaccinated and confidence in vaccination.", [["vaccination", "TREATMENT", 123, 134]]], ["However, the rebuttal mitigated this damage on all outcome measures, again indicating successful manipulation.Results ::: Experiment 2Contrary to the findings in Experiment 1 and contradicting the rebuttal-as-moderator hypothesis, no evidence existed that a higher proportion of advocates present in the debate mitigated deniers\u2019 influence on individuals\u2019 attitude towards vaccination: F(1, 382) = 0.27, p = .605, \u03b72p = .001; intention to get vaccinated: F(1, 382) = 0.15, p = .703, \u03b72p < .001 or confidence: F(1, 382) = 1.35, p = .246, \u03b72p = .004, not even when analysed as a function of whether or not a rebuttal was delivered (Tables 2, 3, 4).", [["p", "TEST", 404, 405], ["\u03b72p", "TEST", 414, 417], ["p", "TEST", 473, 474], ["confidence", "TEST", 497, 507], ["p", "TEST", 527, 528], ["2p", "TEST", 538, 540], ["successful", "OBSERVATION_MODIFIER", 86, 96], ["manipulation", "OBSERVATION", 97, 109], ["no evidence existed", "UNCERTAINTY", 231, 250]]], ["However, analyses revealed promising results on the forewarning hypothesis.", [["analyses", "TEST", 9, 17], ["the forewarning hypothesis", "PROBLEM", 48, 74]]], ["A consistent mitigating effect was found when the audience was forewarned about false balance prior to the discussion compared with the control condition on all outcome measures, that is, attitude: F(1, 382) = 7.52, p = .006, \u03b72p = .019; intention: F(1, 382) = 14.75, p < .001, \u03b72p = .037; confidence: F(1, 382) = 10.44, p = .001, \u03b72p = .027.Results ::: Experiment 2Confirmatory analyses were repeated with preregistered control variables (Supplementary Tables 5\u20136 and 8) and with a reduced sample containing only participants who provided correct answers to all three questions of the attention check (Supplementary Table 9\u201311), obtaining the same patterns of results.Results ::: Experiment 2Further exploration of the ANOVA models revealed no evidence that forewarning\u2019s efficacy was a function of whether or not a rebuttal was delivered (Tables 2, 3, 4; Figure 3).", [["participants", "SPECIES", 514, 526], ["false balance", "PROBLEM", 80, 93], ["p", "TEST", 216, 217], ["p", "TEST", 268, 269], ["confidence", "TEST", 290, 300], ["p", "TEST", 321, 322], ["2p", "TEST", 332, 334], ["Experiment 2Confirmatory analyses", "TEST", 354, 387], ["the ANOVA models", "TEST", 716, 732], ["no evidence", "UNCERTAINTY", 742, 753]]], ["We also found no evidence of a moderating effect from individuals\u2019 issue involvement on the efficacy of any of the two weight-of-evidence strategies (Supplementary Table 7).Discussion ::: Experiment 2As in Experiment 1, we again found no evidence that outnumbering increases the audience\u2019s resistance to science denialism.", [["no evidence of", "UNCERTAINTY", 14, 28], ["no evidence", "UNCERTAINTY", 235, 246]]], ["Moreover, we aimed to replicate findings from Experiment 2 regarding the forewarning hypothesis.Participants and design ::: Method ::: Experiment 3A-priori power analyses using G*Power (Faul et al., 2009) revealed a minimum sample size of N = 368 to detect an interaction effect (minimum effect size of interest of d = 0.20) with a power of .80 in a mixed within-between ANOVA (eight groups, two measurements, \u03b1 = .05).", [["Participants", "SPECIES", 96, 108], ["the forewarning hypothesis", "PROBLEM", 69, 95], ["an interaction effect", "PROBLEM", 257, 278]]], ["The effect size of the power analysis was chosen to detect conventionally small effect sizes (J. Cohen, 1977).", [["the power analysis", "TEST", 19, 37], ["effect", "OBSERVATION_MODIFIER", 4, 10], ["size", "OBSERVATION_MODIFIER", 11, 15], ["small", "OBSERVATION_MODIFIER", 74, 79], ["effect", "OBSERVATION_MODIFIER", 80, 86], ["sizes", "OBSERVATION_MODIFIER", 87, 92]]], ["Due to a technical error, 13 students could not enter demographic data.", [["demographic data", "TEST", 54, 70]]], ["The study design was identical to that of Experiment 2.", [["The study", "TEST", 0, 9]]], ["Again, we did not preregister any exclusion criteria, but stratified results based on individuals\u2019 attention.Materials and procedure ::: Method ::: Experiment 3The number of advocates and deniers was equal to the number of speakers (Figure 1), that is, they served as multiple sources rather than a mere social cue.", [["procedure", "TREATMENT", 123, 132]]], ["Thus, the total number of arguments remained constant across experiments.", [["total", "OBSERVATION_MODIFIER", 10, 15], ["number", "OBSERVATION_MODIFIER", 16, 22], ["constant", "OBSERVATION_MODIFIER", 45, 53]]], ["The forewarning used in this experiment was identical to the forewarning used in Experiment 2.Measures ::: Method ::: Experiment 3All measures were identical to Experiment 2 (Table 1, Supplementary Table 1).Results ::: Experiment 3Sixty-seven percent of the sample was female, with a mean age of 22.96 years (SDage = 4.72) for all participants.", [["participants", "SPECIES", 331, 343], ["SDage", "TEST", 309, 314]]], ["Thus, we again repeated the primary analyses with a reduced sample and reported differences to the full sample.", [["a reduced sample", "PROBLEM", 50, 66]]], ["No evidence existed of differences between conditions in prior intentions to get vaccinated or prior confidence in vaccination, all ps \u2265 .160 in 2 \u00d7 2 \u00d7 2 ANOVA.", [["vaccination", "TREATMENT", 115, 126]]], ["However, a difference did exist between conditions in individuals\u2019 prior attitudes towards vaccination, as revealed through a significant three-way interaction, F(7, 388) = 4.08, p = .044, \u03b72p = .010, in the 2 \u00d7 2 \u00d7 2 ANOVA (all other ps \u2265 .198).", [["vaccination", "TREATMENT", 91, 102], ["p", "TEST", 179, 180], ["2p", "TEST", 190, 192], ["ANOVA", "TEST", 218, 223], ["all other ps", "TEST", 225, 237], ["significant", "OBSERVATION_MODIFIER", 126, 137]]], ["To increase the findings\u2019 robustness, the primary analysis of individuals\u2019 attitudes was repeated using postvalues at T2, controlled for values at T1, rather than difference scores.", [["the primary analysis", "TEST", 38, 58]]], ["Again, attitudes, intention and confidence were damaged after watching the public discussion and the rebuttal mitigated this damage, confirming a successful manipulation.Results ::: Experiment 3Even with all advocates speaking, we again found no evidence for the outnumbering hypothesis, nor for the rebuttal-as-moderator hypothesis: A higher proportion of advocates did not mitigate the denier\u2019s influence on individuals\u2019 attitudes towards vaccination: F(1, 388) = 2.10, p = .148, \u03b72p = .005; intention to get vaccinated: F(1, 388) = 2.44, p = .119, \u03b72p = .006, or confidence: F(1, 388) = 0.81, p = .369, \u03b72p = .002, not even when analysed as a function of rebuttal (Tables 2, 3, 4).", [["this damage", "PROBLEM", 120, 131], ["a successful manipulation", "TREATMENT", 144, 169], ["the outnumbering hypothesis", "PROBLEM", 259, 286], ["p", "TEST", 472, 473], ["p", "TEST", 541, 542], ["2p", "TEST", 552, 554], ["confidence", "TEST", 566, 576], ["p", "TEST", 596, 597], ["no evidence for", "UNCERTAINTY", 243, 258]]], ["Again, we found confirming evidence for the forewarning hypothesis, as damage from denialism was reduced in the audience that was forewarned about false balance compared with the control group, intention: F(1, 388) = 6.92, p = .009, \u03b72p = .018; confidence: F(1, 388) = 8.76, p = .003, \u03b72p = .022.", [["denialism", "DISEASE", 83, 92], ["the forewarning hypothesis", "PROBLEM", 40, 66], ["damage from denialism", "PROBLEM", 71, 92], ["false balance", "PROBLEM", 147, 160], ["p", "TEST", 223, 224], ["confidence", "TEST", 245, 255], ["p", "TEST", 275, 276], ["2p", "TEST", 286, 288], ["confirming evidence for", "UNCERTAINTY", 16, 39]]], ["This trend also was observed for individuals\u2019 attitudes; however, the benefit from using forewarning remained not significant for this outcome, F(1, 388) = 1.11, p = .293, \u03b72p = .003.Results ::: Experiment 3Confirmatory analyses were repeated with preregistered control variables (Supplementary Tables 5 and 6 and 8) and a sample adjusted for failing attention (Supplementary Tables 9\u201311).", [["p", "TEST", 162, 163], ["Experiment 3Confirmatory analyses", "TEST", 195, 228]]], ["The patterns of results did not differ.Results ::: Experiment 3We found no evidence that forewarning\u2019s efficacy was a function of whether a rebuttal was delivered (Tables 2, 3, 4) or a function of individuals\u2019 issue involvement (Supplementary Table 7).", [["no evidence", "UNCERTAINTY", 72, 83]]], ["We found individuals\u2019 issue involvement to be a significant moderator of the efficacy of outnumbering on individuals\u2019 attitudes towards vaccination.", [["vaccination", "TREATMENT", 136, 147]]], ["Less issue involvement led to greater damage from deniers when science advocates outnumbered deniers, while this damaging trend was reversed in the falsely balanced discussion (Supplementary Figure 2).", [["deniers", "DISEASE", 93, 100], ["greater damage", "PROBLEM", 30, 44]]], ["In addition, we found no evidence of a moderation effect on individuals\u2019 confidence in vaccination or intention to get vaccinated (Supplementary Table 7).Results ::: Experiment 3In the preregistration, we also planned to analyse whether the effects from forewarning and rebuttal were mediated by the denier\u2019s perceived expertise.", [["a moderation effect", "PROBLEM", 37, 56], ["vaccination", "TREATMENT", 87, 98], ["no evidence of", "UNCERTAINTY", 22, 36]]], ["However, we accidentally did not ensure causal ordering because perceived expertise was measured after the dependent variables.", [["the dependent variables", "PROBLEM", 103, 126]]], ["We thus refrain from conducting this analysis.Discussion ::: Experiment 3Again, the forewarning mitigated the damage from vaccine denialism messages on the audience\u2019s specific attitudinal beliefs, that is, vaccination safety and trust in institutions.", [["this analysis", "TEST", 32, 45], ["the damage", "PROBLEM", 106, 116]]], ["Thus, forewarnings proved to be a helpful weight-of-evidence strategy against misinformation.", [["weight", "TEST", 42, 48]]], ["As a limitation, and contrary to Experiment 2, we found no significant mitigating effect from forewarnings on the damage to the audience\u2019s general attitudes towards vaccination.", [["significant mitigating effect", "PROBLEM", 59, 88], ["vaccination", "TREATMENT", 165, 176], ["no", "UNCERTAINTY", 56, 58], ["significant", "OBSERVATION_MODIFIER", 59, 70], ["mitigating", "OBSERVATION", 71, 81]]], ["Despite our efforts to increase the persuasive strength of adding more advocates via the multiple-source mechanism, we again found no evidence that outnumbering mitigates science denialism damage from public discussions.Limitations ::: General DiscussionThis study has several limitations.", [["denialism damage", "DISEASE", 179, 195], ["science denialism damage", "PROBLEM", 171, 195], ["This study", "TEST", 254, 264], ["no evidence", "UNCERTAINTY", 131, 142]]], ["First, consistent with other survey experiments of this kind (Nyhan et al. 2019, Barrera et al. 2020), the findings on the efficacy of the forewarning may be influenced by a demand effect.", [["a demand effect", "PROBLEM", 172, 187], ["consistent with", "UNCERTAINTY", 7, 22]]], ["This has implications for the internal and external validity.", [["the internal and external validity", "PROBLEM", 26, 60], ["internal", "ANATOMY_MODIFIER", 30, 38], ["external", "OBSERVATION_MODIFIER", 43, 51], ["validity", "OBSERVATION", 52, 60]]], ["Recent research indicates that demand effects are rather rare in survey experiments; thus, we assume that the threat of the internal validity is rather low (Mummolo and Peterson, 2019).", [["demand effects", "PROBLEM", 31, 45], ["internal", "ANATOMY_MODIFIER", 124, 132], ["low", "OBSERVATION_MODIFIER", 152, 155]]], ["The efficacy of forewarnings may be a function of the participants\u2019 perceived authority of the user of these strategies, which remains subject to further investigation.", [["participants", "SPECIES", 54, 66], ["further investigation", "TEST", 146, 167]]], ["Second, we used a student sample which was both a strength and a limitation.", [["a student sample", "TEST", 16, 32]]], ["On the one hand, selecting student samples was a strong test for the hypothesis that messages of science denial damage the intention to get vaccinated and damage the attitude towards vaccination as student samples are considered more educated than average and therefore more resistant to misinformation (Walter & Murphy, 2018).", [["a strong test", "TEST", 47, 60], ["vaccination", "TREATMENT", 183, 194], ["student samples", "TEST", 198, 213]]], ["On the other hand, the selection of student samples limits the generalisability of results.", [["student samples", "TEST", 36, 51]]], ["Previous online experiments with heterogeneous samples in Germany and the U.S. report similar patterns of results (Schmid & Betsch, 2019) regarding science deniers\u2019 influence and the efficacy of rebuttal messages.", [["heterogeneous", "OBSERVATION_MODIFIER", 33, 46]]], ["However, the outlined weight-of-evidence strategies in this study have not been tested with other samples, that is, the findings may vary with different audiences.", [["the outlined weight", "TEST", 9, 28], ["this study", "TEST", 55, 65]]], ["For example, forewarning about the false-balance effect might be less effective among less-educated audiences compared with highly educated undergraduates.", [["false", "OBSERVATION", 35, 40]]], ["Future studies will address this question.", [["Future studies", "TEST", 0, 14]]], ["The choice to use these fictitious scenarios in studies about vaccination decisions in this study and previous publications (Schmid & Betsch, 2019) is primarily based on ethical considerations.", [["vaccination decisions", "TREATMENT", 62, 83], ["this study", "TEST", 87, 97]]], ["However, this choice may reduce the presented findings\u2019 external validity.ConclusionGiven the results, editors, journalists and other mass media outlets should invest some effort in providing forewarnings as an effective weight-of-evidence strategy.", [["other mass media outlets", "TREATMENT", 128, 152], ["an effective weight", "TEST", 208, 227], ["external validity", "OBSERVATION", 56, 73]]], ["Therefore, we suggest that warning audiences about false-balance reporting prior to debates can serve as a theory-driven, economic and effective weight-of-evidence strategy to support advocates for science in public discussions about scientific topics.", [["weight", "TEST", 145, 151]]], ["To increase the generalisability of the findings, future studies will benefit from analysing the efficacy of weight-of-evidence strategies as a function of varying sample characteristics and participants\u2019 perceived authority of the user of these strategies.Data Accessibility StatementThe materials, data and syntax supporting the findings of this study are archived in the Open Science Framework\u2019s public database and are available to anyone: https://doi.org/10.17605/OSF.IO/SEFQU.", [["participants", "SPECIES", 191, 203], ["future studies", "TEST", 50, 64], ["weight", "TEST", 109, 115], ["these strategies", "TREATMENT", 240, 256], ["this study", "TEST", 343, 353]]]], "d7d59fd39ef8706dbfb424697d0177d9b2a7ef4e": [["We read with interest the paper by Li et al. (1) , which evaluated the prognostic value of speckle-tracking echocardiography derived right ventricular longitudinal strain (RVLS) in 120 hospitalized patients with coronavirus disease 2019 .", [["right ventricular", "ANATOMY", 133, 150], ["coronavirus disease", "DISEASE", 212, 231], ["right ventricular", "MULTI-TISSUE_STRUCTURE", 133, 150], ["patients", "ORGANISM", 198, 206], ["patients", "SPECIES", 198, 206], ["speckle", "TEST", 91, 98], ["tracking echocardiography", "TEST", 99, 124], ["right ventricular longitudinal strain", "PROBLEM", 133, 170], ["coronavirus disease", "PROBLEM", 212, 231], ["right ventricular", "ANATOMY", 133, 150], ["coronavirus disease", "OBSERVATION", 212, 231]]], ["The authors confirmed that impaired RVLS was associated with the mortality, but three key issues deserve further consideration.", [["impaired RVLS", "DISEASE", 27, 40], ["impaired RVLS", "PROBLEM", 27, 40], ["impaired", "OBSERVATION", 27, 35]]]], "ae4ea23d2ef2a0af8fcba290d9dec4c0950096bf": [["Witnessing an outbreak of necrotizing enterocolitis first-hand convinced one of us that this illness must have an infectious aetiology.", [["necrotizing enterocolitis", "DISEASE", 26, 51], ["necrotizing enterocolitis", "PROBLEM", 26, 51], ["an infectious aetiology", "PROBLEM", 111, 134], ["outbreak", "OBSERVATION_MODIFIER", 14, 22], ["necrotizing", "OBSERVATION_MODIFIER", 26, 37], ["enterocolitis", "OBSERVATION", 38, 51], ["infectious", "OBSERVATION", 114, 124]]], ["Despite strong indirect epidemiological evidence for such an aetiology, the search for a specific microbial cause has been frustrating.Direct evidence for a microbial aetiology for necrotizing enterocolitisMany species of micro-organisms have been isolated from infants with necrotizing enterocolitis; some of these are listed in Table 1 was responsible for a related disease, 'pig-bel', and the subsequent prevention of this disease by immunization with ~-toxoid, helped to stimulate the search for Clostridia in necrotizing enterocolitis.", [["necrotizing enterocolitis", "DISEASE", 181, 206], ["necrotizing enterocolitis", "DISEASE", 275, 300], ["Clostridia", "CHEMICAL", 500, 510], ["necrotizing enterocolitis", "DISEASE", 514, 539], ["infants", "ORGANISM", 262, 269], ["pig", "ORGANISM", 378, 381], ["infants", "SPECIES", 262, 269], ["pig", "SPECIES", 378, 381], ["pig", "SPECIES", 378, 381], ["necrotizing enterocolitis", "PROBLEM", 181, 206], ["Many species of micro-organisms", "PROBLEM", 206, 237], ["necrotizing enterocolitis", "PROBLEM", 275, 300], ["a related disease", "PROBLEM", 358, 375], ["this disease", "PROBLEM", 421, 433], ["immunization", "TREATMENT", 437, 449], ["~-toxoid", "TREATMENT", 455, 463], ["Clostridia in necrotizing enterocolitis", "PROBLEM", 500, 539], ["evidence for", "UNCERTAINTY", 142, 154], ["necrotizing", "OBSERVATION_MODIFIER", 181, 192], ["enterocolitis", "OBSERVATION", 193, 206], ["necrotizing", "OBSERVATION_MODIFIER", 275, 286], ["enterocolitis", "OBSERVATION", 287, 300], ["disease", "OBSERVATION", 368, 375], ["necrotizing", "OBSERVATION_MODIFIER", 514, 525], ["enterocolitis", "OBSERVATION", 526, 539]]], ["Darmbrand, a necrotizing enterocolitis occurring in adults in post-Second World War Germany was found to have the same aetiology.", [["necrotizing enterocolitis", "DISEASE", 13, 38], ["a necrotizing enterocolitis", "PROBLEM", 11, 38], ["necrotizing", "OBSERVATION_MODIFIER", 13, 24], ["enterocolitis", "OBSERVATION", 25, 38]]], ["Gram-negative Bacterial colonization, mucosal integrity, host resistance, and necrotizing enterocolitisBacterial overgrowthThe intestinal flora of low-birth-weight infants differs from that of healthy, full term infants.", [["Bacterial", "ANATOMY", 14, 23], ["mucosal", "ANATOMY", 38, 45], ["intestinal flora", "ANATOMY", 127, 143], ["necrotizing enterocolitis", "DISEASE", 78, 103], ["mucosal", "MULTI-TISSUE_STRUCTURE", 38, 45], ["intestinal flora", "PATHOLOGICAL_FORMATION", 127, 143], ["infants", "ORGANISM", 164, 171], ["infants", "ORGANISM", 212, 219], ["infants", "SPECIES", 164, 171], ["infants", "SPECIES", 212, 219], ["Gram-negative Bacterial colonization", "PROBLEM", 0, 36], ["mucosal integrity", "PROBLEM", 38, 55], ["host resistance", "PROBLEM", 57, 72], ["necrotizing enterocolitis", "PROBLEM", 78, 103], ["Bacterial overgrowth", "PROBLEM", 103, 123], ["Bacterial colonization", "OBSERVATION", 14, 36], ["mucosal integrity", "OBSERVATION", 38, 55], ["host resistance", "OBSERVATION", 57, 72], ["necrotizing", "OBSERVATION_MODIFIER", 78, 89], ["enterocolitis", "OBSERVATION", 90, 103], ["Bacterial overgrowth", "OBSERVATION", 103, 123], ["intestinal", "ANATOMY", 127, 137], ["flora", "OBSERVATION", 138, 143]]], ["The establishment of bowel flora in new-born infants receiving intensive care is a protracted process, with a limited number of strains being present initially [4] , Overgrowth of the intestinal tract with Klebddla species has been suggested as a risk factor for necrotizing enterocolitis [5] .", [["bowel flora", "ANATOMY", 21, 32], ["intestinal tract", "ANATOMY", 184, 200], ["Overgrowth of the intestinal tract", "DISEASE", 166, 200], ["necrotizing enterocolitis", "DISEASE", 263, 288], ["bowel flora", "PATHOLOGICAL_FORMATION", 21, 32], ["infants", "ORGANISM", 45, 52], ["intestinal tract", "ORGAN", 184, 200], ["infants", "SPECIES", 45, 52], ["bowel flora", "PROBLEM", 21, 32], ["intensive care", "TREATMENT", 63, 77], ["a protracted process", "PROBLEM", 81, 101], ["strains", "PROBLEM", 128, 135], ["Overgrowth of the intestinal tract", "PROBLEM", 166, 200], ["Klebddla species", "PROBLEM", 206, 222], ["necrotizing enterocolitis", "PROBLEM", 263, 288], ["bowel", "ANATOMY", 21, 26], ["flora", "OBSERVATION", 27, 32], ["intestinal tract", "ANATOMY", 184, 200], ["necrotizing", "OBSERVATION_MODIFIER", 263, 274], ["enterocolitis", "OBSERVATION", 275, 288]]], ["There are many factors present in preterm infants which might predispose to bacterial overgrowth of the small intestine, some of which are listed in Table 2 .Gastric acid productionGastric acid production has been described as markedly decreased in the first month of life [6] .", [["small intestine", "ANATOMY", 104, 119], ["Gastric", "ANATOMY", 158, 165], ["Gastric", "ANATOMY", 181, 188], ["infants", "ORGANISM", 42, 49], ["small intestine", "ORGAN", 104, 119], ["Gastric acid", "SIMPLE_CHEMICAL", 158, 170], ["Gastric acid", "SIMPLE_CHEMICAL", 181, 193], ["infants", "SPECIES", 42, 49], ["bacterial overgrowth of the small intestine", "PROBLEM", 76, 119], ["Gastric acid production", "PROBLEM", 158, 181], ["Gastric acid production", "PROBLEM", 181, 204], ["many", "OBSERVATION_MODIFIER", 10, 14], ["factors", "OBSERVATION", 15, 22], ["bacterial", "OBSERVATION_MODIFIER", 76, 85], ["overgrowth", "OBSERVATION", 86, 96], ["small intestine", "ANATOMY", 104, 119], ["acid", "OBSERVATION_MODIFIER", 166, 170], ["Gastric", "ANATOMY", 181, 188], ["acid production", "OBSERVATION", 189, 204], ["markedly", "OBSERVATION_MODIFIER", 227, 235], ["decreased", "OBSERVATION_MODIFIER", 236, 245]]], ["Although preterm babies can produce an acid intra-gastric pH, overgrowth of the stomach with bacteria in such babies is a frequent occurrence (B. Patel and S. P. Devane, unpublished observations) and may predispose to the development of an abnormal intestinal flora.Immature gastro-intestinal motilityThe cleansing effect of normal gastro-intestinal motility is a further defensive mechanism against colonization of the small intestine by bacteria and the damaging effects of the by-products of fermentation of malabsorbed nutrients by bacteria; antro-duodenal motility is immature in preterm infants [7] .Pancreatic insufficiencyIn an analogous situation to pig-bel in which pancreatic insufficiency leads to decreased intraluminal destruction of ]3-toxin, pancreatic insufficiency has also been described in low-birth-weight babies who developed necrotizing enterocolitis [8] .Pancreatic insufficiencyPancreatic insufficiency was measured indirectly by faecal chymotrypsin activities.Impaired mucus productionIntestinal mucus provides non-specific protection to the intestine, by binding bacteria and bacterial toxins.", [["stomach", "ANATOMY", 80, 87], ["intestinal flora", "ANATOMY", 249, 265], ["gastro-intestinal", "ANATOMY", 275, 292], ["gastro-intestinal", "ANATOMY", 332, 349], ["small intestine", "ANATOMY", 420, 435], ["antro-duodenal", "ANATOMY", 546, 560], ["Pancreatic", "ANATOMY", 606, 616], ["pancreatic", "ANATOMY", 676, 686], ["intraluminal", "ANATOMY", 720, 732], ["pancreatic", "ANATOMY", 758, 768], ["Pancreatic", "ANATOMY", 879, 889], ["Pancreatic", "ANATOMY", 903, 913], ["mucus", "ANATOMY", 995, 1000], ["Intestinal mucus", "ANATOMY", 1011, 1027], ["intestine", "ANATOMY", 1068, 1077], ["overgrowth of the stomach", "DISEASE", 62, 87], ["abnormal intestinal flora", "DISEASE", 240, 265], ["Pancreatic insufficiency", "DISEASE", 606, 630], ["pancreatic insufficiency", "DISEASE", 676, 700], ["pancreatic insufficiency", "DISEASE", 758, 782], ["necrotizing enterocolitis", "DISEASE", 848, 873], ["Pancreatic insufficiency", "DISEASE", 879, 903], ["Pancreatic insufficiency", "DISEASE", 903, 927], ["babies", "ORGANISM", 17, 23], ["stomach", "ORGAN", 80, 87], ["intestinal flora", "PATHOLOGICAL_FORMATION", 249, 265], ["intestinal", "ORGAN", 282, 292], ["intestinal", "ORGAN", 339, 349], ["small intestine", "ORGAN", 420, 435], ["Pancreatic", "ORGAN", 606, 616], ["pig", "ORGANISM", 659, 662], ["pancreatic", "ORGAN", 676, 686], ["intraluminal", "IMMATERIAL_ANATOMICAL_ENTITY", 720, 732], ["]3-toxin", "SIMPLE_CHEMICAL", 748, 756], ["pancreatic", "ORGAN", 758, 768], ["babies", "ORGANISM", 827, 833], ["Pancreatic", "ORGAN", 879, 889], ["Pancreatic", "ORGAN", 903, 913], ["faecal", "ORGANISM_SUBSTANCE", 955, 961], ["chymotrypsin", "GENE_OR_GENE_PRODUCT", 962, 974], ["mucus", "MULTI-TISSUE_STRUCTURE", 995, 1000], ["Intestinal mucus", "MULTI-TISSUE_STRUCTURE", 1011, 1027], ["intestine", "ORGAN", 1068, 1077], ["chymotrypsin", "PROTEIN", 962, 974], ["infants", "SPECIES", 593, 600], ["pig", "SPECIES", 659, 662], ["pig", "SPECIES", 659, 662], ["preterm babies", "PROBLEM", 9, 23], ["an acid intra-gastric pH", "PROBLEM", 36, 60], ["overgrowth of the stomach", "PROBLEM", 62, 87], ["bacteria", "PROBLEM", 93, 101], ["an abnormal intestinal flora", "PROBLEM", 237, 265], ["Immature gastro", "PROBLEM", 266, 281], ["intestinal motility", "PROBLEM", 282, 301], ["The cleansing effect", "TREATMENT", 301, 321], ["colonization of the small intestine", "PROBLEM", 400, 435], ["bacteria", "PROBLEM", 439, 447], ["malabsorbed nutrients", "PROBLEM", 511, 532], ["bacteria", "PROBLEM", 536, 544], ["Pancreatic insufficiency", "PROBLEM", 606, 630], ["pig-bel", "TREATMENT", 659, 666], ["pancreatic insufficiency", "PROBLEM", 676, 700], ["decreased intraluminal destruction of ]3-toxin", "PROBLEM", 710, 756], ["pancreatic insufficiency", "PROBLEM", 758, 782], ["necrotizing enterocolitis", "PROBLEM", 848, 873], ["Pancreatic insufficiency", "PROBLEM", 879, 903], ["Pancreatic insufficiency", "PROBLEM", 903, 927], ["faecal chymotrypsin activities", "TREATMENT", 955, 985], ["Impaired mucus production", "PROBLEM", 986, 1011], ["non-specific protection to the intestine", "PROBLEM", 1037, 1077], ["binding bacteria", "PROBLEM", 1082, 1098], ["bacterial toxins", "PROBLEM", 1103, 1119], ["overgrowth", "OBSERVATION", 62, 72], ["stomach", "ANATOMY", 80, 87], ["bacteria", "OBSERVATION", 93, 101], ["abnormal", "OBSERVATION_MODIFIER", 240, 248], ["intestinal", "ANATOMY", 249, 259], ["flora", "OBSERVATION", 260, 265], ["gastro", "ANATOMY", 275, 281], ["intestinal", "ANATOMY", 282, 292], ["motility", "OBSERVATION", 293, 301], ["normal", "OBSERVATION_MODIFIER", 325, 331], ["gastro", "ANATOMY", 332, 338], ["intestinal motility", "OBSERVATION_MODIFIER", 339, 358], ["small intestine", "ANATOMY", 420, 435], ["bacteria", "OBSERVATION", 439, 447], ["insufficiency", "OBSERVATION", 617, 630], ["pancreatic", "ANATOMY", 676, 686], ["insufficiency", "OBSERVATION", 687, 700], ["decreased", "OBSERVATION_MODIFIER", 710, 719], ["intraluminal", "OBSERVATION_MODIFIER", 720, 732], ["destruction", "OBSERVATION", 733, 744], ["pancreatic", "ANATOMY", 758, 768], ["insufficiency", "OBSERVATION", 769, 782], ["necrotizing", "OBSERVATION_MODIFIER", 848, 859], ["enterocolitis", "OBSERVATION", 860, 873], ["insufficiency", "OBSERVATION", 890, 903], ["insufficiency", "OBSERVATION", 914, 927], ["faecal chymotrypsin", "OBSERVATION", 955, 974], ["mucus", "OBSERVATION", 995, 1000], ["Intestinal", "ANATOMY", 1011, 1021], ["mucus", "OBSERVATION", 1022, 1027], ["intestine", "ANATOMY", 1068, 1077], ["bacterial toxins", "OBSERVATION", 1103, 1119]]], ["This protective mechanism is poorly developed in the new-born mouse [9] due to defective mucus production; the same may also apply to human infants.Glutamine deficiencyAdequate intake of glutamine is important for the integrity of the small bowel mucosa and immune function [10] .", [["mucus", "ANATOMY", 89, 94], ["small bowel mucosa", "ANATOMY", 235, 253], ["Glutamine", "CHEMICAL", 148, 157], ["glutamine", "CHEMICAL", 187, 196], ["Glutamine", "CHEMICAL", 148, 157], ["glutamine", "CHEMICAL", 187, 196], ["mouse", "ORGANISM", 62, 67], ["mucus", "MULTI-TISSUE_STRUCTURE", 89, 94], ["human", "ORGANISM", 134, 139], ["infants", "ORGANISM", 140, 147], ["Glutamine", "AMINO_ACID", 148, 157], ["glutamine", "AMINO_ACID", 187, 196], ["bowel mucosa", "MULTI-TISSUE_STRUCTURE", 241, 253], ["mouse", "SPECIES", 62, 67], ["human", "SPECIES", 134, 139], ["infants", "SPECIES", 140, 147], ["mouse", "SPECIES", 62, 67], ["human", "SPECIES", 134, 139], ["defective mucus production", "PROBLEM", 79, 105], ["Glutamine deficiency", "PROBLEM", 148, 168], ["glutamine", "TREATMENT", 187, 196], ["poorly", "OBSERVATION_MODIFIER", 29, 35], ["mucus production", "OBSERVATION", 89, 105], ["deficiency", "OBSERVATION", 158, 168], ["small", "OBSERVATION_MODIFIER", 235, 240], ["bowel mucosa", "ANATOMY", 241, 253]]], ["Glutamine deficiency could occur in preterm babies on parenteral nutrition, or receiving artificial diets.Decreased concentrations of short chain fatty acids in the colonic lumenDecreased concentrations of short chain fatty acids in the colonic lumen could also decrease integrity of the colonic mucosa [11] .", [["parenteral", "ANATOMY", 54, 64], ["colonic", "ANATOMY", 165, 172], ["colonic lumen", "ANATOMY", 237, 250], ["colonic mucosa", "ANATOMY", 288, 302], ["Glutamine", "CHEMICAL", 0, 9], ["fatty acids", "CHEMICAL", 146, 157], ["fatty acids", "CHEMICAL", 218, 229], ["Glutamine", "CHEMICAL", 0, 9], ["short chain fatty acids", "CHEMICAL", 134, 157], ["short chain fatty acids", "CHEMICAL", 206, 229], ["Glutamine", "AMINO_ACID", 0, 9], ["parenteral", "ORGANISM_SUBDIVISION", 54, 64], ["colonic", "ORGAN", 165, 172], ["fatty acids", "AMINO_ACID", 218, 229], ["colonic lumen", "MULTI-TISSUE_STRUCTURE", 237, 250], ["colonic mucosa", "MULTI-TISSUE_STRUCTURE", 288, 302], ["Glutamine deficiency", "PROBLEM", 0, 20], ["parenteral nutrition", "TREATMENT", 54, 74], ["artificial diets", "TREATMENT", 89, 105], ["Decreased concentrations of short chain fatty acids", "PROBLEM", 106, 157], ["short chain fatty acids in the colonic lumen", "PROBLEM", 206, 250], ["deficiency", "OBSERVATION", 10, 20], ["concentrations", "OBSERVATION_MODIFIER", 116, 130], ["short chain", "OBSERVATION_MODIFIER", 134, 145], ["fatty acids", "OBSERVATION", 146, 157], ["colonic", "ANATOMY", 165, 172], ["lumenDecreased", "OBSERVATION_MODIFIER", 173, 187], ["concentrations", "OBSERVATION_MODIFIER", 188, 202], ["short chain", "OBSERVATION_MODIFIER", 206, 217], ["fatty acids", "OBSERVATION", 218, 229], ["colonic", "ANATOMY", 237, 244], ["lumen", "ANATOMY_MODIFIER", 245, 250], ["decrease", "OBSERVATION_MODIFIER", 262, 270], ["integrity", "OBSERVATION_MODIFIER", 271, 280], ["colonic mucosa", "ANATOMY", 288, 302]]], ["The delayed establishment of a normal flora in preterm infants receiving intensive care [4] could lead to deficiency of short chain fatty acids in the colonic lumen.", [["colonic lumen", "ANATOMY", 151, 164], ["fatty acids", "CHEMICAL", 132, 143], ["short chain fatty acids", "CHEMICAL", 120, 143], ["short chain fatty acids", "SIMPLE_CHEMICAL", 120, 143], ["colonic lumen", "MULTI-TISSUE_STRUCTURE", 151, 164], ["infants", "SPECIES", 55, 62], ["intensive care", "TREATMENT", 73, 87], ["deficiency of short chain fatty acids in the colonic lumen", "PROBLEM", 106, 164], ["flora", "OBSERVATION_MODIFIER", 38, 43], ["short chain", "OBSERVATION_MODIFIER", 120, 131], ["fatty acids", "OBSERVATION", 132, 143], ["colonic", "ANATOMY", 151, 158], ["lumen", "ANATOMY_MODIFIER", 159, 164]]], ["Interaction of this and other factors impairing the barrier function of the gastrointestinal mucosa could explain the frequent isolation of enteric micro-organisms from blood cultures of infants with necrotizing enterocolitis.", [["gastrointestinal mucosa", "ANATOMY", 76, 99], ["blood cultures", "ANATOMY", 169, 183], ["necrotizing enterocolitis", "DISEASE", 200, 225], ["gastrointestinal mucosa", "MULTI-TISSUE_STRUCTURE", 76, 99], ["blood", "ORGANISM_SUBSTANCE", 169, 174], ["infants", "ORGANISM", 187, 194], ["infants", "SPECIES", 187, 194], ["enteric micro-organisms", "PROBLEM", 140, 163], ["blood cultures", "TEST", 169, 183], ["necrotizing enterocolitis", "PROBLEM", 200, 225], ["gastrointestinal mucosa", "ANATOMY", 76, 99], ["enteric micro-organisms", "OBSERVATION", 140, 163], ["necrotizing", "OBSERVATION_MODIFIER", 200, 211], ["enterocolitis", "OBSERVATION", 212, 225]]], ["The balance is a fine one, because the by-products of fermentation of malabsorbed nutrients by bacteria can damage the intestinal mucosa. must contribute to the parlous state of these patients and add to the endotoxaemia to which they are exposed.Protective effect of human milkBreast milk has been shown to contain specific cellular and antibody activity against a variety of bacterial, viral and food-related antigens.", [["intestinal mucosa", "ANATOMY", 119, 136], ["milkBreast milk", "ANATOMY", 274, 289], ["cellular", "ANATOMY", 325, 333], ["endotoxaemia", "DISEASE", 208, 220], ["intestinal mucosa", "MULTI-TISSUE_STRUCTURE", 119, 136], ["patients", "ORGANISM", 184, 192], ["human", "ORGANISM", 268, 273], ["milkBreast milk", "ORGANISM", 274, 289], ["cellular", "CELL", 325, 333], ["patients", "SPECIES", 184, 192], ["human", "SPECIES", 268, 273], ["milk", "SPECIES", 285, 289], ["human", "SPECIES", 268, 273], ["malabsorbed nutrients", "PROBLEM", 70, 91], ["bacteria", "PROBLEM", 95, 103], ["the endotoxaemia", "PROBLEM", 204, 220], ["human milkBreast milk", "TREATMENT", 268, 289], ["bacterial, viral and food-related antigens", "PROBLEM", 377, 419], ["balance", "OBSERVATION", 4, 11], ["intestinal mucosa", "ANATOMY", 119, 136], ["endotoxaemia", "OBSERVATION", 208, 220]]], ["Furthermore, it protects against necrotizing enterocolitis [16] .Gastrointestinal immune defencesBoth cellular and immunological defence mechanisms are immature in infancy.", [["Gastrointestinal", "ANATOMY", 65, 81], ["cellular", "ANATOMY", 102, 110], ["necrotizing enterocolitis", "DISEASE", 33, 58], ["cellular", "CELL", 102, 110], ["necrotizing enterocolitis", "PROBLEM", 33, 58], ["Gastrointestinal immune defences", "PROBLEM", 65, 97], ["necrotizing", "OBSERVATION_MODIFIER", 33, 44], ["enterocolitis", "OBSERVATION", 45, 58], ["immature", "OBSERVATION_MODIFIER", 152, 160]]], ["Intraepithelial B lymphocytes are decreased [12] .", [["Intraepithelial B lymphocytes", "ANATOMY", 0, 29], ["Intraepithelial B lymphocytes", "CELL", 0, 29], ["Intraepithelial B lymphocytes", "CELL_TYPE", 0, 29], ["Intraepithelial B lymphocytes", "TEST", 0, 29], ["lymphocytes", "OBSERVATION", 18, 29], ["decreased", "OBSERVATION_MODIFIER", 34, 43]]], ["Secretory IgA production is virtually non-existent in new-borns [13] .", [["IgA", "GENE_OR_GENE_PRODUCT", 10, 13], ["IgA", "PROTEIN", 10, 13], ["Secretory IgA production", "PROBLEM", 0, 24], ["IgA production", "OBSERVATION", 10, 24]]], ["T lymphocytes are decreased in the intestinal mucosa of new-born animals [14] .", [["T lymphocytes", "ANATOMY", 0, 13], ["intestinal mucosa", "ANATOMY", 35, 52], ["T lymphocytes", "CELL", 0, 13], ["intestinal mucosa", "MULTI-TISSUE_STRUCTURE", 35, 52], ["T lymphocytes", "CELL_TYPE", 0, 13], ["T lymphocytes", "PROBLEM", 0, 13], ["lymphocytes", "OBSERVATION", 2, 13], ["decreased", "OBSERVATION_MODIFIER", 18, 27], ["intestinal mucosa", "ANATOMY", 35, 52], ["new", "OBSERVATION_MODIFIER", 56, 59]]], ["They are important in monitoring the integrity of the mucosa and may destroy cells colonized with an infecting agent.Epidemiology of necrotizing enterocolitisThe strongest indirect evidence for a microbial aetiology arises from the epidemiology of the disease [15] .", [["mucosa", "ANATOMY", 54, 60], ["cells", "ANATOMY", 77, 82], ["necrotizing enterocolitis", "DISEASE", 133, 158], ["mucosa", "MULTI-TISSUE_STRUCTURE", 54, 60], ["cells", "CELL", 77, 82], ["an infecting agent", "TREATMENT", 98, 116], ["necrotizing enterocolitis", "PROBLEM", 133, 158], ["a microbial aetiology", "PROBLEM", 194, 215], ["the disease", "PROBLEM", 248, 259], ["mucosa", "ANATOMY", 54, 60], ["necrotizing", "OBSERVATION_MODIFIER", 133, 144], ["enterocolitis", "OBSERVATION", 145, 158]]], ["Within the six units, 24 of the 56 cases were diagnosed within 3-11 days of each other.Epidemiology of necrotizing enterocolitisThe clinical features of this group were indistinguishable from sporadic cases.Blood culturesOne in three affected neonates have been reported to have a positive blood culture.", [["Blood cultures", "ANATOMY", 207, 221], ["blood", "ANATOMY", 290, 295], ["necrotizing enterocolitis", "DISEASE", 103, 128], ["Blood", "ORGANISM_SUBSTANCE", 207, 212], ["neonates", "ORGANISM", 243, 251], ["blood", "ORGANISM_SUBSTANCE", 290, 295], ["necrotizing enterocolitis", "PROBLEM", 103, 128], ["Blood cultures", "TEST", 207, 221], ["a positive blood culture", "PROBLEM", 279, 303], ["necrotizing", "OBSERVATION_MODIFIER", 103, 114], ["enterocolitis", "OBSERVATION", 115, 128]]], ["The organisms isolated are unlikely to be causal and probably translocated from the bowel lumen through a damaged mucosa.", [["bowel lumen", "ANATOMY", 84, 95], ["mucosa", "ANATOMY", 114, 120], ["bowel lumen", "MULTI-TISSUE_STRUCTURE", 84, 95], ["mucosa", "MULTI-TISSUE_STRUCTURE", 114, 120], ["The organisms", "PROBLEM", 0, 13], ["a damaged mucosa", "PROBLEM", 104, 120], ["unlikely to be", "UNCERTAINTY", 27, 41], ["bowel", "ANATOMY", 84, 89], ["lumen", "ANATOMY_MODIFIER", 90, 95], ["damaged mucosa", "OBSERVATION", 106, 120]]], ["Nevertheless, such organismsProtective effect of oral antibioticsOral vancomycin has been administered to lowbirth-weight infants identified as having a high risk of developing necrotizing enterocolitis prior to the introduction of oral feeds.", [["oral", "ANATOMY", 49, 53], ["Oral", "ANATOMY", 65, 69], ["oral", "ANATOMY", 232, 236], ["vancomycin", "CHEMICAL", 70, 80], ["necrotizing enterocolitis", "DISEASE", 177, 202], ["vancomycin", "CHEMICAL", 70, 80], ["oral", "ORGANISM_SUBDIVISION", 49, 53], ["Oral", "ORGANISM_SUBDIVISION", 65, 69], ["vancomycin", "SIMPLE_CHEMICAL", 70, 80], ["infants", "ORGANISM", 122, 129], ["oral", "ORGANISM_SUBDIVISION", 232, 236], ["infants", "SPECIES", 122, 129], ["such organisms", "PROBLEM", 14, 28], ["oral antibiotics", "TREATMENT", 49, 65], ["Oral vancomycin", "TREATMENT", 65, 80], ["developing necrotizing enterocolitis", "PROBLEM", 166, 202], ["oral feeds", "TREATMENT", 232, 242], ["vancomycin", "OBSERVATION", 70, 80], ["necrotizing", "OBSERVATION_MODIFIER", 177, 188], ["enterocolitis", "OBSERVATION", 189, 202]]], ["Necrotizing enterocolitis developed in 1 of 84 infants, compared with 17 of 120 low risk infants not given vancomycin.", [["Necrotizing enterocolitis", "DISEASE", 0, 25], ["vancomycin", "CHEMICAL", 107, 117], ["vancomycin", "CHEMICAL", 107, 117], ["infants", "ORGANISM", 47, 54], ["infants", "ORGANISM", 89, 96], ["vancomycin", "SIMPLE_CHEMICAL", 107, 117], ["infants", "SPECIES", 47, 54], ["infants", "SPECIES", 89, 96], ["Necrotizing enterocolitis", "PROBLEM", 0, 25], ["vancomycin", "TREATMENT", 107, 117], ["enterocolitis", "OBSERVATION", 12, 25]]], ["While the trial was not double-blind or randomized, this study [19] suggests that vancomycin could have a prophylactic role.Raised breath hydrogenBreath hydrogen concentrations have been studied prospectively in 122 preterm infants as a potential aid to earlier diagnosis [20] .", [["vancomycin", "CHEMICAL", 82, 92], ["hydrogenBreath hydrogen", "CHEMICAL", 138, 161], ["vancomycin", "CHEMICAL", 82, 92], ["hydrogen", "CHEMICAL", 153, 161], ["vancomycin", "SIMPLE_CHEMICAL", 82, 92], ["infants", "ORGANISM", 224, 231], ["infants", "SPECIES", 224, 231], ["this study", "TEST", 52, 62], ["vancomycin", "TREATMENT", 82, 92], ["Raised breath hydrogenBreath hydrogen concentrations", "PROBLEM", 124, 176]]], ["Maximum elevation of breath hydrogen occurred in infants 8-20 hours prior to the onset of necrotizing enterocolitis.", [["hydrogen", "CHEMICAL", 28, 36], ["necrotizing enterocolitis", "DISEASE", 90, 115], ["hydrogen", "CHEMICAL", 28, 36], ["infants", "SPECIES", 49, 56], ["Maximum elevation of breath hydrogen", "PROBLEM", 0, 36], ["necrotizing enterocolitis", "PROBLEM", 90, 115], ["elevation", "OBSERVATION_MODIFIER", 8, 17], ["breath hydrogen", "OBSERVATION", 21, 36], ["necrotizing", "OBSERVATION_MODIFIER", 90, 101], ["enterocolitis", "OBSERVATION", 102, 115]]], ["The presence of elevated breath hydrogen concentrations indicates that bacteria are metabolizing luminal substrates.D-lactic acidosisD-lactate, a product of bacterial metabolism, is found in the urine of infants with necrotizing enterocolitis [21] .Exposure of Thomsen-cryptantigen on RBCNine of 26 infants with necrotizing enterocolitis had exposure of the Thomsen-cryptantigen (T-antigen) with the titre of the antigen correlating with severity.", [["luminal", "ANATOMY", 97, 104], ["urine", "ANATOMY", 195, 200], ["hydrogen", "CHEMICAL", 32, 40], ["luminal", "CHEMICAL", 97, 104], ["D-lactic acidosisD", "CHEMICAL", 116, 134], ["lactate", "CHEMICAL", 135, 142], ["necrotizing enterocolitis", "DISEASE", 217, 242], ["necrotizing enterocolitis", "DISEASE", 312, 337], ["hydrogen", "CHEMICAL", 32, 40], ["D-lactic acidosisD-lactate", "CHEMICAL", 116, 142], ["luminal", "IMMATERIAL_ANATOMICAL_ENTITY", 97, 104], ["D-lactic acidosisD-lactate", "SIMPLE_CHEMICAL", 116, 142], ["urine", "ORGANISM_SUBSTANCE", 195, 200], ["infants", "ORGANISM", 204, 211], ["Thomsen-cryptantigen", "ORGANISM", 261, 281], ["RBCNine", "ORGANISM", 285, 292], ["infants", "ORGANISM", 299, 306], ["T-antigen", "GENE_OR_GENE_PRODUCT", 380, 389], ["Thomsen-cryptantigen (T-antigen", "PROTEIN", 358, 389], ["infants", "SPECIES", 204, 211], ["infants", "SPECIES", 299, 306], ["elevated breath hydrogen concentrations", "PROBLEM", 16, 55], ["bacteria", "PROBLEM", 71, 79], ["metabolizing luminal substrates", "PROBLEM", 84, 115], ["D-lactic acidosisD", "PROBLEM", 116, 134], ["lactate", "TEST", 135, 142], ["bacterial metabolism", "PROBLEM", 157, 177], ["necrotizing enterocolitis", "PROBLEM", 217, 242], ["necrotizing enterocolitis", "PROBLEM", 312, 337], ["the Thomsen", "TEST", 354, 365], ["elevated", "OBSERVATION_MODIFIER", 16, 24], ["breath hydrogen concentrations", "OBSERVATION", 25, 55], ["bacteria", "OBSERVATION_MODIFIER", 71, 79], ["luminal substrates", "OBSERVATION", 97, 115], ["lactic acidosisD", "OBSERVATION", 118, 134], ["bacterial metabolism", "OBSERVATION", 157, 177], ["necrotizing", "OBSERVATION_MODIFIER", 217, 228], ["enterocolitis", "OBSERVATION", 229, 242], ["necrotizing", "OBSERVATION_MODIFIER", 312, 323], ["enterocolitis", "OBSERVATION", 324, 337]]], ["The T-antigen is exposed by cleavage of N-acetylneuramic acid from the red cell surface; neuraminidase is produced by CI. perfringens, CI. butyricum and Bacteriodes fragilis.", [["red cell surface", "ANATOMY", 71, 87], ["N-acetylneuramic acid", "CHEMICAL", 40, 61], ["perfringens", "DISEASE", 122, 133], ["N-acetylneuramic acid", "CHEMICAL", 40, 61], ["T-antigen", "GENE_OR_GENE_PRODUCT", 4, 13], ["N-acetylneuramic acid", "SIMPLE_CHEMICAL", 40, 61], ["red cell surface", "CELLULAR_COMPONENT", 71, 87], ["neuraminidase", "GENE_OR_GENE_PRODUCT", 89, 102], ["perfringens", "ORGANISM", 122, 133], ["butyricum", "ORGANISM", 139, 148], ["Bacteriodes fragilis", "ORGANISM", 153, 173], ["T-antigen", "PROTEIN", 4, 13], ["neuraminidase", "PROTEIN", 89, 102], ["perfringens", "SPECIES", 122, 133], ["butyricum", "SPECIES", 139, 148], ["Bacteriodes fragilis", "SPECIES", 153, 173], ["perfringens", "SPECIES", 122, 133], ["butyricum", "SPECIES", 139, 148], ["Bacteriodes fragilis", "SPECIES", 153, 173], ["N-acetylneuramic acid", "PROBLEM", 40, 61], ["neuraminidase", "PROBLEM", 89, 102], ["perfringens", "PROBLEM", 122, 133], ["CI", "TEST", 135, 137], ["butyricum", "PROBLEM", 139, 148], ["Bacteriodes fragilis", "PROBLEM", 153, 173], ["red cell", "OBSERVATION", 71, 79], ["surface", "OBSERVATION_MODIFIER", 80, 87], ["Bacteriodes fragilis", "OBSERVATION", 153, 173]]], ["This finding is indirect evidence for the presence of circulating bacterial neuraminidase, and neuraminidase-producing Clostridia were isolated from two patients.Animal modelsNecrotizing enterocolitis can be induced in neonatal rats colonized with Klebsiella sp. and subjected to hypoxia or cold stress which reduce mesenteric blood flow [22] .", [["mesenteric blood", "ANATOMY", 316, 332], ["Necrotizing enterocolitis", "DISEASE", 175, 200], ["hypoxia", "DISEASE", 280, 287], ["neuraminidase", "GENE_OR_GENE_PRODUCT", 76, 89], ["neuraminidase", "GENE_OR_GENE_PRODUCT", 95, 108], ["patients", "ORGANISM", 153, 161], ["rats", "ORGANISM", 228, 232], ["Klebsiella sp", "ORGANISM", 248, 261], ["mesenteric", "MULTI-TISSUE_STRUCTURE", 316, 326], ["blood", "ORGANISM_SUBSTANCE", 327, 332], ["circulating bacterial neuraminidase", "PROTEIN", 54, 89], ["neuraminidase", "PROTEIN", 95, 108], ["patients", "SPECIES", 153, 161], ["rats", "SPECIES", 228, 232], ["circulating bacterial neuraminidase", "PROBLEM", 54, 89], ["neuraminidase", "PROBLEM", 95, 108], ["Clostridia", "PROBLEM", 119, 129], ["Animal modelsNecrotizing enterocolitis", "PROBLEM", 162, 200], ["Klebsiella sp", "PROBLEM", 248, 261], ["hypoxia", "PROBLEM", 280, 287], ["cold stress", "PROBLEM", 291, 302], ["mesenteric blood flow", "TEST", 316, 337], ["indirect evidence for", "UNCERTAINTY", 16, 37], ["circulating", "OBSERVATION_MODIFIER", 54, 65], ["bacterial neuraminidase", "OBSERVATION", 66, 89], ["Necrotizing", "OBSERVATION_MODIFIER", 175, 186], ["enterocolitis", "OBSERVATION", 187, 200], ["Klebsiella", "OBSERVATION", 248, 258], ["hypoxia", "OBSERVATION", 280, 287], ["mesenteric", "ANATOMY", 316, 326]]], ["Breast milk has been shown to be protective.", [["Breast milk", "ANATOMY", 0, 11], ["Breast milk", "ORGANISM_SUBSTANCE", 0, 11], ["milk", "SPECIES", 7, 11], ["milk", "OBSERVATION", 7, 11]]], ["Necrotizing enterocolitis has been induced in infant rats by injecting platelet activating factor (PAF) into the splanchnic circulation [23].", [["splanchnic", "ANATOMY", 113, 123], ["Necrotizing enterocolitis", "DISEASE", 0, 25], ["rats", "ORGANISM", 53, 57], ["platelet activating factor", "GENE_OR_GENE_PRODUCT", 71, 97], ["PAF", "GENE_OR_GENE_PRODUCT", 99, 102], ["platelet activating factor", "PROTEIN", 71, 97], ["PAF", "PROTEIN", 99, 102], ["infant", "SPECIES", 46, 52], ["rats", "SPECIES", 53, 57], ["Necrotizing enterocolitis", "PROBLEM", 0, 25], ["PAF", "PROBLEM", 99, 102], ["enterocolitis", "OBSERVATION", 12, 25], ["splanchnic", "ANATOMY", 113, 123]]], ["Platelet activating factor is a phospholipid secreted in response to injection of endotoxin (lipopolysaccharide component of gram negative bacterial cell wall).", [["cell wall", "ANATOMY", 149, 158], ["endotoxin", "CHEMICAL", 82, 91], ["lipopolysaccharide", "CHEMICAL", 93, 111], ["Platelet activating factor", "GENE_OR_GENE_PRODUCT", 0, 26], ["phospholipid", "SIMPLE_CHEMICAL", 32, 44], ["endotoxin", "SIMPLE_CHEMICAL", 82, 91], ["lipopolysaccharide", "SIMPLE_CHEMICAL", 93, 111], ["cell wall", "MULTI-TISSUE_STRUCTURE", 149, 158], ["Platelet activating factor", "PROTEIN", 0, 26], ["endotoxin", "PROTEIN", 82, 91], ["Platelet activating factor", "PROBLEM", 0, 26], ["a phospholipid secreted", "PROBLEM", 30, 53], ["endotoxin (lipopolysaccharide component", "TREATMENT", 82, 121], ["gram negative bacterial cell wall)", "PROBLEM", 125, 159], ["bacterial cell wall", "OBSERVATION", 139, 158]]], ["Platelet activating factor may induce intestinal necrosis by release of the vasoconstrictor leukotriene C 4 [24] .", [["intestinal", "ANATOMY", 38, 48], ["necrosis", "DISEASE", 49, 57], ["leukotriene C 4 [24]", "CHEMICAL", 92, 112], ["leukotriene C", "CHEMICAL", 92, 105], ["Platelet activating factor", "GENE_OR_GENE_PRODUCT", 0, 26], ["intestinal", "ORGAN", 38, 48], ["Platelet activating factor", "PROTEIN", 0, 26], ["Platelet activating factor", "PROBLEM", 0, 26], ["intestinal necrosis", "PROBLEM", 38, 57], ["the vasoconstrictor leukotriene C", "TREATMENT", 72, 105], ["intestinal", "ANATOMY", 38, 48], ["necrosis", "OBSERVATION", 49, 57]]], ["When mesenteric blood flow is re-established the stage is set for reperfusion injury which can be prevented by free-radical scavengers such as superoxide dismutase, catalase or the xanthine oxidase inhibitor, allopurinol [25] .Histological changes in necrotizing enterocolitisVarious authors have cited the presence of inflammatory changes in necrotizing enterocolitis as evidence for an infective aetiology while others have emphasized that the appearances support an ischaemic aetiology.", [["mesenteric blood", "ANATOMY", 5, 21], ["superoxide", "CHEMICAL", 143, 153], ["xanthine", "CHEMICAL", 181, 189], ["allopurinol", "CHEMICAL", 209, 220], ["necrotizing enterocolitis", "DISEASE", 251, 276], ["necrotizing enterocolitis", "DISEASE", 343, 368], ["superoxide", "CHEMICAL", 143, 153], ["xanthine", "CHEMICAL", 181, 189], ["allopurinol", "CHEMICAL", 209, 220], ["mesenteric blood", "MULTI-TISSUE_STRUCTURE", 5, 21], ["free-radical scavengers", "SIMPLE_CHEMICAL", 111, 134], ["superoxide dismutase", "SIMPLE_CHEMICAL", 143, 163], ["catalase", "SIMPLE_CHEMICAL", 165, 173], ["xanthine oxidase", "GENE_OR_GENE_PRODUCT", 181, 197], ["allopurinol", "SIMPLE_CHEMICAL", 209, 220], ["superoxide dismutase", "PROTEIN", 143, 163], ["catalase", "PROTEIN", 165, 173], ["xanthine oxidase", "PROTEIN", 181, 197], ["mesenteric blood flow", "TEST", 5, 26], ["reperfusion injury", "PROBLEM", 66, 84], ["free-radical scavengers", "TREATMENT", 111, 134], ["superoxide dismutase", "TREATMENT", 143, 163], ["catalase", "TREATMENT", 165, 173], ["the xanthine oxidase inhibitor", "TREATMENT", 177, 207], ["allopurinol", "TREATMENT", 209, 220], ["Histological changes", "PROBLEM", 227, 247], ["necrotizing enterocolitis", "PROBLEM", 251, 276], ["inflammatory changes", "PROBLEM", 319, 339], ["necrotizing enterocolitis", "PROBLEM", 343, 368], ["an infective aetiology", "PROBLEM", 385, 407], ["an ischaemic aetiology", "PROBLEM", 466, 488], ["mesenteric", "ANATOMY", 5, 15], ["necrotizing", "OBSERVATION_MODIFIER", 251, 262], ["enterocolitis", "OBSERVATION", 263, 276], ["inflammatory", "OBSERVATION_MODIFIER", 319, 331], ["necrotizing", "OBSERVATION_MODIFIER", 343, 354], ["enterocolitis", "OBSERVATION", 355, 368], ["evidence for", "UNCERTAINTY", 372, 384], ["infective", "OBSERVATION", 388, 397], ["ischaemic", "OBSERVATION_MODIFIER", 469, 478]]], ["In a systematic review of 84 patients from Cleveland, Ohio in which histological changes were correlated with clinical findings, ischaemic changes (tissue necrosis with loss of cellular detail but preservation of overall structure) were confirmed in 75 patients of whom 5 had mesenteric artery thromboses [25] .", [["tissue", "ANATOMY", 148, 154], ["cellular", "ANATOMY", 177, 185], ["mesenteric artery", "ANATOMY", 276, 293], ["necrosis", "DISEASE", 155, 163], ["mesenteric artery thromboses", "DISEASE", 276, 304], ["patients", "ORGANISM", 29, 37], ["tissue", "TISSUE", 148, 154], ["cellular", "CELL", 177, 185], ["patients", "ORGANISM", 253, 261], ["mesenteric artery", "MULTI-TISSUE_STRUCTURE", 276, 293], ["patients", "SPECIES", 29, 37], ["patients", "SPECIES", 253, 261], ["ischaemic changes (tissue necrosis", "PROBLEM", 129, 163], ["loss of cellular detail", "PROBLEM", 169, 192], ["mesenteric artery thromboses", "PROBLEM", 276, 304], ["ischaemic", "OBSERVATION_MODIFIER", 129, 138], ["tissue", "OBSERVATION_MODIFIER", 148, 154], ["necrosis", "OBSERVATION", 155, 163], ["mesenteric artery", "ANATOMY", 276, 293], ["thromboses", "OBSERVATION", 294, 304]]], ["Acute (neutrophils) or chronic (lymphocytes, plasma cells and histiocytes) inflammation was seen in 50 andBacterial toxins and necrotizing enterocolitisBacterial toxins are capable of inducing a lesion resembling necrotizing enterocolitis.", [["neutrophils", "ANATOMY", 7, 18], ["lymphocytes", "ANATOMY", 32, 43], ["plasma cells", "ANATOMY", 45, 57], ["histiocytes", "ANATOMY", 62, 73], ["lesion", "ANATOMY", 195, 201], ["inflammation", "DISEASE", 75, 87], ["necrotizing enterocolitis", "DISEASE", 127, 152], ["necrotizing enterocolitis", "DISEASE", 213, 238], ["neutrophils", "CELL", 7, 18], ["lymphocytes", "CELL", 32, 43], ["plasma cells", "CELL", 45, 57], ["histiocytes", "CELL", 62, 73], ["neutrophils", "CELL_TYPE", 7, 18], ["lymphocytes", "CELL_TYPE", 32, 43], ["plasma cells", "CELL_TYPE", 45, 57], ["Acute (neutrophils)", "PROBLEM", 0, 19], ["chronic (lymphocytes, plasma cells", "PROBLEM", 23, 57], ["histiocytes) inflammation", "PROBLEM", 62, 87], ["Bacterial toxins", "PROBLEM", 106, 122], ["necrotizing enterocolitisBacterial toxins", "PROBLEM", 127, 168], ["a lesion", "PROBLEM", 193, 201], ["necrotizing enterocolitis", "PROBLEM", 213, 238], ["neutrophils", "ANATOMY", 7, 18], ["chronic", "OBSERVATION_MODIFIER", 23, 30], ["lymphocytes", "ANATOMY", 32, 43], ["necrotizing", "OBSERVATION_MODIFIER", 127, 138], ["enterocolitis", "OBSERVATION", 139, 152], ["lesion", "OBSERVATION", 195, 201], ["necrotizing", "OBSERVATION_MODIFIER", 213, 224], ["enterocolitis", "OBSERVATION", 225, 238]]], ["Bacterial toxins previously implicated in necrotizing enterocolitis are listed in Table 3 .", [["necrotizing enterocolitis", "DISEASE", 42, 67], ["Bacterial toxins", "PROBLEM", 0, 16], ["necrotizing enterocolitis", "PROBLEM", 42, 67], ["necrotizing", "OBSERVATION_MODIFIER", 42, 53], ["enterocolitis", "OBSERVATION", 54, 67]]], ["Toxin A, produced by Clostridium difficile induced necrosis of intestinal mucosa in vivo and in vitro [27] the in vitro data indicating that a direct effect on the mucosa was responsible, rather than an effect on mucosal blood supply.", [["intestinal mucosa", "ANATOMY", 63, 80], ["mucosa", "ANATOMY", 164, 170], ["mucosal", "ANATOMY", 213, 220], ["blood", "ANATOMY", 221, 226], ["Toxin A", "CHEMICAL", 0, 7], ["Clostridium difficile", "DISEASE", 21, 42], ["necrosis", "DISEASE", 51, 59], ["Toxin A", "GENE_OR_GENE_PRODUCT", 0, 7], ["Clostridium difficile", "ORGANISM", 21, 42], ["intestinal mucosa", "MULTI-TISSUE_STRUCTURE", 63, 80], ["mucosa", "MULTI-TISSUE_STRUCTURE", 164, 170], ["mucosal blood", "ORGANISM_SUBSTANCE", 213, 226], ["Clostridium difficile", "SPECIES", 21, 42], ["Clostridium difficile", "SPECIES", 21, 42], ["Toxin A", "TEST", 0, 7], ["Clostridium difficile induced necrosis of intestinal mucosa", "PROBLEM", 21, 80], ["the in vitro data", "TEST", 107, 124], ["a direct effect on the mucosa", "PROBLEM", 141, 170], ["mucosal blood supply", "TREATMENT", 213, 233], ["necrosis", "OBSERVATION", 51, 59], ["intestinal mucosa", "ANATOMY", 63, 80], ["mucosa", "ANATOMY", 164, 170]]], ["The species has been implicated in necrotizing enterocolitis but is ubiquitous in healthy neonates [28] .", [["necrotizing enterocolitis", "DISEASE", 35, 60], ["necrotizing enterocolitis", "PROBLEM", 35, 60], ["necrotizing", "OBSERVATION_MODIFIER", 35, 46], ["enterocolitis", "OBSERVATION", 47, 60]]], ["Clostridium perfringens has been isolated from necrotizing enterocolitis and ]3-toxin is involved in the analogous conditions of pig-bel.", [["Clostridium perfringens", "DISEASE", 0, 23], ["necrotizing enterocolitis", "DISEASE", 47, 72], ["Clostridium perfringens", "ORGANISM", 0, 23], ["]3-toxin", "SIMPLE_CHEMICAL", 77, 85], ["pig", "ORGANISM", 129, 132], ["Clostridium perfringens", "SPECIES", 0, 23], ["Clostridium perfringens", "SPECIES", 0, 23], ["pig", "SPECIES", 129, 132], ["Clostridium perfringens", "PROBLEM", 0, 23], ["necrotizing enterocolitis", "PROBLEM", 47, 72], ["necrotizing", "OBSERVATION_MODIFIER", 47, 58], ["enterocolitis", "OBSERVATION", 59, 72]]], ["E. coli producing heat-labile enterotoxin were associated with two clusters of necrotizing enterocolitis [29] .", [["necrotizing enterocolitis", "DISEASE", 79, 104], ["E. coli", "ORGANISM", 0, 7], ["enterotoxin", "GENE_OR_GENE_PRODUCT", 30, 41], ["enterotoxin", "PROTEIN", 30, 41], ["E. coli", "SPECIES", 0, 7], ["E. coli", "SPECIES", 0, 7], ["E. coli", "PROBLEM", 0, 7], ["labile enterotoxin", "PROBLEM", 23, 41], ["necrotizing enterocolitis", "PROBLEM", 79, 104], ["coli", "OBSERVATION", 3, 7], ["labile enterotoxin", "OBSERVATION_MODIFIER", 23, 41], ["clusters", "OBSERVATION_MODIFIER", 67, 75], ["necrotizing", "OBSERVATION_MODIFIER", 79, 90], ["enterocolitis", "OBSERVATION", 91, 104]]], ["Scheifele's group has suggested that Staphylococcus epidermidis, which commonly colonize low-birth-weight infants including those with necrotizing enterocolitis produces a cell-damaging toxin resembling the delta toxin of Staphylococcus aureus.", [["cell", "ANATOMY", 172, 176], ["Staphylococcus epidermidis", "DISEASE", 37, 63], ["necrotizing enterocolitis", "DISEASE", 135, 160], ["Staphylococcus aureus", "DISEASE", 222, 243], ["Staphylococcus epidermidis", "ORGANISM", 37, 63], ["infants", "ORGANISM", 106, 113], ["cell", "CELL", 172, 176], ["delta toxin", "ORGANISM", 207, 218], ["Staphylococcus aureus", "ORGANISM", 222, 243], ["cell-damaging toxin", "PROTEIN", 172, 191], ["delta toxin", "PROTEIN", 207, 218], ["Staphylococcus epidermidis", "SPECIES", 37, 63], ["infants", "SPECIES", 106, 113], ["Staphylococcus aureus", "SPECIES", 222, 243], ["Staphylococcus epidermidis", "SPECIES", 37, 63], ["Staphylococcus aureus", "SPECIES", 222, 243], ["Staphylococcus epidermidis", "PROBLEM", 37, 63], ["necrotizing enterocolitis", "PROBLEM", 135, 160], ["damaging toxin", "PROBLEM", 177, 191], ["Staphylococcus aureus", "PROBLEM", 222, 243], ["Staphylococcus epidermidis", "OBSERVATION", 37, 63], ["necrotizing", "OBSERVATION_MODIFIER", 135, 146], ["enterocolitis", "OBSERVATION", 147, 160], ["Staphylococcus aureus", "OBSERVATION", 222, 243]]], ["The cytotoxin can induce severe mucosal necrosis in rat intestinal loops [30] .", [["mucosal", "ANATOMY", 32, 39], ["intestinal", "ANATOMY", 56, 66], ["necrosis", "DISEASE", 40, 48], ["mucosal", "PATHOLOGICAL_FORMATION", 32, 39], ["rat", "ORGANISM", 52, 55], ["intestinal", "ORGAN", 56, 66], ["cytotoxin", "PROTEIN", 4, 13], ["rat", "SPECIES", 52, 55], ["rat", "SPECIES", 52, 55], ["The cytotoxin", "TREATMENT", 0, 13], ["severe mucosal necrosis in rat intestinal loops", "PROBLEM", 25, 72], ["severe", "OBSERVATION_MODIFIER", 25, 31], ["mucosal", "ANATOMY_MODIFIER", 32, 39], ["necrosis", "OBSERVATION", 40, 48], ["intestinal loops", "ANATOMY", 56, 72]]], ["They suggest that hypertoxigenic strains may be responsible for necrotizing enterocolitis.", [["necrotizing enterocolitis", "DISEASE", 64, 89], ["hypertoxigenic strains", "PROBLEM", 18, 40], ["necrotizing enterocolitis", "PROBLEM", 64, 89], ["may be responsible for", "UNCERTAINTY", 41, 63], ["necrotizing", "OBSERVATION_MODIFIER", 64, 75], ["enterocolitis", "OBSERVATION", 76, 89]]], ["The effects of intestinal infections on mucosal blood supply have not been studied in detail, yet if such effects occur they could explain the link between mucosal infection and ischaemia.", [["intestinal", "ANATOMY", 15, 25], ["mucosal", "ANATOMY", 40, 47], ["blood", "ANATOMY", 48, 53], ["mucosal", "ANATOMY", 156, 163], ["intestinal infections", "DISEASE", 15, 36], ["mucosal infection", "DISEASE", 156, 173], ["ischaemia", "DISEASE", 178, 187], ["intestinal", "ORGAN", 15, 25], ["mucosal blood", "MULTI-TISSUE_STRUCTURE", 40, 53], ["mucosal", "MULTI-TISSUE_STRUCTURE", 156, 163], ["intestinal infections", "PROBLEM", 15, 36], ["mucosal blood supply", "TREATMENT", 40, 60], ["mucosal infection", "PROBLEM", 156, 173], ["ischaemia", "PROBLEM", 178, 187], ["intestinal", "ANATOMY", 15, 25], ["infections", "OBSERVATION", 26, 36], ["mucosal", "ANATOMY", 156, 163], ["infection", "OBSERVATION", 164, 173], ["ischaemia", "OBSERVATION", 178, 187]]], ["The anatomy of the microcirculation of intestinal villi of infant mice has been studied using a histochemical technique that specifically stained erythrocytes [31] .", [["intestinal villi", "ANATOMY", 39, 55], ["erythrocytes", "ANATOMY", 146, 158], ["intestinal villi", "MULTI-TISSUE_STRUCTURE", 39, 55], ["mice", "ORGANISM", 66, 70], ["erythrocytes", "CELL", 146, 158], ["infant", "SPECIES", 59, 65], ["mice", "SPECIES", 66, 70], ["mice", "SPECIES", 66, 70], ["a histochemical technique", "TEST", 94, 119], ["intestinal villi", "ANATOMY", 39, 55]]], ["Over 8-14 days there was little variation between the same region of the gut with the exception of the distal ileum which was markedly less well perfused with erythrocytes in 8 day old mice than older mice.", [["gut", "ANATOMY", 73, 76], ["distal ileum", "ANATOMY", 103, 115], ["erythrocytes", "ANATOMY", 159, 171], ["gut", "ORGANISM_SUBDIVISION", 73, 76], ["ileum", "ORGAN", 110, 115], ["erythrocytes", "CELL", 159, 171], ["mice", "ORGANISM", 185, 189], ["mice", "ORGANISM", 201, 205], ["erythrocytes", "CELL_TYPE", 159, 171], ["mice", "SPECIES", 185, 189], ["mice", "SPECIES", 201, 205], ["mice", "SPECIES", 185, 189], ["mice", "SPECIES", 201, 205], ["little variation", "PROBLEM", 25, 41], ["little", "OBSERVATION_MODIFIER", 25, 31], ["variation", "OBSERVATION_MODIFIER", 32, 41], ["gut", "ANATOMY", 73, 76], ["distal", "ANATOMY_MODIFIER", 103, 109], ["ileum", "ANATOMY", 110, 115], ["markedly", "OBSERVATION_MODIFIER", 126, 134], ["less", "OBSERVATION_MODIFIER", 135, 139]]], ["In the upper intestine, the capillary beds were more complex than in the middle and lower regions.", [["upper intestine", "ANATOMY", 7, 22], ["capillary beds", "ANATOMY", 28, 42], ["upper intestine", "ORGAN", 7, 22], ["capillary beds", "TISSUE", 28, 42], ["upper", "ANATOMY_MODIFIER", 7, 12], ["intestine", "ANATOMY", 13, 22], ["capillary beds", "ANATOMY", 28, 42], ["more", "OBSERVATION_MODIFIER", 48, 52], ["complex", "OBSERVATION", 53, 60], ["middle", "ANATOMY_MODIFIER", 73, 79], ["lower", "ANATOMY_MODIFIER", 84, 89], ["regions", "ANATOMY_MODIFIER", 90, 97]]], ["If the anatomy of the villous microcirculation is duplicated in human villi, this may contribute to the vulnerability of the distal small intestine to ischaemia.", [["villous", "ANATOMY", 22, 29], ["villi", "ANATOMY", 70, 75], ["distal small intestine", "ANATOMY", 125, 147], ["ischaemia", "DISEASE", 151, 160], ["villous microcirculation", "MULTI-TISSUE_STRUCTURE", 22, 46], ["human", "ORGANISM", 64, 69], ["villi", "MULTI-TISSUE_STRUCTURE", 70, 75], ["small intestine", "ORGAN", 132, 147], ["human", "SPECIES", 64, 69], ["human", "SPECIES", 64, 69], ["the distal small intestine", "PROBLEM", 121, 147], ["ischaemia", "PROBLEM", 151, 160], ["villous microcirculation", "OBSERVATION", 22, 46], ["human villi", "ANATOMY", 64, 75], ["distal", "ANATOMY_MODIFIER", 125, 131], ["small intestine", "ANATOMY", 132, 147], ["ischaemia", "OBSERVATION", 151, 160]]], ["Age-matched infant mice infected with rotavirus developed marked ischaemia and atrophy of the villi between 18 and 48 hours post infection [32] with preservation of the crypt microcirculation.", [["villi", "ANATOMY", 94, 99], ["crypt", "ANATOMY", 169, 174], ["rotavirus", "DISEASE", 38, 47], ["ischaemia", "DISEASE", 65, 74], ["atrophy of the villi", "DISEASE", 79, 99], ["infection", "DISEASE", 129, 138], ["infant", "ORGANISM", 12, 18], ["mice", "ORGANISM", 19, 23], ["rotavirus", "ORGANISM", 38, 47], ["villi", "MULTI-TISSUE_STRUCTURE", 94, 99], ["crypt microcirculation", "MULTI-TISSUE_STRUCTURE", 169, 191], ["infant", "SPECIES", 12, 18], ["mice", "SPECIES", 19, 23], ["mice", "SPECIES", 19, 23], ["rotavirus", "SPECIES", 38, 47], ["rotavirus", "PROBLEM", 38, 47], ["marked ischaemia", "PROBLEM", 58, 74], ["atrophy of the villi", "PROBLEM", 79, 99], ["infection", "PROBLEM", 129, 138], ["the crypt microcirculation", "PROBLEM", 165, 191], ["marked", "OBSERVATION_MODIFIER", 58, 64], ["ischaemia", "OBSERVATION", 65, 74], ["atrophy", "OBSERVATION", 79, 86], ["villi", "ANATOMY", 94, 99], ["infection", "OBSERVATION", 129, 138], ["crypt microcirculation", "OBSERVATION", 169, 191]]], ["Between 72 and 96 hours post infection, the capillaries of the small intestinal mucosa became engorged, with recovery of villous height.", [["capillaries", "ANATOMY", 44, 55], ["small intestinal mucosa", "ANATOMY", 63, 86], ["villous", "ANATOMY", 121, 128], ["infection", "DISEASE", 29, 38], ["capillaries", "TISSUE", 44, 55], ["intestinal mucosa", "MULTI-TISSUE_STRUCTURE", 69, 86], ["villous", "TISSUE", 121, 128], ["infection", "PROBLEM", 29, 38], ["engorged", "PROBLEM", 94, 102], ["infection", "OBSERVATION", 29, 38], ["capillaries", "ANATOMY_MODIFIER", 44, 55], ["small", "OBSERVATION_MODIFIER", 63, 68], ["intestinal mucosa", "ANATOMY", 69, 86], ["engorged", "OBSERVATION", 94, 102], ["villous height", "OBSERVATION", 121, 135]]], ["During this phase, the mucosa could have been subjected to a reperfusion injury.", [["mucosa", "ANATOMY", 23, 29], ["reperfusion injury", "DISEASE", 61, 79], ["mucosa", "MULTI-TISSUE_STRUCTURE", 23, 29], ["a reperfusion injury", "PROBLEM", 59, 79], ["mucosa", "ANATOMY", 23, 29], ["reperfusion", "OBSERVATION_MODIFIER", 61, 72], ["injury", "OBSERVATION", 73, 79]]], ["A second phase of villous atrophy followed between 120 and 144 hours which was less marked than the initial episode.", [["villous", "ANATOMY", 18, 25], ["villous atrophy", "DISEASE", 18, 33], ["villous", "MULTI-TISSUE_STRUCTURE", 18, 25], ["villous atrophy", "PROBLEM", 18, 33], ["second", "OBSERVATION_MODIFIER", 2, 8], ["phase", "OBSERVATION_MODIFIER", 9, 14], ["villous", "OBSERVATION_MODIFIER", 18, 25], ["atrophy", "OBSERVATION", 26, 33], ["less marked", "OBSERVATION_MODIFIER", 79, 90]]], ["The villous microcirculation recovered by I68 hours, and the diarrhoea ceased.", [["villous", "ANATOMY", 4, 11], ["diarrhoea", "DISEASE", 61, 70], ["villous microcirculation", "MULTI-TISSUE_STRUCTURE", 4, 28], ["the diarrhoea", "PROBLEM", 57, 70], ["villous microcirculation", "OBSERVATION", 4, 28], ["diarrhoea", "OBSERVATION", 61, 70]]], ["These findings could explain how rotavirus infection could initiate necrotizing enterocolitis.Impact of intestinal infections on intestinal mucosal blood supplyPerturbations of the enteric microcirculation have also been described in clinical or experimental cholera, salmonellosis, shigellosis, and acute diarrhoea.", [["intestinal", "ANATOMY", 104, 114], ["intestinal mucosal", "ANATOMY", 129, 147], ["blood", "ANATOMY", 148, 153], ["rotavirus infection", "DISEASE", 33, 52], ["necrotizing enterocolitis", "DISEASE", 68, 93], ["intestinal infections", "DISEASE", 104, 125], ["cholera", "DISEASE", 259, 266], ["salmonellosis", "DISEASE", 268, 281], ["shigellosis", "DISEASE", 283, 294], ["acute diarrhoea", "DISEASE", 300, 315], ["rotavirus", "ORGANISM", 33, 42], ["necrotizing enterocolitis", "PATHOLOGICAL_FORMATION", 68, 93], ["intestinal", "ORGAN", 104, 114], ["intestinal mucosal", "MULTI-TISSUE_STRUCTURE", 129, 147], ["blood", "ORGANISM_SUBSTANCE", 148, 153], ["enteric microcirculation", "MULTI-TISSUE_STRUCTURE", 181, 205], ["rotavirus", "SPECIES", 33, 42], ["rotavirus infection", "PROBLEM", 33, 52], ["necrotizing enterocolitis", "PROBLEM", 68, 93], ["intestinal infections", "PROBLEM", 104, 125], ["intestinal mucosal blood supplyPerturbations", "TREATMENT", 129, 173], ["salmonellosis", "PROBLEM", 268, 281], ["shigellosis", "PROBLEM", 283, 294], ["acute diarrhoea", "PROBLEM", 300, 315], ["rotavirus", "OBSERVATION_MODIFIER", 33, 42], ["infection", "OBSERVATION", 43, 52], ["necrotizing", "OBSERVATION_MODIFIER", 68, 79], ["enterocolitis", "OBSERVATION", 80, 93], ["intestinal", "ANATOMY", 104, 114], ["infections", "OBSERVATION", 115, 125], ["intestinal mucosal", "ANATOMY", 129, 147], ["enteric microcirculation", "ANATOMY", 181, 205], ["salmonellosis", "OBSERVATION", 268, 281], ["shigellosis", "OBSERVATION", 283, 294], ["acute", "OBSERVATION_MODIFIER", 300, 305], ["diarrhoea", "OBSERVATION", 306, 315]]], ["These data all provide the link between abnormal colonization and ischaemia of the intestinal mucosa.Role of endotoxaemiaEndotoxin is a component of the cell wall of Gram negative bacteria which consists of Iipopolysaccharide.", [["intestinal mucosa", "ANATOMY", 83, 100], ["cell wall", "ANATOMY", 153, 162], ["abnormal colonization", "DISEASE", 40, 61], ["ischaemia", "DISEASE", 66, 75], ["endotoxaemiaEndotoxin", "CHEMICAL", 109, 130], ["Iipopolysaccharide", "CHEMICAL", 207, 225], ["Iipopolysaccharide", "CHEMICAL", 207, 225], ["intestinal mucosa", "MULTI-TISSUE_STRUCTURE", 83, 100], ["endotoxaemiaEndotoxin", "GENE_OR_GENE_PRODUCT", 109, 130], ["cell wall", "CELLULAR_COMPONENT", 153, 162], ["Iipopolysaccharide", "SIMPLE_CHEMICAL", 207, 225], ["abnormal colonization", "PROBLEM", 40, 61], ["ischaemia of the intestinal mucosa", "PROBLEM", 66, 100], ["endotoxaemiaEndotoxin", "TREATMENT", 109, 130], ["Gram negative bacteria", "PROBLEM", 166, 188], ["Iipopolysaccharide", "TREATMENT", 207, 225], ["abnormal", "OBSERVATION_MODIFIER", 40, 48], ["colonization", "OBSERVATION", 49, 61], ["ischaemia", "OBSERVATION", 66, 75], ["intestinal mucosa", "ANATOMY", 83, 100], ["cell", "OBSERVATION", 153, 157], ["wall", "ANATOMY_MODIFIER", 158, 162], ["Gram negative bacteria", "OBSERVATION", 166, 188]]], ["Some systemic effects of endotoxin are listed in Table 4 .", [["endotoxin", "CHEMICAL", 25, 34], ["endotoxin", "SIMPLE_CHEMICAL", 25, 34], ["endotoxin", "PROTEIN", 25, 34], ["endotoxin", "TREATMENT", 25, 34], ["systemic", "OBSERVATION_MODIFIER", 5, 13], ["endotoxin", "OBSERVATION", 25, 34]]], ["Although only providing circumstantial evidence, there are clearly similarities between the signs of necrotizing enterocolitis and the effects of endotoxaemia.", [["necrotizing enterocolitis", "DISEASE", 101, 126], ["endotoxaemia", "DISEASE", 146, 158], ["necrotizing enterocolitis", "PROBLEM", 101, 126], ["endotoxaemia", "PROBLEM", 146, 158], ["necrotizing", "OBSERVATION_MODIFIER", 101, 112], ["enterocolitis", "OBSERVATION", 113, 126], ["endotoxaemia", "OBSERVATION", 146, 158]]], ["Low-birth-weight babies have been shown to experience endotoxaemia when fed [33] .", [["endotoxaemia", "DISEASE", 54, 66], ["babies", "ORGANISM", 17, 23], ["endotoxaemia", "PROBLEM", 54, 66]]], ["Endotoxaemia has variable effects on intestinal blood flow but can induce ischaemia and increased permeability of the intestinal mucosa which could predispose to absorption of more endotoxin or entry of bacteria from the lumen of the gut.Role of endotoxaemiaThe systemic effects of endotoxin are mediated by the release of proteins called cytokines from monocytes and probably endothelial cells [34] .", [["intestinal", "ANATOMY", 37, 47], ["blood", "ANATOMY", 48, 53], ["intestinal mucosa", "ANATOMY", 118, 135], ["lumen", "ANATOMY", 221, 226], ["gut", "ANATOMY", 234, 237], ["monocytes", "ANATOMY", 354, 363], ["endothelial cells", "ANATOMY", 377, 394], ["Endotoxaemia", "DISEASE", 0, 12], ["ischaemia", "DISEASE", 74, 83], ["endotoxaemia", "DISEASE", 246, 258], ["endotoxin", "CHEMICAL", 282, 291], ["intestinal", "ORGAN", 37, 47], ["blood", "ORGANISM_SUBSTANCE", 48, 53], ["intestinal mucosa", "MULTI-TISSUE_STRUCTURE", 118, 135], ["lumen", "IMMATERIAL_ANATOMICAL_ENTITY", 221, 226], ["gut", "ORGANISM_SUBDIVISION", 234, 237], ["endotoxin", "SIMPLE_CHEMICAL", 282, 291], ["monocytes", "CELL", 354, 363], ["endothelial cells", "CELL", 377, 394], ["cytokines", "PROTEIN", 339, 348], ["monocytes", "CELL_TYPE", 354, 363], ["endothelial cells", "CELL_TYPE", 377, 394], ["Endotoxaemia", "PROBLEM", 0, 12], ["intestinal blood flow", "TEST", 37, 58], ["ischaemia", "PROBLEM", 74, 83], ["increased permeability of the intestinal mucosa", "PROBLEM", 88, 135], ["bacteria", "PROBLEM", 203, 211], ["endotoxaemia", "PROBLEM", 246, 258], ["endotoxin", "PROBLEM", 282, 291], ["monocytes", "TEST", 354, 363], ["endothelial cells", "PROBLEM", 377, 394], ["intestinal blood", "ANATOMY", 37, 53], ["ischaemia", "OBSERVATION", 74, 83], ["increased", "OBSERVATION_MODIFIER", 88, 97], ["permeability", "OBSERVATION_MODIFIER", 98, 110], ["intestinal mucosa", "ANATOMY", 118, 135], ["bacteria", "OBSERVATION", 203, 211], ["lumen", "ANATOMY_MODIFIER", 221, 226], ["gut", "ANATOMY", 234, 237], ["endotoxaemia", "OBSERVATION", 246, 258], ["probably", "UNCERTAINTY", 368, 376], ["endothelial cells", "OBSERVATION", 377, 394]]], ["In low concentrations, cytokines co-ordinate essential functions such as immune responses, but higher concentrations may have adverse effects.", [["cytokines", "PROTEIN", 23, 32], ["low concentrations", "OBSERVATION_MODIFIER", 3, 21]]], ["If endotoxaemia is implicated in the pathogenesis of necrotizing enterocolitis then it is likely to be due to the effects of excessive production of cytokines, which in rum trigger the production of substances such as platelet activating factor [35] .Role of endotoxaemiaSevere shigellosis is an example of a disease of the distal bowel in which endotoxaemia is associated with mucosal and on occasion, full thickness necrosis.", [["platelet", "ANATOMY", 218, 226], ["distal bowel", "ANATOMY", 324, 336], ["mucosal", "ANATOMY", 378, 385], ["endotoxaemia", "DISEASE", 3, 15], ["necrotizing enterocolitis", "DISEASE", 53, 78], ["shigellosis", "DISEASE", 278, 289], ["endotoxaemia", "DISEASE", 346, 358], ["necrosis", "DISEASE", 418, 426], ["platelet activating factor", "GENE_OR_GENE_PRODUCT", 218, 244], ["bowel", "ORGAN", 331, 336], ["mucosal", "MULTI-TISSUE_STRUCTURE", 378, 385], ["cytokines", "PROTEIN", 149, 158], ["platelet activating factor", "PROTEIN", 218, 244], ["endotoxaemia", "PROBLEM", 3, 15], ["necrotizing enterocolitis", "PROBLEM", 53, 78], ["excessive production of cytokines", "PROBLEM", 125, 158], ["platelet activating factor", "PROBLEM", 218, 244], ["endotoxaemiaSevere shigellosis", "PROBLEM", 259, 289], ["a disease of the distal bowel", "PROBLEM", 307, 336], ["endotoxaemia", "PROBLEM", 346, 358], ["full thickness necrosis", "PROBLEM", 403, 426], ["endotoxaemia", "OBSERVATION", 3, 15], ["necrotizing", "OBSERVATION_MODIFIER", 53, 64], ["enterocolitis", "OBSERVATION", 65, 78], ["likely to be due to", "UNCERTAINTY", 90, 109], ["shigellosis", "OBSERVATION", 278, 289], ["disease", "OBSERVATION", 309, 316], ["distal", "ANATOMY_MODIFIER", 324, 330], ["bowel", "ANATOMY", 331, 336], ["endotoxaemia", "OBSERVATION", 346, 358], ["mucosal", "ANATOMY", 378, 385], ["full thickness", "OBSERVATION_MODIFIER", 403, 417], ["necrosis", "OBSERVATION", 418, 426]]], ["It may be complicated by disseminated intravascular coagulation, haemolytic uraemic syndrome and occasionally gangrene and perforation of the large bowel.", [["intravascular", "ANATOMY", 38, 51], ["bowel", "ANATOMY", 148, 153], ["intravascular coagulation", "DISEASE", 38, 63], ["haemolytic uraemic syndrome", "DISEASE", 65, 92], ["gangrene", "DISEASE", 110, 118], ["perforation of the large bowel", "DISEASE", 123, 153], ["intravascular", "IMMATERIAL_ANATOMICAL_ENTITY", 38, 51], ["bowel", "ORGAN", 148, 153], ["disseminated intravascular coagulation", "PROBLEM", 25, 63], ["haemolytic uraemic syndrome", "PROBLEM", 65, 92], ["occasionally gangrene", "PROBLEM", 97, 118], ["perforation of the large bowel", "PROBLEM", 123, 153], ["may be complicated", "UNCERTAINTY", 3, 21], ["disseminated", "OBSERVATION_MODIFIER", 25, 37], ["intravascular coagulation", "OBSERVATION", 38, 63], ["haemolytic", "OBSERVATION_MODIFIER", 65, 75], ["uraemic syndrome", "OBSERVATION", 76, 92], ["occasionally", "OBSERVATION_MODIFIER", 97, 109], ["gangrene", "OBSERVATION", 110, 118], ["perforation", "OBSERVATION", 123, 134], ["large", "ANATOMY_MODIFIER", 142, 147], ["bowel", "ANATOMY", 148, 153]]], ["Endotoxaemia induced fibrin degradation products, and deposition of fibrin in glomeruli and in rectal microvasculature have been reported in patients with uncomplicated shigellosis.", [["glomeruli", "ANATOMY", 78, 87], ["rectal microvasculature", "ANATOMY", 95, 118], ["Endotoxaemia", "DISEASE", 0, 12], ["shigellosis", "DISEASE", 169, 180], ["fibrin", "GENE_OR_GENE_PRODUCT", 21, 27], ["fibrin", "GENE_OR_GENE_PRODUCT", 68, 74], ["glomeruli", "MULTI-TISSUE_STRUCTURE", 78, 87], ["rectal microvasculature", "TISSUE", 95, 118], ["patients", "ORGANISM", 141, 149], ["fibrin degradation products", "PROTEIN", 21, 48], ["fibrin", "PROTEIN", 68, 74], ["patients", "SPECIES", 141, 149], ["Endotoxaemia", "PROBLEM", 0, 12], ["fibrin degradation products", "PROBLEM", 21, 48], ["fibrin in glomeruli and in rectal microvasculature", "PROBLEM", 68, 118], ["uncomplicated shigellosis", "PROBLEM", 155, 180], ["fibrin degradation", "OBSERVATION", 21, 39], ["deposition", "OBSERVATION_MODIFIER", 54, 64], ["fibrin", "OBSERVATION", 68, 74], ["glomeruli", "ANATOMY", 78, 87], ["rectal microvasculature", "ANATOMY", 95, 118], ["uncomplicated", "OBSERVATION_MODIFIER", 155, 168], ["shigellosis", "OBSERVATION", 169, 180]]], ["Infusion of either the cytokine tumour necrosis factor or endotoxin in rabbits produced similar pathology including disseminated intravascular coagulation with thrombocytopaenia, damage to glomeruli with leukocyte infiltration, segmental ischaemia, haemorrhage, and necrosis in the liver, bowel, adrenals, pancreas, lung and other tissues.", [["intravascular", "ANATOMY", 129, 142], ["glomeruli", "ANATOMY", 189, 198], ["leukocyte", "ANATOMY", 204, 213], ["liver", "ANATOMY", 282, 287], ["bowel", "ANATOMY", 289, 294], ["adrenals", "ANATOMY", 296, 304], ["pancreas", "ANATOMY", 306, 314], ["lung", "ANATOMY", 316, 320], ["tissues", "ANATOMY", 331, 338], ["necrosis", "DISEASE", 39, 47], ["endotoxin", "CHEMICAL", 58, 67], ["disseminated intravascular coagulation", "DISEASE", 116, 154], ["thrombocytopaenia", "DISEASE", 160, 177], ["ischaemia", "DISEASE", 238, 247], ["haemorrhage", "DISEASE", 249, 260], ["necrosis", "DISEASE", 266, 274], ["tumour necrosis factor", "GENE_OR_GENE_PRODUCT", 32, 54], ["endotoxin", "GENE_OR_GENE_PRODUCT", 58, 67], ["rabbits", "ORGANISM", 71, 78], ["intravascular", "IMMATERIAL_ANATOMICAL_ENTITY", 129, 142], ["glomeruli", "MULTI-TISSUE_STRUCTURE", 189, 198], ["leukocyte", "CELL", 204, 213], ["liver", "ORGAN", 282, 287], ["bowel", "ORGAN", 289, 294], ["adrenals", "ORGAN", 296, 304], ["pancreas", "ORGAN", 306, 314], ["lung", "ORGAN", 316, 320], ["tissues", "TISSUE", 331, 338], ["cytokine tumour necrosis factor", "PROTEIN", 23, 54], ["endotoxin", "PROTEIN", 58, 67], ["rabbits", "SPECIES", 71, 78], ["rabbits", "SPECIES", 71, 78], ["Infusion", "TREATMENT", 0, 8], ["the cytokine tumour necrosis factor", "PROBLEM", 19, 54], ["endotoxin in rabbits", "PROBLEM", 58, 78], ["similar pathology", "PROBLEM", 88, 105], ["disseminated intravascular coagulation", "PROBLEM", 116, 154], ["thrombocytopaenia", "PROBLEM", 160, 177], ["damage to glomeruli", "PROBLEM", 179, 198], ["leukocyte infiltration", "PROBLEM", 204, 226], ["segmental ischaemia", "PROBLEM", 228, 247], ["haemorrhage", "PROBLEM", 249, 260], ["necrosis in the liver, bowel, adrenals, pancreas, lung and other tissues", "PROBLEM", 266, 338], ["cytokine", "OBSERVATION_MODIFIER", 23, 31], ["tumour", "OBSERVATION_MODIFIER", 32, 38], ["necrosis", "OBSERVATION", 39, 47], ["disseminated", "OBSERVATION_MODIFIER", 116, 128], ["intravascular coagulation", "OBSERVATION", 129, 154], ["thrombocytopaenia", "OBSERVATION", 160, 177], ["glomeruli", "ANATOMY", 189, 198], ["leukocyte infiltration", "OBSERVATION", 204, 226], ["segmental", "OBSERVATION_MODIFIER", 228, 237], ["ischaemia", "OBSERVATION", 238, 247], ["haemorrhage", "OBSERVATION", 249, 260], ["necrosis", "OBSERVATION", 266, 274], ["liver", "ANATOMY", 282, 287], ["bowel", "ANATOMY", 289, 294], ["adrenals", "ANATOMY", 296, 304], ["pancreas", "ANATOMY", 306, 314], ["lung", "ANATOMY", 316, 320], ["other tissues", "ANATOMY", 325, 338]]], ["Microscopically there were fibrin deposits, polymorphonuclear infiltration and arterial thromboses.", [["polymorphonuclear", "ANATOMY", 44, 61], ["arterial", "ANATOMY", 79, 87], ["arterial thromboses", "DISEASE", 79, 98], ["fibrin", "GENE_OR_GENE_PRODUCT", 27, 33], ["polymorphonuclear", "CELL", 44, 61], ["arterial thromboses", "PATHOLOGICAL_FORMATION", 79, 98], ["fibrin deposits", "PROBLEM", 27, 42], ["polymorphonuclear infiltration", "PROBLEM", 44, 74], ["arterial thromboses", "PROBLEM", 79, 98], ["fibrin deposits", "OBSERVATION", 27, 42], ["polymorphonuclear infiltration", "OBSERVATION", 44, 74], ["arterial", "ANATOMY", 79, 87], ["thromboses", "OBSERVATION", 88, 98]]], ["Similarities between the pathology of shigellosis and endotoxin or TNF infusions prompted measurement of cytokine concentrations in sera and stool extracts from children with shigellosis [36] .Role of endotoxaemiaSerum interleukin 6 (IL-6) and tumour necrosis factor concentrations were significantly elevated during the acute phase of S. dysenteriae 1 infection in children with a complicated course compared to convalescence, and IL-6 concentrations correlated with the presence of complications such as haemolytic uraemic syndrome, microangiopathic haemolytic anaemia, leukemoid reactions, thrombocytopaenia or thrombocytosis and severe colitis associated with persistent diarrhoea.", [["sera", "ANATOMY", 132, 136], ["extracts", "ANATOMY", 147, 155], ["leukemoid", "ANATOMY", 572, 581], ["shigellosis", "DISEASE", 38, 49], ["endotoxin", "CHEMICAL", 54, 63], ["shigellosis", "DISEASE", 175, 186], ["necrosis", "DISEASE", 251, 259], ["S. dysenteriae 1 infection", "DISEASE", 336, 362], ["haemolytic uraemic syndrome", "DISEASE", 506, 533], ["microangiopathic haemolytic anaemia", "DISEASE", 535, 570], ["leukemoid reactions", "DISEASE", 572, 591], ["thrombocytopaenia", "DISEASE", 593, 610], ["thrombocytosis", "DISEASE", 614, 628], ["colitis", "DISEASE", 640, 647], ["diarrhoea", "DISEASE", 675, 684], ["endotoxin", "SIMPLE_CHEMICAL", 54, 63], ["TNF", "GENE_OR_GENE_PRODUCT", 67, 70], ["sera", "ORGANISM_SUBSTANCE", 132, 136], ["stool extracts", "ORGANISM_SUBSTANCE", 141, 155], ["children", "ORGANISM", 161, 169], ["endotoxaemiaSerum interleukin 6", "GENE_OR_GENE_PRODUCT", 201, 232], ["IL-6", "GENE_OR_GENE_PRODUCT", 234, 238], ["tumour necrosis factor", "GENE_OR_GENE_PRODUCT", 244, 266], ["S. dysenteriae 1", "ORGANISM", 336, 352], ["children", "ORGANISM", 366, 374], ["IL-6", "GENE_OR_GENE_PRODUCT", 432, 436], ["colitis", "PATHOLOGICAL_FORMATION", 640, 647], ["TNF", "PROTEIN", 67, 70], ["cytokine", "PROTEIN", 105, 113], ["endotoxaemiaSerum interleukin 6 (IL-6", "PROTEIN", 201, 238], ["tumour necrosis factor", "PROTEIN", 244, 266], ["children", "SPECIES", 161, 169], ["S. dysenteriae", "SPECIES", 336, 350], ["children", "SPECIES", 366, 374], ["S. dysenteriae 1", "SPECIES", 336, 352], ["shigellosis", "PROBLEM", 38, 49], ["endotoxin", "TREATMENT", 54, 63], ["TNF infusions", "TREATMENT", 67, 80], ["cytokine concentrations in sera and stool extracts", "PROBLEM", 105, 155], ["shigellosis", "PROBLEM", 175, 186], ["endotoxaemiaSerum interleukin", "TREATMENT", 201, 230], ["IL", "TEST", 234, 236], ["tumour necrosis factor concentrations", "PROBLEM", 244, 281], ["significantly elevated", "PROBLEM", 287, 309], ["S. dysenteriae 1 infection", "PROBLEM", 336, 362], ["complications", "PROBLEM", 484, 497], ["haemolytic uraemic syndrome", "PROBLEM", 506, 533], ["microangiopathic haemolytic anaemia", "PROBLEM", 535, 570], ["leukemoid reactions", "PROBLEM", 572, 591], ["thrombocytopaenia", "PROBLEM", 593, 610], ["thrombocytosis", "PROBLEM", 614, 628], ["severe colitis", "PROBLEM", 633, 647], ["persistent diarrhoea", "PROBLEM", 664, 684], ["pathology", "OBSERVATION", 25, 34], ["shigellosis", "OBSERVATION", 38, 49], ["tumour", "OBSERVATION_MODIFIER", 244, 250], ["necrosis", "OBSERVATION", 251, 259], ["acute phase", "OBSERVATION_MODIFIER", 321, 332], ["infection", "OBSERVATION", 353, 362], ["complications", "OBSERVATION", 484, 497], ["haemolytic", "OBSERVATION_MODIFIER", 506, 516], ["uraemic syndrome", "OBSERVATION", 517, 533], ["microangiopathic", "OBSERVATION_MODIFIER", 535, 551], ["haemolytic", "OBSERVATION_MODIFIER", 552, 562], ["anaemia", "OBSERVATION", 563, 570], ["leukemoid reactions", "OBSERVATION", 572, 591], ["thrombocytopaenia", "OBSERVATION", 593, 610], ["thrombocytosis", "OBSERVATION", 614, 628], ["severe", "OBSERVATION_MODIFIER", 633, 639], ["colitis", "OBSERVATION", 640, 647], ["persistent", "OBSERVATION_MODIFIER", 664, 674], ["diarrhoea", "OBSERVATION", 675, 684]]], ["IL-6 has been shown to be a better indicator of disease severity in other septic states although tumour necrosis factor release is essential for the initiation or amplification of IL-6 release.", [["septic", "DISEASE", 74, 80], ["necrosis", "DISEASE", 104, 112], ["IL-6", "GENE_OR_GENE_PRODUCT", 0, 4], ["tumour necrosis factor", "GENE_OR_GENE_PRODUCT", 97, 119], ["IL-6", "GENE_OR_GENE_PRODUCT", 180, 184], ["IL-6", "PROTEIN", 0, 4], ["tumour necrosis factor", "PROTEIN", 97, 119], ["IL-6", "PROTEIN", 180, 184], ["disease severity", "PROBLEM", 48, 64], ["other septic states", "PROBLEM", 68, 87], ["tumour necrosis factor release", "PROBLEM", 97, 127], ["amplification of IL", "TREATMENT", 163, 182], ["disease", "OBSERVATION", 48, 55], ["septic", "OBSERVATION", 74, 80], ["tumour", "OBSERVATION_MODIFIER", 97, 103], ["necrosis", "OBSERVATION", 104, 112]]], ["IL-6 and IL-1 are thought likely to be important mediators of the pathological effects of turnour necrosis factor [34] including endothelial cell damage caused by increasing the adhesiveness of neutrophils and endothelial cells endothelial rearrangement, production of a procoagulant factor by endothelial cells, reduced expression of thrombomodulin, increased production of interleukin 1, which can in turn activate leukocytes to initiate coagulation and stimulation of endothelial cells, polymorphs, and macrophages to produce platelet activating factor [35] .", [["endothelial cell", "ANATOMY", 129, 145], ["neutrophils", "ANATOMY", 194, 205], ["endothelial cells endothelial", "ANATOMY", 210, 239], ["endothelial cells", "ANATOMY", 294, 311], ["leukocytes", "ANATOMY", 417, 427], ["endothelial cells", "ANATOMY", 471, 488], ["macrophages", "ANATOMY", 506, 517], ["platelet", "ANATOMY", 529, 537], ["necrosis", "DISEASE", 98, 106], ["IL-6", "GENE_OR_GENE_PRODUCT", 0, 4], ["IL-1", "GENE_OR_GENE_PRODUCT", 9, 13], ["turnour necrosis factor", "GENE_OR_GENE_PRODUCT", 90, 113], ["endothelial cell", "CELL", 129, 145], ["neutrophils", "CELL", 194, 205], ["endothelial cells", "CELL", 210, 227], ["endothelial", "CELL", 228, 239], ["procoagulant factor", "GENE_OR_GENE_PRODUCT", 271, 290], ["endothelial cells", "CELL", 294, 311], ["thrombomodulin", "GENE_OR_GENE_PRODUCT", 335, 349], ["interleukin 1", "GENE_OR_GENE_PRODUCT", 375, 388], ["leukocytes", "CELL", 417, 427], ["endothelial cells", "CELL", 471, 488], ["macrophages", "CELL", 506, 517], ["platelet activating factor", "GENE_OR_GENE_PRODUCT", 529, 555], ["IL-6", "PROTEIN", 0, 4], ["IL-1", "PROTEIN", 9, 13], ["turnour necrosis factor", "PROTEIN", 90, 113], ["neutrophils", "CELL_TYPE", 194, 205], ["endothelial cells", "CELL_TYPE", 210, 227], ["procoagulant factor", "PROTEIN", 271, 290], ["endothelial cells", "CELL_TYPE", 294, 311], ["thrombomodulin", "PROTEIN", 335, 349], ["interleukin 1", "PROTEIN", 375, 388], ["leukocytes", "CELL_TYPE", 417, 427], ["endothelial cells", "CELL_TYPE", 471, 488], ["macrophages", "CELL_TYPE", 506, 517], ["platelet activating factor", "PROTEIN", 529, 555], ["IL", "TEST", 0, 2], ["turnour necrosis factor", "PROBLEM", 90, 113], ["endothelial cell damage", "PROBLEM", 129, 152], ["increasing the adhesiveness of neutrophils", "PROBLEM", 163, 205], ["endothelial cells endothelial rearrangement", "PROBLEM", 210, 253], ["a procoagulant factor", "PROBLEM", 269, 290], ["endothelial cells", "PROBLEM", 294, 311], ["thrombomodulin", "PROBLEM", 335, 349], ["increased production of interleukin 1", "PROBLEM", 351, 388], ["leukocytes", "TEST", 417, 427], ["coagulation", "TEST", 440, 451], ["endothelial cells", "PROBLEM", 471, 488], ["polymorphs", "TEST", 490, 500], ["macrophages", "PROBLEM", 506, 517], ["platelet activating factor", "TEST", 529, 555], ["thought likely to be", "UNCERTAINTY", 18, 38], ["necrosis", "OBSERVATION", 98, 106], ["endothelial cell damage", "OBSERVATION", 129, 152], ["increasing", "OBSERVATION_MODIFIER", 163, 173], ["endothelial cells endothelial rearrangement", "OBSERVATION", 210, 253], ["endothelial cells", "OBSERVATION", 294, 311]]], ["Future work should be directed to the investigation of the roles of endotoxin, cytokines and their mediators in the pathogenesis of necrotizing enterocolitis.", [["necrotizing enterocolitis", "DISEASE", 132, 157], ["endotoxin", "GENE_OR_GENE_PRODUCT", 68, 77], ["endotoxin", "PROTEIN", 68, 77], ["cytokines", "PROTEIN", 79, 88], ["endotoxin", "TREATMENT", 68, 77], ["cytokines", "TREATMENT", 79, 88], ["necrotizing enterocolitis", "PROBLEM", 132, 157], ["necrotizing", "OBSERVATION_MODIFIER", 132, 143], ["enterocolitis", "OBSERVATION", 144, 157]]], ["In common with shigellosis, serum tumour necrosis factor concentrations were elevated in necrotizing enterocolitis compared with age-matched control infants [23] .", [["serum", "ANATOMY", 28, 33], ["shigellosis", "DISEASE", 15, 26], ["necrosis", "DISEASE", 41, 49], ["necrotizing enterocolitis", "DISEASE", 89, 114], ["serum", "ORGANISM_SUBSTANCE", 28, 33], ["tumour necrosis factor", "GENE_OR_GENE_PRODUCT", 34, 56], ["infants", "ORGANISM", 149, 156], ["serum tumour necrosis factor", "PROTEIN", 28, 56], ["infants", "SPECIES", 149, 156], ["shigellosis", "PROBLEM", 15, 26], ["serum tumour necrosis factor concentrations", "PROBLEM", 28, 71], ["necrotizing enterocolitis", "PROBLEM", 89, 114], ["shigellosis", "OBSERVATION", 15, 26], ["tumour", "OBSERVATION_MODIFIER", 34, 40], ["necrosis", "OBSERVATION", 41, 49], ["concentrations", "OBSERVATION_MODIFIER", 57, 71], ["elevated", "OBSERVATION_MODIFIER", 77, 85], ["necrotizing", "OBSERVATION_MODIFIER", 89, 100], ["enterocolitis", "OBSERVATION", 101, 114]]], ["Tumour necrosis factor levels did not correlate with severity or outcome.", [["necrosis", "DISEASE", 7, 15], ["Tumour necrosis factor", "GENE_OR_GENE_PRODUCT", 0, 22], ["Tumour necrosis factor", "PROTEIN", 0, 22], ["Tumour necrosis factor levels", "PROBLEM", 0, 29], ["necrosis", "OBSERVATION", 7, 15]]], ["Larger, longitudinal studies are required to investigate the role of inflammatory mediators in necrotizing enterocolitis.Micro-organisms and management of necrotizing enterocolitistreated with vancomycin and aztreonam had lower viable counts of enterobacteriaceae in the stools [37] .AntibioticsBroad spectrum antibiotics with anaerobic cover are part of the treatment regimen for established necrotizing enterocolitis.Barrier nursingThe documentation of outbreaks of necrotizing enterocolitis suggests that affected infants should be nursed with particular attention to the prevention of cross-infection [15].Breast milkLucas et al.Breast milk[38] estimated that necrotizing enterocolitis was 6-10 times as common in artificially fed infants (20 times more common in infants over 30 weeks gestation) and that 500 infants are developing necrotizing enterocolitis in the UK every year as a result of artificial feeding.", [["Breast", "ANATOMY", 610, 616], ["Breast milk", "ANATOMY", 633, 644], ["necrotizing enterocolitis", "DISEASE", 95, 120], ["vancomycin", "CHEMICAL", 193, 203], ["aztreonam", "CHEMICAL", 208, 217], ["necrotizing enterocolitis", "DISEASE", 393, 418], ["necrotizing enterocolitis", "DISEASE", 468, 493], ["necrotizing enterocolitis", "DISEASE", 664, 689], ["necrotizing enterocolitis", "DISEASE", 837, 862], ["vancomycin", "CHEMICAL", 193, 203], ["aztreonam", "CHEMICAL", 208, 217], ["vancomycin", "SIMPLE_CHEMICAL", 193, 203], ["aztreonam", "SIMPLE_CHEMICAL", 208, 217], ["infants", "ORGANISM", 517, 524], ["infants", "ORGANISM", 735, 742], ["infants", "ORGANISM", 768, 775], ["infants", "ORGANISM", 814, 821], ["inflammatory mediators", "PROTEIN", 69, 91], ["infants", "SPECIES", 517, 524], ["infants", "SPECIES", 735, 742], ["infants", "SPECIES", 768, 775], ["infants", "SPECIES", 814, 821], ["longitudinal studies", "TEST", 8, 28], ["inflammatory mediators", "PROBLEM", 69, 91], ["necrotizing enterocolitis", "PROBLEM", 95, 120], ["Micro-organisms", "TEST", 121, 136], ["management", "TREATMENT", 141, 151], ["necrotizing enterocolitistreated", "PROBLEM", 155, 187], ["vancomycin", "TREATMENT", 193, 203], ["aztreonam", "TREATMENT", 208, 217], ["enterobacteriaceae in the stools", "PROBLEM", 245, 277], ["Antibiotics", "TREATMENT", 284, 295], ["Broad spectrum antibiotics", "TREATMENT", 295, 321], ["anaerobic cover", "TREATMENT", 327, 342], ["the treatment regimen", "TREATMENT", 355, 376], ["established necrotizing enterocolitis", "PROBLEM", 381, 418], ["necrotizing enterocolitis", "PROBLEM", 468, 493], ["cross-infection", "PROBLEM", 589, 604], ["necrotizing enterocolitis", "PROBLEM", 664, 689], ["necrotizing enterocolitis", "PROBLEM", 837, 862], ["artificial feeding", "TREATMENT", 899, 917], ["inflammatory", "OBSERVATION_MODIFIER", 69, 81], ["necrotizing", "OBSERVATION_MODIFIER", 95, 106], ["enterocolitis", "OBSERVATION", 107, 120], ["necrotizing", "OBSERVATION_MODIFIER", 155, 166], ["enterobacteriaceae", "OBSERVATION", 245, 263], ["necrotizing", "OBSERVATION_MODIFIER", 393, 404], ["enterocolitis", "OBSERVATION", 405, 418], ["necrotizing", "OBSERVATION_MODIFIER", 468, 479], ["enterocolitis", "OBSERVATION", 480, 493], ["necrotizing", "OBSERVATION_MODIFIER", 664, 675], ["enterocolitis", "OBSERVATION", 676, 689], ["necrotizing", "OBSERVATION_MODIFIER", 837, 848], ["enterocolitis", "OBSERVATION", 849, 862], ["artificial feeding", "OBSERVATION", 899, 917]]], ["They attribute the protective effect to the IgA present in breast milk.Chemoprophylaxis(See above: Protective effect of oral antibiotics.)", [["breast milk", "ANATOMY", 59, 70], ["oral", "ANATOMY", 120, 124], ["IgA", "GENE_OR_GENE_PRODUCT", 44, 47], ["breast milk", "ORGANISM_SUBSTANCE", 59, 70], ["oral", "ORGANISM_SUBDIVISION", 120, 124], ["IgA", "PROTEIN", 44, 47], ["Chemoprophylaxis", "TREATMENT", 71, 87], ["oral antibiotics", "TREATMENT", 120, 136], ["breast", "ANATOMY", 59, 65]]], ["A report from Leeds, UK suggested that the use of vancomycin and aztreonam to treat episodes of sepsis prevented necrotizing enterocolitis compared with vancomycin and gentamicin; infantsProtection against endotoxaemiaIf endotoxaemia does play a role in the pathogenesis or complications of necrotizing enterocolitis then affected infants may benefit from therapeutic attempts to neutralize endotoxins or their mediators.", [["vancomycin", "CHEMICAL", 50, 60], ["aztreonam", "CHEMICAL", 65, 74], ["sepsis", "DISEASE", 96, 102], ["necrotizing enterocolitis", "DISEASE", 113, 138], ["vancomycin", "CHEMICAL", 153, 163], ["gentamicin", "CHEMICAL", 168, 178], ["endotoxaemia", "DISEASE", 221, 233], ["necrotizing enterocolitis", "DISEASE", 291, 316], ["vancomycin", "CHEMICAL", 50, 60], ["aztreonam", "CHEMICAL", 65, 74], ["vancomycin", "CHEMICAL", 153, 163], ["gentamicin", "CHEMICAL", 168, 178], ["vancomycin", "SIMPLE_CHEMICAL", 50, 60], ["aztreonam", "SIMPLE_CHEMICAL", 65, 74], ["vancomycin", "SIMPLE_CHEMICAL", 153, 163], ["gentamicin", "SIMPLE_CHEMICAL", 168, 178], ["infants", "ORGANISM", 180, 187], ["infants", "ORGANISM", 331, 338], ["infants", "SPECIES", 180, 187], ["infants", "SPECIES", 331, 338], ["vancomycin", "TREATMENT", 50, 60], ["aztreonam", "TREATMENT", 65, 74], ["sepsis", "PROBLEM", 96, 102], ["necrotizing enterocolitis", "PROBLEM", 113, 138], ["vancomycin", "TREATMENT", 153, 163], ["gentamicin", "TREATMENT", 168, 178], ["infantsProtection", "TREATMENT", 180, 197], ["endotoxaemiaIf endotoxaemia", "PROBLEM", 206, 233], ["necrotizing enterocolitis", "PROBLEM", 291, 316], ["sepsis", "OBSERVATION", 96, 102], ["necrotizing", "OBSERVATION_MODIFIER", 113, 124], ["enterocolitis", "OBSERVATION", 125, 138], ["necrotizing", "OBSERVATION_MODIFIER", 291, 302], ["enterocolitis", "OBSERVATION", 303, 316]]], ["Human polyclonal anti-E, coli J5 Human monoclonal (HA-IA) anti-lipid A Mufine monoclonal (E5) anti-lipid A Monoclonal anti-turnout necrosis factor antibody Monoclonal anti IL-6 antibody Soluble tumour necrosis factor receptor IL-6 receptor antagonist (ra) While these potential interventions await clinical trials, there is experimental evidence that platelet activating factor antagonist prevents necrotizing enterocolitis.", [["platelet", "ANATOMY", 351, 359], ["necrosis", "DISEASE", 131, 139], ["ra", "CHEMICAL", 252, 254], ["necrotizing enterocolitis", "DISEASE", 398, 423], ["Human", "ORGANISM", 0, 5], ["anti-E", "GENE_OR_GENE_PRODUCT", 17, 23], ["coli J5", "ORGANISM", 25, 32], ["Human", "ORGANISM", 33, 38], ["HA-IA", "SIMPLE_CHEMICAL", 51, 56], ["E5", "ORGANISM", 90, 92], ["IL-6", "GENE_OR_GENE_PRODUCT", 172, 176], ["tumour necrosis factor receptor IL-6 receptor antagonist", "GENE_OR_GENE_PRODUCT", 194, 250], ["ra", "SIMPLE_CHEMICAL", 252, 254], ["platelet activating factor antagonist", "GENE_OR_GENE_PRODUCT", 351, 388], ["Human polyclonal anti-E, coli J5 Human monoclonal (HA-IA) anti-lipid A Mufine monoclonal (E5) anti-lipid A Monoclonal anti-turnout necrosis factor antibody Monoclonal anti IL-6 antibody Soluble tumour necrosis factor receptor IL-6 receptor", "PROTEIN", 0, 239], ["platelet activating factor", "PROTEIN", 351, 377], ["Human", "SPECIES", 0, 5], ["E, coli", "SPECIES", 22, 29], ["Human", "SPECIES", 33, 38], ["Human", "SPECIES", 0, 5], ["Human", "SPECIES", 33, 38], ["Human polyclonal anti", "TEST", 0, 21], ["coli J5 Human monoclonal (HA-IA", "TREATMENT", 25, 56], ["anti-lipid A Mufine monoclonal (E5", "TREATMENT", 58, 92], ["anti-lipid", "TREATMENT", 94, 104], ["A Monoclonal anti-turnout necrosis factor antibody", "TREATMENT", 105, 155], ["Monoclonal anti IL", "TREATMENT", 156, 174], ["antibody Soluble tumour necrosis factor receptor IL", "TREATMENT", 177, 228], ["receptor antagonist (ra)", "TREATMENT", 231, 255], ["platelet activating factor antagonist", "TREATMENT", 351, 388], ["necrotizing enterocolitis", "PROBLEM", 398, 423], ["necrotizing", "OBSERVATION_MODIFIER", 398, 409], ["enterocolitis", "OBSERVATION", 410, 423]]], ["Endotoxin and tumour necrosis factor act synergistically to induce shock, neutropaenia, focal bowel necrosis in young rats; these effects are inhibited by platelet activating factor receptor antagonists [39] .Conclusion and classificationConventionally, a review such as this should conclude with a complex diagram of 'vicious cycles' summarizing our uncertainty about precise causes.", [["bowel", "ANATOMY", 94, 99], ["Endotoxin", "CHEMICAL", 0, 9], ["necrosis", "DISEASE", 21, 29], ["shock", "DISEASE", 67, 72], ["neutropaenia", "DISEASE", 74, 86], ["bowel necrosis", "DISEASE", 94, 108], ["Endotoxin", "GENE_OR_GENE_PRODUCT", 0, 9], ["tumour necrosis factor", "GENE_OR_GENE_PRODUCT", 14, 36], ["bowel", "ORGAN", 94, 99], ["rats", "ORGANISM", 118, 122], ["platelet activating factor receptor antagonists", "GENE_OR_GENE_PRODUCT", 155, 202], ["Endotoxin", "PROTEIN", 0, 9], ["tumour necrosis factor", "PROTEIN", 14, 36], ["platelet activating factor receptor", "PROTEIN", 155, 190], ["rats", "SPECIES", 118, 122], ["Endotoxin", "TREATMENT", 0, 9], ["tumour necrosis factor", "PROBLEM", 14, 36], ["shock", "PROBLEM", 67, 72], ["neutropaenia", "PROBLEM", 74, 86], ["focal bowel necrosis in young rats", "PROBLEM", 88, 122], ["platelet activating factor receptor antagonists", "TREATMENT", 155, 202], ["tumour", "OBSERVATION_MODIFIER", 14, 20], ["necrosis", "OBSERVATION", 21, 29], ["shock", "OBSERVATION", 67, 72], ["focal", "OBSERVATION_MODIFIER", 88, 93], ["bowel", "ANATOMY", 94, 99], ["necrosis", "OBSERVATION", 100, 108]]], ["The basic cause of necrotizing enterocolitis remains a mystery, not the least because of occurrence of the disease in infants who 'break the rules' on necrotizing enterocolitis by being full-term or older, previously well, unfed or exclusively breast fed.", [["breast", "ANATOMY", 244, 250], ["necrotizing enterocolitis", "DISEASE", 19, 44], ["necrotizing enterocolitis", "DISEASE", 151, 176], ["infants", "ORGANISM", 118, 125], ["breast", "ORGANISM_SUBDIVISION", 244, 250], ["infants", "SPECIES", 118, 125], ["necrotizing enterocolitis", "PROBLEM", 19, 44], ["the disease in infants", "PROBLEM", 103, 125], ["necrotizing enterocolitis", "PROBLEM", 151, 176], ["necrotizing", "OBSERVATION_MODIFIER", 19, 30], ["enterocolitis", "OBSERVATION", 31, 44], ["disease", "OBSERVATION", 107, 114], ["necrotizing", "OBSERVATION_MODIFIER", 151, 162], ["enterocolitis", "OBSERVATION", 163, 176]]], ["Perhaps a note of greater clarity would be sounded by reproducing a classification of necrotizing enterocolitis (Table 6 ) [40] .", [["necrotizing enterocolitis", "DISEASE", 86, 111], ["necrotizing enterocolitis", "PROBLEM", 86, 111], ["necrotizing", "OBSERVATION_MODIFIER", 86, 97], ["enterocolitis", "OBSERVATION", 98, 111]]], ["Any studies on necrotizing enterocolitis should clearly differentiate between these subgroups, which are likely to have different mechanisms with a final common pathway.", [["necrotizing enterocolitis", "DISEASE", 15, 40], ["Any studies", "TEST", 0, 11], ["necrotizing enterocolitis", "PROBLEM", 15, 40], ["necrotizing", "OBSERVATION_MODIFIER", 15, 26], ["enterocolitis", "OBSERVATION", 27, 40]]]], "e07a68e06cf2c33ce5f58c9a0af10e3edd8e906e": [["In Brief Garay et al. adopt BrU-seq to profile bona fide transcriptional dynamics triggered by neuronal activity shifts.", [["neuronal", "ANATOMY", 95, 103], ["BrU-seq", "GENE_OR_GENE_PRODUCT", 28, 35], ["neuronal", "CELL", 95, 103], ["BrU", "PROTEIN", 28, 31], ["seq", "PROTEIN", 32, 35], ["transcriptional dynamics", "OBSERVATION", 57, 81], ["neuronal activity", "OBSERVATION", 95, 112]]], ["An integrated genomics approach including BrU-seq, combined with electrophysiology, reveals that RAI1, the Smith-Magenis syndrome protein, controls baseline synaptic strength and homeostatic synaptic upscaling by regulating the transcriptome associated with network inactivity.INTRODUCTIONProper cognitive development and brain function rely on synaptic plasticity, the ability of synapses to strengthen or weaken in response to sensory or neuromodulatory inputs.", [["synaptic", "ANATOMY", 157, 165], ["synaptic", "ANATOMY", 191, 199], ["brain", "ANATOMY", 322, 327], ["synaptic", "ANATOMY", 345, 353], ["synapses", "ANATOMY", 381, 389], ["BrU-seq", "GENE_OR_GENE_PRODUCT", 42, 49], ["RAI1", "GENE_OR_GENE_PRODUCT", 97, 101], ["network", "MULTI-TISSUE_STRUCTURE", 258, 265], ["brain", "ORGAN", 322, 327], ["BrU", "PROTEIN", 42, 45], ["seq", "DNA", 46, 49], ["RAI1", "PROTEIN", 97, 101], ["Smith-Magenis syndrome protein", "PROTEIN", 107, 137], ["electrophysiology", "TEST", 65, 82], ["RAI1", "TEST", 97, 101], ["the Smith", "TEST", 103, 112], ["Magenis syndrome protein", "PROBLEM", 113, 137], ["homeostatic synaptic upscaling", "TREATMENT", 179, 209], ["brain", "ANATOMY", 322, 327]]], ["Synaptic scaling is one mechanism of plasticity, which buffers potentially destabilizing patterns of network activity (Abbott and Nelson, 2000; Miller and MacKay, 1994; Turrigiano, 2008) .", [["Synaptic scaling", "PROBLEM", 0, 16], ["one mechanism", "OBSERVATION_MODIFIER", 20, 33]]], ["In response to a sustained increase in neuronal firing rate, neurons decrease, or ''scale down,'' the receptivity of the neuron to excitatory neurotransmitters.", [["neuronal", "ANATOMY", 39, 47], ["neurons", "ANATOMY", 61, 68], ["neuron", "ANATOMY", 121, 127], ["neuronal", "CELL", 39, 47], ["neurons", "CELL", 61, 68], ["neuron", "CELL", 121, 127], ["a sustained increase in neuronal firing rate", "PROBLEM", 15, 59], ["neurons decrease", "PROBLEM", 61, 77], ["increase", "OBSERVATION_MODIFIER", 27, 35], ["neuronal firing", "OBSERVATION", 39, 54]]], ["Conversely, global decreases in firing rate cause neurons to ''scale up'' and increase synaptic efficacy.", [["neurons", "ANATOMY", 50, 57], ["synaptic", "ANATOMY", 87, 95], ["neurons", "CELL", 50, 57], ["global decreases in firing rate", "PROBLEM", 12, 43], ["neurons", "PROBLEM", 50, 57], ["global", "OBSERVATION_MODIFIER", 12, 18], ["decreases", "OBSERVATION_MODIFIER", 19, 28], ["synaptic efficacy", "OBSERVATION", 87, 104]]], ["Synaptic scaling can accommodate other forms of plasticity, such as long-term potentiation (LTP), that impose long-lasting increase of individual synaptic efficacy, which left uncompensated would result in circuits that are overly active (Turrigiano, 2017) .", [["Synaptic", "ANATOMY", 0, 8], ["synaptic", "ANATOMY", 146, 154], ["Synaptic scaling", "PROBLEM", 0, 16], ["individual synaptic efficacy", "PROBLEM", 135, 163]]], ["Synaptic scaling plays important roles in neurodevelopment, learning, and memory (Fernandes and Carvalho, 2016; Yee et al., 2017) .", [["Synaptic", "ANATOMY", 0, 8]]], ["Dysregulated homeostatic plasticity is a common pathological hallmark in several neurodevelopmental disorders, including fragile X syndrome (Soden and Chen, 2010) , Rett syndrome (Zhong et al., 2012) , tuberous sclerosis (Bateup et al., 2013) , Kleefstra syndrome (Benevento et al., 2016) , and some autism spectrum conditions (Bourgeron, 2015) .INTRODUCTIONSynaptic scaling requires de novo synthesis of RNAs and proteins that directly modulate synaptic efficacy (Benito and Barco, 2015; Ibata et al., 2008; Igaz et al., 2002) .", [["synaptic", "ANATOMY", 446, 454], ["neurodevelopmental disorders", "DISEASE", 81, 109], ["fragile X syndrome", "DISEASE", 121, 139], ["Rett syndrome", "DISEASE", 165, 178], ["tuberous sclerosis", "DISEASE", 202, 220], ["Kleefstra syndrome", "DISEASE", 245, 263], ["autism spectrum conditions", "DISEASE", 300, 326], ["RNAs", "RNA", 405, 409], ["Dysregulated homeostatic plasticity", "PROBLEM", 0, 35], ["a common pathological hallmark", "PROBLEM", 39, 69], ["several neurodevelopmental disorders", "PROBLEM", 73, 109], ["fragile X syndrome", "PROBLEM", 121, 139], ["Rett syndrome", "PROBLEM", 165, 178], ["tuberous sclerosis", "PROBLEM", 202, 220], ["Kleefstra syndrome", "PROBLEM", 245, 263], ["some autism spectrum conditions", "PROBLEM", 295, 326], ["de novo synthesis of RNAs and proteins", "TREATMENT", 384, 422], ["several", "OBSERVATION_MODIFIER", 73, 80], ["neurodevelopmental disorders", "OBSERVATION", 81, 109], ["fragile X syndrome", "OBSERVATION_MODIFIER", 121, 139], ["Rett syndrome", "OBSERVATION", 165, 178], ["tuberous", "OBSERVATION_MODIFIER", 202, 210], ["sclerosis", "OBSERVATION", 211, 220]]], ["DNA-binding transcription factors (TFs), such as cyclic AMP-response binding protein (CREB), drive transcriptional responses to neuronal activation (West et al., 2002) .", [["neuronal", "ANATOMY", 128, 136], ["AMP", "CHEMICAL", 56, 59], ["AMP", "CHEMICAL", 56, 59], ["DNA", "CELLULAR_COMPONENT", 0, 3], ["-binding transcription factors", "GENE_OR_GENE_PRODUCT", 3, 33], ["TFs", "GENE_OR_GENE_PRODUCT", 35, 38], ["cyclic AMP-response binding protein", "GENE_OR_GENE_PRODUCT", 49, 84], ["CREB", "GENE_OR_GENE_PRODUCT", 86, 90], ["neuronal", "CELL", 128, 136], ["DNA-binding transcription factors", "PROTEIN", 0, 33], ["TFs", "PROTEIN", 35, 38], ["cyclic AMP-response binding protein", "PROTEIN", 49, 84], ["CREB", "PROTEIN", 86, 90], ["DNA-binding transcription factors", "PROBLEM", 0, 33], ["cyclic AMP", "TEST", 49, 59]]], ["The initial response is a rapid induction of immediate-early genes, such as Arc and Homer1 (Brakeman et al., 1997; Bramham et al., 2008) .", [["Arc", "GENE_OR_GENE_PRODUCT", 76, 79], ["Homer1", "GENE_OR_GENE_PRODUCT", 84, 90], ["immediate-early genes", "DNA", 45, 66], ["Arc", "DNA", 76, 79], ["Homer1", "DNA", 84, 90], ["rapid", "OBSERVATION_MODIFIER", 26, 31]]], ["The gene expression programs triggered by reductions in network activity involves distinct TFs, such as SRF and ELK1 .INTRODUCTIONIn eukaryotic cells, transcriptional responses must occur in a refractory environment in which DNA is packaged into chromatin.", [["TFs", "ANATOMY", 91, 94], ["cells", "ANATOMY", 144, 149], ["chromatin", "ANATOMY", 246, 255], ["TFs", "CELL", 91, 94], ["SRF", "GENE_OR_GENE_PRODUCT", 104, 107], ["ELK1", "GENE_OR_GENE_PRODUCT", 112, 116], ["cells", "CELL", 144, 149], ["DNA", "CELLULAR_COMPONENT", 225, 228], ["chromatin", "CELLULAR_COMPONENT", 246, 255], ["TFs", "PROTEIN", 91, 94], ["SRF", "PROTEIN", 104, 107], ["ELK1", "PROTEIN", 112, 116], ["eukaryotic cells", "CELL_TYPE", 133, 149], ["chromatin", "DNA", 246, 255], ["The gene expression programs", "TREATMENT", 0, 28], ["distinct TFs", "PROBLEM", 82, 94], ["SRF", "PROBLEM", 104, 107], ["ELK1 .INTRODUCTIONIn eukaryotic cells", "TREATMENT", 112, 149], ["ELK1", "ANATOMY", 112, 116]]], ["The strong linkage between cognitive disorders and chromatin-regulatory genes suggests that activity-dependent chromatin reorganization is essential for proper brain development and mental health (Ebert and Greenberg, 2013; Guzman-Karlsson et al., 2014; Mullins et al., 2016) .", [["chromatin", "ANATOMY", 51, 60], ["chromatin", "ANATOMY", 111, 120], ["brain", "ANATOMY", 160, 165], ["cognitive disorders", "DISEASE", 27, 46], ["chromatin", "CELLULAR_COMPONENT", 51, 60], ["chromatin", "CELLULAR_COMPONENT", 111, 120], ["brain", "ORGAN", 160, 165], ["chromatin", "DNA", 51, 60], ["regulatory genes", "DNA", 61, 77], ["chromatin", "DNA", 111, 120], ["The strong linkage between cognitive disorders", "PROBLEM", 0, 46], ["chromatin-regulatory genes", "PROBLEM", 51, 77], ["activity-dependent chromatin reorganization", "PROBLEM", 92, 135]]], ["Indeed, activitydependent gene expression underlying LTP and memory requires chromatin regulators, such as histone acetyltransferases and deacetylases (Campbell and Wood, 2019) .", [["chromatin", "ANATOMY", 77, 86], ["chromatin", "CELLULAR_COMPONENT", 77, 86], ["histone acetyltransferases", "GENE_OR_GENE_PRODUCT", 107, 133], ["activitydependent gene", "DNA", 8, 30], ["chromatin regulators", "PROTEIN", 77, 97], ["histone acetyltransferases", "PROTEIN", 107, 133], ["deacetylases", "PROTEIN", 138, 150], ["chromatin regulators", "TREATMENT", 77, 97], ["histone acetyltransferases", "TREATMENT", 107, 133]]], ["A handful of chromatin regulators, TET3 DNA demethylase , EHMT1/2 histone H3K9 methyltransferases (Benevento et al., 2016) , and L3MBTL1 methyl-histone binding factor (Mao et al., 2018) affect synaptic scaling.", [["chromatin", "ANATOMY", 13, 22], ["synaptic", "ANATOMY", 193, 201], ["methyl", "CHEMICAL", 137, 143], ["methyl", "CHEMICAL", 137, 143], ["chromatin", "CELLULAR_COMPONENT", 13, 22], ["TET3 DNA demethylase", "GENE_OR_GENE_PRODUCT", 35, 55], ["EHMT1/2", "GENE_OR_GENE_PRODUCT", 58, 65], ["histone H3K9 methyltransferases", "GENE_OR_GENE_PRODUCT", 66, 97], ["L3MBTL1 methyl-histone binding factor", "GENE_OR_GENE_PRODUCT", 129, 166], ["chromatin regulators", "PROTEIN", 13, 33], ["TET3 DNA demethylase", "PROTEIN", 35, 55], ["EHMT1/2 histone H3K9 methyltransferases", "PROTEIN", 58, 97], ["histone binding factor", "PROTEIN", 144, 166], ["chromatin regulators", "TREATMENT", 13, 33], ["TET3 DNA demethylase", "TREATMENT", 35, 55], ["EHMT1/2 histone H3K9 methyltransferases", "TREATMENT", 58, 97], ["synaptic scaling", "PROBLEM", 193, 209]]], ["Yet these molecules constitute an infinitesimal fraction of the many chromatin regulators that have genetic links to neurodevelopmental disorders.", [["chromatin", "ANATOMY", 69, 78], ["neurodevelopmental disorders", "DISEASE", 117, 145], ["chromatin", "CELLULAR_COMPONENT", 69, 78], ["chromatin regulators", "PROTEIN", 69, 89], ["neurodevelopmental disorders", "PROBLEM", 117, 145], ["infinitesimal fraction", "OBSERVATION", 34, 56], ["chromatin regulators", "OBSERVATION", 69, 89]]], ["We do not know the extent to which disease-associated chromatin regulators play roles in transcription-dependent synaptic plasticity.INTRODUCTIONAnother unresolved issue is the precise mechanisms by which these chromatin regulators contribute to transcription.", [["chromatin", "ANATOMY", 54, 63], ["synaptic", "ANATOMY", 113, 121], ["chromatin", "ANATOMY", 211, 220], ["chromatin", "CELLULAR_COMPONENT", 54, 63], ["synaptic", "CELLULAR_COMPONENT", 113, 121], ["chromatin", "CELLULAR_COMPONENT", 211, 220], ["chromatin regulators", "PROTEIN", 54, 74], ["chromatin regulators", "PROTEIN", 211, 231], ["disease", "PROBLEM", 35, 42], ["disease", "OBSERVATION", 35, 42], ["chromatin regulators", "OBSERVATION", 54, 74], ["synaptic plasticity", "OBSERVATION", 113, 132]]], ["Most prior studies have monitored steady-state mRNA levels, using qRT-PCR, cDNA microarray, and mRNA sequencing (mRNA-seq).", [["Most prior studies", "TEST", 0, 18], ["mRNA levels", "TEST", 47, 58], ["qRT", "TEST", 66, 69], ["PCR", "TEST", 70, 73], ["cDNA microarray", "TEST", 75, 90], ["mRNA sequencing", "TEST", 96, 111], ["mRNA", "TEST", 113, 117]]], ["The brain exhibits notorious complexity of post-transcriptional regulation, including activity-dependent mRNA splicing (Hermey et al., 2017) , mRNA decay (Widagdo and Anggono, 2018) , mRNA transport, and local translation (Glock et al., 2017) .", [["brain", "ANATOMY", 4, 9], ["brain", "ORGAN", 4, 9], ["post-transcriptional regulation", "PROBLEM", 43, 74], ["brain", "ANATOMY", 4, 9], ["notorious", "OBSERVATION_MODIFIER", 19, 28], ["post-transcriptional regulation", "OBSERVATION", 43, 74]]], ["Therefore, reliance on steadystate mRNA measurements may obscure the roles of chromatin regulators in transcription.INTRODUCTIONIn the present work, we developed genome-wide measurement of bona fide transcriptional dynamics in response to bidirectional network activity alterations.", [["chromatin", "ANATOMY", 78, 87], ["chromatin", "CELLULAR_COMPONENT", 78, 87], ["steadystate mRNA", "RNA", 23, 39], ["chromatin regulators", "PROTEIN", 78, 98], ["steadystate mRNA measurements", "TEST", 23, 52], ["bidirectional network activity alterations", "PROBLEM", 239, 281], ["bona fide", "OBSERVATION", 189, 198], ["transcriptional dynamics", "OBSERVATION", 199, 223], ["network activity", "OBSERVATION", 253, 269]]], ["We then used this approach to uncover a role for the chromatin regulator retinoic acid-induced 1 (RAI1) in the transcriptional program.", [["chromatin", "ANATOMY", 53, 62], ["retinoic acid-induced", "CHEMICAL", 73, 94], ["chromatin", "CELLULAR_COMPONENT", 53, 62], ["retinoic acid-induced 1", "GENE_OR_GENE_PRODUCT", 73, 96], ["RAI1", "GENE_OR_GENE_PRODUCT", 98, 102], ["chromatin regulator", "PROTEIN", 53, 72], ["retinoic acid-induced 1 (RAI1)", "PROTEIN", 73, 103], ["this approach", "TREATMENT", 13, 26], ["the chromatin regulator retinoic acid-induced", "TREATMENT", 49, 94]]], ["RAI1 is a nucleosome-binding protein (Darvekar et al., 2012 (Darvekar et al., , 2013 and is expressed throughout the embryonic and adult brain .", [["embryonic", "ANATOMY", 117, 126], ["brain", "ANATOMY", 137, 142], ["RAI1", "GENE_OR_GENE_PRODUCT", 0, 4], ["nucleosome", "CELLULAR_COMPONENT", 10, 20], ["embryonic", "DEVELOPING_ANATOMICAL_STRUCTURE", 117, 126], ["brain", "ORGAN", 137, 142], ["RAI1", "PROTEIN", 0, 4], ["nucleosome-binding protein", "PROTEIN", 10, 36], ["brain", "ANATOMY", 137, 142]]], ["RAI1 is associated with two human intellectual disability syndromes.", [["intellectual disability", "DISEASE", 34, 57], ["RAI1", "GENE_OR_GENE_PRODUCT", 0, 4], ["human", "ORGANISM", 28, 33], ["RAI1", "PROTEIN", 0, 4], ["human", "SPECIES", 28, 33], ["human", "SPECIES", 28, 33], ["two human intellectual disability syndromes", "PROBLEM", 24, 67]]], ["RAI1 haploinsufficiency leads to Smith-Magenis syndrome (SMS; MIM: 182290), while RAI1 duplication results in Potocki-Lupski syndrome (PTLS; MIM: 610883) (Bi et al., 2004; Girirajan et al., 2005; Potocki et al., 2007; Slager et al., 2003) .", [["Smith-Magenis syndrome", "DISEASE", 33, 55], ["SMS", "DISEASE", 57, 60], ["Potocki-Lupski syndrome", "DISEASE", 110, 133], ["PTLS", "DISEASE", 135, 139], ["RAI1", "GENE_OR_GENE_PRODUCT", 0, 4], ["RAI1", "PROTEIN", 0, 4], ["RAI1 duplication", "DNA", 82, 98], ["RAI1 haploinsufficiency", "PROBLEM", 0, 23], ["Magenis syndrome", "PROBLEM", 39, 55], ["Lupski syndrome", "PROBLEM", 118, 133], ["haploinsufficiency", "OBSERVATION", 5, 23], ["Lupski syndrome", "OBSERVATION", 118, 133]]], ["Studies in mouse models and human patient cells have uncovered roles of RAI1 in gene expression, neuronal structure, and behavior (Bi et al., 2005 (Bi et al., , 2007 Huang et al., 2016 Huang et al., , 2018 Lacaria et al., 2013) .", [["cells", "ANATOMY", 42, 47], ["neuronal", "ANATOMY", 97, 105], ["mouse", "ORGANISM", 11, 16], ["human", "ORGANISM", 28, 33], ["patient cells", "CELL", 34, 47], ["RAI1", "GENE_OR_GENE_PRODUCT", 72, 76], ["neuronal", "CELL", 97, 105], ["human patient cells", "CELL_TYPE", 28, 47], ["RAI1", "PROTEIN", 72, 76], ["mouse", "SPECIES", 11, 16], ["human", "SPECIES", 28, 33], ["patient", "SPECIES", 34, 41], ["mouse", "SPECIES", 11, 16], ["human", "SPECIES", 28, 33], ["Studies in mouse models", "TEST", 0, 23]]], ["However, no study has described RAI1 in activity-dependent transcription and synaptic plasticity to date.", [["synaptic", "ANATOMY", 77, 85], ["RAI1", "GENE_OR_GENE_PRODUCT", 32, 36], ["RAI1", "PROTEIN", 32, 36], ["study", "TEST", 12, 17]]], ["We therefore explored the roles of RAI1 in activity-dependent transcription and synaptic scaling.Altered Neuronal Network Activity Triggers Genomewide Transcriptional ChangesTo overcome the major limitation of steady-state RNA sequencing (RNA-seq), we adopted bromouridine sequencing (BrU-seq), a genome-wide profiling technique of nascent transcripts .", [["synaptic", "ANATOMY", 80, 88], ["Neuronal", "ANATOMY", 105, 113], ["bromouridine", "CHEMICAL", 260, 272], ["bromouridine", "CHEMICAL", 260, 272], ["RAI1", "GENE_OR_GENE_PRODUCT", 35, 39], ["bromouridine", "SIMPLE_CHEMICAL", 260, 272], ["RAI1", "PROTEIN", 35, 39], ["nascent transcripts", "RNA", 332, 351], ["Altered Neuronal Network", "PROBLEM", 97, 121], ["Transcriptional Changes", "PROBLEM", 151, 174], ["bromouridine sequencing", "TREATMENT", 260, 283], ["Neuronal Network", "OBSERVATION", 105, 121], ["nascent transcripts", "OBSERVATION", 332, 351]]], ["We prepared primary forebrain neuron cultures from embryonic day 18 (E18) mouse embryos and allowed them to mature for 17 days in vitro (DIV).", [["forebrain neuron cultures", "ANATOMY", 20, 45], ["embryonic day 18", "ANATOMY", 51, 67], ["embryos", "ANATOMY", 80, 87], ["forebrain neuron cultures", "CELL", 20, 45], ["mouse", "ORGANISM", 74, 79], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 80, 87], ["primary forebrain neuron cultures", "CELL_LINE", 12, 45], ["mouse", "SPECIES", 74, 79], ["mouse", "SPECIES", 74, 79]]], ["To monitor bidirectional transcriptional responses to activity shifts, network activity was elevated by 20 mM bicuculline (BIC; a GABA A receptor antagonist) or suppressed by 1 mM tetrodotoxin (TTX; a sodium channel blocker) for 4 h.", [["bicuculline", "CHEMICAL", 110, 121], ["BIC", "CHEMICAL", 123, 126], ["GABA", "CHEMICAL", 130, 134], ["tetrodotoxin", "CHEMICAL", 180, 192], ["TTX", "CHEMICAL", 194, 197], ["sodium", "CHEMICAL", 201, 207], ["bicuculline", "CHEMICAL", 110, 121], ["BIC", "CHEMICAL", 123, 126], ["GABA", "CHEMICAL", 130, 134], ["tetrodotoxin", "CHEMICAL", 180, 192], ["TTX", "CHEMICAL", 194, 197], ["sodium", "CHEMICAL", 201, 207], ["bicuculline", "SIMPLE_CHEMICAL", 110, 121], ["GABA A receptor", "GENE_OR_GENE_PRODUCT", 130, 145], ["tetrodotoxin", "SIMPLE_CHEMICAL", 180, 192], ["TTX", "SIMPLE_CHEMICAL", 194, 197], ["sodium channel blocker", "SIMPLE_CHEMICAL", 201, 223], ["a GABA A receptor antagonist)", "TREATMENT", 128, 157], ["1 mM tetrodotoxin (TTX", "TREATMENT", 175, 197], ["a sodium channel blocker", "TREATMENT", 199, 223]]], ["During the last 20 min of BIC or TTX treatment, we added BrU to the culture me-dium to label newly synthesized transcripts.", [["BIC", "CHEMICAL", 26, 29], ["TTX", "CHEMICAL", 33, 36], ["TTX", "CHEMICAL", 33, 36], ["BrU", "CHEMICAL", 57, 60], ["TTX", "SIMPLE_CHEMICAL", 33, 36], ["BrU", "SIMPLE_CHEMICAL", 57, 60], ["BrU", "PROTEIN", 57, 60], ["BIC or TTX treatment", "TREATMENT", 26, 46], ["the culture", "TEST", 64, 75]]], ["We isolated the labeled RNAs using an anti-BrU antibody and subjected them to next-generation sequencing ( Figure 1A ).Altered Neuronal Network Activity Triggers Genomewide Transcriptional ChangesOur BrU-seq dataset demonstrated the expected induction of Arc and Fos by BIC ( Figure 1B) .", [["anti-BrU", "GENE_OR_GENE_PRODUCT", 38, 46], ["Arc", "GENE_OR_GENE_PRODUCT", 255, 258], ["Fos", "GENE_OR_GENE_PRODUCT", 263, 266], ["labeled RNAs", "RNA", 16, 28], ["anti-BrU antibody", "PROTEIN", 38, 55], ["BrU", "PROTEIN", 200, 203], ["Arc", "PROTEIN", 255, 258], ["Fos", "PROTEIN", 263, 266], ["an anti-BrU antibody", "TREATMENT", 35, 55], ["Altered Neuronal Network", "PROBLEM", 119, 143], ["BrU", "TEST", 200, 203], ["Neuronal Network", "OBSERVATION", 127, 143]]], ["Other well-characterized activity-dependent genes, such as Npas4, Egr1, Homer1, Tet3, and Txnip, also showed expected transcriptional induction (Table S1 ).", [["Npas4", "GENE_OR_GENE_PRODUCT", 59, 64], ["Egr1", "GENE_OR_GENE_PRODUCT", 66, 70], ["Homer1", "GENE_OR_GENE_PRODUCT", 72, 78], ["Tet3", "GENE_OR_GENE_PRODUCT", 80, 84], ["Txnip", "GENE_OR_GENE_PRODUCT", 90, 95], ["Npas4", "DNA", 59, 64], ["Egr1", "DNA", 66, 70], ["Homer1", "DNA", 72, 78], ["Tet3", "DNA", 80, 84], ["Txnip", "DNA", 90, 95], ["Txnip", "TEST", 90, 95]]], ["Differential gene expression analysis of the BrU-seq data using DESeq2 (Love et al., 2014) revealed widespread transcriptional changes, in which 45% of expressed genes (7,592 of 16,682) were up-or downregulated by network activity shifts (p adj < 0.05; Figure 1C ).", [["BrU", "GENE_OR_GENE_PRODUCT", 45, 48], ["BrU", "DNA", 45, 48], ["the BrU", "TEST", 41, 48], ["widespread transcriptional changes", "PROBLEM", 100, 134], ["widespread", "OBSERVATION_MODIFIER", 100, 110], ["transcriptional changes", "OBSERVATION", 111, 134]]], ["BIC increased transcription of 2,908 genes, while TTX did so for 1,820 genes.", [["TTX", "CHEMICAL", 50, 53], ["TTX", "CHEMICAL", 50, 53], ["TTX", "SIMPLE_CHEMICAL", 50, 53], ["2,908 genes", "DNA", 31, 42], ["1,820 genes", "DNA", 65, 76], ["BIC increased transcription", "PROBLEM", 0, 27]]], ["The magnitude of transcriptional induction is higher with BIC treatment compared with TTX treatment ( Figure 1D ).", [["BIC", "CHEMICAL", 58, 61], ["TTX", "CHEMICAL", 86, 89], ["BIC", "CHEMICAL", 58, 61], ["TTX", "CHEMICAL", 86, 89], ["BIC", "SIMPLE_CHEMICAL", 58, 61], ["TTX", "SIMPLE_CHEMICAL", 86, 89], ["transcriptional induction", "TREATMENT", 17, 42], ["BIC treatment", "TREATMENT", 58, 71], ["TTX treatment", "TREATMENT", 86, 99], ["magnitude", "OBSERVATION_MODIFIER", 4, 13], ["transcriptional induction", "OBSERVATION", 17, 42], ["higher", "OBSERVATION_MODIFIER", 46, 52]]], ["To examine the relationship between nascent and steady-state transcriptomes, we compared our BrU-seq data with published mRNA-seq datasets of mouse cortical neurons treated with TTX or BIC for 4 or 6 h Yu et al., 2015b) with identical data processing.", [["cortical neurons", "ANATOMY", 148, 164], ["TTX", "CHEMICAL", 178, 181], ["TTX", "CHEMICAL", 178, 181], ["mouse", "ORGANISM", 142, 147], ["cortical neurons", "CELL", 148, 164], ["TTX", "SIMPLE_CHEMICAL", 178, 181], ["BrU", "PROTEIN", 93, 96], ["mouse cortical neurons", "CELL_TYPE", 142, 164], ["mouse", "SPECIES", 142, 147], ["mouse", "SPECIES", 142, 147], ["published mRNA", "TEST", 111, 125], ["mouse cortical neurons", "PROBLEM", 142, 164]]], ["Our 4 h BrU-seq results showed a much stronger similarity with 4 h mRNA-seq than 6 h mRNAseq data ( Figure S1B ).", [["BrU", "PROTEIN", 8, 11], ["mRNA", "TEST", 67, 71], ["mRNAseq data", "TEST", 85, 97]]], ["Thus, BrU-seq reliably captures known transcriptional responses to bidirectional shifts in network activity.Altered Neuronal Network Activity Triggers Genomewide Transcriptional ChangesBrU-seq might be a better approach than mRNA-seq to detect downregulation of transcription, because the persistence of RNAs after transcription does not contribute to BrU-seq signals.", [["BrU-seq", "GENE_OR_GENE_PRODUCT", 6, 13], ["BrU-seq", "GENE_OR_GENE_PRODUCT", 352, 359], ["BrU", "PROTEIN", 6, 9], ["seq", "PROTEIN", 10, 13], ["ChangesBrU", "PROTEIN", 178, 188], ["seq", "DNA", 189, 192], ["mRNA", "RNA", 225, 229], ["RNAs", "RNA", 304, 308], ["BrU", "PROTEIN", 352, 355], ["seq", "PROTEIN", 356, 359], ["Altered Neuronal Network", "PROBLEM", 108, 132], ["mRNA", "TEST", 225, 229], ["downregulation of transcription", "PROBLEM", 244, 275], ["Neuronal Network", "OBSERVATION", 116, 132]]], ["Indeed, we found significantly larger suppression of Fos, Arc, Bdnf, and Npas4 (4-to 16-fold) by TTX treatment in BrU-seq compared with mRNA-seq performed with 4 h BIC and TTX treatments, in which downregulation was less than 2-fold (Figure 1E) Yu et al., 2015b) .", [["TTX", "CHEMICAL", 97, 100], ["TTX", "CHEMICAL", 172, 175], ["TTX", "CHEMICAL", 97, 100], ["TTX", "CHEMICAL", 172, 175], ["Fos", "GENE_OR_GENE_PRODUCT", 53, 56], ["Arc", "GENE_OR_GENE_PRODUCT", 58, 61], ["Bdnf", "GENE_OR_GENE_PRODUCT", 63, 67], ["Npas4", "GENE_OR_GENE_PRODUCT", 73, 78], ["TTX", "SIMPLE_CHEMICAL", 97, 100], ["BrU-seq", "GENE_OR_GENE_PRODUCT", 114, 121], ["TTX", "SIMPLE_CHEMICAL", 172, 175], ["Fos", "PROTEIN", 53, 56], ["Arc", "PROTEIN", 58, 61], ["Bdnf", "PROTEIN", 63, 67], ["Npas4", "PROTEIN", 73, 78], ["BrU", "PROTEIN", 114, 117], ["significantly larger suppression of Fos", "PROBLEM", 17, 56], ["Npas4", "TEST", 73, 78], ["TTX treatment", "TREATMENT", 97, 110], ["mRNA", "TEST", 136, 140], ["4 h BIC", "TREATMENT", 160, 167], ["TTX treatments", "TREATMENT", 172, 186], ["significantly", "OBSERVATION_MODIFIER", 17, 30], ["larger", "OBSERVATION_MODIFIER", 31, 37], ["suppression", "OBSERVATION", 38, 49]]], ["The magnitude of upregulation in response to BIC was smaller in BrU-seq, likely because the early transcriptional induction is largely complete 4 h after BIC treatment.", [["BIC", "CHEMICAL", 154, 157], ["BrU-seq", "GENE_OR_GENE_PRODUCT", 64, 71], ["BrU", "PROTEIN", 64, 67], ["BIC", "TEST", 45, 48], ["the early transcriptional induction", "TREATMENT", 88, 123], ["BIC treatment", "TREATMENT", 154, 167], ["magnitude", "OBSERVATION_MODIFIER", 4, 13], ["upregulation", "OBSERVATION_MODIFIER", 17, 29], ["smaller", "OBSERVATION_MODIFIER", 53, 60]]], ["At a genome-wide scale, BrU-seq allowed us to detect transcriptional suppression of numerous genes (BIC, n = 2,842; TTX, n = 2,307).", [["TTX", "CHEMICAL", 116, 119], ["TTX", "CHEMICAL", 116, 119], ["BrU-seq", "GENE_OR_GENE_PRODUCT", 24, 31], ["BrU", "DNA", 24, 27], ["seq", "DNA", 28, 31], ["transcriptional suppression of numerous genes (BIC", "PROBLEM", 53, 103], ["TTX", "TEST", 116, 119]]], ["These data highlight an advantage of the BrU-seq approach to probe mechanisms underlying highly dynamic activity-dependent transcription.Altered Neuronal Network Activity Triggers Genomewide Transcriptional ChangesOn the basis of the behavior of well-defined activity-response genes ( Figure 1E ), one could assume that BIC and TTX trigger reciprocal transcriptional responses.", [["Neuronal", "ANATOMY", 145, 153], ["TTX", "CHEMICAL", 328, 331], ["BIC", "CHEMICAL", 320, 323], ["TTX", "CHEMICAL", 328, 331], ["TTX", "SIMPLE_CHEMICAL", 328, 331], ["BrU", "PROTEIN", 41, 44], ["activity-response genes", "DNA", 259, 282], ["the BrU-seq approach", "TREATMENT", 37, 57], ["Altered Neuronal Network", "PROBLEM", 137, 161], ["highly", "OBSERVATION_MODIFIER", 89, 95], ["dynamic activity", "OBSERVATION", 96, 112], ["Neuronal Network", "OBSERVATION", 145, 161]]], ["Unexpectedly, only a small fraction of activity-response genes (24% [1,798 of 7,592]) displayed such mirrored responses between BIC and TTX treatments ( Figure 1F ).", [["TTX", "CHEMICAL", 136, 139], ["TTX", "CHEMICAL", 136, 139], ["TTX", "SIMPLE_CHEMICAL", 136, 139], ["activity-response genes", "DNA", 39, 62], ["BIC and TTX treatments", "TREATMENT", 128, 150], ["small", "OBSERVATION_MODIFIER", 21, 26], ["fraction", "OBSERVATION_MODIFIER", 27, 35]]], ["Six percent of activity-response genes (487 of 7,592) altered their transcription levels in the same direction after BIC and TTX treatments.", [["TTX", "CHEMICAL", 125, 128], ["TTX", "CHEMICAL", 125, 128], ["TTX", "SIMPLE_CHEMICAL", 125, 128], ["activity-response genes", "DNA", 15, 38], ["altered their transcription levels", "PROBLEM", 54, 88], ["BIC and TTX treatments", "TREATMENT", 117, 139]]], ["The remaining majority of genes (70% [5,307 of 7,592]) responded to BIC or TTX uniquely.", [["BIC", "CHEMICAL", 68, 71], ["TTX", "CHEMICAL", 75, 78], ["BIC", "CHEMICAL", 68, 71], ["TTX", "CHEMICAL", 75, 78], ["TTX", "SIMPLE_CHEMICAL", 75, 78]]], ["These data suggest that synaptic up-and downscaling involves distinct transcriptional programs.", [["synaptic", "ANATOMY", 24, 32], ["These data", "TEST", 0, 10]]], ["Table S1 lists genes that displayed greater than 2-fold changes in transcription upon network activity shifts.Altered Neuronal Network Activity Triggers Genomewide Transcriptional ChangesRecent studies have reported that different cell types, such as astrocytes and neuronal subtypes, induce distinct sets of genes in an activity-dependent manner (Hasel et al., 2017; Hrvatin et al., 2018) .", [["Neuronal", "ANATOMY", 118, 126], ["cell", "ANATOMY", 231, 235], ["astrocytes", "ANATOMY", 251, 261], ["neuronal", "ANATOMY", 266, 274], ["S1", "GENE_OR_GENE_PRODUCT", 6, 8], ["cell", "CELL", 231, 235], ["astrocytes", "CELL", 251, 261], ["neuronal", "CELL", 266, 274], ["astrocytes", "CELL_TYPE", 251, 261], ["Altered Neuronal Network", "PROBLEM", 110, 134], ["Transcriptional Changes", "PROBLEM", 164, 187], ["Recent studies", "TEST", 187, 201], ["different cell types", "PROBLEM", 221, 241], ["astrocytes", "PROBLEM", 251, 261], ["greater", "OBSERVATION_MODIFIER", 36, 43], ["Neuronal Network", "OBSERVATION", 118, 134], ["different cell types", "OBSERVATION", 221, 241], ["neuronal subtypes", "OBSERVATION", 266, 283]]], ["We sought to assess the contribution of various cell types in our datasets.", [["cell", "ANATOMY", 48, 52], ["cell", "CELL", 48, 52], ["various cell types", "PROBLEM", 40, 58], ["various cell types", "OBSERVATION", 40, 58]]], ["Using immunocytochemistry of a set of cell type markers, NeuN, GAD67, GFAP, CD11b, and Olig2, we estimated that our cultures comprise 41% excitatory neurons, 11% (D) BIC-response genes show a greater median fold change (Wilcoxon rank-sum test).", [["cell", "ANATOMY", 38, 42], ["cultures", "ANATOMY", 116, 124], ["excitatory neurons", "ANATOMY", 138, 156], ["cell type", "CELL", 38, 47], ["NeuN", "GENE_OR_GENE_PRODUCT", 57, 61], ["GAD67", "GENE_OR_GENE_PRODUCT", 63, 68], ["GFAP", "GENE_OR_GENE_PRODUCT", 70, 74], ["CD11b", "GENE_OR_GENE_PRODUCT", 76, 81], ["Olig2", "GENE_OR_GENE_PRODUCT", 87, 92], ["neurons", "CELL", 149, 156], ["cell type markers", "PROTEIN", 38, 55], ["NeuN", "PROTEIN", 57, 61], ["GAD67", "PROTEIN", 63, 68], ["GFAP", "PROTEIN", 70, 74], ["CD11b", "PROTEIN", 76, 81], ["Olig2", "PROTEIN", 87, 92], ["immunocytochemistry", "TEST", 6, 25], ["cell type markers", "TEST", 38, 55], ["NeuN", "TEST", 57, 61], ["GAD67", "TEST", 63, 68], ["GFAP", "TEST", 70, 74], ["CD11b", "TEST", 76, 81], ["Olig2", "TEST", 87, 92], ["our cultures", "TEST", 112, 124], ["excitatory neurons", "TEST", 138, 156], ["% (D) BIC-response genes", "TEST", 160, 184], ["a greater median fold change", "PROBLEM", 190, 218], ["Wilcoxon rank", "TEST", 220, 233], ["greater", "OBSERVATION_MODIFIER", 192, 199], ["median fold", "OBSERVATION", 200, 211]]], ["Whiskers represent 1.5 times the inter-quartile range (IQR), and the notch represents the 95% confidence interval of the median.", [["1.5 times", "OBSERVATION_MODIFIER", 19, 28]]], ["(E) Downregulation of immediate-early gene in the TTX condition is captured more sensitively in BrU-seq data compared with mRNA-seq data .", [["TTX", "CHEMICAL", 50, 53], ["TTX", "CHEMICAL", 50, 53], ["TTX", "SIMPLE_CHEMICAL", 50, 53], ["BrU-seq", "GENE_OR_GENE_PRODUCT", 96, 103], ["immediate-early gene", "DNA", 22, 42], ["mRNA", "TEST", 123, 127]]], ["(F) The majority of TTX and BIC response genes are uniquely regulated (70%).", [["TTX", "CHEMICAL", 20, 23], ["TTX", "CHEMICAL", 20, 23], ["TTX", "SIMPLE_CHEMICAL", 20, 23], ["TTX and BIC response genes", "DNA", 20, 46]]], ["See also Figure S1 and Tables S1 and S2.Altered Neuronal Network Activity Triggers Genomewide Transcriptional ChangesCell Reports 32, 108002, August 11, 2020 3 Article ll OPEN ACCESS inhibitory neurons, 33% astrocytes, 15% of cells within the oligodendrocyte lineage, and no microglia (Figures S1D and S1E).", [["Cell", "ANATOMY", 117, 121], ["neurons", "ANATOMY", 194, 201], ["astrocytes", "ANATOMY", 207, 217], ["cells", "ANATOMY", 226, 231], ["oligodendrocyte lineage", "ANATOMY", 243, 266], ["microglia", "ANATOMY", 275, 284], ["neurons", "CELL", 194, 201], ["astrocytes", "CELL", 207, 217], ["cells", "CELL", 226, 231], ["oligodendrocyte lineage", "CELL", 243, 266], ["microglia", "CELL", 275, 284], ["S1", "PROTEIN", 30, 32], ["S2", "PROTEIN", 37, 39], ["inhibitory neurons", "CELL_TYPE", 183, 201], ["astrocytes", "CELL_TYPE", 207, 217], ["oligodendrocyte lineage", "CELL_TYPE", 243, 266], ["microglia", "CELL_TYPE", 275, 284], ["S1E", "PROTEIN", 302, 305], ["Altered Neuronal Network", "PROBLEM", 40, 64], ["neurons", "TEST", 194, 201], ["astrocytes", "TEST", 207, 217], ["the oligodendrocyte lineage", "TEST", 239, 266], ["microglia", "PROBLEM", 275, 284], ["S2", "ANATOMY", 37, 39], ["Neuronal Network", "OBSERVATION", 48, 64], ["oligodendrocyte lineage", "OBSERVATION", 243, 266], ["no", "UNCERTAINTY", 272, 274], ["microglia", "ANATOMY", 275, 284]]], ["We found several non-neuronal genes in our dataset, including Thbs1, a synaptic regulator expressed specifically in astrocytes (Risher and Eroglu, 2012) .", [["non-neuronal", "ANATOMY", 17, 29], ["synaptic", "ANATOMY", 71, 79], ["astrocytes", "ANATOMY", 116, 126], ["non-neuronal", "CELL", 17, 29], ["Thbs1", "GENE_OR_GENE_PRODUCT", 62, 67], ["astrocytes", "CELL", 116, 126], ["non-neuronal genes", "DNA", 17, 35], ["Thbs1", "PROTEIN", 62, 67], ["astrocytes", "CELL_TYPE", 116, 126], ["several", "OBSERVATION_MODIFIER", 9, 16], ["non-neuronal genes", "OBSERVATION", 17, 35]]], ["We detected enrichment of biological processes specific for both neurons and non-neuronal cell types (Table S2 ).", [["neurons", "ANATOMY", 65, 72], ["non-neuronal cell", "ANATOMY", 77, 94], ["neurons", "CELL", 65, 72], ["non-neuronal cell types", "CELL", 77, 100], ["non-neuronal cell types", "CELL_TYPE", 77, 100], ["both neurons", "PROBLEM", 60, 72], ["non-neuronal cell types", "OBSERVATION", 77, 100]]], ["Intersection of the BrU-seq data with published celltype-enriched genes revealed that the majority (>80%) of the activity-response genes do not exhibit cell type-specific expression ( Figure S1F ).", [["cell", "ANATOMY", 152, 156], ["BrU", "GENE_OR_GENE_PRODUCT", 20, 23], ["cell", "CELL", 152, 156], ["BrU", "DNA", 20, 23], ["celltype-enriched genes", "DNA", 48, 71], ["activity-response genes", "DNA", 113, 136], ["the BrU", "TEST", 16, 23]]], ["Thus, the present dataset represents an aggregate view of transcriptional response occurring in multiple cell types.", [["cell", "ANATOMY", 105, 109], ["cell", "CELL", 105, 109], ["transcriptional response", "PROBLEM", 58, 82], ["transcriptional response", "OBSERVATION", 58, 82], ["multiple cell types", "OBSERVATION", 96, 115]]], ["Figure S2 and Tables S3 and S4. roles in activity-dependent transcription and synaptic plasticity.", [["synaptic", "ANATOMY", 78, 86], ["S4", "PROTEIN", 28, 30], ["Tables S3", "ANATOMY", 14, 23], ["S4", "ANATOMY", 28, 30], ["synaptic plasticity", "OBSERVATION", 78, 97]]], ["We developed an anti-RAI1 antibody and confirmed that RAI1 protein was present in virtually all MAP2-positive neurons and primarily localized to the nucleus, with subtle signals in the soma ( Figure S2A ).", [["MAP2-positive neurons", "ANATOMY", 96, 117], ["nucleus", "ANATOMY", 149, 156], ["soma", "ANATOMY", 185, 189], ["RAI1", "GENE_OR_GENE_PRODUCT", 54, 58], ["MAP2", "GENE_OR_GENE_PRODUCT", 96, 100], ["nucleus", "CELLULAR_COMPONENT", 149, 156], ["soma", "CELLULAR_COMPONENT", 185, 189], ["anti-RAI1 antibody", "PROTEIN", 16, 34], ["RAI1 protein", "PROTEIN", 54, 66], ["MAP2", "PROTEIN", 96, 100], ["an anti-RAI1 antibody", "TEST", 13, 34], ["RAI1 protein", "PROBLEM", 54, 66], ["positive neurons", "PROBLEM", 101, 117], ["positive neurons", "OBSERVATION", 101, 117], ["nucleus", "ANATOMY", 149, 156], ["subtle", "OBSERVATION_MODIFIER", 163, 169], ["soma", "OBSERVATION_MODIFIER", 185, 189]]], ["We found lower RAI1 levels in non-neuronal (MAP2-negative) cell nuclei ( Figure S2A Having established nascent transcriptional profiling in neural ensembles and the presence of RAI1 in our cultures, we sought to test if RAI1 has any roles in synaptic scaling and transcriptional responses to altered neuronal activity.", [["non-neuronal (MAP2-negative) cell nuclei", "ANATOMY", 30, 70], ["neural", "ANATOMY", 140, 146], ["cultures", "ANATOMY", 189, 197], ["synaptic", "ANATOMY", 242, 250], ["neuronal", "ANATOMY", 300, 308], ["RAI1", "GENE_OR_GENE_PRODUCT", 15, 19], ["non-neuronal", "CELL", 30, 42], ["MAP2", "GENE_OR_GENE_PRODUCT", 44, 48], ["RAI1", "GENE_OR_GENE_PRODUCT", 177, 181], ["RAI1", "GENE_OR_GENE_PRODUCT", 220, 224], ["neuronal", "CELL", 300, 308], ["RAI1", "PROTEIN", 15, 19], ["MAP2", "PROTEIN", 44, 48], ["RAI1", "PROTEIN", 177, 181], ["RAI1", "PROTEIN", 220, 224], ["lower RAI1 levels", "PROBLEM", 9, 26], ["non-neuronal (MAP2", "TEST", 30, 48], ["cell nuclei ( Figure S2A", "PROBLEM", 59, 83], ["our cultures", "TEST", 185, 197], ["synaptic scaling", "PROBLEM", 242, 258], ["altered neuronal activity", "PROBLEM", 292, 317], ["lower", "ANATOMY_MODIFIER", 9, 14], ["cell nuclei", "OBSERVATION", 59, 70], ["nascent transcriptional profiling", "OBSERVATION", 103, 136], ["neuronal activity", "OBSERVATION", 300, 317]]], ["We knocked down Rai1 in primary cortical cultures using lentiviral vectors (LVs) carrying Rai1 or scrambled short hairpin RNAs (shRNAs) (sh-Ctrl).", [["cortical cultures", "ANATOMY", 32, 49], ["LVs", "ANATOMY", 76, 79], ["Rai1", "GENE_OR_GENE_PRODUCT", 16, 20], ["cortical cultures", "CELL", 32, 49], ["lentiviral", "ORGANISM", 56, 66], ["LVs", "ORGANISM", 76, 79], ["Rai1", "GENE_OR_GENE_PRODUCT", 90, 94], ["short hairpin RNAs", "GENE_OR_GENE_PRODUCT", 108, 126], ["Rai1", "PROTEIN", 16, 20], ["primary cortical cultures", "CELL_LINE", 24, 49], ["LVs", "DNA", 76, 79], ["Rai1", "DNA", 90, 94], ["scrambled short hairpin RNAs", "RNA", 98, 126], ["shRNAs", "DNA", 128, 134], ["primary cortical cultures", "TEST", 24, 49], ["lentiviral vectors", "TREATMENT", 56, 74], ["carrying Rai1", "PROBLEM", 81, 94], ["scrambled short hairpin RNAs (shRNAs)", "PROBLEM", 98, 135]]], ["To minimize the impact of RAI1 loss on network connectivity, we delivered LV shRNA at DIV 14, a time by which functional synapses have formed.", [["LV", "ANATOMY", 74, 76], ["RAI1", "GENE_OR_GENE_PRODUCT", 26, 30], ["network", "MULTI-TISSUE_STRUCTURE", 39, 46], ["RAI1", "PROTEIN", 26, 30], ["LV shRNA", "DNA", 74, 82], ["DIV 14", "DNA", 86, 92], ["RAI1 loss", "PROBLEM", 26, 35], ["LV shRNA", "TREATMENT", 74, 82], ["RAI1 loss", "OBSERVATION", 26, 35]]], ["The knockdown (KD) achieved near complete loss of RAI1 protein by 3 days post-LV infection ( Figure 2A ).", [["LV", "ANATOMY", 78, 80], ["LV infection", "DISEASE", 78, 90], ["RAI1", "GENE_OR_GENE_PRODUCT", 50, 54], ["LV", "MULTI-TISSUE_STRUCTURE", 78, 80], ["RAI1 protein", "PROTEIN", 50, 62], ["near complete loss of RAI1 protein", "PROBLEM", 28, 62], ["LV infection", "PROBLEM", 78, 90], ["LV", "ANATOMY", 78, 80], ["infection", "OBSERVATION", 81, 90]]], ["We then modulated network activity of LV-treated cultures by applying TTX or BIC for 4 h and carried out BrU-seq as described above.RAI1 Suppresses the TTX-Induced Transcriptional Program in Resting NetworksWe initially tested if Rai1 KD alters nascent transcription in control ''resting'' neuronal cultures with stable basal levels of activity.", [["LV", "ANATOMY", 38, 40], ["cultures", "ANATOMY", 49, 57], ["neuronal cultures", "ANATOMY", 290, 307], ["TTX", "CHEMICAL", 70, 73], ["BIC", "CHEMICAL", 77, 80], ["TTX", "CHEMICAL", 152, 155], ["TTX", "CHEMICAL", 70, 73], ["TTX", "CHEMICAL", 152, 155], ["LV", "CELL", 38, 40], ["TTX", "SIMPLE_CHEMICAL", 70, 73], ["BrU-seq", "GENE_OR_GENE_PRODUCT", 105, 112], ["RAI1", "SIMPLE_CHEMICAL", 132, 136], ["TTX", "SIMPLE_CHEMICAL", 152, 155], ["Rai1", "GENE_OR_GENE_PRODUCT", 230, 234], ["neuronal cultures", "CELL", 290, 307], ["LV-treated cultures", "CELL_LINE", 38, 57], ["BrU", "PROTEIN", 105, 108], ["RAI1", "PROTEIN", 132, 136], ["Rai1 KD", "PROTEIN", 230, 237], ["neuronal cultures", "CELL_LINE", 290, 307], ["LV", "TEST", 38, 40], ["cultures", "TEST", 49, 57], ["nascent transcription", "TREATMENT", 245, 266], ["resting'' neuronal cultures", "TEST", 280, 307], ["LV", "ANATOMY", 38, 40]]], ["DESeq2 analysis revealed 122 differentially expressed (DE) genes: 104 downregulated and 18 upregulated following Rai1 KD (p adj < 0.05; Figure 2B ; Table S3 ).", [["DESeq2", "DNA", 0, 6], ["122 differentially expressed (DE) genes", "DNA", 25, 64], ["DESeq2 analysis", "TEST", 0, 15], ["Rai1 KD", "TEST", 113, 120], ["adj", "TEST", 124, 127]]], ["The finding that Rai1 KD downregulates more genes than it upregulates is consistent with the previous studies on RAI1 (Elsea and Williams, 2011; Huang et al., 2016) .", [["Rai1", "GENE_OR_GENE_PRODUCT", 17, 21], ["RAI1", "GENE_OR_GENE_PRODUCT", 113, 117], ["Rai1 KD", "PROTEIN", 17, 24], ["the previous studies", "TEST", 89, 109], ["consistent with", "UNCERTAINTY", 73, 88]]], ["A majority of genes altered by Rai1 KD at baseline were BIC-or TTX-response genes ( Figure 2C ).", [["TTX", "CHEMICAL", 63, 66], ["TTX", "CHEMICAL", 63, 66], ["Rai1", "GENE_OR_GENE_PRODUCT", 31, 35], ["TTX", "SIMPLE_CHEMICAL", 63, 66], ["TTX-response genes", "DNA", 63, 81], ["BIC", "TEST", 56, 59], ["TTX", "TEST", 63, 66]]], ["To further characterize the relationship between RAI1 deficiency and BIC-or TTX-response genes, we examined how individual genes behave upon Rai1 KD.", [["TTX", "CHEMICAL", 76, 79], ["TTX", "CHEMICAL", 76, 79], ["RAI1", "GENE_OR_GENE_PRODUCT", 49, 53], ["TTX", "SIMPLE_CHEMICAL", 76, 79], ["Rai1", "GENE_OR_GENE_PRODUCT", 141, 145], ["RAI1", "PROTEIN", 49, 53], ["BIC-or TTX-response genes", "DNA", 69, 94], ["RAI1 deficiency", "PROBLEM", 49, 64], ["BIC", "TEST", 69, 72]]], ["We found a clear positive correlation between the normal transcriptional response to TTX and the transcriptional impairment by Rai1 KD at baseline (Spearman rank correlation coefficient r = 0.53, t test p = 2.2 3 10 \u00c016 ; Figure 2D, left panel).", [["TTX", "CHEMICAL", 85, 88], ["TTX", "CHEMICAL", 85, 88], ["TTX", "SIMPLE_CHEMICAL", 85, 88], ["the transcriptional impairment", "PROBLEM", 93, 123], ["coefficient r", "TEST", 174, 187], ["t test p", "TEST", 196, 204], ["Figure 2D, left panel", "TEST", 222, 243], ["clear", "OBSERVATION_MODIFIER", 11, 16], ["positive", "OBSERVATION", 17, 25], ["normal transcriptional response to TTX", "OBSERVATION", 50, 88], ["left", "ANATOMY_MODIFIER", 233, 237]]], ["BIC-response genes showed no correlation with Rai1 KD ( Figure 2D , right panel).", [["BIC-response genes", "DNA", 0, 18], ["Rai1", "PROTEIN", 46, 50], ["Figure 2D , right panel", "TEST", 56, 79], ["right", "ANATOMY_MODIFIER", 68, 73]]], ["The group of genes that respond reciprocally to TTX and BIC ( Figure 1F ) showed a similar correlation as there was with all TTX-responsive genes (Figure S2D ).", [["TTX", "CHEMICAL", 48, 51], ["TTX", "CHEMICAL", 125, 128], ["TTX", "CHEMICAL", 48, 51], ["TTX", "CHEMICAL", 125, 128], ["TTX", "SIMPLE_CHEMICAL", 48, 51], ["TTX", "SIMPLE_CHEMICAL", 125, 128], ["TTX-responsive genes", "DNA", 125, 145], ["TTX", "TEST", 48, 51]]], ["When we removed all DE genes upon Rai1 KD from the plot, the correlation remained significant (r = 0.52, p = 2.2 3 10 \u00c016 ; Figure S2E ), suggesting that the DE genes are not the sole driver for the observed correlation.", [["Rai1 KD", "GENE_OR_GENE_PRODUCT", 34, 41], ["DE genes", "DNA", 20, 28], ["Rai1 KD", "DNA", 34, 41], ["DE genes", "DNA", 158, 166], ["p", "TEST", 105, 106]]], ["We also analyzed the published mRNA-seq of the Rai1-knockout (KO) cortices and found a similar trend in expression pattern of the TTX-and BIC-response genes in vivo ( Figure S2F ).", [["Rai1-knockout (KO) cortices", "ANATOMY", 47, 74], ["TTX", "CHEMICAL", 130, 133], ["TTX", "CHEMICAL", 130, 133], ["Rai1", "GENE_OR_GENE_PRODUCT", 47, 51], ["TTX", "SIMPLE_CHEMICAL", 130, 133], ["Rai1", "PROTEIN", 47, 51], ["TTX-and BIC-response genes", "DNA", 130, 156], ["the TTX", "TEST", 126, 133], ["response genes", "OBSERVATION", 142, 156]]], ["These data show that RAI1 deficiency shifts the transcriptional profile toward the TTX-treated state without drug application and that Rai1 KD does not affect transcription of non-reciprocal BIC-responsive genes.RAI1 Deficiency Promotes Synaptic UpscalingChronic perturbation of neuronal activity by BIC or TTX induces decreases and increases in synaptic strength, which respectively underlie homeostatic synaptic downscaling and upscaling (Abbott and Nelson, 2000; Miller and MacKay, 1994; Turrigiano, 2008) .", [["Synaptic", "ANATOMY", 237, 245], ["neuronal", "ANATOMY", 279, 287], ["synaptic", "ANATOMY", 346, 354], ["synaptic", "ANATOMY", 405, 413], ["RAI1", "CHEMICAL", 21, 25], ["TTX", "CHEMICAL", 83, 86], ["TTX", "CHEMICAL", 307, 310], ["TTX", "CHEMICAL", 83, 86], ["BIC", "CHEMICAL", 300, 303], ["TTX", "CHEMICAL", 307, 310], ["RAI1", "GENE_OR_GENE_PRODUCT", 21, 25], ["TTX", "SIMPLE_CHEMICAL", 83, 86], ["Rai1", "GENE_OR_GENE_PRODUCT", 135, 139], ["BIC", "GENE_OR_GENE_PRODUCT", 191, 194], ["RAI1", "GENE_OR_GENE_PRODUCT", 212, 216], ["neuronal", "CELL", 279, 287], ["TTX", "SIMPLE_CHEMICAL", 307, 310], ["RAI1", "PROTEIN", 21, 25], ["non-reciprocal BIC-responsive genes", "DNA", 176, 211], ["RAI1", "PROTEIN", 212, 216], ["These data", "TEST", 0, 10], ["RAI1 deficiency", "PROBLEM", 21, 36], ["the TTX", "TREATMENT", 79, 86], ["drug application", "TREATMENT", 109, 125], ["RAI1 Deficiency", "PROBLEM", 212, 227], ["neuronal activity", "PROBLEM", 279, 296], ["increases in synaptic strength", "PROBLEM", 333, 363], ["responsive genes", "OBSERVATION", 195, 211], ["Deficiency", "OBSERVATION", 217, 227], ["Synaptic Upscaling", "OBSERVATION", 237, 255], ["Chronic", "OBSERVATION_MODIFIER", 255, 262], ["neuronal activity", "OBSERVATION", 279, 296], ["decreases", "OBSERVATION_MODIFIER", 319, 328], ["increases", "OBSERVATION_MODIFIER", 333, 342], ["synaptic strength", "OBSERVATION", 346, 363], ["synaptic downscaling", "OBSERVATION", 405, 425]]], ["Given that Rai1 KD shifted the nascent transcriptome toward the TTX-like state, we asked whether Rai1 KD would similarly shift excitatory synapse function toward a state similar to synaptic upscaling.", [["excitatory synapse", "ANATOMY", 127, 145], ["synaptic", "ANATOMY", 181, 189], ["TTX", "CHEMICAL", 64, 67], ["TTX", "CHEMICAL", 64, 67], ["Rai1 KD", "GENE_OR_GENE_PRODUCT", 11, 18], ["TTX", "SIMPLE_CHEMICAL", 64, 67], ["Rai1", "GENE_OR_GENE_PRODUCT", 97, 101], ["excitatory synapse", "CELLULAR_COMPONENT", 127, 145], ["Rai1 KD", "PROTEIN", 11, 18], ["Rai1 KD", "PROTEIN", 97, 104]]], ["We used sparse transfection of DIV 12-14 hippocampal cultures with either Rai1 or scrambled shRNA and recorded miniature excitatory postsynaptic currents (mEPSCs) from transfected pyramidal-like neurons 48 h later.", [["hippocampal cultures", "ANATOMY", 41, 61], ["excitatory postsynaptic", "ANATOMY", 121, 144], ["pyramidal-like neurons", "ANATOMY", 180, 202], ["hippocampal cultures", "CELL", 41, 61], ["Rai1", "GENE_OR_GENE_PRODUCT", 74, 78], ["pyramidal-like neurons", "CELL", 180, 202], ["DIV 12-14 hippocampal cultures", "CELL_LINE", 31, 61], ["Rai1", "PROTEIN", 74, 78], ["transfected pyramidal-like neurons", "CELL_LINE", 168, 202], ["hippocampal cultures", "TEST", 41, 61], ["scrambled shRNA", "PROBLEM", 82, 97]]], ["If Rai1 KD induces synaptic strengthening in a cell-autonomous manner, we would expect to see a rightward shift in the distribution of mEPSC amplitudes as is observed during synaptic upscaling following chronic activity suppression with TTX.", [["synaptic", "ANATOMY", 19, 27], ["cell", "ANATOMY", 47, 51], ["synaptic", "ANATOMY", 174, 182], ["TTX", "CHEMICAL", 237, 240], ["TTX", "CHEMICAL", 237, 240], ["Rai1", "GENE_OR_GENE_PRODUCT", 3, 7], ["cell", "CELL", 47, 51], ["TTX", "SIMPLE_CHEMICAL", 237, 240], ["Rai1 KD", "PROTEIN", 3, 10], ["Rai1 KD", "PROBLEM", 3, 10], ["a rightward shift", "PROBLEM", 94, 111], ["mEPSC amplitudes", "PROBLEM", 135, 151], ["chronic activity suppression", "TREATMENT", 203, 231], ["synaptic strengthening", "OBSERVATION", 19, 41], ["rightward shift", "OBSERVATION", 96, 111], ["mEPSC amplitudes", "OBSERVATION", 135, 151], ["chronic", "OBSERVATION_MODIFIER", 203, 210], ["activity suppression", "OBSERVATION", 211, 231]]], ["Consistent with this idea, we found that the expression of two distinct shRNAs targeting Rai1 mRNA each induced a significant increase in baseline mEPSC amplitude ( Figures 3A and 3B ), without significantly altering mEPSC frequency or decay time ( Figures 3C and 3D ; Figures S3A-S3E) .", [["Rai1", "GENE_OR_GENE_PRODUCT", 89, 93], ["shRNAs", "DNA", 72, 78], ["Rai1 mRNA", "RNA", 89, 98], ["a significant increase", "PROBLEM", 112, 134], ["baseline mEPSC amplitude", "PROBLEM", 138, 162], ["significantly altering mEPSC frequency", "PROBLEM", 194, 232], ["Figures", "TEST", 269, 276], ["distinct", "OBSERVATION_MODIFIER", 63, 71], ["shRNAs", "OBSERVATION", 72, 78], ["significant", "OBSERVATION_MODIFIER", 114, 125], ["increase", "OBSERVATION_MODIFIER", 126, 134], ["mEPSC amplitude", "OBSERVATION", 147, 162], ["without", "UNCERTAINTY", 186, 193]]], ["Moreover, Rai1 KD induced a clear rightward shift in the cumulative probability distribution of mEPSC amplitudes relative to control neurons ( Figure 3E ; Figure S3E ), an effect that was significantly (albeit partially) rescued by expression of RNAi-resistant RAI1 (F[2, 41] = 4.452, p = 0.017; sh-Ctrl, sh-Rai1 #1, and rescue, n = 15, 15, and 14; sh-Ctrl versus sh-Rai1 #1, p = 0.068; sh-Rai1 #1 versus rescue, p = 0.0359; sh-Ctrl versus sh-Rai1 #2, n = 14-13, p = 0.0012; Figures 3A-3E ).", [["neurons", "ANATOMY", 133, 140], ["Rai1", "GENE_OR_GENE_PRODUCT", 10, 14], ["mEPSC", "SIMPLE_CHEMICAL", 96, 101], ["neurons", "CELL", 133, 140], ["RAI1", "GENE_OR_GENE_PRODUCT", 261, 265], ["sh-Rai1 #1", "GENE_OR_GENE_PRODUCT", 305, 315], ["Rai1 KD", "PROTEIN", 10, 17], ["control neurons", "CELL_TYPE", 125, 140], ["a clear rightward shift", "PROBLEM", 26, 49], ["mEPSC amplitudes", "PROBLEM", 96, 112], ["RNAi-resistant RAI1", "PROBLEM", 246, 265], ["p", "TEST", 285, 286], ["sh", "TEST", 296, 298], ["Ctrl", "TEST", 299, 303], ["sh", "TEST", 305, 307], ["rescue", "TEST", 321, 327], ["sh", "TEST", 349, 351], ["Ctrl", "TEST", 352, 356], ["sh", "TEST", 364, 366], ["Rai1", "TEST", 367, 371], ["p", "TEST", 376, 377], ["sh", "TEST", 387, 389], ["Rai1", "TEST", 390, 394], ["rescue", "TEST", 405, 411], ["p", "TEST", 413, 414], ["sh", "TEST", 425, 427], ["Ctrl", "TEST", 428, 432], ["sh", "TEST", 440, 442], ["Rai1", "TEST", 443, 447], ["n", "TEST", 452, 453], ["p", "TEST", 463, 464], ["Figures", "TEST", 475, 482], ["clear", "OBSERVATION_MODIFIER", 28, 33], ["rightward shift", "OBSERVATION", 34, 49], ["mEPSC amplitudes", "OBSERVATION", 96, 112]]], ["The shift in distribution of mEPSC am-plitudes with Rai1 KD bears a striking similarity to changes in mEPSC distributions following chronic TTX treatment ( Figure 3F ), although Rai1 KD did not shift mEPSC amplitudes to quite the same degree as TTX.", [["TTX", "CHEMICAL", 140, 143], ["TTX", "CHEMICAL", 245, 248], ["TTX", "CHEMICAL", 140, 143], ["TTX", "CHEMICAL", 245, 248], ["Rai1", "GENE_OR_GENE_PRODUCT", 52, 56], ["mEPSC", "SIMPLE_CHEMICAL", 102, 107], ["TTX", "SIMPLE_CHEMICAL", 140, 143], ["TTX", "SIMPLE_CHEMICAL", 245, 248], ["Rai1 KD", "PROTEIN", 52, 59], ["mEPSC am-plitudes", "PROBLEM", 29, 46], ["Rai1 KD", "PROBLEM", 52, 59], ["changes in mEPSC distributions", "PROBLEM", 91, 121], ["chronic TTX treatment", "TREATMENT", 132, 153], ["shift", "OBSERVATION_MODIFIER", 4, 9], ["distribution", "OBSERVATION_MODIFIER", 13, 25], ["mEPSC distributions", "OBSERVATION", 102, 121], ["chronic TTX", "OBSERVATION", 132, 143]]], ["An increase in surface expression of AMPA receptors (AMPARs) at synapses is a signature of synaptic upscaling following activity suppression.", [["surface", "ANATOMY", 15, 22], ["synaptic", "ANATOMY", 91, 99], ["AMPA", "CHEMICAL", 37, 41], ["AMPA", "CHEMICAL", 37, 41], ["surface", "CELLULAR_COMPONENT", 15, 22], ["AMPA receptors", "GENE_OR_GENE_PRODUCT", 37, 51], ["AMPARs", "GENE_OR_GENE_PRODUCT", 53, 59], ["AMPA receptors", "PROTEIN", 37, 51], ["AMPARs", "PROTEIN", 53, 59], ["AMPA receptors", "TREATMENT", 37, 51], ["activity suppression", "TREATMENT", 120, 140], ["increase", "OBSERVATION_MODIFIER", 3, 11], ["surface expression", "OBSERVATION_MODIFIER", 15, 33]]], ["Consistent with previous observations, surface expression of the GluA1 AMPAR subunit at PSD-95-labeled excitatory synapses is significantly increased following long-term (24 h) TTX treatment (sh-Ctrl vehicle [Veh] versus TTX, n = 13-12, p = 0.0019; Figure 3G ); likewise, we found a similar enhancement of surface GluA1 at synapses following 72 h Rai1 KD (sh-Ctrl versus sh-Rai1, n = 6-6, p = 0.0065; Figure 3G) .", [["surface", "ANATOMY", 39, 46], ["excitatory synapses", "ANATOMY", 103, 122], ["surface", "ANATOMY", 306, 313], ["TTX", "CHEMICAL", 177, 180], ["TTX", "CHEMICAL", 221, 224], ["TTX", "CHEMICAL", 177, 180], ["TTX", "CHEMICAL", 221, 224], ["surface", "CELLULAR_COMPONENT", 39, 46], ["GluA1", "GENE_OR_GENE_PRODUCT", 65, 70], ["PSD-95", "GENE_OR_GENE_PRODUCT", 88, 94], ["TTX", "SIMPLE_CHEMICAL", 177, 180], ["TTX", "SIMPLE_CHEMICAL", 221, 224], ["GluA1", "GENE_OR_GENE_PRODUCT", 314, 319], ["GluA1 AMPAR subunit", "PROTEIN", 65, 84], ["PSD", "PROTEIN", 88, 91], ["GluA1", "PROTEIN", 314, 319], ["PSD", "TEST", 88, 91], ["excitatory synapses", "PROBLEM", 103, 122], ["TTX treatment", "TREATMENT", 177, 190], ["TTX", "TEST", 221, 224], ["KD", "TEST", 352, 354], ["sh", "TEST", 356, 358], ["Ctrl", "TEST", 359, 363], ["sh", "TEST", 371, 373], ["Rai1", "TEST", 374, 378], ["significantly", "OBSERVATION_MODIFIER", 126, 139], ["increased", "OBSERVATION_MODIFIER", 140, 149]]], ["Together, these results suggest that reduced Rai1 expression induces functional changes in excitatory synaptic function that mimic synaptic upscaling induced by activity suppression.", [["excitatory synaptic", "ANATOMY", 91, 110], ["synaptic", "ANATOMY", 131, 139], ["Rai1", "GENE_OR_GENE_PRODUCT", 45, 49], ["synaptic", "IMMATERIAL_ANATOMICAL_ENTITY", 102, 110], ["Rai1", "PROTEIN", 45, 49], ["reduced Rai1 expression", "PROBLEM", 37, 60], ["functional changes in excitatory synaptic function", "PROBLEM", 69, 119], ["reduced", "OBSERVATION_MODIFIER", 37, 44]]], ["Two scenarios could explain the increase in mEPSC amplitude by Rai1 KD accompanied by TTX-like transcription in resting neurons.", [["neurons", "ANATOMY", 120, 127], ["TTX", "CHEMICAL", 86, 89], ["TTX", "CHEMICAL", 86, 89], ["mEPSC", "SIMPLE_CHEMICAL", 44, 49], ["Rai1", "GENE_OR_GENE_PRODUCT", 63, 67], ["TTX", "SIMPLE_CHEMICAL", 86, 89], ["neurons", "CELL", 120, 127], ["resting neurons", "CELL_TYPE", 112, 127], ["the increase in mEPSC amplitude", "PROBLEM", 28, 59], ["TTX", "PROBLEM", 86, 89], ["increase", "OBSERVATION_MODIFIER", 32, 40], ["mEPSC amplitude", "OBSERVATION", 44, 59], ["neurons", "ANATOMY", 120, 127]]], ["The first possibility is that Rai1 KD suppresses network activity, which in turn indirectly promotes a TTX-like transcriptional program and synaptic upscaling.", [["synaptic", "ANATOMY", 140, 148], ["TTX", "CHEMICAL", 103, 106], ["TTX", "CHEMICAL", 103, 106], ["Rai1 KD", "GENE_OR_GENE_PRODUCT", 30, 37], ["TTX", "SIMPLE_CHEMICAL", 103, 106], ["Rai1 KD", "PROTEIN", 30, 37], ["a TTX", "TREATMENT", 101, 106], ["transcriptional program", "TREATMENT", 112, 135], ["synaptic upscaling", "TREATMENT", 140, 158]]], ["An alternative possibility is that release of RAI1-mediated suppression of a TTX-responsive transcriptional program directly upscales synapse function.", [["synapse", "ANATOMY", 134, 141], ["RAI1", "CHEMICAL", 46, 50], ["TTX", "CHEMICAL", 77, 80], ["TTX", "CHEMICAL", 77, 80], ["RAI1", "GENE_OR_GENE_PRODUCT", 46, 50], ["TTX", "SIMPLE_CHEMICAL", 77, 80], ["RAI1", "PROTEIN", 46, 50], ["a TTX", "TREATMENT", 75, 80]]], ["To distinguish these possibilities, we measured ongoing basal network activity of control hippocampal cultures and Rai1 KD cultures using 60-channel microelectrode arrays (MEAs; Figures S3F and S3G ).", [["basal network", "ANATOMY", 56, 69], ["hippocampal cultures", "ANATOMY", 90, 110], ["Rai1 KD cultures", "ANATOMY", 115, 131], ["basal network", "MULTI-TISSUE_STRUCTURE", 56, 69], ["hippocampal cultures", "CELL", 90, 110], ["Rai1 KD cultures", "CELL", 115, 131], ["control hippocampal cultures", "CELL_LINE", 82, 110], ["Rai1 KD cultures", "CELL_LINE", 115, 131], ["S3G", "DNA", 194, 197], ["hippocampal cultures", "TEST", 90, 110], ["Rai1 KD cultures", "TEST", 115, 131], ["60-channel microelectrode arrays", "TREATMENT", 138, 170], ["MEAs", "TEST", 172, 176], ["Figures", "TEST", 178, 185], ["basal", "ANATOMY_MODIFIER", 56, 61], ["network activity", "OBSERVATION", 62, 78]]], ["On DIV 11, we transduced the cultures with LV control or Rai1 shRNA and recorded network activity on DIV 14.", [["cultures", "ANATOMY", 29, 37], ["LV", "ANATOMY", 43, 45], ["Rai1", "GENE_OR_GENE_PRODUCT", 57, 61], ["Rai1 shRNA", "DNA", 57, 67], ["the cultures", "TEST", 25, 37], ["LV control", "TREATMENT", 43, 53], ["Rai1 shRNA", "PROBLEM", 57, 67]]], ["We used semi-automatic principal-component analysis to sort individual neuronal units ( Figures S3H-S3K ).", [["neuronal", "ANATOMY", 71, 79], ["neuronal", "CELL", 71, 79], ["S3H", "PROTEIN", 96, 99], ["S3K", "PROTEIN", 100, 103], ["Figures S3H", "TEST", 88, 99]]], ["If the changes in mEPSCs and transcriptional dynamics are an indirect effect secondary to Rai1 KD suppressing network activity, then we would predict a marked decrease in neural firing.", [["neural", "ANATOMY", 171, 177], ["mEPSCs", "CELL", 18, 24], ["Rai1", "GENE_OR_GENE_PRODUCT", 90, 94], ["network", "MULTI-TISSUE_STRUCTURE", 110, 117], ["Rai1", "PROTEIN", 90, 94], ["the changes in mEPSCs", "PROBLEM", 3, 24], ["transcriptional dynamics", "TEST", 29, 53], ["a marked decrease in neural firing", "PROBLEM", 150, 184], ["marked", "OBSERVATION_MODIFIER", 152, 158], ["decrease", "OBSERVATION_MODIFIER", 159, 167], ["neural firing", "OBSERVATION", 171, 184]]], ["Contrary to this prediction, Rai1 KD did not suppress firing in the network and instead led to 1.4-to 2.1-fold increase in spontaneous firing rate compared with scrambled shRNA (Figures 3H and 3I; Kruskal-Wallis test: 9.36, p = 0.009; Dunn's post hoc test: sh-Ctrl versus sh-Rai1 #1, p = 0.053; sh-Ctrl versus sh-Rai1 #2, p = 0.010), likely because of enhanced excitatory drive that accompanies Rai1 KD-mediated synaptic strengthening.", [["synaptic", "ANATOMY", 412, 420], ["Rai1", "GENE_OR_GENE_PRODUCT", 29, 33], ["Rai1 KD", "GENE_OR_GENE_PRODUCT", 395, 402], ["Rai1", "PROTEIN", 395, 399], ["spontaneous firing rate", "PROBLEM", 123, 146], ["Kruskal-Wallis test", "TEST", 197, 216], ["p", "TEST", 224, 225], ["Dunn's post hoc test", "TEST", 235, 255], ["sh", "TEST", 257, 259], ["Ctrl", "TEST", 260, 264], ["sh", "TEST", 272, 274], ["Rai1", "TEST", 275, 279], ["p", "TEST", 284, 285], ["sh", "TEST", 295, 297], ["Ctrl", "TEST", 298, 302], ["sh", "TEST", 310, 312], ["spontaneous firing", "OBSERVATION", 123, 141]]], ["These data thus support the second explanation, whereby RAI1 suppresses a TTX-responsive transcriptional program and synaptic upscaling in naive neural networks.RAI1 Promotes Transcriptional Responses Triggered by Reductions in Network ActivityHaving uncovered that RAI1 was essential to suppress the TTX-associated transcriptional program under basal activity (G) Representative images of surface GluA1 (sGluA1, fire), PSD-95 (green), and sGluA1 and PSD-95 (merge) of sh-Ctrl and sh-Rai1-infected dendrites.", [["synaptic", "ANATOMY", 117, 125], ["neural networks", "ANATOMY", 145, 160], ["surface", "ANATOMY", 390, 397], ["dendrites", "ANATOMY", 498, 507], ["TTX", "CHEMICAL", 74, 77], ["TTX", "CHEMICAL", 301, 304], ["TTX", "CHEMICAL", 74, 77], ["TTX", "CHEMICAL", 301, 304], ["RAI1", "GENE_OR_GENE_PRODUCT", 56, 60], ["TTX", "SIMPLE_CHEMICAL", 74, 77], ["neural networks", "MULTI-TISSUE_STRUCTURE", 145, 160], ["RAI1", "SIMPLE_CHEMICAL", 161, 165], ["RAI1", "GENE_OR_GENE_PRODUCT", 266, 270], ["TTX", "SIMPLE_CHEMICAL", 301, 304], ["GluA1", "GENE_OR_GENE_PRODUCT", 398, 403], ["GluA1", "GENE_OR_GENE_PRODUCT", 406, 411], ["PSD-95", "GENE_OR_GENE_PRODUCT", 420, 426], ["green)", "GENE_OR_GENE_PRODUCT", 428, 434], ["sGluA1", "GENE_OR_GENE_PRODUCT", 440, 446], ["PSD-95", "GENE_OR_GENE_PRODUCT", 451, 457], ["sh-Ctrl", "GENE_OR_GENE_PRODUCT", 469, 476], ["sh-Rai1", "GENE_OR_GENE_PRODUCT", 481, 488], ["dendrites", "CELL", 498, 507], ["RAI1", "PROTEIN", 56, 60], ["RAI1", "PROTEIN", 161, 165], ["RAI1", "PROTEIN", 266, 270], ["GluA1", "PROTEIN", 398, 403], ["GluA1", "PROTEIN", 406, 411], ["fire", "PROTEIN", 413, 417], ["PSD", "PROTEIN", 420, 423], ["sGluA1", "PROTEIN", 440, 446], ["PSD", "PROTEIN", 451, 454], ["Rai1", "PROTEIN", 484, 488], ["a TTX-responsive transcriptional program", "TREATMENT", 72, 112], ["synaptic upscaling in naive neural networks", "TREATMENT", 117, 160], ["Representative images of surface GluA1", "TEST", 365, 403], ["GluA1", "TEST", 406, 411], ["PSD", "TEST", 420, 423], ["sGluA1", "TEST", 440, 446], ["PSD", "TEST", 451, 454], ["sh", "TEST", 469, 471], ["Ctrl", "TEST", 472, 476], ["sh", "TEST", 481, 483], ["infected dendrites", "PROBLEM", 489, 507], ["naive neural", "OBSERVATION", 139, 151], ["Transcriptional Responses", "OBSERVATION", 175, 200], ["infected", "OBSERVATION", 489, 497]]], ["Scale bar, 10 mm.", [["10 mm", "OBSERVATION_MODIFIER", 11, 16]]], ["Bar graph of mean sGluA1 signal intensity in PSD-95-positive regions for vehicle or TTX (n = 13-12) and sh-Ctrl or sh-Rai1 (n = 6-6) treated neurons.", [["neurons", "ANATOMY", 141, 148], ["TTX", "CHEMICAL", 84, 87], ["TTX", "CHEMICAL", 84, 87], ["sGluA1", "GENE_OR_GENE_PRODUCT", 18, 24], ["PSD-95", "GENE_OR_GENE_PRODUCT", 45, 51], ["TTX", "SIMPLE_CHEMICAL", 84, 87], ["sh-Rai1", "GENE_OR_GENE_PRODUCT", 115, 122], ["neurons", "CELL", 141, 148], ["sGluA1", "PROTEIN", 18, 24], ["PSD-95-positive regions", "DNA", 45, 68], ["Bar graph", "TEST", 0, 9], ["mean sGluA1 signal intensity", "PROBLEM", 13, 41], ["PSD", "TEST", 45, 48], ["vehicle", "PROBLEM", 73, 80], ["TTX", "TEST", 84, 87], ["sh", "TEST", 104, 106], ["Ctrl", "TEST", 107, 111], ["mean sGluA1", "OBSERVATION", 13, 24], ["intensity", "OBSERVATION_MODIFIER", 32, 41]]], ["(H) Prototypical local field potential recordings from individual electrodes exhibiting a single neuronal unit from cultures transfected with: sh-Ctrl, sh-Rai1 #1, or sh-Rai1 #2 lentivirus.", [["neuronal unit", "ANATOMY", 97, 110], ["cultures", "ANATOMY", 116, 124], ["neuronal unit", "CELL", 97, 110], ["sh-Rai1 #1", "GENE_OR_GENE_PRODUCT", 152, 162], ["lentivirus", "ORGANISM", 178, 188], ["cultures", "TEST", 116, 124], ["sh", "TEST", 167, 169], ["lentivirus", "PROBLEM", 178, 188]]], ["(I) Firing frequency of individual neuronal units recorded from cultures transfected with sh-Ctrl, sh-Rai1 #1, or sh-Rai1 #2 (n = 115, 140, and 131 for sh-Ctrl, sh-Rai1 #1, and sh-Rai1 #2, respectively).", [["neuronal units", "ANATOMY", 35, 49], ["cultures", "ANATOMY", 64, 72], ["neuronal units", "CELL", 35, 49], ["sh-Rai1 #1", "GENE_OR_GENE_PRODUCT", 99, 109], ["sh-Rai1 #2", "GENE_OR_GENE_PRODUCT", 114, 124], ["sh", "DNA", 114, 116], ["Rai1 #2", "DNA", 117, 124], ["sh", "DNA", 161, 163], ["Rai1", "DNA", 164, 168], ["sh", "DNA", 177, 179], ["Rai1", "DNA", 180, 184], ["individual neuronal units", "TEST", 24, 49], ["cultures", "TEST", 64, 72], ["sh", "TEST", 152, 154], ["Ctrl", "TEST", 155, 159], ["sh", "TEST", 161, 163], ["sh", "TEST", 177, 179], ["Ctrl", "ANATOMY", 155, 159]]], ["All bar graphs represent mean \u00b1 SEM.", [["All bar graphs", "TEST", 0, 14], ["mean \u00b1 SEM", "OBSERVATION", 25, 35]]], ["For (B)-(D), one-way ANOVA, followed by post hoc Fisher's least significant difference (LSD) test were performed.", [["LSD) test", "TEST", 88, 97]]], ["For (G), unpaired Student's t tests were performed.", [["Student's t tests", "TEST", 18, 35]]], ["For (I), Kruskal-Wallis (K-W) test followed by post hoc Dunn's multiple-comparisons test was performed.", [["Kruskal-Wallis (K-W) test", "TEST", 9, 34], ["comparisons test", "TEST", 72, 88]]], ["K-W: 9.358, p = 0.0003. p < 0.001.", [["K", "CHEMICAL", 0, 1], ["K", "TEST", 0, 1], ["p", "TEST", 12, 13]]], ["(Figure 2) , we next tested if Rai1 KD has any impact on transcriptional responses to TTX and BIC treatments.", [["TTX", "CHEMICAL", 86, 89], ["BIC", "CHEMICAL", 94, 97], ["TTX", "CHEMICAL", 86, 89], ["BIC", "CHEMICAL", 94, 97], ["Rai1", "GENE_OR_GENE_PRODUCT", 31, 35], ["TTX", "SIMPLE_CHEMICAL", 86, 89], ["BIC", "SIMPLE_CHEMICAL", 94, 97], ["Rai1", "PROTEIN", 31, 35], ["TTX", "TREATMENT", 86, 89], ["BIC treatments", "TREATMENT", 94, 108]]], ["By calculating fold changes of transcription, we found that Rai1 KD led to a significant impairment of transcriptional response to TTX, while transcriptional responses to BIC were slightly weaker only for downregulation ( Figure 4A ).", [["TTX", "CHEMICAL", 131, 134], ["TTX", "CHEMICAL", 131, 134], ["Rai1", "GENE_OR_GENE_PRODUCT", 60, 64], ["TTX", "SIMPLE_CHEMICAL", 131, 134], ["Rai1 KD", "PROTEIN", 60, 67], ["Rai1 KD", "PROBLEM", 60, 67], ["TTX", "TREATMENT", 131, 134], ["BIC", "TEST", 171, 174], ["slightly weaker", "PROBLEM", 180, 195], ["significant", "OBSERVATION_MODIFIER", 77, 88], ["impairment", "OBSERVATION", 89, 99], ["transcriptional response", "OBSERVATION", 103, 127]]], ["However, in contrast to the 130 genes transcriptionally altered at baseline, DESeq2 comparing Rai1 KD and control revealed only 8 DE genes after TTX or BIC treatment, indicating that the impact of Rai1 KD is greater in resting neurons compared with drug-treated neurons ( Figure 4B ; Table S3 ).RAI1 Promotes Transcriptional Responses Triggered by Reductions in Network ActivityWe then sought to determine if the strongly impaired transcriptional response to TTX ( Figure 4A ) was due entirely to the TTXlike transcriptional state of Rai1-KD cultures at baseline or if RAI1 also contributes to the transcriptional response to TTX.", [["neurons", "ANATOMY", 227, 234], ["neurons", "ANATOMY", 262, 269], ["TTX", "CHEMICAL", 145, 148], ["BIC", "CHEMICAL", 152, 155], ["TTX", "CHEMICAL", 459, 462], ["TTX", "CHEMICAL", 626, 629], ["TTX", "CHEMICAL", 145, 148], ["BIC", "CHEMICAL", 152, 155], ["TTX", "CHEMICAL", 459, 462], ["TTX", "CHEMICAL", 626, 629], ["Rai1 KD", "GENE_OR_GENE_PRODUCT", 94, 101], ["TTX", "SIMPLE_CHEMICAL", 145, 148], ["Rai1", "GENE_OR_GENE_PRODUCT", 197, 201], ["neurons", "CELL", 227, 234], ["neurons", "CELL", 262, 269], ["RAI1", "SIMPLE_CHEMICAL", 295, 299], ["TTX", "SIMPLE_CHEMICAL", 459, 462], ["Rai1", "GENE_OR_GENE_PRODUCT", 534, 538], ["RAI1", "GENE_OR_GENE_PRODUCT", 569, 573], ["TTX", "SIMPLE_CHEMICAL", 626, 629], ["130 genes", "DNA", 28, 37], ["DESeq2", "DNA", 77, 83], ["DE genes", "DNA", 130, 138], ["Rai1 KD", "PROTEIN", 197, 204], ["resting neurons", "CELL_TYPE", 219, 234], ["drug-treated neurons", "CELL_LINE", 249, 269], ["RAI1", "PROTEIN", 295, 299], ["Rai1-KD cultures", "CELL_LINE", 534, 550], ["RAI1", "PROTEIN", 569, 573], ["TTX", "TREATMENT", 145, 148], ["BIC treatment", "TREATMENT", 152, 165], ["Rai1 KD", "PROBLEM", 197, 204], ["KD cultures", "TEST", 539, 550], ["RAI1", "PROBLEM", 569, 573], ["greater", "OBSERVATION_MODIFIER", 208, 215], ["Transcriptional Responses", "OBSERVATION", 309, 334]]], ["Differential gene expression analysis by DESeq2 relies on an arbitrary statistical significance cutoff to report DE genes.", [["DESeq2", "DNA", 41, 47], ["DE genes", "DNA", 113, 121], ["Differential gene expression analysis", "TEST", 0, 37]]], ["However, the individual gene plot in the baseline condition revealed a global transcriptional trend resulting from minor changes in many genes, including those that failed to achieve statistical significance ( Figure S2E ).", [["the individual gene plot", "TEST", 9, 33], ["a global transcriptional trend", "PROBLEM", 69, 99], ["minor changes in many genes", "PROBLEM", 115, 142]]], ["To define the impact of RAI1 loss after TTX and BIC treatment, we therefore used this individual gene plot approach.", [["TTX", "CHEMICAL", 40, 43], ["BIC", "CHEMICAL", 48, 51], ["TTX", "CHEMICAL", 40, 43], ["BIC", "CHEMICAL", 48, 51], ["RAI1", "GENE_OR_GENE_PRODUCT", 24, 28], ["TTX", "SIMPLE_CHEMICAL", 40, 43], ["RAI1", "PROTEIN", 24, 28], ["RAI1 loss", "PROBLEM", 24, 33], ["TTX", "TREATMENT", 40, 43], ["BIC treatment", "TREATMENT", 48, 61], ["this individual gene plot approach", "TREATMENT", 81, 115]]], ["We found that after TTX treatment, the transcriptional changes of TTX-response genes in Rai1-KD cultures inversely correlated with their changes upon TTX treatment in the control condition ( Figure 4C , left panel; Spearman rank correlation coefficient r = 0.32, t test p = 2.2 3 10 \u00c016 ).", [["Rai1-KD cultures", "ANATOMY", 88, 104], ["TTX", "CHEMICAL", 20, 23], ["TTX", "CHEMICAL", 66, 69], ["TTX", "CHEMICAL", 150, 153], ["TTX", "CHEMICAL", 20, 23], ["TTX", "CHEMICAL", 66, 69], ["TTX", "CHEMICAL", 150, 153], ["TTX", "SIMPLE_CHEMICAL", 20, 23], ["TTX", "SIMPLE_CHEMICAL", 66, 69], ["Rai1", "GENE_OR_GENE_PRODUCT", 88, 92], ["TTX", "SIMPLE_CHEMICAL", 150, 153], ["TTX-response genes", "DNA", 66, 84], ["Rai1-KD cultures", "CELL_LINE", 88, 104], ["TTX treatment", "TREATMENT", 20, 33], ["TTX", "TEST", 66, 69], ["KD cultures", "TEST", 93, 104], ["TTX treatment", "TREATMENT", 150, 163], ["left panel", "TEST", 203, 213], ["coefficient r", "TEST", 241, 254], ["t test p", "TEST", 263, 271], ["left", "ANATOMY_MODIFIER", 203, 207]]], ["This result indicates incomplete downregulation and upregulation upon TTX treatment independent of the impact of Rai1 KD in the resting state.", [["TTX", "CHEMICAL", 70, 73], ["TTX", "CHEMICAL", 70, 73], ["TTX", "SIMPLE_CHEMICAL", 70, 73], ["Rai1", "GENE_OR_GENE_PRODUCT", 113, 117], ["Rai1 KD", "PROTEIN", 113, 120], ["incomplete downregulation", "PROBLEM", 22, 47], ["TTX treatment", "TREATMENT", 70, 83], ["incomplete", "OBSERVATION_MODIFIER", 22, 32], ["downregulation", "OBSERVATION", 33, 47]]], ["The same TTX-response genes did not show obvious changes after BIC treatment of Rai1-KD culture ( Figure S4A , left panel).", [["TTX", "CHEMICAL", 9, 12], ["BIC", "CHEMICAL", 63, 66], ["TTX", "CHEMICAL", 9, 12], ["TTX", "SIMPLE_CHEMICAL", 9, 12], ["TTX-response genes", "DNA", 9, 27], ["Rai1", "PROTEIN", 80, 84], ["The same TTX", "TEST", 0, 12], ["obvious changes", "PROBLEM", 41, 56], ["BIC treatment", "TREATMENT", 63, 76], ["Rai1", "TEST", 80, 84], ["KD culture", "TEST", 85, 95], ["Figure S4A", "TEST", 98, 108], ["left panel", "TEST", 111, 121], ["left", "ANATOMY_MODIFIER", 111, 115]]], ["Transcription of the BIC-response genes did not show changes by Rai1 KD under any condition ( Figure 4C , right panel; Figure S4A , right panel).", [["BIC-response genes", "DNA", 21, 39], ["Rai1", "PROTEIN", 64, 68], ["right panel", "TEST", 106, 117], ["right", "ANATOMY_MODIFIER", 106, 111], ["right", "ANATOMY_MODIFIER", 132, 137]]], ["Thus, Rai1 deficiency leads to a subtle yet widespread impairment of the transcriptional response to TTX but not to BIC.", [["TTX", "CHEMICAL", 101, 104], ["TTX", "CHEMICAL", 101, 104], ["Rai1", "GENE_OR_GENE_PRODUCT", 6, 10], ["TTX", "SIMPLE_CHEMICAL", 101, 104], ["Rai1", "PROTEIN", 6, 10], ["Rai1 deficiency", "PROBLEM", 6, 21], ["TTX", "TREATMENT", 101, 104], ["widespread", "OBSERVATION_MODIFIER", 44, 54], ["impairment", "OBSERVATION", 55, 65], ["transcriptional response", "OBSERVATION", 73, 97]]], ["Taken together, these results led us to conclude that RAI1 is selectively required for the transcriptional response driven by network activity suppression.RAI1 Promotes Transcriptional Responses Triggered by Reductions in Network ActivityWe then explored biological implications for the impaired transcriptional response to TTX.", [["TTX", "CHEMICAL", 324, 327], ["TTX", "CHEMICAL", 324, 327], ["RAI1", "GENE_OR_GENE_PRODUCT", 54, 58], ["RAI1", "SIMPLE_CHEMICAL", 155, 159], ["TTX", "SIMPLE_CHEMICAL", 324, 327], ["RAI1", "PROTEIN", 54, 58], ["RAI1", "PROTEIN", 155, 159], ["biological implications", "TREATMENT", 255, 278], ["the impaired transcriptional response", "PROBLEM", 283, 320], ["Transcriptional Responses", "OBSERVATION", 169, 194]]], ["Notably, RNA-Enrich identified many more RAI1-dependent biological processes after TTX treatment than vehicle or BIC treatment (45 in TTX-treated cultures, 3 in Veh-treated cultures, and 7 in BIC-treated cultures; Figure 4D ).", [["cultures", "ANATOMY", 146, 154], ["cultures", "ANATOMY", 173, 181], ["cultures", "ANATOMY", 204, 212], ["TTX", "CHEMICAL", 83, 86], ["BIC", "CHEMICAL", 113, 116], ["TTX", "CHEMICAL", 134, 137], ["Veh", "CHEMICAL", 161, 164], ["TTX", "CHEMICAL", 83, 86], ["TTX", "CHEMICAL", 134, 137], ["RAI1", "GENE_OR_GENE_PRODUCT", 41, 45], ["TTX", "SIMPLE_CHEMICAL", 83, 86], ["TTX", "SIMPLE_CHEMICAL", 134, 137], ["Veh", "SIMPLE_CHEMICAL", 161, 164], ["RAI1", "PROTEIN", 41, 45], ["BIC-treated cultures", "CELL_LINE", 192, 212], ["RNA", "TEST", 9, 12], ["dependent biological processes", "PROBLEM", 46, 76], ["TTX treatment", "TREATMENT", 83, 96], ["vehicle", "TREATMENT", 102, 109], ["BIC treatment", "TREATMENT", 113, 126], ["TTX", "TEST", 134, 137], ["cultures", "TEST", 146, 154], ["Veh", "TEST", 161, 164], ["cultures", "TEST", 173, 181], ["BIC", "TEST", 192, 195], ["cultures", "TEST", 204, 212]]], ["The p adj values were evidently lower in the post-TTX transcriptome data compared with BIC conditions.", [["TTX", "CHEMICAL", 50, 53], ["TTX", "CHEMICAL", 50, 53], ["The p adj values", "TEST", 0, 16], ["lower", "OBSERVATION_MODIFIER", 32, 37]]], ["The RAI1-dependent gene ontologies after TTX treatment represent synapse-related processes, whereas those altered in the BIC and Veh-treated conditions show fewer ontologies directly relevant to neuronal activity ( Figure 4D ; Table S4 ).", [["neuronal", "ANATOMY", 195, 203], ["TTX", "CHEMICAL", 41, 44], ["Veh", "CHEMICAL", 129, 132], ["TTX", "CHEMICAL", 41, 44], ["RAI1", "GENE_OR_GENE_PRODUCT", 4, 8], ["TTX", "SIMPLE_CHEMICAL", 41, 44], ["Veh", "SIMPLE_CHEMICAL", 129, 132], ["neuronal", "CELL", 195, 203], ["RAI1", "PROTEIN", 4, 8], ["TTX treatment", "TREATMENT", 41, 54]]], ["RNA-Enrich provides the identity of signature genes, called Siggenes, which contributed to the enrichment of an ontology (Kim et al., 2012; Lee et al., 2016) .", [["signature genes", "DNA", 36, 51], ["Siggenes", "DNA", 60, 68], ["signature genes", "OBSERVATION", 36, 51]]], ["As expected, Sig-genes for the synapse-related ontologies, including Ngf, Syn3, Cacna1b, and Rab3a, showed mild yet reproducible transcriptional changes upon Rai1 KD ( Figure 4E ; Figure S4B ).RAI1 Dissociates from Chromatin in Response to Activity ChangesThe activity state-dependent requirement of RAI1 in regulating transcription led us to hypothesize that activity shifts of neuronal network might alter RAI1 distribution on chromatin.", [["neuronal network", "ANATOMY", 379, 395], ["chromatin", "ANATOMY", 429, 438], ["Sig", "GENE_OR_GENE_PRODUCT", 13, 16], ["Ngf", "GENE_OR_GENE_PRODUCT", 69, 72], ["Syn3", "GENE_OR_GENE_PRODUCT", 74, 78], ["Cacna1b", "GENE_OR_GENE_PRODUCT", 80, 87], ["Rab3a", "GENE_OR_GENE_PRODUCT", 93, 98], ["Chromatin", "CELLULAR_COMPONENT", 215, 224], ["RAI1", "GENE_OR_GENE_PRODUCT", 300, 304], ["neuronal network", "MULTI-TISSUE_STRUCTURE", 379, 395], ["RAI1", "GENE_OR_GENE_PRODUCT", 408, 412], ["chromatin", "CELLULAR_COMPONENT", 429, 438], ["Sig-genes", "DNA", 13, 22], ["Ngf", "PROTEIN", 69, 72], ["Syn3", "PROTEIN", 74, 78], ["Cacna1b", "PROTEIN", 80, 87], ["Rab3a", "DNA", 93, 98], ["Rai1 KD", "PROTEIN", 158, 165], ["RAI1", "PROTEIN", 193, 197], ["RAI1", "PROTEIN", 300, 304], ["RAI1", "PROTEIN", 408, 412], ["chromatin", "DNA", 429, 438], ["Ngf", "TEST", 69, 72], ["Rab3a", "TEST", 93, 98], ["mild yet reproducible transcriptional changes", "PROBLEM", 107, 152], ["RAI1 Dissociates", "PROBLEM", 193, 209], ["Activity Changes", "PROBLEM", 240, 256], ["RAI1", "TREATMENT", 300, 304], ["mild", "OBSERVATION_MODIFIER", 107, 111]]], ["To test this, we performed chromatin immunoprecipitation coupled with deep sequencing (ChIP-seq) for RAI1 in DIV 17 neuronal cultures treated for 4 h with TTX, BIC, or vehicle.", [["chromatin", "ANATOMY", 27, 36], ["DIV 17 neuronal cultures", "ANATOMY", 109, 133], ["TTX", "CHEMICAL", 155, 158], ["BIC", "CHEMICAL", 160, 163], ["TTX", "CHEMICAL", 155, 158], ["BIC", "CHEMICAL", 160, 163], ["chromatin", "CELLULAR_COMPONENT", 27, 36], ["DIV 17 neuronal cultures", "CELL", 109, 133], ["TTX", "SIMPLE_CHEMICAL", 155, 158], ["chromatin", "DNA", 27, 36], ["RAI1", "PROTEIN", 101, 105], ["DIV 17 neuronal cultures", "CELL_LINE", 109, 133], ["chromatin immunoprecipitation", "TREATMENT", 27, 56], ["deep sequencing (ChIP-seq)", "TREATMENT", 70, 96], ["RAI1", "PROBLEM", 101, 105], ["neuronal cultures", "TEST", 116, 133]]], ["We observed clear RAI1 binding at the promoters of RAI1-dependent genes such as Homer1 and Per2 ( Figure 5A ).", [["RAI1", "GENE_OR_GENE_PRODUCT", 18, 22], ["RAI1", "GENE_OR_GENE_PRODUCT", 51, 55], ["Homer1", "GENE_OR_GENE_PRODUCT", 80, 86], ["Per2 ( Figure 5A", "GENE_OR_GENE_PRODUCT", 91, 107], ["RAI1", "PROTEIN", 18, 22], ["promoters", "DNA", 38, 47], ["RAI1", "DNA", 51, 55], ["Homer1", "DNA", 80, 86], ["Per2", "DNA", 91, 95], ["Figure 5A", "DNA", 98, 107], ["clear RAI1 binding", "PROBLEM", 12, 30], ["clear", "OBSERVATION", 12, 17]]], ["The control ChIP using Rai1-KD cultures showed no such events, demonstrating the specificity of ChIP experiments.", [["Rai1", "GENE_OR_GENE_PRODUCT", 23, 27], ["Rai1-KD cultures", "CELL_LINE", 23, 39], ["The control ChIP", "TEST", 0, 16], ["Rai1", "TEST", 23, 27], ["KD cultures", "TEST", 28, 39], ["such events", "PROBLEM", 50, 61]]], ["RAI1 binding was much weaker in TTXor BIC-treated cultures ( Figure 5A ).", [["cultures", "ANATOMY", 50, 58], ["BIC", "CHEMICAL", 38, 41], ["RAI1", "GENE_OR_GENE_PRODUCT", 0, 4], ["TTXor BIC", "SIMPLE_CHEMICAL", 32, 41], ["RAI1", "PROTEIN", 0, 4], ["TTXor BIC-treated cultures", "CELL_LINE", 32, 58], ["RAI1 binding", "PROBLEM", 0, 12], ["much weaker in TTXor BIC", "PROBLEM", 17, 41]]], ["Consistent with visual observations, peak calling identified only 13 RAI1 peaks across all three Rai1-KD ChIP-seq samples (not shown), and they were removed from all subsequent analyses.", [["RAI1", "DNA", 69, 73], ["Rai1", "PROTEIN", 97, 101], ["visual observations", "TEST", 16, 35], ["13 RAI1 peaks", "PROBLEM", 66, 79], ["seq samples", "TEST", 110, 121], ["all subsequent analyses", "TEST", 162, 185]]], ["In shCtrl cells, 6,065 RAI1 peaks were found in the Veh-treated condition, and a drastic reduction of RAI1 peaks upon TTX (98 peaks) and BIC (1 peak) treatments ( Figure 5B ).", [["shCtrl cells", "ANATOMY", 3, 15], ["TTX", "CHEMICAL", 118, 121], ["TTX", "CHEMICAL", 118, 121], ["shCtrl cells", "CELL", 3, 15], ["RAI1", "GENE_OR_GENE_PRODUCT", 23, 27], ["RAI1", "GENE_OR_GENE_PRODUCT", 102, 106], ["TTX", "SIMPLE_CHEMICAL", 118, 121], ["shCtrl cells", "CELL_LINE", 3, 15], ["RAI1", "PROTEIN", 23, 27], ["RAI1", "PROTEIN", 102, 106], ["RAI1 peaks", "PROBLEM", 23, 33], ["a drastic reduction of RAI1 peaks", "PROBLEM", 79, 112], ["TTX", "TEST", 118, 121], ["BIC", "TEST", 137, 140], ["shCtrl cells", "ANATOMY", 3, 15], ["drastic", "OBSERVATION_MODIFIER", 81, 88], ["reduction", "OBSERVATION_MODIFIER", 89, 98]]], ["Variable ChIP efficiency or sequencing depth cannot explain the scarce peaks in TTX and BIC conditions, because we spiked in Drosophila chromatin and fly-specific H2Av antibody and ensured consistent sequencing depth and ChIP efficiency across the samples (Figure S5A ).", [["chromatin", "ANATOMY", 136, 145], ["samples", "ANATOMY", 248, 255], ["TTX", "CHEMICAL", 80, 83], ["TTX", "CHEMICAL", 80, 83], ["TTX", "SIMPLE_CHEMICAL", 80, 83], ["Drosophila", "ORGANISM", 125, 135], ["chromatin", "CELLULAR_COMPONENT", 136, 145], ["H2Av", "GENE_OR_GENE_PRODUCT", 163, 167], ["Drosophila chromatin", "DNA", 125, 145], ["H2Av antibody", "PROTEIN", 163, 176], ["Drosophila", "SPECIES", 125, 135], ["Drosophila", "SPECIES", 125, 135], ["Variable ChIP efficiency", "PROBLEM", 0, 24], ["sequencing depth", "PROBLEM", 28, 44], ["the scarce peaks in TTX and BIC conditions", "PROBLEM", 60, 102], ["Drosophila chromatin", "PROBLEM", 125, 145], ["fly-specific H2Av antibody", "TREATMENT", 150, 176], ["ChIP efficiency", "PROBLEM", 221, 236], ["ChIP efficiency", "OBSERVATION", 9, 24], ["scarce", "OBSERVATION_MODIFIER", 64, 70], ["peaks", "OBSERVATION", 71, 76]]], ["Neither RAI1 protein levels ( Figure S5B ) nor nuclear localization ( Figure S2A ) changed after TTX or BIC treatment.", [["nuclear", "ANATOMY", 47, 54], ["TTX", "CHEMICAL", 97, 100], ["BIC", "CHEMICAL", 104, 107], ["TTX", "CHEMICAL", 97, 100], ["BIC", "CHEMICAL", 104, 107], ["RAI1", "GENE_OR_GENE_PRODUCT", 8, 12], ["Figure S5B", "GENE_OR_GENE_PRODUCT", 30, 40], ["nuclear", "CELLULAR_COMPONENT", 47, 54], ["Figure S2A", "GENE_OR_GENE_PRODUCT", 70, 80], ["TTX", "SIMPLE_CHEMICAL", 97, 100], ["RAI1 protein", "PROTEIN", 8, 20], ["Figure S2A", "PROTEIN", 70, 80], ["RAI1 protein levels", "TEST", 8, 27], ["nuclear localization", "TEST", 47, 67], ["TTX", "TREATMENT", 97, 100], ["BIC treatment", "TREATMENT", 104, 117]]], ["Thus, activity alterations largely release RAI1 from chromatin, which is remarkably consistent with the greater number of RAI1-dependent genes in resting neurons ( Figure 4B ).RAI1 Directly Controls Activity-Responsive Gene Transcription in Stable NetworksIntersection with BrU-seq data revealed that that RAI1-bound genes are much more likely responsive to network activity shifts than RAI1-free genes (p < 2.2 3 10 \u00c016 , chi-square test; Figure 5C ; (D) RAI1-dependent gene ontologies (biological process, p adj < 0.005) discovered using RNA-Enrich and filtered using ReviGO software (Supek et al., 2011) .", [["chromatin", "ANATOMY", 53, 62], ["neurons", "ANATOMY", 154, 161], ["RAI1", "GENE_OR_GENE_PRODUCT", 43, 47], ["chromatin", "CELLULAR_COMPONENT", 53, 62], ["RAI1", "GENE_OR_GENE_PRODUCT", 122, 126], ["neurons", "CELL", 154, 161], ["RAI1", "SIMPLE_CHEMICAL", 176, 180], ["RAI1", "GENE_OR_GENE_PRODUCT", 306, 310], ["RAI1", "GENE_OR_GENE_PRODUCT", 387, 391], ["RAI1", "PROTEIN", 43, 47], ["chromatin", "DNA", 53, 62], ["RAI1", "PROTEIN", 122, 126], ["resting neurons", "CELL_TYPE", 146, 161], ["RAI1", "DNA", 176, 180], ["BrU-seq data", "DNA", 274, 286], ["RAI1", "DNA", 306, 310], ["RAI1-free genes", "DNA", 387, 402], ["activity alterations", "PROBLEM", 6, 26], ["BrU-seq data", "TEST", 274, 286], ["bound genes", "PROBLEM", 311, 322], ["RAI1", "TEST", 387, 391], ["chi-square test", "TEST", 423, 438], ["RAI1", "PROBLEM", 456, 460], ["dependent gene ontologies", "PROBLEM", 461, 486], ["neurons", "ANATOMY", 154, 161]]], ["(E) RPKM (reads per kilobase of transcript per million mapped reads) values of four Sig-genes downregulated by Rai1 KD in the TTX-treated condition.", [["TTX", "CHEMICAL", 126, 129], ["TTX", "CHEMICAL", 126, 129], ["Sig", "GENE_OR_GENE_PRODUCT", 84, 87], ["Rai1", "GENE_OR_GENE_PRODUCT", 111, 115], ["TTX", "SIMPLE_CHEMICAL", 126, 129], ["(E) RPKM", "RNA", 0, 8], ["Sig-genes", "DNA", 84, 93]]], ["The Siggenes represent ''neurotransmitter transport'' (p adj = 9.3 3 10 \u00c08 ), the top downregulated biological processes.", [["the top downregulated biological processes", "PROBLEM", 78, 120]]], ["The remaining Sig-genes are shown in Figure S7 .", [["Sig", "GENE_OR_GENE_PRODUCT", 14, 17], ["Sig-genes", "DNA", 14, 23]]], ["Note slight but consistent inter-replicate changes upon Rai1 KD.", [["slight", "OBSERVATION_MODIFIER", 5, 11]]], ["See also Figure S4 and Tables S3 and S4.", [["S4", "PROTEIN", 37, 39], ["S4", "ANATOMY", 37, 39]]], ["Figure S5 and Table S5 .RAI1 Directly Controls Activity-Responsive Gene Transcription in Stable NetworksCell Reports 32, 108002, August 11, 2020 9 Article ll OPEN ACCESS Figure S5C ).", [["Cell", "ANATOMY", 104, 108], ["RAI1", "PROTEIN", 24, 28]]], ["Consistently, RAI1-bound genes associated with plasticity-related ontologies including synapse organization (Figure S5D ).", [["synapse", "ANATOMY", 87, 94], ["RAI1", "GENE_OR_GENE_PRODUCT", 14, 18], ["RAI1", "PROTEIN", 14, 18]]], ["Most of these peaks are present at the promoters in the resting culture ( Figure 5B ) and exhibited a bimodal distribution around transcription start sites (TSSs) that harbor H3K4me3 (Figure 5D ).", [["H3K4me3", "GENE_OR_GENE_PRODUCT", 175, 182], ["promoters", "DNA", 39, 48], ["transcription start sites", "DNA", 130, 155], ["TSSs", "DNA", 157, 161], ["H3K4me3", "PROTEIN", 175, 182], ["the resting culture", "TEST", 52, 71], ["a bimodal distribution", "PROBLEM", 100, 122], ["peaks", "OBSERVATION", 14, 19], ["bimodal distribution", "OBSERVATION", 102, 122]]], ["Binding motifs of activity-dependent TFs (e.g., MEF2A, AP1, LHX2, CREB3L) are enriched in RAI1-bound promoters ( Figure 5D ).", [["TFs", "ANATOMY", 37, 40], ["TFs", "CELL", 37, 40], ["MEF2A", "GENE_OR_GENE_PRODUCT", 48, 53], ["AP1", "GENE_OR_GENE_PRODUCT", 55, 58], ["LHX2", "GENE_OR_GENE_PRODUCT", 60, 64], ["CREB3L", "GENE_OR_GENE_PRODUCT", 66, 72], ["RAI1", "GENE_OR_GENE_PRODUCT", 90, 94], ["TFs", "PROTEIN", 37, 40], ["MEF2A", "DNA", 48, 53], ["AP1", "PROTEIN", 55, 58], ["LHX2", "PROTEIN", 60, 64], ["CREB3L", "DNA", 66, 72], ["RAI1-bound promoters", "DNA", 90, 110], ["activity-dependent TFs", "TREATMENT", 18, 40]]], ["RAI1 also occupied intra-and intergenic regions.", [["RAI1", "GENE_OR_GENE_PRODUCT", 0, 4], ["RAI1", "PROTEIN", 0, 4], ["intra-and intergenic regions", "DNA", 19, 47], ["occupied", "OBSERVATION_MODIFIER", 10, 18], ["intra-and", "OBSERVATION_MODIFIER", 19, 28], ["intergenic", "OBSERVATION_MODIFIER", 29, 39], ["regions", "ANATOMY_MODIFIER", 40, 47]]], ["In the resting culture, 54% of such non-promoter regions overlapped with DNase-I hypersensitivity sites (DHSs) identified in 8-week-old mouse whole brain , and the rest were DHS free ( Figure 5B ).", [["brain", "ANATOMY", 148, 153], ["hypersensitivity", "DISEASE", 81, 97], ["DNase-I hypersensitivity sites", "GENE_OR_GENE_PRODUCT", 73, 103], ["mouse", "ORGANISM", 136, 141], ["brain", "ORGAN", 148, 153], ["non-promoter regions", "DNA", 36, 56], ["DNase-I hypersensitivity sites", "DNA", 73, 103], ["DHSs", "DNA", 105, 109], ["mouse", "SPECIES", 136, 141], ["mouse", "SPECIES", 136, 141], ["the resting culture", "TEST", 3, 22], ["DNase-I hypersensitivity sites", "PROBLEM", 73, 103], ["hypersensitivity sites", "OBSERVATION", 81, 103], ["brain", "ANATOMY", 148, 153]]], ["Some RAI1-bound DHS coincided with H3K4me1 or H3K27ac (Creyghton et al., 2010) , indicating that these elements are likely transcriptional enhancers ( Figure 5B ; see STAR Methods).", [["RAI1", "GENE_OR_GENE_PRODUCT", 5, 9], ["H3K4me1", "GENE_OR_GENE_PRODUCT", 35, 42], ["RAI1", "PROTEIN", 5, 9], ["DHS", "DNA", 16, 19], ["H3K4me1", "PROTEIN", 35, 42], ["transcriptional enhancers", "DNA", 123, 148], ["STAR Methods", "DNA", 167, 179], ["Some RAI1-bound DHS", "PROBLEM", 0, 19], ["H3K27ac", "PROBLEM", 46, 53], ["transcriptional enhancers", "PROBLEM", 123, 148], ["bound DHS", "OBSERVATION", 10, 19], ["likely", "UNCERTAINTY", 116, 122], ["transcriptional enhancers", "OBSERVATION", 123, 148]]], ["A substantial fraction (67%) of RAI1 peaks overlapped with previously reported RAI1 peaks in adult mouse brain with common TF motifs ( Figures S5E and S5F ).", [["brain", "ANATOMY", 105, 110], ["RAI1", "GENE_OR_GENE_PRODUCT", 32, 36], ["RAI1", "GENE_OR_GENE_PRODUCT", 79, 83], ["mouse", "ORGANISM", 99, 104], ["brain", "ORGAN", 105, 110], ["TF", "GENE_OR_GENE_PRODUCT", 123, 125], ["RAI1", "PROTEIN", 32, 36], ["RAI1", "PROTEIN", 79, 83], ["TF motifs", "DNA", 123, 132], ["S5F", "DNA", 151, 154], ["mouse", "SPECIES", 99, 104], ["mouse", "SPECIES", 99, 104], ["A substantial fraction", "TEST", 0, 22], ["RAI1 peaks", "PROBLEM", 32, 42], ["RAI1 peaks in adult mouse brain", "PROBLEM", 79, 110], ["common TF motifs", "PROBLEM", 116, 132], ["substantial", "OBSERVATION_MODIFIER", 2, 13], ["fraction", "OBSERVATION_MODIFIER", 14, 22], ["mouse brain", "ANATOMY", 99, 110]]], ["In sum, these analyses show that RAI1 preferentially engages activity-responsive promoters with H3K4me3 in neural networks with stable basal levels of activity.RAI1 Directly Controls Activity-Responsive Gene Transcription in Stable NetworksAre the RAI1-dependent genes found in BrU-seq direct targets of RAI1?", [["neural networks", "ANATOMY", 107, 122], ["RAI1", "CHEMICAL", 33, 37], ["RAI1", "GENE_OR_GENE_PRODUCT", 33, 37], ["H3K4me3", "GENE_OR_GENE_PRODUCT", 96, 103], ["neural networks", "MULTI-TISSUE_STRUCTURE", 107, 122], ["RAI1", "SIMPLE_CHEMICAL", 160, 164], ["RAI1", "GENE_OR_GENE_PRODUCT", 248, 252], ["BrU", "GENE_OR_GENE_PRODUCT", 278, 281], ["RAI1", "GENE_OR_GENE_PRODUCT", 304, 308], ["RAI1", "PROTEIN", 33, 37], ["responsive promoters", "DNA", 70, 90], ["H3K4me3", "PROTEIN", 96, 103], ["RAI1", "PROTEIN", 160, 164], ["RAI1-dependent genes", "DNA", 248, 268], ["BrU", "PROTEIN", 278, 281], ["RAI1", "DNA", 304, 308], ["these analyses", "TEST", 8, 22], ["H3K4me3 in neural networks", "TREATMENT", 96, 122]]], ["Of the genes up-or downregulated by Rai1 KD, RAI1 occupied 40 of 122 genes (30%) in the baseline culture, which is significantly higher than the genomic average (p < 0.05, chi-square test; Figure S5G ).", [["Rai1", "GENE_OR_GENE_PRODUCT", 36, 40], ["RAI1", "GENE_OR_GENE_PRODUCT", 45, 49], ["Rai1 KD", "DNA", 36, 43], ["RAI1", "DNA", 45, 49], ["the baseline culture", "TEST", 84, 104], ["chi-square test", "TEST", 172, 187], ["significantly", "OBSERVATION_MODIFIER", 115, 128], ["higher", "OBSERVATION_MODIFIER", 129, 135]]], ["The direct targets of RAI1 can be up-or downregulated upon RAI1 loss (Table S5) .", [["RAI1", "GENE_OR_GENE_PRODUCT", 22, 26], ["RAI1", "GENE_OR_GENE_PRODUCT", 59, 63], ["RAI1", "PROTEIN", 22, 26], ["RAI1", "PROTEIN", 59, 63], ["RAI1 loss", "PROBLEM", 59, 68]]], ["Of the 18 genes upregulated by Rai1 KD, RAI1 binds to 10 promoters ( Figure 5F ), while RAI1 occupies 29 of 104 genes downregulated by Rai1 KD.", [["Rai1", "GENE_OR_GENE_PRODUCT", 31, 35], ["RAI1", "GENE_OR_GENE_PRODUCT", 40, 44], ["Figure 5F", "GENE_OR_GENE_PRODUCT", 69, 78], ["RAI1", "GENE_OR_GENE_PRODUCT", 88, 92], ["Rai1", "GENE_OR_GENE_PRODUCT", 135, 139], ["Rai1 KD", "PROTEIN", 31, 38], ["RAI1", "DNA", 40, 44], ["10 promoters", "DNA", 54, 66], ["Figure 5F", "DNA", 69, 78], ["RAI1", "DNA", 88, 92]]], ["These results support the idea that RAI1 uses both positive and negative regulation to repress the TTX-like transcription state in cultures with stable basal levels of activity ( Figures 2B-2D ).", [["RAI1", "CHEMICAL", 36, 40], ["TTX", "CHEMICAL", 99, 102], ["TTX", "CHEMICAL", 99, 102], ["RAI1", "GENE_OR_GENE_PRODUCT", 36, 40], ["TTX", "SIMPLE_CHEMICAL", 99, 102], ["RAI1", "PROTEIN", 36, 40], ["the TTX", "TEST", 95, 102], ["cultures", "TEST", 131, 139]]], ["Of note, BIC-response genes, which show no dependence on RAI1, also showed RAI1 peak enrichment ( Figure S5C ); therefore, RAI1 at these genes is dispensable for suppressing BIC-triggered transcription.RAI1 Directly Contributes to Transcriptional Response to TTXFinally, we inspected the 98 RAI1 peaks found in TTX-treated cultures, because we detected a compromised transcriptional response of Rai1-KD cells to TTX (Figures 4C-4E) .", [["cultures", "ANATOMY", 323, 331], ["Rai1-KD cells", "ANATOMY", 395, 408], ["TTX", "CHEMICAL", 311, 314], ["TTX", "CHEMICAL", 412, 415], ["TTX", "CHEMICAL", 311, 314], ["TTX", "CHEMICAL", 412, 415], ["RAI1", "GENE_OR_GENE_PRODUCT", 57, 61], ["RAI1", "GENE_OR_GENE_PRODUCT", 75, 79], ["RAI1", "GENE_OR_GENE_PRODUCT", 123, 127], ["RAI1", "SIMPLE_CHEMICAL", 202, 206], ["RAI1", "GENE_OR_GENE_PRODUCT", 291, 295], ["TTX", "SIMPLE_CHEMICAL", 311, 314], ["Rai1-KD cells", "CELL", 395, 408], ["TTX", "SIMPLE_CHEMICAL", 412, 415], ["BIC-response genes", "DNA", 9, 27], ["RAI1", "DNA", 57, 61], ["RAI1", "PROTEIN", 75, 79], ["RAI1", "PROTEIN", 123, 127], ["BIC", "DNA", 174, 177], ["RAI1", "PROTEIN", 202, 206], ["TTXFinally", "PROTEIN", 259, 269], ["98 RAI1 peaks", "DNA", 288, 301], ["TTX-treated cultures", "CELL_LINE", 311, 331], ["Rai1-KD cells", "CELL_LINE", 395, 408], ["dependence on RAI1", "PROBLEM", 43, 61], ["RAI1 peak enrichment", "PROBLEM", 75, 95], ["TTX", "TEST", 311, 314], ["cultures", "TEST", 323, 331], ["TTX", "TEST", 412, 415], ["no", "UNCERTAINTY", 40, 42], ["Transcriptional Response", "OBSERVATION", 231, 255]]], ["Most of these peaks were common between the TTX and vehicle conditions (promoter-occupied, 89% overlap; non-promoter-occupied, 77% overlap; Figure S5H ).", [["TTX", "CHEMICAL", 44, 47], ["TTX", "CHEMICAL", 44, 47], ["TTX", "SIMPLE_CHEMICAL", 44, 47], ["S5H", "DNA", 147, 150], ["peaks", "OBSERVATION", 14, 19]]], ["We found a much greater proportion of non-promoter peaks (60%) compared with the resting cells (22%) ( Figure S5I ).", [["cells", "ANATOMY", 89, 94], ["cells", "CELL", 89, 94], ["resting cells", "CELL_TYPE", 81, 94], ["the resting cells", "TEST", 77, 94], ["much", "OBSERVATION_MODIFIER", 11, 15], ["greater", "OBSERVATION_MODIFIER", 16, 23], ["non-promoter peaks", "OBSERVATION", 38, 56]]], ["Thus, RAI1 at non-promoter regions preferentially persists when network activity decreases.", [["RAI1", "GENE_OR_GENE_PRODUCT", 6, 10], ["RAI1", "PROTEIN", 6, 10], ["non-promoter regions", "DNA", 14, 34], ["activity", "OBSERVATION_MODIFIER", 72, 80], ["decreases", "OBSERVATION_MODIFIER", 81, 90]]], ["The genes bound or nearest to these RAI1-TTX peaks showed incomplete induction and suppression upon TTX treatment of Rai1-KD cultures ( Figure 5G ) but not upon BIC treatment ( Figure S5J ).", [["TTX", "CHEMICAL", 41, 44], ["TTX", "CHEMICAL", 100, 103], ["BIC", "CHEMICAL", 161, 164], ["TTX", "CHEMICAL", 41, 44], ["TTX", "CHEMICAL", 100, 103], ["RAI1", "GENE_OR_GENE_PRODUCT", 36, 40], ["TTX", "SIMPLE_CHEMICAL", 41, 44], ["TTX", "SIMPLE_CHEMICAL", 100, 103], ["RAI1", "DNA", 36, 40], ["Rai1-KD cultures", "CELL_LINE", 117, 133], ["The genes bound", "PROBLEM", 0, 15], ["these RAI1", "TEST", 30, 40], ["TTX peaks", "PROBLEM", 41, 50], ["incomplete induction", "PROBLEM", 58, 78], ["TTX treatment", "TREATMENT", 100, 113], ["Rai1", "TEST", 117, 121], ["KD cultures", "TEST", 122, 133], ["BIC treatment", "TREATMENT", 161, 174]]], ["These results suggest that RAI1 directly contributes to the transcriptional response (both negative and positive) to TTX and that this role involves primarily non-promoter regulation.Loss of RAI1 Prevents Synaptic Upscaling but Not DownscalingWe next examined RAI1's role in homeostatic synaptic scaling induced by chronic activity suppression (TTX, 24 h) or chronic network hyperactivation (BIC, 24 h).", [["synaptic", "ANATOMY", 287, 295], ["RAI1", "CHEMICAL", 27, 31], ["TTX", "CHEMICAL", 117, 120], ["TTX", "CHEMICAL", 345, 348], ["TTX", "CHEMICAL", 117, 120], ["TTX", "CHEMICAL", 345, 348], ["RAI1", "GENE_OR_GENE_PRODUCT", 27, 31], ["TTX", "SIMPLE_CHEMICAL", 117, 120], ["RAI1", "GENE_OR_GENE_PRODUCT", 191, 195], ["RAI1", "GENE_OR_GENE_PRODUCT", 260, 264], ["TTX", "SIMPLE_CHEMICAL", 345, 348], ["RAI1", "PROTEIN", 27, 31], ["RAI1", "PROTEIN", 191, 195], ["RAI1", "PROTEIN", 260, 264], ["Loss of RAI1", "PROBLEM", 183, 195], ["homeostatic synaptic scaling", "PROBLEM", 275, 303], ["chronic activity suppression", "PROBLEM", 315, 343], ["chronic network hyperactivation", "PROBLEM", 359, 390], ["Synaptic Upscaling", "OBSERVATION", 205, 223], ["chronic", "OBSERVATION_MODIFIER", 315, 322], ["chronic", "OBSERVATION_MODIFIER", 359, 366], ["network hyperactivation", "OBSERVATION", 367, 390]]], ["Consistent with the misregu-lation of TTX-responsive genes by Rai1 KD after TTX treatment (Figures 4 and 5) , we found that loss of RAI1 significantly impaired the induction of homeostatic upscaling during activity suppression in a cell-autonomous manner.", [["cell", "ANATOMY", 232, 236], ["TTX", "CHEMICAL", 38, 41], ["TTX", "CHEMICAL", 76, 79], ["TTX", "CHEMICAL", 38, 41], ["TTX", "CHEMICAL", 76, 79], ["TTX", "SIMPLE_CHEMICAL", 38, 41], ["TTX", "SIMPLE_CHEMICAL", 76, 79], ["RAI1", "GENE_OR_GENE_PRODUCT", 132, 136], ["cell", "CELL", 232, 236], ["TTX-responsive genes", "DNA", 38, 58], ["RAI1", "PROTEIN", 132, 136], ["TTX treatment", "TREATMENT", 76, 89], ["loss of RAI1", "PROBLEM", 124, 136], ["homeostatic upscaling", "TREATMENT", 177, 198], ["activity suppression", "TREATMENT", 206, 226]]], ["Following transfection of scrambled or Rai1-targeted shRNAs (24 h prior to TTX/BIC), we found that control neurons expressing the scrambled shRNA exhibited the normal increase in mEPSC amplitude 24 h post-TTX (sh-Ctrl Veh versus TTX, n = 29-21, p < 0.0001; Figures 6A and 6B ) and the distribution of mEPSCs exhibited a clear and multiplicative rightward shift in cumulative frequency plots.", [["neurons", "ANATOMY", 107, 114], ["TTX", "CHEMICAL", 75, 78], ["TTX", "CHEMICAL", 205, 208], ["TTX", "CHEMICAL", 229, 232], ["TTX", "CHEMICAL", 75, 78], ["TTX", "CHEMICAL", 205, 208], ["TTX", "CHEMICAL", 229, 232], ["Rai1", "GENE_OR_GENE_PRODUCT", 39, 43], ["neurons", "CELL", 107, 114], ["TTX", "SIMPLE_CHEMICAL", 205, 208], ["Rai1", "DNA", 39, 43], ["shRNAs", "DNA", 53, 59], ["targeted shRNAs", "PROBLEM", 44, 59], ["TTX/BIC", "TEST", 75, 82], ["the scrambled shRNA", "PROBLEM", 126, 145], ["mEPSC amplitude", "TEST", 179, 194], ["TTX", "TEST", 229, 232], ["p", "TEST", 245, 246], ["Figures", "TEST", 257, 264], ["mEPSCs", "PROBLEM", 301, 307], ["multiplicative rightward shift in cumulative frequency plots", "PROBLEM", 330, 390], ["normal", "OBSERVATION_MODIFIER", 160, 166], ["increase", "OBSERVATION_MODIFIER", 167, 175], ["clear", "OBSERVATION", 320, 325], ["rightward shift", "OBSERVATION", 345, 360]]], ["In contrast, mEPSCs from neurons expressing either of two distinct Rai1 shRNAs did not significantly increase following TTX exposure (Figures 6A-6C) .", [["neurons", "ANATOMY", 25, 32], ["TTX", "CHEMICAL", 120, 123], ["TTX", "CHEMICAL", 120, 123], ["mEPSCs", "CELL", 13, 19], ["neurons", "CELL", 25, 32], ["Rai1", "GENE_OR_GENE_PRODUCT", 67, 71], ["TTX", "SIMPLE_CHEMICAL", 120, 123], ["mEPSCs", "CELL_TYPE", 13, 19], ["neurons", "CELL_TYPE", 25, 32], ["Rai1 shRNAs", "DNA", 67, 78], ["two distinct Rai1 shRNAs", "PROBLEM", 54, 78], ["TTX exposure", "TEST", 120, 132]]], ["Importantly, expression of an RNAi-resistant RAI1 fully rescued TTX-induced upscaling (Figures 6A-6C) .", [["TTX", "CHEMICAL", 64, 67], ["TTX", "CHEMICAL", 64, 67], ["RAI1", "GENE_OR_GENE_PRODUCT", 45, 49], ["TTX", "SIMPLE_CHEMICAL", 64, 67], ["RNAi-resistant RAI1", "PROTEIN", 30, 49], ["an RNAi-resistant RAI1", "TREATMENT", 27, 49]]], ["Despite a clear role in homeostatic upscaling, Rai1 KD had no effect on the induction of homeostatic downscaling following network hyperactivation with BIC ( Figures 6D-6F ).", [["Rai1 KD", "GENE_OR_GENE_PRODUCT", 47, 54], ["Rai1 KD", "PROTEIN", 47, 54], ["Rai1 KD", "PROBLEM", 47, 54], ["homeostatic downscaling", "TREATMENT", 89, 112], ["network hyperactivation", "PROBLEM", 123, 146]]], ["Both control neurons expressing scrambled shRNA and those neurons expressing Rai1 shRNA exhibited significantly decreased mEPSC amplitudes (sh-Ctrl Veh versus BIC, n = 26-17, p = 0.0026; sh-Rai1-#1 Veh versus BIC, n = 21-8, p = 0.0003; and sh-Rai1-#2 Veh versus BIC, n = 12-8, p < 0.0001; Figure 6E ), as well as a clear leftward multiplicative shift in mEPSC cumulative probability distributions ( Figure 6F ).", [["neurons", "ANATOMY", 13, 20], ["neurons", "ANATOMY", 58, 65], ["neurons", "CELL", 13, 20], ["neurons", "CELL", 58, 65], ["Rai1", "GENE_OR_GENE_PRODUCT", 77, 81], ["Rai1 shRNA", "DNA", 77, 87], ["Rai1 shRNA", "PROBLEM", 77, 87], ["significantly decreased mEPSC amplitudes", "PROBLEM", 98, 138], ["BIC", "TEST", 159, 162], ["n", "TEST", 164, 165], ["p", "TEST", 175, 176], ["sh", "TEST", 187, 189], ["Rai1", "TEST", 190, 194], ["BIC", "TEST", 209, 212], ["n", "TEST", 214, 215], ["p", "TEST", 224, 225], ["sh", "TEST", 240, 242], ["Rai1", "TEST", 243, 247], ["BIC", "TEST", 262, 265], ["n", "TEST", 267, 268], ["p", "TEST", 277, 278], ["Figure 6E", "TEST", 289, 298], ["a clear leftward multiplicative shift", "PROBLEM", 313, 350], ["neurons", "ANATOMY", 13, 20], ["mEPSC cumulative", "OBSERVATION", 354, 370]]], ["These results demonstrate that RAI is essential for homeostatic upscaling during activity suppression but is otherwise dispensable for homeostatic downscaling during periods of network hyperactivation.DiscussionOur BrU-seq analysis has provided insights into activity-dependent transcriptional regulation.", [["RAI", "CHEMICAL", 31, 34], ["RAI", "SIMPLE_CHEMICAL", 31, 34], ["BrU", "PROTEIN", 215, 218], ["activity suppression", "TREATMENT", 81, 101], ["homeostatic downscaling", "PROBLEM", 135, 158], ["network hyperactivation", "PROBLEM", 177, 200], ["network hyperactivation", "OBSERVATION", 177, 200]]], ["We found widespread transcriptional responses to network activity shifts attributable to BrU-seq's high sensitivity in detecting transcriptional downregulation.", [["BrU", "GENE_OR_GENE_PRODUCT", 89, 92], ["BrU", "PROTEIN", 89, 92], ["BrU", "TEST", 89, 92], ["high sensitivity", "PROBLEM", 99, 115], ["transcriptional downregulation", "PROBLEM", 129, 159], ["widespread", "OBSERVATION_MODIFIER", 9, 19], ["transcriptional responses", "OBSERVATION", 20, 45], ["transcriptional downregulation", "OBSERVATION", 129, 159]]], ["Most dynamically regulated genes altered by hyperactivity or suppression are unique rather than reciprocal (Figure 1 ).", [["hyperactivity", "DISEASE", 44, 57], ["hyperactivity", "PROBLEM", 44, 57]]], ["This is interesting given that gene expression studies have focused on reciprocal regulation of genes (e.g., Arc, Fos, Hom-er1, and Bdnf) (Okuno, 2011) .", [["Arc", "GENE_OR_GENE_PRODUCT", 109, 112], ["Fos", "GENE_OR_GENE_PRODUCT", 114, 117], ["Hom-er1", "GENE_OR_GENE_PRODUCT", 119, 126], ["Bdnf", "GENE_OR_GENE_PRODUCT", 132, 136], ["Arc", "DNA", 109, 112], ["Fos", "DNA", 114, 117], ["Hom-er1", "DNA", 119, 126], ["Bdnf", "DNA", 132, 136], ["gene expression studies", "TEST", 31, 54]]], ["Our results agree with a nascent proteome study on rat hippocampal neurons, in which the authors observed unique, common, and reciprocal changes in protein synthesis upon TTX and BIC treatments (Schanzenb\u00e4 cher et al., 2016) .", [["hippocampal neurons", "ANATOMY", 55, 74], ["TTX", "CHEMICAL", 171, 174], ["BIC", "CHEMICAL", 179, 182], ["TTX", "CHEMICAL", 171, 174], ["BIC", "CHEMICAL", 179, 182], ["rat", "ORGANISM", 51, 54], ["hippocampal neurons", "CELL", 55, 74], ["TTX", "SIMPLE_CHEMICAL", 171, 174], ["rat hippocampal neurons", "CELL_TYPE", 51, 74], ["rat", "SPECIES", 51, 54], ["a nascent proteome study", "TEST", 23, 47], ["reciprocal changes in protein synthesis", "PROBLEM", 126, 165], ["TTX", "TREATMENT", 171, 174], ["BIC treatments", "TREATMENT", 179, 193]]], ["These observations suggest that besides the reciprocal transcriptional changes of key factors, distinct transcriptional mechanisms may underlie upscaling and downscaling.", [["These observations", "TEST", 0, 18], ["the reciprocal transcriptional changes of key factors", "PROBLEM", 40, 93]]], ["Our data therefore provide a resource to begin an exploration of such distinct molecular machineries.DiscussionSeveral lines of evidence support a model in which RAI1 acts to constrain synaptic upscaling in networks with baseline levels of activity by preventing premature transcriptional responses normally driven by altered network activity (Figure 7) .", [["synaptic", "ANATOMY", 185, 193], ["RAI1", "GENE_OR_GENE_PRODUCT", 162, 166], ["RAI1", "PROTEIN", 162, 166], ["an exploration", "TEST", 47, 61], ["a model in which RAI1 acts", "TREATMENT", 145, 171], ["premature transcriptional responses", "PROBLEM", 263, 298], ["molecular machineries", "OBSERVATION", 79, 100]]], ["First, RAI1 deficiency shifts gene expression toward TTX-associated transcriptional states (Figure 2) .", [["TTX", "CHEMICAL", 53, 56], ["TTX", "CHEMICAL", 53, 56], ["RAI1", "GENE_OR_GENE_PRODUCT", 7, 11], ["TTX", "SIMPLE_CHEMICAL", 53, 56], ["RAI1", "PROTEIN", 7, 11], ["RAI1 deficiency", "PROBLEM", 7, 22], ["deficiency", "OBSERVATION", 12, 22]]], ["Second, RAI1 occupies its target promoters strongly in the resting cells and dissociates when network activity shifts ( Figure 5) .", [["cells", "ANATOMY", 67, 72], ["RAI1", "GENE_OR_GENE_PRODUCT", 8, 12], ["cells", "CELL", 67, 72], ["RAI1", "PROTEIN", 8, 12], ["target promoters", "DNA", 26, 42], ["resting cells", "CELL_TYPE", 59, 72], ["target promoters", "OBSERVATION", 26, 42]]], ["Third, Rai1 KD led to an increase in excitatory synaptic strength, reflected by enhanced mEPSC amplitudes and associated with an increase in network firing rate (Figure 3 ).", [["excitatory synaptic", "ANATOMY", 37, 56], ["network", "ANATOMY", 141, 148], ["Rai1", "GENE_OR_GENE_PRODUCT", 7, 11], ["synaptic", "IMMATERIAL_ANATOMICAL_ENTITY", 48, 56], ["Rai1 KD", "PROTEIN", 7, 14], ["an increase in excitatory synaptic strength", "PROBLEM", 22, 65], ["enhanced mEPSC amplitudes", "PROBLEM", 80, 105], ["an increase in network firing rate", "PROBLEM", 126, 160], ["increase", "OBSERVATION_MODIFIER", 25, 33], ["excitatory synaptic strength", "OBSERVATION", 37, 65], ["mEPSC amplitudes", "OBSERVATION", 89, 105], ["increase", "OBSERVATION_MODIFIER", 129, 137]]], ["Our data further indicate the additional role of RAI1 in promoting synaptic upscaling when the network All bar graphs are represented as mean \u00b1 SEM, and unpaired Student's t tests were performed. ***p < 0.0001.", [["synaptic", "ANATOMY", 67, 75], ["RAI1", "GENE_OR_GENE_PRODUCT", 49, 53], ["RAI1", "PROTEIN", 49, 53], ["RAI1", "TREATMENT", 49, 53], ["unpaired Student's t tests", "TEST", 153, 179]]], ["Cell Reports 32, 108002, August 11, 2020 11 Article ll OPEN ACCESS experiences prolonged activity depression ( Figure 6 ).", [["Cell", "ANATOMY", 0, 4], ["prolonged activity depression", "DISEASE", 79, 108], ["Cell", "CELL", 0, 4], ["prolonged activity depression", "PROBLEM", 79, 108]]], ["This latter role of RAI1 again involves direct control of TTX-induced transcriptional responses (Figures 4 and 5) .", [["TTX", "CHEMICAL", 58, 61], ["TTX", "CHEMICAL", 58, 61], ["RAI1", "GENE_OR_GENE_PRODUCT", 20, 24], ["TTX", "SIMPLE_CHEMICAL", 58, 61], ["RAI1", "PROTEIN", 20, 24]]], ["The most remarkable aspect of these observations might be the predictive capability of BrU-seq results for RAI1's roles in chromatin regulation and synaptic plasticity.DiscussionThe present work provides insights into RAI1-mediated regulation of gene transcription.", [["chromatin", "ANATOMY", 123, 132], ["synaptic", "ANATOMY", 148, 156], ["BrU", "GENE_OR_GENE_PRODUCT", 87, 90], ["RAI1", "GENE_OR_GENE_PRODUCT", 107, 111], ["chromatin", "CELLULAR_COMPONENT", 123, 132], ["synaptic", "CELLULAR_COMPONENT", 148, 156], ["RAI1", "GENE_OR_GENE_PRODUCT", 218, 222], ["BrU", "PROTEIN", 87, 90], ["RAI1", "PROTEIN", 107, 111], ["chromatin", "DNA", 123, 132], ["RAI1", "PROTEIN", 218, 222], ["RAI1's roles", "TREATMENT", 107, 119], ["chromatin regulation", "TREATMENT", 123, 143], ["gene transcription", "TREATMENT", 246, 264], ["most remarkable", "OBSERVATION_MODIFIER", 4, 19], ["synaptic plasticity", "OBSERVATION", 148, 167]]], ["RAI1 is a nucleosome-binding protein and is thought to act as a transcriptional coactivator (Bi et al., 2005) .", [["RAI1", "GENE_OR_GENE_PRODUCT", 0, 4], ["nucleosome", "CELLULAR_COMPONENT", 10, 20], ["RAI1", "PROTEIN", 0, 4], ["nucleosome-binding protein", "PROTEIN", 10, 36], ["transcriptional coactivator", "PROTEIN", 64, 91]]], ["Our data demonstrate that RAI1 can also repress transcription depending on the target genes ( Figure 5 ).", [["RAI1", "CHEMICAL", 26, 30], ["RAI1", "GENE_OR_GENE_PRODUCT", 26, 30], ["RAI1", "PROTEIN", 26, 30], ["target genes", "DNA", 79, 91], ["Our data", "TEST", 0, 8]]], ["We could not identify genomic features that separate coactivator and corepressor functions (not shown), but other studies suggest some possibilities.", [["corepressor functions", "TEST", 69, 90], ["other studies", "TEST", 108, 121]]], ["Like RAI1, TET3 and EHMT1/2 have important roles in homeostatic upscaling (Benevento et al., 2016; Yu et al., 2015b) .", [["RAI1", "GENE_OR_GENE_PRODUCT", 5, 9], ["TET3", "GENE_OR_GENE_PRODUCT", 11, 15], ["EHMT1/2", "GENE_OR_GENE_PRODUCT", 20, 27], ["RAI1", "PROTEIN", 5, 9], ["TET3", "PROTEIN", 11, 15], ["EHMT1/2", "PROTEIN", 20, 27]]], ["While TET3 positively regulates transcription by removing CpG methylation (Ito et al., 2010) , EHMT1/2 generally acts as a transcriptional repressor by placing the repressive histone H3K9 methylation mark (Tachibana et al., 2005) .", [["CpG", "CHEMICAL", 58, 61], ["TET3", "GENE_OR_GENE_PRODUCT", 6, 10], ["EHMT1/2", "GENE_OR_GENE_PRODUCT", 95, 102], ["histone H3K9", "GENE_OR_GENE_PRODUCT", 175, 187], ["TET3", "PROTEIN", 6, 10], ["EHMT1/2", "DNA", 95, 102], ["transcriptional repressor", "PROTEIN", 123, 148], ["H3K9", "PROTEIN", 183, 187], ["CpG methylation", "TREATMENT", 58, 73], ["a transcriptional repressor", "TREATMENT", 121, 148]]], ["Thus, the two facets of RAI1's role in transcriptional dynamics could be through interactions with positive and negative transcriptional regulators, such as TET3 and EHMT1/2.DiscussionIt is noteworthy that all the four previously characterized chromatin regulators in synaptic scaling (i.e., TET3, EHMT1/2, and L3MBTL1) were chosen for investigations, because network activity alters their expression or target histone modifications (Benevento et al., 2016; Mao et al., 2018; Yu et al., 2015b) .", [["chromatin", "ANATOMY", 244, 253], ["synaptic", "ANATOMY", 268, 276], ["RAI1", "GENE_OR_GENE_PRODUCT", 24, 28], ["TET3", "GENE_OR_GENE_PRODUCT", 157, 161], ["EHMT1/2", "GENE_OR_GENE_PRODUCT", 166, 173], ["chromatin", "CELLULAR_COMPONENT", 244, 253], ["TET3", "GENE_OR_GENE_PRODUCT", 292, 296], ["EHMT1/2", "GENE_OR_GENE_PRODUCT", 298, 305], ["L3MBTL1", "GENE_OR_GENE_PRODUCT", 311, 318], ["histone", "GENE_OR_GENE_PRODUCT", 411, 418], ["RAI1", "PROTEIN", 24, 28], ["positive and negative transcriptional regulators", "PROTEIN", 99, 147], ["TET3", "PROTEIN", 157, 161], ["EHMT1/2", "PROTEIN", 166, 173], ["chromatin regulators", "PROTEIN", 244, 264], ["TET3", "PROTEIN", 292, 296], ["EHMT1", "PROTEIN", 298, 303], ["L3MBTL1", "PROTEIN", 311, 318], ["histone", "PROTEIN", 411, 418], ["synaptic scaling", "TEST", 268, 284], ["TET3", "TEST", 292, 296], ["EHMT1", "TEST", 298, 303], ["investigations", "TEST", 336, 350]]], ["We found no indication that neuronal activity influences RAI1 expression ( Figures S2A and S5B) .", [["neuronal", "ANATOMY", 28, 36], ["neuronal", "CELL", 28, 36], ["RAI1", "GENE_OR_GENE_PRODUCT", 57, 61], ["Figures S2A", "GENE_OR_GENE_PRODUCT", 75, 86], ["S5B", "GENE_OR_GENE_PRODUCT", 91, 94], ["RAI1", "PROTEIN", 57, 61], ["S5B", "PROTEIN", 91, 94], ["no indication", "UNCERTAINTY", 9, 22]]], ["These observations suggest that chromatin regulators linked to human cognitive disorders could participate in synaptic scaling and other forms of transcription- dependent plasticity, even when their expression remains stable during the process.", [["chromatin", "ANATOMY", 32, 41], ["synaptic", "ANATOMY", 110, 118], ["cognitive disorders", "DISEASE", 69, 88], ["chromatin", "CELLULAR_COMPONENT", 32, 41], ["human", "ORGANISM", 63, 68], ["chromatin regulators", "PROTEIN", 32, 52], ["human", "SPECIES", 63, 68], ["human", "SPECIES", 63, 68], ["chromatin regulators", "PROBLEM", 32, 52], ["human cognitive disorders", "PROBLEM", 63, 88], ["synaptic scaling", "PROBLEM", 110, 126], ["transcription- dependent plasticity", "PROBLEM", 146, 181], ["stable", "OBSERVATION", 218, 224]]], ["The predominant chromatin occupancy by RAI1 during stable periods of network activity ( Figure 5) is unique among the scaling-associated chromatin factors, which all appear to be activated by network activity alterations.", [["chromatin", "ANATOMY", 16, 25], ["chromatin", "ANATOMY", 137, 146], ["chromatin", "CELLULAR_COMPONENT", 16, 25], ["RAI1", "GENE_OR_GENE_PRODUCT", 39, 43], ["chromatin", "CELLULAR_COMPONENT", 137, 146], ["chromatin", "DNA", 16, 25], ["RAI1", "PROTEIN", 39, 43], ["chromatin factors", "PROTEIN", 137, 154], ["The predominant chromatin occupancy", "PROBLEM", 0, 35], ["the scaling", "PROBLEM", 114, 125], ["chromatin factors", "PROBLEM", 137, 154], ["predominant", "OBSERVATION_MODIFIER", 4, 15], ["chromatin occupancy", "OBSERVATION", 16, 35], ["stable", "OBSERVATION_MODIFIER", 51, 57], ["chromatin factors", "OBSERVATION", 137, 154]]], ["Post-translational modifications on RAI1 itself or chromatin are potential mechanisms for the RAI1 dissociation from chromatin.", [["chromatin", "ANATOMY", 51, 60], ["chromatin", "ANATOMY", 117, 126], ["RAI1", "GENE_OR_GENE_PRODUCT", 36, 40], ["chromatin", "CELLULAR_COMPONENT", 51, 60], ["RAI1", "GENE_OR_GENE_PRODUCT", 94, 98], ["chromatin", "CELLULAR_COMPONENT", 117, 126], ["RAI1", "DNA", 36, 40], ["chromatin", "DNA", 51, 60], ["RAI1", "PROTEIN", 94, 98], ["chromatin", "DNA", 117, 126], ["translational modifications on RAI1", "TREATMENT", 5, 40], ["the RAI1 dissociation", "PROBLEM", 90, 111]]], ["Thus, RAI1 offers a molecular mechanism that stabilizes network activity, and future investigations may uncover a similar mode of action in other chromatin regulators associated with human cognitive deficits.DiscussionHow do RAI1's roles in synaptic scaling relate to cognitive function?", [["chromatin", "ANATOMY", 146, 155], ["synaptic", "ANATOMY", 241, 249], ["RAI1", "CHEMICAL", 6, 10], ["cognitive deficits", "DISEASE", 189, 207], ["RAI1", "GENE_OR_GENE_PRODUCT", 6, 10], ["chromatin", "CELLULAR_COMPONENT", 146, 155], ["human", "ORGANISM", 183, 188], ["RAI1", "GENE_OR_GENE_PRODUCT", 225, 229], ["synaptic", "MULTI-TISSUE_STRUCTURE", 241, 249], ["RAI1", "PROTEIN", 6, 10], ["chromatin regulators", "PROTEIN", 146, 166], ["RAI1", "PROTEIN", 225, 229], ["human", "SPECIES", 183, 188], ["human", "SPECIES", 183, 188], ["future investigations", "TEST", 78, 99], ["human cognitive deficits", "PROBLEM", 183, 207], ["cognitive function", "TEST", 268, 286]]], ["Thorough characterization of cell type-specific Rai1-KO mice attributed their learning deficits to GABAergic interneurons rather than glutamatergic excitatory neurons .", [["cell", "ANATOMY", 29, 33], ["GABAergic interneurons", "ANATOMY", 99, 121], ["glutamatergic excitatory neurons", "ANATOMY", 134, 166], ["learning deficits", "DISEASE", 78, 95], ["cell", "CELL", 29, 33], ["Rai1", "GENE_OR_GENE_PRODUCT", 48, 52], ["interneurons", "CELL", 109, 121], ["glutamatergic excitatory neurons", "CELL", 134, 166], ["Rai1", "PROTEIN", 48, 52], ["glutamatergic excitatory neurons", "CELL_TYPE", 134, 166], ["mice", "SPECIES", 56, 60], ["Thorough characterization", "TEST", 0, 25], ["cell type-specific Rai1", "TEST", 29, 52], ["their learning deficits", "PROBLEM", 72, 95], ["GABAergic interneurons", "PROBLEM", 99, 121], ["GABAergic interneurons", "OBSERVATION", 99, 121]]], ["Because we measured mEPSCs in the pyramidal cells that incorporated the sparsely transfected Rai1-shRNA plasmid, RAI1's role in synaptic scaling is cell autonomous to excitatory neurons.", [["pyramidal cells", "ANATOMY", 34, 49], ["plasmid", "ANATOMY", 104, 111], ["synaptic", "ANATOMY", 128, 136], ["cell", "ANATOMY", 148, 152], ["excitatory neurons", "ANATOMY", 167, 185], ["mEPSCs", "CELL", 20, 26], ["pyramidal cells", "CELL", 34, 49], ["Rai1", "GENE_OR_GENE_PRODUCT", 93, 97], ["RAI1", "GENE_OR_GENE_PRODUCT", 113, 117], ["cell", "CELL", 148, 152], ["neurons", "CELL", 178, 185], ["pyramidal cells", "CELL_TYPE", 34, 49], ["Rai1", "PROTEIN", 93, 97], ["shRNA plasmid", "DNA", 98, 111], ["RAI1", "PROTEIN", 113, 117], ["excitatory neurons", "CELL_TYPE", 167, 185], ["mEPSCs in the pyramidal cells", "PROBLEM", 20, 49], ["shRNA plasmid", "TREATMENT", 98, 111], ["pyramidal cells", "OBSERVATION", 34, 49], ["sparsely", "OBSERVATION_MODIFIER", 72, 80], ["cell autonomous", "OBSERVATION", 148, 163]]], ["The lack of learning deficits in forebrain-specific Rai1-KO (Emx1-Cre: Rai1 flox/flox ) may suggest that impaired cognitive function is independent of RAI1's role in synaptic scaling.", [["forebrain", "ANATOMY", 33, 42], ["synaptic", "ANATOMY", 166, 174], ["learning deficits", "DISEASE", 12, 29], ["Rai1", "GENE_OR_GENE_PRODUCT", 52, 56], ["Emx1-Cre", "GENE_OR_GENE_PRODUCT", 61, 69], ["Rai1 flox/flox", "GENE_OR_GENE_PRODUCT", 71, 85], ["RAI1", "GENE_OR_GENE_PRODUCT", 151, 155], ["Rai1", "PROTEIN", 52, 56], ["Emx1", "PROTEIN", 61, 65], ["Cre", "PROTEIN", 66, 69], ["Rai1 flox", "PROTEIN", 71, 80], ["flox", "CELL_LINE", 81, 85], ["RAI1", "PROTEIN", 151, 155], ["learning deficits", "PROBLEM", 12, 29], ["impaired cognitive function", "PROBLEM", 105, 132], ["impaired", "OBSERVATION", 105, 113]]], ["Alternatively, unknown genes may compensate for synaptic scaling deficits during development thus obscuring the contribution of RAI1 in excitatory neurons that can only be seen in acute RAI1 deficiency.", [["synaptic", "ANATOMY", 48, 56], ["excitatory neurons", "ANATOMY", 136, 154], ["RAI1", "GENE_OR_GENE_PRODUCT", 128, 132], ["excitatory neurons", "CELL", 136, 154], ["RAI1", "GENE_OR_GENE_PRODUCT", 186, 190], ["RAI1", "PROTEIN", 128, 132], ["excitatory neurons", "CELL_TYPE", 136, 154], ["RAI1", "PROTEIN", 186, 190], ["synaptic scaling deficits", "PROBLEM", 48, 73], ["RAI1 in excitatory neurons", "PROBLEM", 128, 154], ["acute RAI1 deficiency", "PROBLEM", 180, 201], ["acute", "OBSERVATION_MODIFIER", 180, 185], ["RAI1 deficiency", "OBSERVATION", 186, 201]]], ["Of note, a recent study reported reduced dendritic spine density in the prefrontal cortex of 4-week-old Rai1-heterozygous mice (Huang et al., 2018) , which are genetically similar to SMS patients.", [["dendritic spine", "ANATOMY", 41, 56], ["prefrontal cortex", "ANATOMY", 72, 89], ["dendritic spine", "MULTI-TISSUE_STRUCTURE", 41, 56], ["prefrontal cortex", "MULTI-TISSUE_STRUCTURE", 72, 89], ["Rai1", "GENE_OR_GENE_PRODUCT", 104, 108], ["mice", "ORGANISM", 122, 126], ["patients", "ORGANISM", 187, 195], ["Rai1", "PROTEIN", 104, 108], ["mice", "SPECIES", 122, 126], ["patients", "SPECIES", 187, 195], ["a recent study", "TEST", 9, 23], ["reduced dendritic spine density", "PROBLEM", 33, 64], ["heterozygous mice", "PROBLEM", 109, 126], ["reduced", "OBSERVATION_MODIFIER", 33, 40], ["dendritic", "OBSERVATION_MODIFIER", 41, 50], ["spine", "ANATOMY", 51, 56], ["density", "OBSERVATION", 57, 64], ["prefrontal", "ANATOMY_MODIFIER", 72, 82], ["cortex", "ANATOMY_MODIFIER", 83, 89]]], ["The spine deficits in Rai1-heterozygous mice may relate to RAI1's role in synaptic upscaling identified here.", [["spine", "ANATOMY", 4, 9], ["synaptic", "ANATOMY", 74, 82], ["spine deficits", "DISEASE", 4, 18], ["spine", "MULTI-TISSUE_STRUCTURE", 4, 9], ["Rai1", "GENE_OR_GENE_PRODUCT", 22, 26], ["mice", "ORGANISM", 40, 44], ["RAI1", "GENE_OR_GENE_PRODUCT", 59, 63], ["Rai1", "PROTEIN", 22, 26], ["RAI1", "PROTEIN", 59, 63], ["mice", "SPECIES", 40, 44], ["The spine deficits", "PROBLEM", 0, 18], ["heterozygous mice", "PROBLEM", 27, 44], ["spine", "ANATOMY", 4, 9], ["deficits", "OBSERVATION", 10, 18]]], ["Identifying RAI1target genes that mediate the synaptic phenotype will illuminate the molecular pathways underlying the cell-autonomous roles of RAI1.DiscussionA limitation of the BrU-seq approach is the lack of cell type specificity.", [["synaptic", "ANATOMY", 46, 54], ["cell", "ANATOMY", 119, 123], ["cell", "ANATOMY", 211, 215], ["RAI1target", "GENE_OR_GENE_PRODUCT", 12, 22], ["cell", "CELL", 119, 123], ["RAI1", "GENE_OR_GENE_PRODUCT", 144, 148], ["BrU", "GENE_OR_GENE_PRODUCT", 179, 182], ["cell", "CELL", 211, 215], ["RAI1target genes", "DNA", 12, 28], ["RAI1", "PROTEIN", 144, 148], ["BrU", "PROTEIN", 179, 182], ["the synaptic phenotype", "PROBLEM", 42, 64]]], ["Recently, Zajaczkowski et al. (2018) reported nascent RNA-seq specifically in neurons.", [["neurons", "ANATOMY", 78, 85], ["neurons", "CELL", 78, 85], ["neurons", "CELL_TYPE", 78, 85], ["nascent RNA", "PROBLEM", 46, 57], ["neurons", "ANATOMY", 78, 85]]], ["They used Synapsin I promoterdriven expression of uracil phosphoribosyltransferase (UPRT) to label RNAs of neurons.", [["neurons", "ANATOMY", 107, 114], ["uracil", "CHEMICAL", 50, 56], ["uracil", "CHEMICAL", 50, 56], ["Synapsin I", "GENE_OR_GENE_PRODUCT", 10, 20], ["uracil phosphoribosyltransferase", "GENE_OR_GENE_PRODUCT", 50, 82], ["UPRT", "GENE_OR_GENE_PRODUCT", 84, 88], ["neurons", "CELL", 107, 114], ["Synapsin I", "PROTEIN", 10, 20], ["uracil phosphoribosyltransferase", "PROTEIN", 50, 82], ["UPRT", "PROTEIN", 84, 88], ["neurons", "CELL_TYPE", 107, 114], ["uracil phosphoribosyltransferase (UPRT)", "TREATMENT", 50, 89], ["uracil phosphoribosyltransferase", "OBSERVATION", 50, 82], ["neurons", "ANATOMY", 107, 114]]], ["The UPRT system identified more than 3,000 depolarization-regulated genes over the 3 h KCl treatments, which likely detected both nascent transcripts and steady-state mRNAs.", [["KCl", "CHEMICAL", 87, 90], ["KCl", "CHEMICAL", 87, 90], ["KCl", "SIMPLE_CHEMICAL", 87, 90], ["regulated genes", "DNA", 58, 73], ["nascent transcripts", "RNA", 130, 149], ["steady-state mRNAs", "RNA", 154, 172], ["The UPRT system", "TEST", 0, 15], ["the 3 h KCl treatments", "TREATMENT", 79, 101], ["nascent transcripts", "OBSERVATION", 130, 149]]], ["Cell type specificity of the UPRT system comes with the cost of introducing the UPRT transgene and additional experimental steps to label RNAs.", [["Cell", "ANATOMY", 0, 4], ["Cell", "CELL", 0, 4], ["UPRT", "GENE_OR_GENE_PRODUCT", 80, 84], ["UPRT", "PROTEIN", 29, 33], ["UPRT transgene", "DNA", 80, 94], ["label RNAs", "RNA", 132, 142], ["the UPRT transgene", "TREATMENT", 76, 94]]], ["Furthermore, single-cell RNA-seq of Rai1-KD neurons might illuminate cell type-specific roles for RAI1.Discussion12 Cell Reports 32, 108002, August 11, 2020 Article ll OPEN ACCESS Single-cell RNA-seq, however, mostly characterizes poly(A)selected steady-state mRNAs.", [["Rai1-KD neurons", "ANATOMY", 36, 51], ["cell", "ANATOMY", 69, 73], ["Cell", "ANATOMY", 116, 120], ["Rai1", "GENE_OR_GENE_PRODUCT", 36, 40], ["cell", "CELL", 69, 73], ["RAI1", "GENE_OR_GENE_PRODUCT", 98, 102], ["Cell", "CELL", 116, 120], ["cell", "CELL", 187, 191], ["poly(A)", "GENE_OR_GENE_PRODUCT", 231, 238], ["Rai1", "PROTEIN", 36, 40], ["RAI1", "PROTEIN", 98, 102], ["poly(A)selected steady-state mRNAs", "RNA", 231, 265], ["single-cell RNA", "TEST", 13, 28]]], ["Thus, it will be important to choose the most suitable experimental approach for RNA profiling depending on specific goals of the study.DiscussionOur RAI1 ChIP-seq study involves a single replicate because of the unexpected and sustained laboratory closures during the ongoing coronavirus disease 2019 (COVID-19) pandemic.", [["coronavirus disease", "DISEASE", 277, 296], ["RNA profiling", "TREATMENT", 81, 94], ["the study", "TEST", 126, 135], ["seq study", "TEST", 160, 169], ["the ongoing coronavirus disease", "PROBLEM", 265, 296], ["COVID", "TEST", 303, 308], ["pandemic", "PROBLEM", 313, 321], ["coronavirus disease", "OBSERVATION", 277, 296]]], ["When laboratory operations resume, we plan to collect data of a second replicate and share the data via the GEO database.", [["the GEO database", "TEST", 104, 120]]], ["Our ChIP-seq data, nonetheless, include robust controls (i.e., Rai1-KD samples and internal spike-in controls); therefore, it is unlikely that the conclusion will change with new datasets.DiscussionIn summary, our results indicate that nascent RNA-seq with BrU-seq uncovers robust and dynamic transcriptional responses during alterations in network activity.", [["Rai1", "GENE_OR_GENE_PRODUCT", 63, 67], ["BrU-seq", "GENE_OR_GENE_PRODUCT", 257, 264], ["Rai1", "PROTEIN", 63, 67], ["BrU", "PROTEIN", 257, 260], ["Our ChIP", "TEST", 0, 8], ["Rai1", "TEST", 63, 67], ["KD samples", "TEST", 68, 78], ["internal spike", "TEST", 83, 97], ["BrU", "TEST", 257, 260]]], ["Transcriptional changes are largely unique in response to network hyperactivation or suppression, rather than reciprocal.", [["Transcriptional changes", "PROBLEM", 0, 23], ["network hyperactivation", "PROBLEM", 58, 81], ["hyperactivation", "OBSERVATION", 66, 81]]], ["Our studies further identify a unique role for RAI1 in homeostatic synaptic plasticity, whereby during stable patterns of activity, it suppresses a transcriptional program engaged during activity suppression.", [["synaptic", "ANATOMY", 67, 75], ["RAI1", "GENE_OR_GENE_PRODUCT", 47, 51], ["RAI1", "PROTEIN", 47, 51], ["Our studies", "TEST", 0, 11], ["a transcriptional program", "TREATMENT", 146, 171], ["activity suppression", "TREATMENT", 187, 207], ["synaptic plasticity", "OBSERVATION", 67, 86]]], ["These findings illuminate principles whereby dysregulated chromatin signaling may contribute to neurodevelopmental disorders.STAR+METHODSDetailed methods are provided in the online version of this paper and include the following:Lead ContactFurther information and requests for resources and reagents should be directed to and will be fulfilled by Shigeki Iwase (siwase@ umich.edu)Materials AvailabilityThere are restrictions to the availability of the custom RAI1 antibody due to limited supply.Data and Code AvailabilitySequencing data generated for this study have been submitted to the NCBI Gene Expression Omnibus (GEO; https://www.ncbi.nlm. nih.gov/geo/) under accession number GSE121749.", [["chromatin", "ANATOMY", 58, 67], ["neurodevelopmental disorders", "DISEASE", 96, 124], ["GSE121749", "CHEMICAL", 684, 693], ["chromatin", "CELLULAR_COMPONENT", 58, 67], ["RAI1 antibody", "GENE_OR_GENE_PRODUCT", 460, 473], ["chromatin", "DNA", 58, 67], ["RAI1 antibody", "PROTEIN", 460, 473], ["dysregulated chromatin signaling", "PROBLEM", 45, 77], ["neurodevelopmental disorders", "PROBLEM", 96, 124], ["the custom RAI1 antibody", "TREATMENT", 449, 473], ["Sequencing data", "TEST", 522, 537], ["this study", "TEST", 552, 562], ["dysregulated chromatin", "OBSERVATION", 45, 67]]], ["Custom MEA analysis scripts can be found at https://github.com/Jcrd25/NeuroMEACodePrimary Mouse Forebrain CulturesCortices and hippocampi from E18.5 CD1 mouse pups (Charles River, Strain 022) were pooled into biological replicates with identical female:male ratios.", [["Forebrain CulturesCortices", "ANATOMY", 96, 122], ["hippocampi", "ANATOMY", 127, 137], ["Mouse", "ORGANISM", 90, 95], ["Forebrain CulturesCortices", "CELL", 96, 122], ["hippocampi", "ORGAN", 127, 137], ["E18.5 CD1", "ORGANISM", 143, 152], ["mouse", "ORGANISM", 153, 158], ["Charles River", "ORGANISM", 165, 178], ["Mouse", "SPECIES", 90, 95], ["mouse", "SPECIES", 153, 158], ["Mouse", "SPECIES", 90, 95], ["mouse", "SPECIES", 153, 158], ["Custom MEA analysis", "TEST", 0, 19], ["Mouse Forebrain CulturesCortices", "TEST", 90, 122], ["hippocampi", "TEST", 127, 137], ["Forebrain", "ANATOMY", 96, 105], ["hippocampi", "ANATOMY", 127, 137]]], ["Sex of the pups was determined by PCR using primers for the ZFY gene (Table S6 ).", [["pups", "ORGANISM", 11, 15], ["ZFY", "GENE_OR_GENE_PRODUCT", 60, 63], ["ZFY gene", "DNA", 60, 68], ["the ZFY gene", "TREATMENT", 56, 68]]], ["Primary culture of neurons was carried out as previously described .", [["neurons", "ANATOMY", 19, 26], ["neurons", "CELL", 19, 26], ["Primary culture of neurons", "TEST", 0, 26]]], ["Briefly, dissociated tissues were plated at 4 million cells/6 cm poly-D-lysine-coated plate (Sigma) grown in Neurobasal Media supplemented with B27 (GIBCO, #17504044).", [["tissues", "ANATOMY", 21, 28], ["cells", "ANATOMY", 54, 59], ["poly-D-lysine", "CHEMICAL", 65, 78], ["poly-D-lysine", "CHEMICAL", 65, 78], ["tissues", "TISSUE", 21, 28], ["cells", "CELL", 54, 59], ["poly-D-lysine", "SIMPLE_CHEMICAL", 65, 78], ["dissociated tissues", "PROBLEM", 9, 28], ["poly", "TEST", 65, 69], ["D-lysine-coated plate (Sigma", "TREATMENT", 70, 98], ["tissues", "ANATOMY", 21, 28], ["6 cm", "OBSERVATION_MODIFIER", 60, 64], ["coated plate", "OBSERVATION_MODIFIER", 79, 91]]], ["No mitotic inhibitors or antibiotics were added.", [["mitotic inhibitors", "TREATMENT", 3, 21], ["antibiotics", "TREATMENT", 25, 36], ["mitotic inhibitors", "OBSERVATION", 3, 21]]], ["Half the culture medium was freshened every 3-5 days.Primary Rat Hippocampal CulturesAll animal use followed NIH guidelines and was in compliance with the University of Michigan Committee on Use and Care of Animals.", [["Hippocampal Cultures", "ANATOMY", 65, 85], ["Rat", "SPECIES", 61, 64], ["the culture medium", "TEST", 5, 23], ["Primary Rat Hippocampal Cultures", "TEST", 53, 85], ["Hippocampal", "ANATOMY", 65, 76]]], ["Dissociated postnatal (P0-3) hippocampal neuron cultures were prepared from Sprague-Dawley rats (Charles River, Strain 001) as previously described .", [["hippocampal neuron cultures", "ANATOMY", 29, 56], ["P0-3", "CELL", 23, 27], ["hippocampal neuron cultures", "CELL", 29, 56], ["Sprague-Dawley rats", "ORGANISM", 76, 95], ["Charles River", "ORGANISM", 97, 110], ["Dissociated postnatal (P0-3) hippocampal neuron cultures", "CELL_LINE", 0, 56], ["Sprague-Dawley rats", "SPECIES", 76, 95], ["Sprague-Dawley rats", "SPECIES", 76, 95], ["Dissociated postnatal (P0", "PROBLEM", 0, 25], ["hippocampal neuron cultures", "TEST", 29, 56]]], ["Sex of rat pups was not determined.", [["rat", "ORGANISM", 7, 10], ["pups", "ORGAN", 11, 15], ["rat", "SPECIES", 7, 10], ["rat", "SPECIES", 7, 10]]], ["For MEA experiments, neurons were plated onto sterile multi-electrode arrays chips (MEAs) (60MEA200/30IR-TI; Multichannel Systems, Reutlingen, Germany) at a density of $350 cells/ mm2.", [["neurons", "ANATOMY", 21, 28], ["cells", "ANATOMY", 173, 178], ["neurons", "CELL", 21, 28], ["MEA experiments", "TREATMENT", 4, 19], ["sterile multi-electrode arrays chips", "TREATMENT", 46, 82]]], ["MEAs were coated with 0.05% polyethyleneimine and laminin (1 ug/ul).", [["polyethyleneimine", "CHEMICAL", 28, 45], ["polyethyleneimine", "CHEMICAL", 28, 45], ["MEAs", "SIMPLE_CHEMICAL", 0, 4], ["polyethyleneimine", "SIMPLE_CHEMICAL", 28, 45], ["laminin", "GENE_OR_GENE_PRODUCT", 50, 57], ["MEAs", "TEST", 0, 4], ["0.05% polyethyleneimine and laminin", "TREATMENT", 22, 57]]], ["MEAs were transferred to the incubator for > 3 h to allow for cell adhesion.", [["cell", "ANATOMY", 62, 66], ["cell", "CELL", 62, 66], ["cell adhesion", "PROBLEM", 62, 75], ["cell adhesion", "OBSERVATION", 62, 75]]], ["Media was composed of Neurobasal Plus Medium with 1X B-27 Plus supplement, 1X GlutaMax and 50 U/ml of Pen/Strep (ThermoFisher, Waltham, MA).", [["1X B-27 Plus", "CHEMICAL", 50, 62], ["GlutaMax", "CHEMICAL", 78, 86], ["GlutaMax", "SIMPLE_CHEMICAL", 78, 86], ["Neurobasal Plus Medium", "TREATMENT", 22, 44], ["1X GlutaMax", "TREATMENT", 75, 86], ["Strep", "PROBLEM", 106, 111], ["Strep", "OBSERVATION", 106, 111]]], ["MEAs were covered with a gas permeable ethlylene propylene membrane (MEA-MEM, Multichannel Systems, Reutlingen, Germany).", [["ethlylene propylene", "CHEMICAL", 39, 58], ["ethlylene propylene", "CHEMICAL", 39, 58], ["MEAs", "SIMPLE_CHEMICAL", 0, 4], ["ethlylene propylene membrane", "SIMPLE_CHEMICAL", 39, 67], ["MEAs", "TEST", 0, 4], ["a gas permeable ethlylene propylene membrane", "TREATMENT", 23, 67]]], ["Half-volume media exchanges were done every 3-4 days.", [["Half-volume media exchanges", "TREATMENT", 0, 27]]], ["Cultures that exhibited spontaneous spiking activity on R 10 electrodes on DIV10 were considered healthy and included in the study.Lentivirus preparationLentivirus were generated using co-transfection into HEK293t cells of psPAX2 (Addgene, 12260), pMD2.G (AddGene, 12259) and pLKO plasmids containing shRNA against Rai1 untranslated region (Rai1-shRNA #1: Sigma, TRCN0000124984) or coding region (Rai1-shRNA #2: Sigma, TRCN0000328334) or scramble shRNA (Sigma, SHC202).", [["HEK293t cells", "ANATOMY", 206, 219], ["Lentivirus", "ORGANISM", 131, 141], ["HEK293t cells", "CELL", 206, 219], ["psPAX2", "GENE_OR_GENE_PRODUCT", 223, 229], ["Addgene", "GENE_OR_GENE_PRODUCT", 231, 238], ["AddGene, 12259)", "GENE_OR_GENE_PRODUCT", 256, 271], ["HEK293t cells", "CELL_LINE", 206, 219], ["psPAX2 (Addgene, 12260), pMD2.G (AddGene, 12259)", "DNA", 223, 271], ["pLKO plasmids", "DNA", 276, 289], ["Rai1 untranslated region", "DNA", 315, 339], ["Rai1", "DNA", 341, 345], ["shRNA #1", "DNA", 346, 354], ["TRCN0000124984", "DNA", 363, 377], ["coding region", "DNA", 382, 395], ["Rai1", "DNA", 397, 401], ["shRNA #2", "DNA", 402, 410], ["TRCN0000328334", "DNA", 419, 433], ["scramble shRNA", "DNA", 438, 452], ["SHC202", "DNA", 461, 467], ["Lentivirus", "SPECIES", 131, 141], ["Cultures", "TEST", 0, 8], ["spontaneous spiking activity", "PROBLEM", 24, 52], ["R 10 electrodes", "TREATMENT", 56, 71], ["DIV10", "TREATMENT", 75, 80], ["the study", "TEST", 121, 130], ["Lentivirus preparationLentivirus", "TREATMENT", 131, 163], ["AddGene", "TEST", 256, 263], ["pLKO plasmids", "TREATMENT", 276, 289], ["Rai1 untranslated region", "PROBLEM", 315, 339], ["coding region", "PROBLEM", 382, 395], ["Rai1", "TEST", 397, 401], ["spontaneous", "OBSERVATION_MODIFIER", 24, 35], ["spiking", "OBSERVATION_MODIFIER", 36, 43], ["activity", "OBSERVATION_MODIFIER", 44, 52]]], ["For Bru-seq and ChIP-seq experiments, we used SHC202 and Rai1-shRNA #1.", [["SHC202", "DNA", 46, 52], ["Rai1", "DNA", 57, 61], ["shRNA #1", "DNA", 62, 70], ["Bru-seq and ChIP", "TREATMENT", 4, 20], ["SHC202", "TEST", 46, 52]]], ["For electrophysiology, we used SHC202, Rai1-shRNA #1 and #2, whose target sequences are Article ll Multi-Electrode Array Electrophysiology Spontaneous activity was captured during 5 min epochs.", [["SHC202", "DNA", 31, 37], ["Rai1", "DNA", 39, 43], ["shRNA #1 and #2", "DNA", 44, 59], ["target sequences", "DNA", 67, 83], ["SHC202", "TEST", 31, 37]]], ["Data were imported into MATLAB (MathWorks, Natick, MA) and analyzed using custom written scripts (https://github.com/Jcrd25/NeuroMEACode) The LFP signal was high pass filtered at 100 Hz using a Butterworth filter.", [["LFP", "PROTEIN", 142, 145], ["The LFP signal", "TEST", 138, 152], ["a Butterworth filter", "TREATMENT", 192, 212]]], ["Spikes were detected using amplitude thresholds set at five times the root mean square of the noise.", [["root", "ANATOMY", 70, 74], ["Spikes", "PROBLEM", 0, 6], ["amplitude thresholds", "TEST", 27, 47]]], ["Neuronal units were identified by spike sporting using principal component analysis of the detected spike and manually identifying clusters.", [["Neuronal", "ANATOMY", 0, 8], ["Neuronal units", "CELL", 0, 14], ["Neuronal units", "TREATMENT", 0, 14], ["principal component analysis", "TEST", 55, 83], ["the detected spike", "PROBLEM", 87, 105]]], ["A spike was defined by the signal 1 ms before the peak to 3 ms after the peak.", [["A spike", "PROBLEM", 0, 7]]], ["The inter spike interval was defined as the time between two adjacent spikes.", [["two adjacent spikes", "PROBLEM", 57, 76], ["spikes", "OBSERVATION_MODIFIER", 70, 76]]], ["Mean firing frequency was calculated by dividing the total number of spikes detected for each neuronal unit by the recording duration.", [["neuronal", "ANATOMY", 94, 102], ["neuronal", "CELL", 94, 102], ["Mean firing frequency", "PROBLEM", 0, 21]]], ["Statistical analyses were done in MATLAB and GraphPad Prism (GraphPad Software, San Diego, CA).", [["Statistical analyses", "TEST", 0, 20]]], ["Kruskal-Wallis test followed by post hoc Dunn's multiple comparisons test were performed on data from three biological replicates.ImmunofluorescenceFor RAI1 and cell-type marker staining, immunoreactivity was quantified blinded to condition and semi-automatedly using ImageJ after confirming specific staining by visual inspection.", [["cell", "ANATOMY", 161, 165], ["RAI1", "GENE_OR_GENE_PRODUCT", 152, 156], ["cell", "CELL", 161, 165], ["RAI1", "PROTEIN", 152, 156], ["Kruskal-Wallis test", "TEST", 0, 19], ["Dunn's multiple comparisons test", "TEST", 41, 73], ["ImmunofluorescenceFor", "TEST", 130, 151], ["cell-type marker staining", "PROBLEM", 161, 186], ["ImageJ", "TEST", 268, 274], ["visual inspection", "TEST", 313, 330]]], ["For synaptic GluA1 staining, synaptic GluA1 was anlayzed on maximal intensity z-projections.", [["synaptic", "ANATOMY", 4, 12], ["synaptic", "ANATOMY", 29, 37], ["GluA1", "GENE_OR_GENE_PRODUCT", 13, 18], ["GluA1", "GENE_OR_GENE_PRODUCT", 38, 43], ["GluA1", "PROTEIN", 13, 18], ["synaptic GluA1", "PROTEIN", 29, 43], ["synaptic GluA1 staining", "TEST", 4, 27], ["synaptic GluA1", "TEST", 29, 43], ["maximal intensity z-projections", "TREATMENT", 60, 91], ["GluA1 staining", "OBSERVATION", 13, 27], ["synaptic GluA1", "OBSERVATION", 29, 43]]], ["Synaptic GluA1 was defined as a particle that occupied >10% of the PSD-95 positive area, and the average integrated intensity of synapatic GluA1 was calculated using custom-written analyses on ImageJ and MATLAB.", [["Synaptic", "ANATOMY", 0, 8], ["PSD-95 positive area", "ANATOMY", 67, 87], ["GluA1", "GENE_OR_GENE_PRODUCT", 9, 14], ["GluA1", "GENE_OR_GENE_PRODUCT", 139, 144], ["GluA1", "PROTEIN", 9, 14], ["PSD", "PROTEIN", 67, 70], ["synapatic GluA1", "PROTEIN", 129, 144], ["the PSD", "TEST", 63, 70], ["synapatic GluA1", "PROBLEM", 129, 144], ["ImageJ", "TEST", 193, 199]]], ["Statistical differences between experimental conditions were determined by unpaired Student's t tests.Western blotProtein band intensity was visualized and quantified in the linear range using LI-COR C-Digit and Image Studio software.", [["Statistical differences between experimental conditions", "PROBLEM", 0, 55], ["Western blotProtein band intensity", "PROBLEM", 102, 136], ["LI", "TEST", 193, 195], ["band intensity", "OBSERVATION", 122, 136]]], ["Three biological replicates were used.", [["Three biological replicates", "TREATMENT", 0, 27]]], ["Results were compared using one-way ANOVA with Dunnett's test.Western blote5 Cell Reports 32, 108002, August 11, 2020 Article ll OPEN ACCESS", [["Cell", "ANATOMY", 77, 81], ["Dunnett's test", "TEST", 47, 61]]]]}